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Abstract 
Primary open angle glaucoma (POAG) is a leading cause of irreversible blindness 
worldwide, and the only modifiable risk factor is intraocular pressure (IOP). 
Glaucoma is a complex disease with specific endophenotypes, and disease 
pathogenesis is likely to involve multiple pathways linking genetic and 
environmental interactions. Growth factors present in the aqueous humour in 
POAG increase outflow resistance and elevate IOP. TGF-β2 alters ECM production 
and turnover in the trabecular meshwork (TM) and has been shown in numerous 
studies to play a role in the pathogenesis of POAG. No current pharmacological 
interventions target the deleterious effects of TGF-β2 of the TM which produced 
elevated IOP.  In addition to TGF-β another well characterised glaucoma stimulus is 
corticosteroids. Corticosteroids are used in ophthalmology to decrease 
inflammation and preserve ocular function. However side effects including cataract, 
enhanced infection, and glaucoma are associated with their use. Small, naturally 
occurring regulatory genes, micro RNAs (miRNAs), target many genes downstream 
of TGF-β2 and are expressed in response to corticosteroids. 
The current work set out to identify key differentially expressed genes by RNA-Seq 
in the human trabecular meshwork (TM) in response to two glaucoma stimuli; TGF-
β2 and dexamethasone; and investigate the ability of miRNAs to manipulate gene 
expression within the TM to reduce pathological insults central to glaucoma. 
Investigating the influence of TGF-β2 on gene expression in primary human TM cells 
demonstrated that the majority of the significantly differentially expressed genes 
were involved in extracellular matrix remodelling and actin cytoskeletal re-
organisation likely via the RhoA signalling pathway. The influence of 
dexamethasone on gene expression in primary human TM cells identified genes 
involved in extracellular matrix remodelling and genes required for glucocorticoid 
receptor nuclear translocation. Differentially expressed miRNAs in healthy and 
glaucomatous human TM cells were identified by a miRNA microarray. 
Manipulation of validated mRNA targets by identified miRNAs indicated a complex 
regulatory network and in vitro functional analyses further identified regulation of 
actin cytoskeleton remodelling via miRNA inhibition.  
The findings of this study indicate that TGF-β2 and dexamethasone have significant 
effects on extracellular matrix remodelling and actin cytoskeletal re-organisation in 
human TM cells. The RNA-Seq and miRNA array have identified potential novel 
therapeutic targets for glaucoma.  
iii 
 
Acknowledgments 
First and foremost I would like to thank my supervisors Prof. Colin Willoughby 
(Bob), Dr. Carl Sheridan, and Mrs. Anshoo Choudhary. Thank you firstly for affording 
me the wonderful opportunity and for your continued help and support over the 
last three years. Carlos, thanks for keeping me going over the last few months! Bob, 
I understand now why you wanted to drag me from the lab and encourage my 
reading! I have learned so much under your guidance and everything you taught me 
will stick with me throughout my scientific career. You have encouraged me every 
step of the way and for this I will always be grateful.  
Thank you to Dr. Kevin Hamill for being an honorary supervisor, an everyday llama 
expert and a teacher extraordinaire!  Your enthusiasm for science is admirable. 
Thank you to Dr. S. Senthilkumari (Aravind Medical Research Foundation, Madurai, 
India) for providing training on the H.O.C.A.S setup. Thank you to Dr. Abbot Clark 
(UNTHSC, Texas, USA) for providing glaucomatous TM samples for this research. 
Thank you to Dr. David Simpson and his team  (Queens University Belfast, UK) for 
RNA-Sequencing services. Thank you to Dr. Natalie Pollock and Dr. Stephnie 
Kennedy for your help with primary cell culture. Thank you Neeru for you advice 
and collection of corneal rims. 
Thank you NC3R, International Glaucoma Association/UK and Eire Glaucoma, 
International Glaucoma Association and Fight for Sight for funding this work. 
In addition I would like to thank everyone in E.V.S who have made my time in U.of.L 
such an enjoyable experience, and have been so helpful throughout. Miss. Jessica 
Eyre, thank you for dragging me to yoga even when I protested and being there 
over the last year to provide the lols.  
Thank you to my girls back home, your support has been phenomenal and I 
apologise for only knowing how to talk about one thing for the past three years. 
To my best friend and partner in crime, Leeburt, thank you for being with me every 
step of the way since the very beginning. You have cheered me up no end every 
time I needed it and stood by me through it all. You’ve held my hand every step of 
the way and encouraged me always. Endless Netflix binges and Lindt chocolate was 
key. It has been the best experience ever doing this with you by my side every day.   
I especially want to thank my Mum, Dad, and sister Amy. Mum and Dad, you’ve 
given me the best of everything, always, and I know without your support 
throughout my life I would not be where I am today. Amy, thanks for making me 
smile when all I wanted to do was cry, you’ve dealt with my ups and downs 
throughout this whole process expertly and I know I wouldn’t have gotten through 
it without you all by my side.   
~“Always look someone in the eye, even if they’re blind, just say “I’m looking you in 
the eye.”~ 
  
iv 
 
Table of Figures 
Figure 1.1: Optic Disc and Schematic Cross-section of the ONH to Show Central 
Cup………………………………………………………………………………………………………………………    3 
Figure 1.2: Characteristic Visual Field Defects in 
Glaucoma……………………………………………………………………………………………………………..   5 
Figure 1.3: Gonioscope Drainage Angle 
Images…………………………………………………………………………………………………………………    7 
Figure 1.4: Posterior View of the Iris and Ciliary Body Showing the Ciliary 
Processes…………………………………………………………………………………………………………….  16 
Figure 1.5: Active Secretion of Aqueous Humour……………………………………………….    17 
Figure 1.6: Cross Section of the Human Eye 
…………………………………………………………………………………………………………………….          20   
Figure  1.7: Anatomical Structure of the Human Trabecular Meshowrk………..          21 
Figure 1.8: Structure and Transcriptional Isoforms of the Human GR 
Gene…………………………………………………………………………………………………………….          27 
Figure 1.9: Glucocorticoid Mechanisms of 
Action…………………………………………………………………………………………………………….        30 
Figure 1.10: TGF-β Structure, Latency, Activation and 
Signalling……………………………………………………………………………………………………………    36  
Figure 1.11: miRNA Biosynthesis- Canonical 
Pathway…………………………………………………………………………………………………………….    45 
Figure 1.12: miRNA Biosynthesis- Non-Canonical 
Pathway…………………………………………………………………………………………………………….    47 
Figure 2.1: Representative Images Depicting Human Anterior Segment Dissection 
Protocol…………………………………………………………………………………………………………….     55 
Figure 3.1: Representative Phase Contrast Microscope Images of Human Cultured 
TM Cells…………………………………………………………………………………………………………….     88 
v 
 
Figure 3.2: Representative Fluorescent Confocal Microscope Images of Human TM 
Cells………………………………………………………………………………………………………………….     89 
Figure 3.3: Principal Component Analysis of RNA-Seq Data for Control Untreated 
TM Cells and TGF-β2 Treated TM Cells…………………………………………………………..        94 
Figure 3.4: Heat Map and Unsupervised Clustering of Human TM Cells Treated with 
TGF-β2…………………………………………………………………………………………………………….       96 
Figure 3.5: volcano Plot Showing the Relationship Between LogFC and the Average 
Log Counts-Per-Million (CPM) ………………………………………………………………………       101 
Figure 3.6: Top Canonical Pathways of the Top 1% Differentially Expressed Genes in 
TGF-β2 Treated Human TM Cells Vs Control TM Cells…………………………………         107 
Figure 3.7: Canonical Pathway Map for RhoA Signalling 
Pathway………………………………………………………………………………………………………..       108 
Figure 3.8 Expression Levels of Candidate Genes in Cultured Normal Human Tm 
Cells…………………………………………………………………………………………………………….         116 
Figure 3.9: Expression Levels of Candidate Genes in Cultured Normal Human TM 
Cells and Glaucomatous TM Cells……………………………………………………………..          120 
Figure 3.10: Schematic of Rho/ROCK Signalling 
Pathway…………………………………………………………………………………………………………….  124 
Figure 3.11: NOX4 Mediated TGF-β-Induced Pro-Fibrotic 
Responses…………………………………………………………………………………………………            127 
Figure 3.12: Pathological Role of EDN1 in 
Glaucoma………………………………………………………………………………………………………       129 
Figure 3.13: Localisation of CDKN2B and CDKN2B-AS1 on 
Chr9p21………………………………………………………………………………………………………         131 
Figure 3.14: Effects of CDKN2B and CDKN2b-AS1 on Cell Cycle via CDK4 
Inhibition…………………………………………………………………………………………………………    131 
vi 
 
Figure 4.1: Principal Component Analysis of RNA-Seq Data for Control Untreated 
TM Cells and DEX Treated TM Cells…………………………………………………………………     151 
Figure 4.2: Heat Map and Unsupervised Clustering of RNA-Seq Data from Control 
Untreated TM Cells and DEX Treated TM 
Cells…………………………………………………………………………………………………………….         153 
Figure 4.3: Volcano Plot of the Relationship Between the LogFC and the Average Log 
Counts-Per-Million (CPM) in Control Untreated TM Cells Compared to DEX Treated 
TM Cells………………………………………………………………………………………………………          160 
Figure 4.4: Top Canonical Pathways of the Top 1% Differentially Expressed Genes in 
Human TM Cells +/- Dexamethasone………………………………………………………….          164 
Figure 4.5: Heat Map of Highest Ranked Over-Lapping Canonical Pathways between 
TGF-β2 Treated Human TM Cells and DEX Treated Human TM 
Cells…………………………………………………………………………………………………………….         165 
Figure 4.6: Expression Levels of Glucocorticoid Receptor (GRα and β) in Paired 
Human TM Cells +/- DEX Treatments………………………………………………………………     167 
Figure 4.7: Expression Levels of Candidate Genes in Cultures Human TM 
Cells…………………………………………………………………………………………………………….         170 
Figure 4.8: Alternate Splicing of Glucocorticoid Receptor Generates Two 
Functionally Distinct Splice Isoforms: GRα and GRβ………………………………………       175 
Figure 4.9: Putative Integrin Signalling Pathways Through PYK2 or 
FAK…………………………………………………………………………………………………………….           177 
Figure 4.10: FKBP51/FKBP5 Structure……………………………………………………                180 
Figure 4.11: The FKBP51 and FKBP52 Genes Regulate Glucocorticoid Receptor 
Nuclear Translocation………………………………………………………………………………            181 
Figure 4.12: PAI-2 Inhibits tPA Activity…………………………………………………………        184 
Figure 5.1: Interplay Between miR-200 Family, TGF-β, and ZEB1/2 in EMT 
Regulation……………………………………………………………………………………………..              191 
vii 
 
Figure 5.2: Cross-talk Between TGF-β and miRNAs…………………………………..             193 
Figure 5.3: Present Calls and Threshold Filtering Plot……………………………..              206 
Figure 5.4: Volcano Plot Analysis of Untreated and TGF-β2 Treated Human TM Cells 
miRNA Expression……………………………………………………………………………………………    210 
Figure 5.5: q-PCR Validation of Significantly Up-regulated miRNAs from Microarray 
Data of TGF-β2 Cultured Human TM Cells…………………………………………………………  212 
Figure 5.6: Expression Levels of miR-143, miR-145, and miR-4328 in Cultured 
Human Glaucomatous TM Cells…………………………………………………………………          213 
Figure 5.7: Transfection Optimisation; Cell Viability Assessment………………………   215 
Figure 5.8: TGF-βR2 Expression Profiles in TGF-β2 TM Cells Treated with a miR-145-
5p Mimic and Inhibitor…………………………………………………………………………                217 
Figure 5.9: SMAD2 Expression Profiles in the Presence of Synthesised Mimics and 
Inhibitors for miR-145-5p……………………………………………………………………                  218 
Figure 5.10: CTGF Expression Profiles in the Presence of Synthesised Mimics and 
Inhibitors for miR-145-5p…………………………………………………………………………             219 
Figure 5.11: E-Cadherin Expression Profiles in the Presence of Synthesised Mimics 
and Inhibitors for miR-145-5p……………………………………………………………………           220 
Figure 5.12: N-Cadherin Expression Profiles in the Presence of Synthesised Mimics 
and Inhibitors for miR-145-5p………………………………………………………………………        221 
Figure 5.13: SLUG Expression Profiles in the Presence of Synthesised Mimics and 
Inhibitors for miR-145-5p…………………………………………………………………………             222 
Figure 5.14: SNAIL Expression Profiles in the Presence of Synthesised Mimics and 
Inhibitors for miR-145-5p…………………………………………………………………………            223 
Figure 5.15: Vimentin Expression Profiles in the Presence of Synthesised Mimics and 
Inhibitors for miR-145-5p…………………………………………………………………………             224 
viii 
 
Figure 5.16: Principal Component Analysis Across All Sample 
Groups………………………………………………………………………………………………………            228 
Figure 5.17: Venn Diagram of Overlap of Differentially Expressed Genes Between 
Scrambled Negative Control, 143i, or 145i Transfected TM Cells Treated with TGF-
β2…………………………………………………………………………………………………………….             238 
Figure 5.18: Comparison Analysis of Canonical TGF-β Signalling Pathway between 
143i, 145i and SNC Transfected TGF-β2 Treated Human TM 
Cells…………………………………………………………………………………………………………….         246 
Figure 5.19: Comparison Upstream Analysis of miR145 Between 143i, 145i, and SNC 
Transfected TGF-β2 Treated Human TM Cells………………………………………………        247 
Figure 5.20: Comparison Upstream Analysis of ZEB1 Between 143i, 145i, and SNC 
Transfected TGF-β2 Treated Human TM Cells………………………………………………        248 
Figure 5.21: q-PCR Analysis of ACTA2 Gene Expression in Transfected TGF-β2 
Human TM Cells…………………………………………………………………………………………..        250 
Figure 5.22: ACTA2 Protein Expression Reduced in Presence of miRNA 
Inhibitors………………………………………………………………………………………………………      252 
Figure 5.23: The miR143/145 Cluster…………………………………………………………..       254 
Figure 5.24: Regulation of Vascular Smooth Muscle Cell 
Phenotype…………………………………………………………………………………………………..        256 
Figure 5.25: Summary of miR143/145 Regulation……………………………………..         261 
Figure 7.1: Anterior Segment Organ Culture Perfusion Setup……………………          290 
 
 
 
 
 
 
ix 
 
Website Index 
miRTarBase (v8): http://mirtarbase.mbc.nctu.edu.tw/php/index.php 
Validated Target Module of miRWalk 2.0: http://zmf.umm.uni-
heidelberg.de/apps/zmf/mirwalk2 
PrimerBank: https://pga.mgh.harvard.edu/primerbank/ 
 
List of Abbreviations 
TM   Trabecular meshwork  
AH   Aqueous humour 
TGF-β   Transforming Growth Factor Beta 
PBS   Phosphate buffered saline  
DMEM   Dulbeccos modified eagles medium 
POAG   Primary open angle glaucoma 
q-PCR   Quantitative polymerase chain reaction 
TC   Tissue culture 
CLAN   Cross-linked actin network 
miRNA   Micro-Ribonucleic Acid 
RNA   Ribonucleic Acid  
IOP   Intraocular pressure 
OHT   Ocular hypertension 
ONH   Optic nerve head 
RGC   Retinal ganglion cells  
DEX   Dexamethasone 
GAGs   Glycosaminoglycans 
WHO   World Health Organisation 
PACG   Primary angle closure glaucoma 
OCT   Optical coherence tomography 
CCT   Central corneal thickness 
DM   Diabetes mellitus 
NPE   Non-pigmented epithelium 
SC   Schlemms’ canal 
x 
 
ECM   Extracellular matrix  
JCT   Juxtacanalicular meshwork 
BM   Basement Membrane  
LC   Lamina Cribrosa 
AGEs   Advanced glycation end products  
MMPs   Matrix metalloproteinases  
TNF-α    Tumour necrosis factor alpha 
GC   Glucocorticoids 
GR   Glucocorticoid receptor 
GREs   Glucocorticoid response elements 
BMPs   Bone morphogenic proteins 
LAP   Latency-associated protein 
LTBP   Latent TGF-β-binding proteins 
r-SMADs  Receptor-mediated SMADs 
co-SMADs  Common partner SMADs 
CTGF   Connective tissue growth factor 
ncRNA   Non-coding RNA 
tRNA   Transfer RNA 
rRNA   Ribosomal RNA 
snoRNA  Small nucleolar RNA 
bp   Base pairs 
nt   Nucleotides 
DGCR8   DiGeorge syndrome critical region 8 
UTR   Untranslated region 
RISC   RNA-induced silencing complex 
SNP   Single nucleotide polymorphism 
FPKM   Fragments per kilobase per million mapped fragments 
FDR   False discovery rate 
LogFC   Log fold change 
CPM   Counts per million 
GO    Gene ontology 
xi 
 
IPA   Ingenuity Pathway Analysis 
DEGs   Differentially expressed genes 
GWAS   Genome-wise association studies 
FECD   Fuchs endothelial corneal dystrophy   
ROS   Reactive oxygen species 
FN   Fibronectin 
  
xii 
 
Table of Contents 
1. Introduction……………………………………………………………………………………           2 
1.1 Glaucoma…………………………………………………………………………………….          2 
1.2 Primary Open Angle Glaucoma…………………………………………………….        10 
1.2.1 Risk Factors for Primary Open Angle Glaucoma…………………..      10 
1.2.1.1 Demographic Risk Factors………………………………….      10 
1.2.1.2 Systemic Risk Factors…………………………………………….      13 
1.2.1.3 Ocular Risk Factors…………………………………………………..     14 
1.3 Aqueous Humour Dynamics……………………………………………………………   15 
1.3.1 Aqueous Humour Formation……………………………………………….   15 
1.4 The Trabecular Meshwork……………………………………………………………….  19 
1.4.1 Trabecular Meshwork and Aqueous Humour Outflow……….. 19  
1.4.2 Anatomical Structure and Function……………………………………… 20 
1.4.3 The Trabecular Meshwork and Intraocular Pressure………………. 23 
1.4.4 Extracellular Matrix in the Trabecular Meshwork…………………… 25 
1.5 Role of Known Glaucoma Stimuli Resulting in Raised IOP……………  26 
1.5.1 Corticosteroids……………………………………………………………………     26 
1.5.1.1 Glucocorticoid Mechanism of Action…………………………… 27 
1.5.1.2 Corticosteroids Effect in the Eye………………………………… 31 
1.5.1.3 Corticosteroid-Induced Glaucoma……………………………… 31 
1.5.1.4 Corticosteroid-Induced Glaucoma Pathophysiology….. 32 
1.5.2 Transforming Growth Factor Beta (TGF-β)……………………   34 
1.5.2.1 TGF-β-Induced Glaucoma Pathophysiology…………… 37 
1.5.2.1.1 TGF-β and Extracellular Matrix……………………      38 
1.5.2.1.2 TGF-β and the Trabecular Meshwork 
Cytoskelton……………………………………………             38 
1.6 The microRNA………………………………………………………………………………….. 39 
1.6.1 microRNA Biosynthesis- The Canonical Story………………….   39 
1.6.1.1 Nuclear Events in microRNA Biosynthesis……………    40 
1.6.1.2 Nuclear Export……………………………………………….              43 
1.6.1.3 Cytoplasmic Processing or pre-miRNA…………………………  43 
1.6.2 Non-Canonical Biosynthesis……………………………………………….    46 
xiii 
 
1.6.3 microRNA Mechanism of Action…………………………………          48 
1.6.3.1 microRNA-Mediated mRNA Decay……………………...      48 
1.6.3.2 microRNA Translational Repression…………………..      49 
1.6.4 miRNAs and Human Disease…………………………………………      49 
2. Materials and Methods………………………………………………………………    51 
2.1 Tissue Culture………………………………………………………………………………..    52 
2.1.1 Tissue Samples……………………………………………………………………..    52 
2.1.2 Dissection of Anterior Segment From Porcine and Human 
Eyes……………………………………………………………………………………..    53 
2.1.3 Dissection of Trabecular Meshwork from Anterior 
Segment………………………………………………………………………………     53 
2.1.4 Cell Culture Maintenance……………………………………………….           56 
2.1.5 Mycoplasma Testing and Treatment of Cells………………………       56 
2.1.6 Sub-Culturing Cells…………………………………………………………….        56 
2.1.7 Long-Term Storage of Cells……………………………………………….        57 
2.2 Cells for Experimentation……………………………………………….                    58 
2.2.1 Characterisation of TM Cells……………………………………………       58 
2.2.1.1 Morphological Assessment TM Cells……………………       58 
2.2.1.2 Fluorescent Staining of TM Cells In Vitro………………     58 
2.2.2 Cell Stimulations with TGF-β2 and Dexamethasone…………    60 
2.2.3 Transfection for miRNA Manipulation Experiments……………  61 
2.3 Protein Based Methods……………………………………………………………….       62 
2.3.1 Whole Cell Lysis-Protein Extraction………………………………         62 
2.3.2 SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) ……     62 
2.4 Nucleic Acid Based Methods……………………………………………….                63 
2.4.1 Ribonucleic Acid (RNA) Extraction…………………………                63 
2.4.2 Nucleic Acid Concentration Measurements by NanoDrop 2000 
Spectrophotometer……………………………………………….                  63 
2.4.3 RNA Quality Assurance with Agilent Bioanalyser 2100……………  64 
2.4.4 cDNA Synthesis………………………………………………………………………   64 
2.4.5 End-Point PCR…………………………………………………………………………  65 
2.4.6 Agarose Gel Electrophoresis…………………………………………………..  66 
xiv 
 
2.4.7 Primer Design and Optimisation……………………………………………    66 
2.4.8 Relative Quantification real-time PCR (q-PCR) ……………………     67 
2.5 RNA-Seq and Microarray Analyses……………………………………………….    73 
2.5.1 Bioinformatic Methodology……………………………………………….     73 
2.5.1.1 Exiqon RNA-Seq Analysis…………………………………………   73 
2.5.1.2 IPA RNA-Seq Analyses………………………………………………   73 
2.5.1.3 R/Bioconductor RNA-Seq Analyses…………………………  74 
2.5.2 Statistical Analysis……………………………………………………………75 
3. Transforming Growth Factor-β2 Modulates Gene Expression in the 
Human Trabecular Meshwork……………………………………………………   76 
3.1 Introduction…………………………………………………………………………………       77 
3.2 Aim……………………………………………………………………………………………………   80 
3.3 Materials and Methods……………………………………………………………………    81 
3.3.1 Sample Collection, Preparation and Tissue Culture 
Establishment…………………………………………………………………………  81 
3.3.2 Characterisation of Human Trabecular Meshwork 
Cells……………………………………………….…………………………………         83 
3.3.3 TGF-β2 Stimulations…………………………………………………………..       83 
3.3.4 Total RNA Extraction and QC……………………………………………….     83 
3.3.5 RNA-Seq of Cultured Normal Human Trabecular Meshwork 
Cells…………………………………………………………………………………….      84 
3.3.5.1 Template Preparation, rRNA Depletion, and cDNA Library 
Construction, Purification and QC………………………………   84 
3.3.6 RNA-Seq Data Analysis……………………………………………….             84 
3.3.7 mRNA-Seq Data Validation……………………………………………….      85 
3.4 Results……………………………………………….……………………………………………    88 
3.4.1 Characterisation of Human Trabecular Meshwork 
Cells…………..……………………………………………….                              88 
3.4.2 RNA-Seq Analysis of Human Trabecular Meshwork Cells in the 
Absence of Presence of TGF-β2……………………………………………  90 
3.4.2.1 RNA-Seq Summary……………………………………………….       90 
3.4.2.2 Principal Component Analyses………………………………    93 
xv 
 
3.4.2.3 Heat Map and Unsupervised Clustering……………………   95 
3.4.3 Functional Analysis of Gene Pathways Involved in TGF-β2 
Stimulation of Human Trabecular Meshwork Cells……………… 97 
3.4.3.1 Differentially Expressed Genes in Human Trabecular 
Meshwork Cells in the Presence of Absence of TGF-β2 
Obtained from RNA-Seq Analysis  ………………………       97 
3.4.3.2 Visual Identification of RNA Transcripts Obtained by 
RNA-Seq Analysis……………………………………………….        100 
3.4.3.3 TGF-β2 Activated Processes in Cultured Human 
Trabecular Meshwork Cells……………………………………   102 
3.4.4 q-PCR Assay Validation of Top Differentially Expressed Genes 
in Cultured Human TM in the Presence or Absence of TGF-
β2……………………………………………….………………………………………    111 
3.5 Discussion……………………………………………….……………………………………… 121 
3.5.1 Genome-Wide Transcriptome Profiling in TGF-β2 Treated 
Human TM Cells……………………………………………….                     121 
3.6 Summary……………………………………………….…………………………………        137  
4. A Comparison of Global Gene Expression Profiles in Human 
Trabecular Meshwork Cells Treated with Dexamethasone using 
RNA-Sequencing……………………………………………….………………………………    139 
4.1 Introduction……………………………………………….…………………………………    140 
4.2 Aim……………………………………………….…………………………………………………  143 
4.3 Materials and Methods 
4.3.1 Sample Collection, Preparation and Tissue Culture 
Establishment………………………………………………………………………   144 
4.3.2 Dexamethasone Stimulations………………………………………………   144 
4.3.3 Total RNA Extraction and QC………………………………………………    145 
4.3.4 RNA-Seq of Cultured Normal Human Trabecular Meshwork 
Cells………………………………………………………………………………          145 
4.3.5 RNA-Seq Data Analysis…………………………………………………………   145 
4.3.6 RNA-Seq Data Validation……………………………………………………     145 
4.4 Results………………………………………………………………………………                 147 
xvi 
 
4.4.1 RNA-Seq Analysis of Human Trabecular Meshwork Cells in the 
Absence or Presence of Dexamethasone…………………………     147 
4.4.1.1 RNA-Seq Summary………………………………………………      147 
4.4.1.2 Principal Component Analysis………………………………    150 
4.4.1.3 Heat Map and Unsupervised Clustering……………….    152 
4.4.2 Functional Analysis of Gene Pathways Involved in 
Dexamethasone Stimulation of Human Trabecular Meshwork 
Cells………………………………………………………………………………          154 
4.4.2.1 Differentially Expressed Genes in Human Trabecular 
Meshwork Cells in the Presence or Absence of 
Dexamethasone Obtained from RNA-Seq 
Analysis……………………………………………………………………  154 
4.4.2.2 Visual Identification of RNA Transcripts Obtained by 
RNA-Seq 
Analysis……………………………………………………………………  159 
4.4.2.3 Dexamethasone Activated Processes in Cultured 
Human Trabecular Meshwork 
Cells…………………………………………………………………………   159 
4.4.3 q-PCR Assay Assessment of Glucocorticoid Receptor Isoforms 
Expressed in Cultured Human TM Cells +/- 
Dexamethasone…………………………………………………………………… 166                          
4.4.3.1 q-PCR Assay Validation of Top Differentially Expressed 
Genes in Cultured Human TM in the Presence or 
Absence of Dexamethasone……………………………………   168 
4.5 Discussion………………………………………………………………………………            173 
4.6 Summary………………………………………………………………………………              187 
5. Identification of TGF-β2 Inducible miRNAs in Human Trabecular 
Meshwork Cells………………………………………………………………………………       188 
5.1 Introduction………………………………………………………………………………        189 
5.1.1 miRNAs in Glaucoma………………………………………………………       189 
5.2 Aim………………………………………………………………………………                       193 
5.3 Materials and Methods………………………………………………………………       194 
xvii 
 
5.3.1 Tissue Culture and TGF-β2 Stimulations…………………………     194 
5.3.2 miRNA Isolation and QC……………………………………………………    196 
5.3.3 Microarray Analysis of Human TM Cells…………………………    196 
5.3.4 MicroRNA Array Data Validation………………………………………   197 
5.3.5 Human Trabecular Meshwork Transfection 
Optimisation………………………………………………………………………    198 
5.3.5.1 q-PCR Assessment of miRNA Mimics and Inhibitors of 
miR-145-5p on Target Genes and EMT-related 
Genes………………………………………………………………            199 
5.3.6 RNA-Seq Analysis of Genome-wide Transcriptional Effects of 
miRNA Inhibitors of miR-145-5p and miR-143-3p to Identify 
Target Genes…………………………………………………………………         202 
5.3.7 RNA-Seq of TGF-β2 Positive Cells Co-Transfected with miRNA 
Inhibitors (miR-143i and miR-
145i)………………………………………………………………………………         202 
5.3.7.1 cDNA Library Construction, Purification and 
QC………………………………………………………………………         203 
5.3.7.2 RNA-Seq Data Analysis of TGF-β2 Positive Cells Co-
Transfected with miRNA Inhibitors (miR-143i and 
miR-145i)……………………………………………………………        203 
5.3.8 RNA-Seq Validation………………………………………………………         204 
5.3.8.1 ACTA2 Differential Gene Expression Validation by q-
PCR………………………………………………………………………      204 
5.3.8.2 ACTA2 Differential Protein Expression Validation by 
Western Blot Analysis……………………………………………   204 
5.4 Results………………………………………………………………………………                206 
5.4.1 miRNA Array Data Analyses……………………………………………     206 
5.4.1.1 Calls and Threshold Filtering………………………………     206 
5.4.1.2 miRNA Expression Analysis of TGF-β2 Treated TM 
Cells…………………………………………………………………………   207 
5.4.1.2.1 volcano Plot Analysis of Untreated and TGF-β2 
Treated Human TM Cells…………………………………    209 
xviii 
 
5.4.2 q-PCR Assay Validation of Top Differentially Expressed miRNA 
in Cultured Human TM +/- TGF-β2……………………………………  211 
5.4.3 Human Trabecular Meshwork Transfection 
Optimisation………………………………………………………………………… 214 
5.4.3.1 Human TM Cell Viability with Varying Volumes of 
HiPerfect Reagent……………………………………………………  214 
5.4.3.2 Effects if miRNA Inhibitors (miR-143i and miR-145i) 
on Target Gene and EMT-related Gene 
Expression……………………………………………………………     216 
5.4.4 RNA-Seq Analysis of hsa-miR-145-5p and hsa-miR-143-3p 
Inhibitor Target Expression Profiles……………………………       225 
5.4.4.1 mRNA-Seq Summary…………………………………………        225 
5.4.4.2 Principal Component Analysis……………………………       227 
5.4.5 Functional Analysis of Genes Associated with miR-143 and 
miR-145 Inhibition Following TGF-β2 Treatment…………     229 
5.4.5.1 Differentially Expressed Genes in Human Trabecular 
Meshwork Cells Post miR-143/miR-145 Inhibition 
Following TGF-β2 Treatment………………………………      229 
5.4.5.2 Comparison Analysis of 143i and 145i in Human TM 
Cells +/- TGF-β2…………………………………………                 245 
5.4.5.3 Validation of hsa-miR-145-5p and hsa-miR-143-3p 
Inhibitor Effects of ACTA2 at mRNA 
Level………………………………………………………………….          249 
5.4.5.4 Validation of hsa-miR-145-5p and hsa-miR-143-3p 
Inhibitor Effects of ACTA2 at Protein 
Level…………………………………………………………………………  251 
5.5 Discussion………………………………………………………………………………           253 
5.6 Summary………………………………………………………………………………             262 
6. Emerging and Novel Glaucoma Therapeutics…………………………        264 
7. Summary and Future Work…………………………………………………………       280 
 
1 
 
 
  
 
 
 
 
 
 
 
 
 
Chapter 1 
Introduction  
2 
 
1. Introduction  
1.1 Glaucoma 
In 2002 the World Health Organisation (WHO) estimated that 161 million 
individuals worldwide had visual impairment and 37 million were blind1. Glaucoma 
accounted for 12.3% of global blindness2. Glaucoma is second only to cataracts as a 
leading cause of blindness worldwide; glaucoma  is the leading cause of irreversible 
visual loss1. Visual impairment due to glaucoma is a huge socio-economic burden, 
and affects adults more than children and females more than males1. 
Glaucoma is a heterogeneous group of disorders primarily divided into open 
angle and close angle glaucoma3. By the year 2020 it is estimated that there will be 
79.6 million individuals in the world with either primary open angle glaucoma 
(POAG) or primary angle-closure glaucoma (PACG); the majority of which will have 
POAG2. It is inevitable with increasing population sizes that the health and social 
burden of vision loss will also increase. Visual loss and related health conditions, 
including glaucoma in the ageing population impacts families, caregivers and 
society as a whole. Mobility and daily activities are among lifestyle factors that are 
affected that can often lead to injury, long-term care, and depression.  It is 
therefore paramount that progress be made with regards to innovative solutions 
for prevention and treatment of this disease4,5. 
Clinical Diagnosis of Glaucoma 
An international consensus panel published definitions of POAG and PACG in 
20026. Glaucoma is a progressive optic neuropathy, characterised by specific 
structural changes to the optic nerve head and associated visual field changes. 
Often referred to as “The Silent Thief” of sight, glaucoma patients (POAG) do not 
exhibit any symptoms or discomfort until very late in the progression of the 
disease. A familial history of the disease increases risk of glaucoma and mandates 
careful eye examinations. Myopia patients are at higher risk for POAG7 and 
hypermetropia patients are at higher risk for PACG8.  
The diagnosis of glaucoma in its earliest stages requires the accurate 
measurement of functional disturbances of the eye and is a challenge for clinical 
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ophthalmology. POAG is a progressive disease distinguished only from other optic 
neuropathies by its slow progression over months or years9, and characteristic 
appearance of the optic nerve head10. The progressive optic neuropathy in 
glaucoma results from apoptosis of the retinal ganglion cells (RGC) whose axons 
make up the optic nerve head (ONH)11. Pathogenesis of RGC apoptosis is poorly 
understand however it is thought to be a cascade initiated by mechanical factors, 
such as elevated intraocular pressure (IOP), or vascular factors, or a combination of 
both12. Diagnosis of glaucoma is made when both the structural and functional 
changes, that are the consequence of apoptosis, can be identified by clinical 
examination, visual field analysis and imaging. 
 The ONH has a central depression where retinal vessels enter the eye, this is 
known as the ‘cup’13. Peripheral nerve fibres are lost in glaucoma resulting in 
compensation of function by remaining fibres, and a larger ‘cup’ (Figure 1.1)14.  
Figure 1.1: Optic Disc and Schematic Cross-section of the ONH to Show Central 
Cup. Modified from Williams et al. 200114. (A) Normal optic disc, (B) Moderate optic 
disc cupping, and (C) Cavernous optic atrophy- fully cupped disc. 
Fundoscopy images allow for the visualisation of optic disc cupping as an area of 
central pallor. Although during early stages of glaucoma, disc-cupping may occur 
faster than area of pallor15. Therefore, interpreting optic nerve head cupping can be 
A B C 
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challenging and must involve identification of the area of pallor and the 
identification of kinking of vessels found within the periphery of optic disc cupping. 
Some degree of cupping is normal, and individuals may have physiologically large 
cups, so quantitative measures are required. The degree of cupping is measured as 
a ratio of the cup size to disc size and must be greater than 0.5mm, vertical cup/disc 
ratio must be greater than horizontal cup/disc ratio, and asymmetry between 
cup/disc ratios of the two eyes should be more than 0.2mm14. The degree of 
cupping is evaluated by objective assessment using slit-lamp biomicroscopy, stereo-
photography and optical coherence tomography (OCT) imaging.  
The diagnosis of glaucoma cannot be made purely on structural changes but by 
a combination of structural and functional defects. The RGC axonal loss which 
produces optic disc-cupping, begins in the periphery of the nerve16. The origin of 
these axons are in the RGCs of the mid-peripheral retina and so, glaucoma results in  
characteristic visual field loss in these regions. This early visual field loss is often 
unnoticed by patients. Visual field testing identifies these defects using targets of 
differing intensity at different points within the patient’s visual field. Visual field 
threshold at these different points are analysed to identify the size of the ‘blind 
spot’ which corresponds to the ONH17 and any disease associated visual loss. In 
glaucoma there is an initial enlargement of the ‘blind spot’ followed by mid-
peripheral curved scotomas18. End stage glaucoma patients present with tunnel 
vision when all but central area of fixation is involved19. Visual field loss is significant 
if it occurs in the context of cupping and if the degree of visual field loss 
corresponds with the degree of cupping20.  Primary open angle glaucoma is 
bilateral, but asymmetric21. If left untreated, or, inadequately treated, POAG leads 
to irreversible blindness or severe visual impairment respectively. 
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Figure 1.2: Characteristic Visual Field Defects in Glaucoma. (Top) A normal visual 
field. Black spot on the right side is the normal ‘blind spot’. (Bottom) Progressive 
glaucoma visual field, tunnel vision.  
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Glaucoma can be broadly classified in to open-angle glaucomas (POAG) and 
closed-angle (PACG) after an evaluation of the anterior chamber drainage angle. 
The drainage angle in the anterior segment cannot be directly visualised because of 
the principle known as the critical angle; the critical angle is related to the 
properties of light passing through media with different indices of refraction22. Light 
from the anterior chamber angle exceeds this critical angle and is therefore 
reflected back into the anterior chamber, thus preventing direct visualisation of the 
drainage angle. This can be overcome using gonioscopy to eliminate the cornea-air 
interface and involves the use of a mirrored contact lens to eliminate the optical 
effect of the front of the corneal surface. Gonioscopy identifies the angle 
structures: from posterior to anterior these include the ciliary body, scleral spur, 
trabecular meshwork, and Schwalbe line23.  Grading of angle width is essential to 
assess glaucoma patients and glaucoma suspects24. Gonioscopy aims to identify the 
functional status of the angle, degree of closure, and risk of future closure. Angles 
are graded based on the shape and contour of the iris, the deepest structure visible, 
the amount of trabecular pigmentation and the presence of peripheral anterior 
synechia25.  
 
 
 
 
 
 
 
 
 
 
7 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3: Gonioscopic Drainage Angle Images. (A) Gonioscopic image of an open 
angle as seen in POAG (American Academy of Ophthalmology, online resource26). 
(B) Gonioscopic image of peripheral anterior synechiae as seen in PACG. Red arrows 
identify iris-cornea adherence points (Glaucoma Associates of Texas, online 
resource27). 
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In the general population the mean intraocular pressure (IOP) is 16mmHg and 
two standard deviations either side of the mean gives a “normal” IOP range of 11 to 
21mmHg28. In the ageing population the mean IOP is higher, with women typically 
showing propensity for elevated IOP over men. The “normal” IOP range in elderly 
women is increased to 24mmHg29. Elevated IOP is an important functional risk 
factor in glaucoma because risk of optic disc damage and RGC loss increases as IOP 
rises. Patients may have glaucoma in the absence of elevated IOP (normal tension 
glaucoma) and may have raised IOP (ocular hypertension: OHT) without glaucoma. 
However, IOP is currently the only modifiable risk factor of glaucoma and therefore 
assessment and management of IOP is still of great clinical importance.  
 IOP is determined by the dynamics of aqueous humour and outflow as will 
be discussed in section 1.2. The Goldmann tonometer is the gold standard for IOP 
measurement30 and is based on the principle that IOP equals the force divided by 
the area of application of that force, with one major assumption that the eye is 
perfectly spherical. Importantly, diurnal fluctuations in IOP of up to 5mmHg occurs 
in approximately 30% of normal individuals and this fluctuation is increased to 90% 
in POAG patients31. To detect fluctuations IOP should be measured at different 
intervals throughout the day. It is also important to note that asymmetry in IOP 
measurements from two eyes is also possible and can be a feature of glaucoma32. 
At present decreasing IOP is the only currently available therapeutic intervention to 
treat glaucoma and this is accomplished with pharmacological and surgical 
intervention.  
Primary and Secondary Glaucoma 
Glaucoma is an umbrella term33 used to describe a group of neuropathies and is 
not a single disease entity. Glaucoma is subdivided into open-angle and closed-
angle and also whether or not the disease is caused by primary of secondary 
factors. The term primary glaucoma (POAG and PACG), is used when there is no 
underlying disease whereas secondary glaucoma arises as a results of an initiating 
disease or intervention: such as trauma, inflammation, tumours, surgery or medical 
therapies such as corticosteroids34. Secondary glaucoma often results from 
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decreased aqueous humour outflow35 due to inflammatory debris36, red blood cells 
from intraocular haemorrhage37 and growth of new blood vessels in the drainage 
angle38. Neo-vascularisation in the drainage angle is most common in patients with 
diabetes and individuals with occlusions of major retinal blood vessels38.  
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1.2 Primary Open Angle Glaucoma 
Primary open angle glaucoma (POAG) is an insidious sight threatening optic 
neuropathy which affects a growing proportion of the ageing population 
worldwide. According to WHO, approximately 70% of POAG cases are found in the 
developing world. The prevalence of POAG is high in Africa and in established 
market economies where the proportion of the population over 40 years old is 
above average39. The incidence of POAG increases with age and there is a female 
preponderance40. In the United Kingdom, POAG is the second most common cause 
of blind registration after macular degeneration and is estimated to cost over 300 
million per annum41.     
  Numerous epidemiological studies, conducted across continents, have 
investigated the prevalence of POAG. Case definition has been problematic in 
epidemiological studies and standardised definitions of POAG have been 
established42. More than 50 populations studies have been conducted worldwide43–
51 and these studies have highlighted that prevalence of POAG varies worldwide 
and that differential risk factors may be involved.  
1.2.1 Risk Factors for Primary Open Angle Glaucoma 
 POAG is a heterogeneous and multifaceted disease and an extensive list of 
risk factors possibly or probably associated with the development of the disease 
have been identified from a variety of studies including observational and 
experimental work52. For the purpose of this thesis these risk factors have been 
separated to include demographic, ocular, systemic, environmental, and genetic 
risk factors. The overall risk of developing POAG increases with both number and 
severity of risk factors53.  
1.2.1.1 Demographic Risk Factors 
Age 
 The main demographic factor associated with increased POAG risk is age. 
Increasing age has been associated consistently with increasing risk across 
numerous studies, not only observational studies but in large multi-centre 
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randomised controlled trials including the Ocular Hypertension Treatment Study54 
and the European Glaucoma Prevention Study55. The magnitude of risk also 
consistently multiplies with increasing age, increasing several fold from 40-50 years 
of age to over 80 years of age56–58. No other demographic factor, other than 
ancestry, has been consistently associated with increased risk.   
Gender 
 The relationship between gender and primary open angle glaucoma has 
been debated for many years with inconsistent findings across many 
studies45,48,59,60. Prevalence studies have identified increased frequency in men, 
increased frequency in women, and others have demonstrated little difference 
between the two genders. For example, the Baltimore Eye Survey59 and the Beaver 
Dam Eye Study48 showed no significant difference between gender and POAG 
prevalence. However, the Rotterdam Study45 and the Framingham Eye Study61 both 
showed an increase in prevalence among the male cohort, whereas the Blue 
Mountains Eye Study46 showed an increase among the female cohort.  
 The reason for these inconsistencies are not clear, they may relate to case 
definition with the used of different study criterion across different populations. A 
Bayesian meta-analysis, identified variation in POAG prevalence with age, gender, 
race, year of publication, and survey methods57.  Biologically, there is evidence to 
suggest that female sex hormones may be protective against raised IOP62. 
Oestrogen receptors have been found in the ciliary body and outflow tract63 and it 
is therefore possible that it could influence glaucoma via the AH formation and 
outflow facility. Evidence from population based studies suggests that females who 
undergo early menopause are at an increased risk of developing POAG as oestrogen 
protective qualities decrease40,64.  
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Race and Ethnicity   
 Ethnicity is a category of people who identify with each other based on 
similarities such as common ancestry, language, culture or society. Race is 
associated with biology in which populations are distinguished from one another 
based on physical traits65. Several studies have been performed that examine race 
and ethnicity and their potential involvement in POAG development and 
progression. Using a meta-analysis of published epidemiological studies, race and 
ethnicity influenced POAG prevalence57. The highest prevalence was among the 
African-Caribbean populations at all ages compared to Caucasian and Asian 
populations57. POAG prevalence was estimated as 16% in those over 70 years of age 
in the African-Caribbean population compared to 6% and 3% in the Caucasian and 
Asian populations respectively57. Individuals of African descent who develop POAG 
tend to exhibit a more aggressive form of the disease and blindness is more likely to 
follow in these cases66. Inter-population differences in ONH structure, central 
corneal thickness (CCT), and IOP levels have been cited as potential explanations for 
differential incidences67. 
 Classification of population diversity remains a challenging, complex and 
sensitive issue; statistics of POAG prevalence should be interpreted with caution. It 
is worth noting that individuals coined of African descent belong to one of the most 
genetically diversified populations in the world. Therefore, if the prevalence of 
POAG in populations deemed to be “of the same race” there can be significant 
variations in POAG prevalence between populations68. For example, POAG 
prevalence amongst individuals of African descent is significantly lower (p<0.001) in 
South Africa, Nigeria, Tanzania, and Baltimore compare to Ghana, St. Lucia or 
Barbados. Amongst Caucasian populations prevalence is significantly higher in 
white Australians than in the Dutch (p<0.001)69. 
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1.2.1.2 Systemic Risk Factors  
Hypertension and Primary Open Angle Glaucoma 
 There are a number of systemic diseases associated with the development 
and progression of POAG52. Hypertension is proposed to increase the risk of 
developing POAG. Hypertension, or elevated blood pressure, is defined by either; 
blood pressure measurements at a screening exam, or, the reported taking of 
medication for hypertension, or both70. Several mechanisms have been suggested 
to explain the association between hypertension and POAG development. Firstly, 
hypertension may lead to microvascular impairment in the retina and optic nerve 
head region, which may, in turn, result in reduced blood flow to the anterior ONH71. 
Secondly, hypertension may impair auto-regulation of posterior ciliary circulation 
which is the main source of blood supply for the ONH72. Thirdly, previous studies 
have suggested that anti-hypertensives may induce excessive nocturnal dipping in 
blood pressure which may inadvertently lead to lower ocular perfusion to the 
ONH73. Finally, hypertension can also lead to retinal vasculature narrowing, which 
may also affect the blood supply to the ONH74. Despite these findings, previous 
epidemiological studies have so far led to inconclusive findings across large varying 
populations over longitudinal studies59,75. 
The Blue Mountains Eye Study reported that individuals with systemic 
hypertension were 1.5 times as likely to have POAG75. In contrast, the Baltimore 
Eye Study reported that hypertension did not increase the risk of POAG in a 
population59. Instead, it was observed that younger hypertensives were less likely 
to develop POAG in comparison to an ageing cohort, suggesting that age was a 
surrogate for duration of hypertension, and some aspects of hypertensive effects 
on vessels or their function over years of exposure could lead to a predisposed risk 
for developing POAG75,76. Inconsistencies like these suggest that the effects of these 
factors are potentially modified by the presence of other confounding risk factors 
(e.g. age in this instance).   
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Diabetes and Primary Open Angle Glaucoma 
 The potential association between diabetes mellitus (DM) and POAG has 
been studied by many groups, with most studies reporting a weak association 
between the two diseases77–79. An early meta-analysis indicated that DM is 
associated with an increased risk for developing POAG80. However, the meta-
analysis did not include any cohort studies, but instead was performed on seven 
cross-sectional and five case-controlled studies of DM and the risk of POAG. This 
meant that a temporal relationship between exposure and outcome could not be 
established. Since this, numerous epidemiological studies, including cohort studies, 
of an association between DM and POAG have been reported77–79, however, the 
relationship has been deemed somewhat contradictory and inconclusive.   
1.2.1.3 Ocular Risk Factors  
Intraocular Pressure 
The relationship between glaucoma and intraocular pressure dates back as 
far as 986 AD when Arabic ophthalmologist Abdul Tabari first describes “migraine in 
the eye” which involved a pressure sensation81. Since then, IOP has become an 
established risk factor for POAG with the risk of POAG increasing with increasing 
levels of IOP82. The relationship between elevated IOP and POAG risk however is 
best examined from population-based data on incidence over prevalence.   
Several different population-based studies have investigated the 
distribution of IOP in both normal and glaucomatous eyes and findings have 
suggested that mean IOP can vary between populations. For example, the mean 
IOP in white Caucasian adult populations has consistently been estimated to being 
between approximately 15-16mmHg, with standard deviations reaching as high as 
3.2mmHg45,46. However, higher mean IOP between 16.5 and 18.7 mmHg were 
reported in populations of Afro-Caribbean origin49,59. Persons having elevated IOP 
and no optic nerve damage are termed “ocular hypertensives” with population 
frequencies varying widely from study to study. The prevalence of “ocular 
hypertension” is typically between 5-10% in persons of European descent and lower 
in Japanese or Mexican-American populations54.  
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Population cross-sectional studies conducted across all continents have 
provided strong evidence to suggest IOP is intimately related to glaucoma. Studies 
from the USA60, Australia46, to India50 have yielded findings that show an increased 
IOP is associated with an increased prevalence of glaucoma. Furthermore, in 
individuals with bilateral POAG, the eye with higher IOP tends to lose visual field 
more rapidly than if both IOPs were in the “normal” range. Randomised clinical 
trials have shown that lowering of IOP by means of medication, surgery, or laser all 
slow the onset/progression of optic neuropathy and visual field defects83,84. In the 
Early Manifest Glaucoma trial84, patients with early POAG were randomised into 
observational or treatment cohort; treatment consisted of reduction of IOP by 
selective laser trabeculoplasty or medication (β-blocker: betaxolol). Reduction in 
IOP clearly reduced the progression of glaucoma by 17% in the treatment group. 
Overall, it is believed that elevated IOP induces a series of events which will 
eventually lead RGC death by apoptosis and irreparable visual loss.  
1.3 Aqueous Humour Dynamics  
1.3.1 Aqueous Humour Formation 
Aqueous humour (AH) formation is related to circadian rhythms85. The main 
structures associated with AH are the ciliary body, the trabecular meshwork, and 
the uveoscleral pathway. The ciliary body is the site of AH production86 where AH is 
formed by the ciliary processes, which are finger-like projections consisting of a 
double layered epithelium associated with a core of stroma supplied by a  rich 
plexus of fenestrated capillaries87. Each of the ciliary processes contain many 
capillaries that are sourced from the major arterial circle of the iris. The ciliary body 
has both an inner non-pigmented layer and outer pigmented layer; the epithelium 
of both layers face each other and are joined by tight junctions. These tight 
junctions are essential to maintain the blood-aqueous barrier. The inner non-
pigmented epithelia contain a number of mitochondria and microvilli and is the 
main site of AH production88.  
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AH formation and secretion to the posterior chamber is a combination of 
three processes; active secretion, ultrafiltration, and diffusion89. AH is derived from 
plasma ultra-filtrate. Diffusion and ultrafiltration are responsible for the accrual of 
plasma ultrafiltrate in the stroma, behind the tight junctions of non-pigmented 
ciliary epithelium cells90. Diffusion involves the transport of lipid soluble solutes 
through lipid portions of the membrane, whereas ultrafiltration is the flow of 
water-soluble substances across the fenestrated capillaries of the ciliary body, in to 
the ciliary stroma. These occur in response to an osmotic gradient or hydrostatic 
pressure.  
 Active secretion is the major part of AH formation, responsible for up to 
90% of total AH formation91. The main site of active transport is the non-pigmented 
epithelia of the ciliary processes (Figure 1.5). Active transport involves the selective 
transport of anions, cations, among other molecules across a concentration 
gradient in the blood-aqueous barrier. Protein transporters located in the epithelial 
cell membranes mediate this process. Aquaporins, facilitate the transport of fluids 
when there is insufficient osmotic pressure92; aquaporin 1, and 4 contribute to AH 
secretion93. Carbonic anhydrase II, and enzymes found in the non-pigmented and 
pigmented ciliary epithelia are also involved in the active transport of AH94.  
Carbonic anhydrase II initiates bicarbonate formation to influence fluid transport 
and the energy required for active transport is catalysed by Na+-K+-ATPase; an 
Figure 1.4: Posterior View of the Iris and Ciliary Body Showing 
the Ciliary Processes. Image modified from online resource860. 
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enzyme found within the pigmented and non-pigmented epithelial cells of the 
ciliary body95. Na+-K+-ATPase can be regulated by a number of molecules85,96 and is 
a target for pharmacological agents (such as dorzolamide and brinzolamide) to alter 
AH dynamics and lower IOP to treat glaucoma52. 
 
 
Figure 1.5: Active Secretion of Aqueous Humour. The NPE (non-pigmented 
epithelium) of the ciliary processes are responsible for the bulk of active secretion 
of AH. AH secretion is catalysed by carbonic anhydrase II and Na+-K+-ATPase. Image 
adapted from Marcel et al 200297. 
 
AH is secreted in to the posterior chamber of the eye and is transported to the 
anterior chamber to provide nourishment for avascular structures including the 
lens, the posterior surface of the cornea and the trabecular meshwork. As well as 
nourishment of avascular structures, AH dynamics also help in the maintenance of 
intraocular pressure98.  
Compared to blood plasma, the composition of AH has an excess of hydrogen 
and chloride ions and ascorbate but is deficient of bicarbonate. Protein levels are 
relatively low in AH (approximately 0.2mg/mL) to maintain visual clarity and 
include: albumin which accounts for nearly half of the total protein content, SERPIN 
family members, and prostaglandin D2 synthase (PTGDS)98,99 as examples. 
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Additional components of the AH include growth factors: TGF-β, transferrin100, 
endothelin-1101 and indoleamine 2,3-dioxygenase102, enzymes: carbonic 
anhydrase87, lysozyme87, diamine oxidase103, plasminogen activator104, and 
prostaglandins; cAMPs105, steroid hormones106 and hyaluronic acid107.  
AH turnover rate differs throughout the day and the mechanism of this 
biological rhythm is still unknown. However, it is hypothesised that circulating 
epinephrine may have an influence on circadian rhythm108.  The rate of AH turnover 
is estimated to be between 1-1.5% of the anterior chamber volume per minute, 
which is 2.4 ± 0.6µL/min in adults on average109.  
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1.4 The Trabecular Meshwork  
1.4.1 Trabecular Meshwork and Aqueous Humour Outflow 
The trabecular meshwork (TM) and Schlemm’s canal (SC) comprise the 
drainage tissues of the anterior chamber of the human eye85. Aqueous humour 
exits the eye via two outflow pathways, the conventional pathway and non-
conventional pathway. The physiology of these two outflow pathways differ in 
several important aspects.  
  Unlike the conventional outflow pathway, the non-conventional pathway, 
or, the uveoscleral pathway, is relatively independent of intraocular pressure 
(IOP)110. AH secreted by the ciliary processes enters the ciliary muscle and exits the 
eye via the supraciliary space and across the anterior and posterior sclera via canals 
around the vortex veins or into choroidal vessels111. In the ageing population, 
uveoscleral outflow decreases112 leading to compensation by the conventional 
outflow pathway in order to maintain IOP. 
 The conventional outflow pathway consists of the TM and Schlemm’s canal. 
The TM is a filter made up of extracellular matrix (ECM) derived beams ensconced 
by TM cells, (see 1.4.2 below). Fluid movement takes place down a pressure 
gradient from the TM to Schlemm’s canal which has a passive-pressure dependent 
mechanism such as giant vacuoles and pores. The organisation of trabecular beams 
and presence of SC pores all influence AH outflow. Pore sizes range from 0.1-3µM 
in diameter and their presence can be influenced by changes in the IOP.  
 After exiting Schlemm’s canal, AH enters aqueous veins and subsequently 
mixes with circulating blood in the episcleral veins. The pressure within the 
episcleral veins, combined with resistance of the conventional AH drainage 
pathway, results in an average IOP in humans of 15.5 ± 2.6mmHg for the general 
population85. 
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1.4.2 Anatomical Structure and Function 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6: Cross Section of the Human Eye. AH is produced by the ciliary 
body, namely the non-pigmented ciliary epithelium. The ciliary body is 
indicated in the top right of the cross sectional image. Modified from online 
resource113. 
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Figure 1.7: Anatomical Structure of the Human Trabecular Meshwork. (A) A build -
up of AH produced by the ciliary body is transported across the TM following the 
route (arrow) indicated. (B) Structurally the TM is comprised of a number of layers 
surrounded by elastic fibres (EL) necessary for contractility. The AH first flows 
through the TM before reaching the inner wall (IW) of Schlemm’s canal (SC) and 
exiting via the surrounding circulatory system. Modified from Overby et al114. 
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The TM is located within the iridocorneal angle, where the iris and cornea 
meet, and the sclera transitions in to the cornea. The TM is anatomically a miniscule 
triangular tissue of approximately 350 X 50-150µm in cross section115. Structurally 
the TM comprises of layers made up of connecting fenestrated beams and sheets of 
ECM overlaid by trabecular cells116. TM beams, or lamellae, contain a central core 
composed of collagens and elastic fibres embedded in hyaluronan and 
proteoglycans117. Elastic fibres contained within the lamellae core differ in both 
structure and composition to other fibres found throughout the body, and, have 
therefore, previously been termed “elastic-like” fibres118. TM cells located on these 
beams have a robust basement membrane, and long cellular projections quite often 
traverse adjacent beams119. Although relatively basic in structure, variation in the 
orientation of the lamellae has led to the description of distinct regions of the TM. 
The three distinct differentiated layers of the TM include; the uveal meshwork, the 
corneoscleral meshwork and the juxtacanalicular meshwork (JCT; also known as the 
cribriform meshwork)120. Previous studies, using electron microscopy, have 
revealed that the arrangement of the trabecular lamellae and intra-trabecular 
spaces noticeably change from the inner to the outer-most sections of the TM121.  
The inner-most layer, the uveal meshwork, is fixed to connective tissue 
located in front of the ciliary body and to the iris root and is continuous posteriorly 
to the uvea. The uveal meshwork is the furthest from the JCT region and thus is the 
first layer to come in to contact with AH. The uveal portion is approximately three 
layers of interconnecting lamellae covered by flat confluent TM cells which form 
large irregular intra-trabecular fenestrations115. TM beam cells are aggressively 
phagocytic and are thought to act as a pre-filter to remove debris from the 
AH119,122. The elastic fibre net of the uveal meshwork is continuous posteriorly with 
some fibres embedded in the connective tissue between the ciliary muscle tips in 
front of the circular muscle portion123. The irregular arrangement of intra-
trabecular spaces allows for the relatively unrestricted movement of AH to the 
deeper layers of the TM.  
  The corneoscleral meshwork is contiguous with the uveal meshwork and 
completes the lamellated portion of the TM. The corneoscleral meshwork is the 
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most extensive part of the TM consisting of approximately 8-15 lamellae layers124. 
The corneoscleral meshwork is characterised by the presence of lamellae, 
previously seen in the uveal portion, ensconced by TM cells attached to a basement 
membrane (BM). Unlike the uveal portion however the lamellae and intra-
trabecular spaces are much more highly organised. Intra-trabecular spaces also 
narrow the closer they get to the JCT region resulting in an increased resistance to 
AH outflow not previously observed.  
 The third and smallest region of the TM, the JCT, is the deepest area 
anatomically located adjacent to the inner wall endothelium of SC extending from 
the last trabecular beam120. Typically 2-15µm thick, the JCT has many large, empty 
spaces and is considered to be more porous than most other connective tissues125. 
Unlike the uveal and corneoscleral meshwork, the JCT is not arranged into lamellae 
structures. Conversely the JCT is comprised of  loosely arranged ECM to which TM 
cells are sparsely embedded125. The ECM in which the JCT cells are embedded is 
highly hydrated and provides a channel for AH to traverse the JCT to exit the eye via 
Schlemm’s canal126.  The ECM components include collagen types, I, III, IV, V, and VI 
but not type II, elastin, laminin-γ1, fibronectin and glycosaminoglycans126–128. It is 
generally agreed that the inner wall region formed by the JCT and endothelium of 
SC is the site of trabecular outflow resistance however exact location is still 
debated129. The SC inner endothelium has one of the highest conductivities in the 
body, comparable only with that of the fenestrated endothelia130. 
1.4.3 The Trabecular Meshwork and Intraocular Pressure 
Intraocular pressure is generated within the TM outflow pathways by 
providing resistance to aqueous humour outflow. IOP builds in response to reduced 
outflow facilities until it is high enough to drive AH across the TM into Schlemm’s 
canal. In a healthy eye, IOP is a strict balance between aqueous formation by the 
ciliary body and outflow resistance131. In ageing, and various forms of POAG, the 
resistance to outflow increases leading to elevated IOP.  
IOP homeostasis has been defined as “corrective adjustments of the AH 
outflow resistance, which occur in direct response to sustained pressure 
24 
 
changes”122. This definition is primarily based on evidence from perfused human 
anterior segment organ culture or perfused ex-vivo eyes. In disease states, such as 
POAG, mechanisms through which IOP homeostasis is interrupted have not been 
fully elucidated. However, it has been hypothesised, that elevated IOP forces 
produce mechanical stretching on the JCT and SC inner wall in the TM resulting in 
distortion of the extracellular matrix (ECM) since much of the resistance is 
putatively provided by the ECM itself122,119. Distortion and changes to the ECM can 
be sensed by TM cells which could possibly lead to activation of specific signalling 
pathways triggering key gene expression changes, including, but not limited to, 
specific ECM turnover components129.  
Increasing age is associated with several naturally occurring physiological 
changes to the eye and its associated blood supply- changes like these may 
promote the pathogenesis of POAG. The trabecular meshwork is the key route of 
aqueous humour outflow in the eye. AH outflow pathways show a natural decrease 
in outflow with age and it has been postulated that this is due to both the loss of 
TM cells and the accumulation of extracellular plaque-like deposits within the 
meshwork132. Furthermore, there is an increased amount of fibronectin133, 
progressive formation of collagen aggregates134, decreased levels of hyaluronic 
acid135, and accumulation of chondroitin sulphates134,135. In the endothelial cells of 
Schlemm’s canal there is also a reduction of intracellular pores and giant 
vacuoles136. These age-related changes in the TM and SC can cause a decrease in AH 
outflow which may be attributed to observed age related elevated intraocular 
pressure noted in numerous population-based studies82,137–140.  
 The cell bodies of the retinal ganglion cells make up the inner most layer of 
the retina. They receive input from the photoreceptors via bipolar and amacrine 
cells. Unmyelinated axons of the RGCs exit the eye via the optic nerve head which is 
supported by the lamina cribrosa (LC). Glial cells provide structural support for 
retinal ganglion cells as well as functional support including metabolism, regulation 
of extracellular environment and the phagocytosis of neuronal debris141. Microglia 
function to protect neurons from destructive inflammatory cytokines142. Viability 
and regenerative capacity of the microglial cells of the central nervous system are 
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negatively affected by ageing143. Similar age dependent attrition may be seen in the 
glial cells of the retina and optic nerve and it is possible that these changes may 
adversely affect their neuro-supportive and neuro-protective functions. With 
ageing there is a decrease in the amount of RGCs144 and optic nerve fibres as well as 
decreasing thickness of the retinal nerve fibre layer145. 
 The lamina cribrosa (LC) is a fibrous network encapsulated by astrocytes 
which supports the ONH. Astrocytes are the main cell types of the ONH and are 
essential for RGCs health146. The main function of astrocytes is ECM remodelling 
and removal of waste products147. Upon ageing, the LC has been observed to 
increase in thickness148 and becomes increasingly collagenous149. These structural 
changes result in increased stiffness and decreased resilience making older 
populations more susceptible to axonal damage150. The retina and optic nerve of 
donor eyes have been demonstrated to show an increased accumulation of 
advanced glycation end (AGE) products151. Accrual of AGEs may contribute to 
biomechanical changes of the LC and may also promote intracellular changes in the 
RGCs and glial cells that encourage impaired function and apoptosis152.  
 
1.4.4 Extracellular Matrix in the Trabecular Meshwork 
A wide range of ECM components have been identified within the TM which 
have different functional roles depending on their location in the TM153. Collagens, 
elastic fibre components, proteoglycans, glycosaminoglycans (GAGs), fibronectin 
and matricellular proteins have all been found at different levels throughout all 
layers of the TM154–156. Although majority of these are similar to components 
identified in other tissues, apparent unique isoforms have also been identified157. 
Matrix and contractile genes have been shown to be highly expressed in the JCT 
cells in comparison to inner wall cells of Schlemm’s canal158.  
Extracellular matrix turnover is a highly co-ordinated process consisting of 
ECM production, remodelling and degradation. Numerous stimuli that affect 
outflow facility change the activity of matrix metalloproteinases (MMPs), which are 
known to be responsible for the majority of ECM turnover. These MMP-inducing 
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stimuli include tumour necrosis factor alpha (TNF-α), dexamethasone (DEX), 
elevated IOP and mechanical stress159. MMP activity triggers changes in ECM 
protein expression levels and the replacement ECM is slightly different in 
composition and/or amount each time in order to maintain outflow facilities116,122. 
The extracellular matrix of the TM is a source of latent growth factors and 
small regulatory molecules; the activity of which needs to be tightly regulated159,160. 
Maintenance remodelling by MMPs may aid in removal of bound molecules to 
prevent saturation of the ECM. When the ECM becomes saturated, for example in 
response to elevated IOP, these regulatory molecules gain access to outflow 
channels and modify resistance accordingly. The ECM of the TM provides a 
microenvironment with distinctive properties necessary for normal biological 
function. In comparison to other adult tissues throughout the body, TM cells 
express high levels of MMP-2, tenascin C, and α-smooth muscle actin, typically 
associated with tissues undergoing remodelling during development or disease116. 
Elevated expression of these molecules in the TM suggests that TM cells may have 
evolved transient remodelling processes as a normal function in order to maintain 
outflow facilities120. 
1.5 Role of Known Glaucoma Stimuli Resulting in Raised IOP 
Glaucoma is a complex disease with specific endophenotypes, and disease 
pathogenesis is likely to involve multiple pathways linking interactions between 
genetics and environmental interactions161,162. In addition, there are several known 
glaucoma stimuli that exert their effects by a combination of over-lapping and 
distinct pathophysiological processes. The most well characterised stimuli resulting 
in raised IOP and glaucoma are corticosteroids and transforming growth factor beta 
(TGF-β)162–164. 
1.5.1 Corticosteroids  
Corticosteroids are subdivided into glucocorticoids and 
mineralocorticoids165. Glucocorticoids (GC) are synthesised by the adrenal cortex in 
humans and secreted into blood plasma where levels fluctuate according to 
circadian rhythm166. The naturally occurring glucocorticoid in humans is 
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hydrocortisone synthesised in the adrenal cortex from its precursor cortisone. 
Beneficial effects of glucocorticoids in inflammatory disorders have been described 
since the early 1950s, and since then a number of synthetic glucocorticoids have 
been developed167,168.  
1.5.1.1 Glucocorticoid Mechanism of Action 
Despite the identification of GCs some years ago, the exact mechanism of 
action is still not fully understood. GCs exert both genomic and non-genomic 
functions169. At the cellular level every individual GC functions through the same 
receptor mechanism170. GC receptors are present on all cell types except anuclear 
cells171. Activation of the GC receptor is brought about by binding of naturally 
occurring or synthetic GCs, known as ligands, and results in a change in the 
regulation of gene expression. The GC receptor gene is composed of nine exons and 
alternative splicing results in four isoforms, glucocorticoid receptor (GR)-α, GR-β, 
GR-δ, and GR-γ172.  
 
Figure 1.8: Structure and Transcriptional Isoforms of the Human GR Gene. 
Modified from Vega et al 2006173. (A) 9 different exons comprise the human GR 
gene. (B) Different isoforms are generated by alternative splicing; GR-α and GR-β 
represent the major isoforms. 
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GR-α is the only fully active isoform, while GR-β, GR-δ, and GR-γ retain 
structural similarities for the active receptor (Figure 1.9)173. GR-β is shorter than the 
active α isoform by 35 amino acids and lacks a ligand binding domain, but retains its 
DNA binding domain; allowing it to competitively bind DNA and negatively regulate 
the actions of GR-α174. Furthermore, Gr-β can bind to GR-α and form a non-active 
heterodimer, additionally inhibiting GR-α activity. Gr-β also has a half-life two times 
longer than that of GR-α, and given its antagonist role, GR-β can inhibit signalling of 
GR-α and cause secondary resistance to glucocorticoids175.  
The wide range of actions of glucocorticoids has been attributed to the 
cellular distribution of their receptors; glucocorticoid receptors (GRs) are found in 
the cytoplasm, nucleus, and cell membranes (Figure 1.9). GRs can be cytoplasmic, 
or membrane bound on the cell surface, or present as homo/hetero-dimers in the 
nucleus176,177. Cytoplasmic GR are monomers until a GC ligand is bound wherein 
ligand-binding induces the formation of GR homodimer178, and translocation to the 
nucleus via microtubules179. GRs remain within the nucleus as dimers and exert 
positive or negative effects on gene expression. This is the proposed mechanism of 
action for genomic roles of GCs180. Membrane bound GRs initiate rapid changes in 
various signalling pathways when ligands bind and perform a non-genomic role177.  
As a homodimer, GRs can bind to DNA-regulatory glucocorticoid response 
elements (GREs) in the nucleus. GREs are found within the promoter region of 
glucocorticoid regulated genes170. Positive GREs lead to gene expression activation, 
whereas negative GREs result in suppression of gene expression181. GR binding to 
DNA initiates the recruitment of co-activator CRB proteins (CREB binding proteins), 
and steroid receptor co-activator 1 (SRC-1)182. Co-activators use inner histone 
deacetylases to weaken DNA strands and facilitate RNA Polymerase II and TATA 
box-binding protein actions to begin transcription183.  
In addition, GC-GR monomers within the cytoplasm can inhibit gene 
expression without the need to bind DNA, this is termed ‘indirect trans-
repression’184. GC-GR monomers interact with numerous proteins in the cytoplasm, 
including signalling pathway kinases and transcription factors185. GCs can inhibit 
transcription factors such as nuclear factor kappa B (NFκB)186. NFκB activates the 
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expression of genes involved in inflammation, and cellular processes such as 
proliferation. NFκB protein-protein interaction with GC-GR complex inhibits 
regulatory gene expression functions186.   
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  Figure 1.9: Glucocorticoid Mechanisms of Action. GCs exert their effects via membrane bound, cytoplasmic, and nuclear GC 
receptors. Effects may be non-genomic or genomic depending on the activation of specific receptors. GREs within the promoter 
region of steroid-regulated genes allow binding of GC-GR dimer complexes to initiate gene expression regulation. Cytoplasmic 
monomers inhibit gene expression via protein-protein interactions. Modified from online resource Tulane University861. 
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1.5.1.2 Corticosteroids Effect in the Eye 
Synthetic glucocorticoids are of great interest in ophthalmology due to their 
ability to decrease inflammation and preserve ocular function187. The actions of 
corticosteroids on ocular tissues has been widely studied188. Cortisone was seen to 
inhibit the formation of fibrotic material, reduce cellular infiltration, fibroblastic 
repair and endothelial regeneration in corneal wounds189. In addition, high doses of 
cortisone were able to prevent wound healing entirely190.  Apart from their effects 
in reducing wound scarring, the major use for corticosteroids is for their anti-
inflammatory traits. Early studies identified that cortisone reduced permeability of 
ocular capillaries during inflammation, and withdrawal of treatment saw capillary 
recovery191.  
Despite their benefits in wound healing and inflammation, corticosteroids 
mode of action, and in turn, complications, are largely dependent on dose and 
duration192. Relatively high doses of corticosteroids can result in adverse systemic 
side effects193. Several ocular diseases require steroids daily in order to maintain 
the condition. Interestingly, ocular side effects are seen irrespective of whether the 
steroid is taken for systemic or ocular disease194. Corticosteroid ocular side effects 
include cataract, enhanced infection and glaucoma192.  
1.5.1.3 Corticosteroid-Induced Glaucoma 
Elevated IOP is one of the major risk factors for developing glaucoma, and 
ocular hypertension (OHT) due to secondary factors, can convert to glaucoma. IOP 
elevation can occur as an adverse side effect of corticosteroid therapy. GC therapies 
reduce phagocytic capabilities of the TM195, resulting in a build-up of ECM debris 
which can block and reduce outflow facilities in the drainage angle196. Reduced 
outflow facility results in elevated IOP. If the effect of OHT is of sufficient 
magnitude, for a significant amount of time, damage to the ONH may arise resulting 
in steroid-induced glaucoma. Clinical use of corticosteroids was first described in 
the 1950’s and shortly thereafter the phenomenon of corticosteroid induced 
elevated IOP was first described in literature197,198. Adrenocorticotrophic hormone 
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(ACTH) and cortisone when administered systemically and locally induced elevated 
IOP199.  
The corticosteroid-IOP response is not limited to a specific method of 
steroid administration but has been shown to be most commonly associated with 
topical administration of drugs such as dexamethasone and prednisolone. The 
ocular hypertensive response observed in patients is however relative to the 
intraocular potency of the steroid administered200. Differences have been reported 
in the level of steroid response, in known high steroid responders, to different 
steroid preparations. The mode of therapy is important when one considers 
corticosteroid use in individuals with pre-existing risk factors (discussed below), to 
developing secondary glaucoma. Previous studies have identified that patients 
treated topically with corticosteroids exhibited an IOP response within several 
weeks in comparison to several months when treated systemically201,202. 
 Risk factors for developing secondary glaucoma include; markedly elevated 
IOP in response to corticosteroids and familial history of glaucoma and systemic 
diseases such as arthritis. 30% of the general population are steroid responders, 
and this increases to 46-92% in a cohort with primary open angle glaucoma (POAG) 
203. Familial history of diseases such as POAG, diabetes mellitus, high myopia, and 
connective tissue diseases such as rheumatoid arthritis have also been identified as 
a risk factor for IOP alterations in response to corticosteroids than in other 
populations199.  
1.5.1.4 Corticosteroid-Induced Glaucoma Pathophysiology 
 The main pathophysiological response to corticosteroid-induced IOP is 
increased resistance to AH outflow. The trabecular meshwork undergoes structural 
changes in response to corticosteroids supporting the theory that corticosteroids 
increase outflow resistance. TM cells express GRs, and in response to receptor 
activation, the TM cellular morphology changes with an increased nuclear size and 
DNA content. The microstructure of the TM is also altered in response to steroids.  
Extracellular matrix deposition and turnover is dysregulated in glaucoma. Steroid-
responsive patients have shown an excessive ECM deposition within the TM and 
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GAGs, fibronectin, and elastin were all found to be deposited at higher rates in 
response to dexamethasone treatment204. Excessive ECM obstructs intercellular 
space within the TM causing decreased outflow facility. Furthermore, prolonged 
steroid exposure elicited a further increase in GAG deposition and it has been 
proposed that corticosteroids stabilise lysosomal membranes, exacerbating GAG 
deposition by decreasing the availability of catabolic enzymes. Additionally, 
indigestible GAGs, when hydrated, can cause oedema and subsequently a 
narrowing of trabecular spaces. The effects of corticosteroids on the aqueous 
outflow pathway have been investigated using cellular, animal and perfusion 
models205,206. Human anterior segments perfused with DEX (10-7 mol/L) in organ 
culture for 12 days not only showed an increase in IOP but also an increase in 
amorphogranular and fibrillar material in the ECM spaces within the JCT207. 
Cultured human TM cells also showed decreased phagocytic activity208,209 and 
increased ECM protein expression in response to DEX (100nM) after 24 hours or 
long-term respectively210. 
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1.5.2 Transforming Growth Factor Beta (TGF-β) 
The transforming growth factor beta (TGF-β) superfamily belongs to the 
cytokine family that have crucial roles in tissue development and differentiation in 
vertebrates, as well as control of immunological responses and tissue healing211. 
The TGF-β superfamily is a large group of regulatory polypeptides including the 
potent TGF-β family and other families such as bone morphogenic proteins (BMPs), 
growth and differentiation factors (GDFs), activins (ACTs), inhibins (INHs), and glial-
derived neurotrophic factors (GDNFs), as well as nodal growth differentiation factor 
(Nodal), and left-right determination factor (LEFTY)211. The TGF-β superfamily is 
characterised by its pleiotropic and redundant effects212. TGF-β members act in an 
autocrinic, paracrinic, and endocrinic manner212. 
TGF-βs are synthesized as precursor proteins, which are biologically inactive. 
They consist of pre–pro-peptides, which require a 2-step process to give rise to 
active TGF-βs (for review see Matthews et al 1991)213. A first proteolytic cleavage 
leads to the elimination of a hydrophobic signal peptide, in the N-terminal region of 
the precursor protein, yielding pro–TGF-β214. A second cleavage leads to the 
separation of the pro-region of the protein from the TGF-β mature peptide (Figure 
1.10)215. The bioactive forms of TGF-βs are composed of 2 mature peptide chains 
linked by di-sulfide bonds. TGF-βs are usually produced as homodimers, but natural 
heterodimeric molecules have also been identified216. 
 Once synthesized and processed, TGF-βs are released by cells as latent 
complexes, which are biologically inactive217. Two forms of latent complexes have 
been described: the “small” and “large” latent complexes (Figure 1.10)215. In the 
small latent complex, one molecule of mature, active TGF-β is non-covalently 
associated with latency-associated protein (LAP)218. In the large latent complex, LAP 
is linked by di-sulfide bonds to one member of the latent TGF-β–binding proteins 
(LTBPs)219. LTBPs induce association of the complex with the extracellular matrix, 
permitting the storage of TGF-β (for review see Taipale and Keski-Oja, 1998220). A 
number of LTBPs isoforms exist, therefore, the bioavailability of TGF-β and its 
specific targeting to different organs can be regulated, in part, by the formation of 
large latent complexes with different LTBP isoforms221. The release of latent TGF-β 
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from the extracellular matrix is triggered by proteolytic enzymes such as plasmin, 
which are able to cleave LTBPs222. Plasmin cleaves the non-covalent bonds within 
the N-terminal of LAP resulting in the release of active TGF-β223. Thrombospondin 
(TSP), an extracellular matrix protein, also promotes the activation of TGF-β224. In 
contrast to what has been described for plasmin, TSP-mediated activation of latent 
TGF-β occurs through a cell- and protease-independent mechanism225. TSP induces 
a conformational change of LAP, which then results in the release of active TGF-
β226. 
Multiple receptors interact with TGF-βs227,228. TGF-β receptor 1 (TGF-βR1) 
and TGF-βR2 are directly involved in signal transduction211. TGF-βR1 and TGF-βR2 
are serine/threonine kinases that interact to form heterotetrameric complexes211. 
TGF-β ligands first bind TGF-βR2. TGF-βR1 is then recruited to the complex and 
phosphorylated by TGF-βR2 which propagates the TGF-β intracellular signalling 
cascade229.   
SMAD proteins are intracellular substrates of TGF-β signalling230. Three 
groups of SMADs exist: receptor-mediated SMADs (rSMADs) which are directly 
phosphorylated by TGF-βR1; common partner SMADs (co-SMADs), which interact 
directly with phosphorylated rSMADs to form heterodimeric complexes231. These 
are then translocated to the nucleus where they interact with DNA binding 
elements that can regulate gene expression232. Finally, inhibitory SMADs prevent 
interaction between rSMADs and co-SMADs thereby acting as a negative feedback 
to repress TGF-β signalling233.  
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Figure 1.10: TGF-β Structure, Latency, Activation, and Signalling. Modified from Fortunel et al 2000215. 
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1.5.2.1 TGF-β-Induced Glaucoma Pathophysiology  
Primary open angle glaucoma is the most common form of glaucoma21. 
Several prospective studies have identified IOP as the most critical risk factor for 
developing POAG45,46. TGF-β2 is the predominant isoform in the eye and is found in 
elevated concentrations in the AH of POAG patients234. Expression of TGF-β2 in the 
trabecular meshwork and optic nerve head of normal eyes235, and its increased 
expression in POAG eyes has been reported236. Increased expression of TGF-β2 
appears to be a characteristic phenomenon in eyes with POAG237. Cultured 
trabecular meshwork cells secrete both TGF-β1 and TGF-β2, and express TGF-β 
receptors238,239, indicating its function in the AH outflow pathway. Furthermore, it is 
reasonable to assume that the TM is under the influence of TGF-β2 present in the 
AH that bathes the anterior segment.  
1.5.2.1.1 TGF-β and Extracellular Matrix  
Disruption of ECM secretion and turnover is central to the pathophysiology 
of glaucoma240. TGF-β signalling has been implicated in multiple disorders 
throughout the body as a mediator of the pathological increase in ECM secretion 
and deposition and negatively involved in fibrosis241. Numerous in-vitro studies 
indicate that elevated TGF-β levels in POAG are involved in ECM deposition within 
the TM237,242–244. In-vitro studies of TM cells stimulated with TGF-β2 have increased 
expression of ECM-related proteins including: collagens (Type I, III, IV, and VI), 
laminin, elastin, cochlin, fibronectin, and thrombospondin-1237,242–244. Connective 
tissue growth factor (CTGF), a downstream mediator of TGF-β2 activities, is also 
elevated in response to TGF-β2, and is believed to mediate fibronectin 
synthesis237,242–244. TGF-β2 not only exerts its effects on ECM synthesis but also 
decreases the expression of key matrix metallopeptidases required for ECM 
degradation243. Decreased ECM degradation within the TM leads to a pathological 
accumulation resulting in elevated IOP and eventually glaucoma. TGF-β2 induces 
the expression of plasminogen activator inhibitor-1 (PAI-1), a potent inhibitor of 
matrix metallopeptidases (MMPs) 243. Additionally, PAI-1 levels are also elevated in 
the AH of POAG patients243.  
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1.5.2.1.2 TGF-β and the Trabecular Meshwork Cytoskeleton  
Increased stiffness of the trabecular meshwork has been observed in POAG 
patients245. Increased stiffness reduces intercellular spaces thus reducing the 
outflow capacity of the TM246. TGF-β2 enhances TM stiffness via the activation of 
tissue transglutaminase247. Tissue transglutaminase is found in normal eyes and 
expression is increased in POAG eyes248. TGF-β2 enhances cross-linking of 
fibronectin via tissue transglutaminase in the TM, increasing overall TM stiffness247. 
Lysyl oxidase (LOX) family members have also been localised to the TM and are 
influenced by TGF-β1-3249. LOX family members crosslink ECM components such as 
elastin and collagens which are present in the TM249.  
The normal TM is more labile than the TM of POAG patients, thus outflow 
facilities function well. Increased contractility of TM cells prevents substantial AH 
outflow250. In general, TGF-β is a potent enhancer of myofibroblast contractile 
phenotypes via increased expression of alpha smooth muscle actin (α-SMA) in actin 
stress fibres251. Trabecular meshwork cells in culture treated with TGF-β2 have 
increased expression of α-SMA252. However, it is yet to be shown that increasing 
TGF-β2 levels in POAG is directly correlated to increased expression of α-SMA.  
The cellular architecture of TM cells is altered in POAG patients and in 
response to TGF-β2253,254. TM cells of POAG patients have cross-linked actin 
networks (CLANs)253. CLANs are more commonly associated with glucocorticoid-
treated and glaucomatous cultured TM cells255–257. Recently, however, studies have 
shown CLANs can also be induced by TGF-β254. 
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1.6 The microRNA 
 Non-coding RNAs (ncRNA) is a term that encompasses RNAs that do not 
code for protein such as transfer RNA (tRNA), ribosomal RNA (rRNA), small 
nucleolar RNA (snoRNA), long non-coding RNA (lncRNA), and micro RNA (miRNA). 
Individual RNAs have specific functions258. tRNA is responsible for the transfer of 
amino acids to the ribosome during translation where it then interacts with rRNA 
which catalyses peptide bond formation for each amino acid required for the 
polypeptide being synthesised259. In order to become functional, both tRNAs and 
rRNAs need to undergo modifications such as methylation or pseudoridylation 
which is facilitated by snoRNAs259. Small RNAs were first discovered in 1993 with 
identification of lin-4 during genetic screening of nematodes260. Further research in 
the same year lead to the discovery that lin-14 could be regulated by lin-4 
demonstrating the regulatory abilities of small RNAs for the first time261. Presently, 
the shorter lin-4 RNA is now recognised as the origin of a class of small regulatory 
RNAs also known as micro RNAs (miRNAs)262. With the advent of high-throughput 
sequencing techniques and enhanced bioinformatics hundreds of different miRNAs 
have been identified and their regulatory targets and potential function continually 
elucidated263,264. A number of miRNAs have been identified as central to diverse 
processes such as cell death, cell proliferation, metabolism, neuronal patterning 
and hematopoietic differentiation265–271. Developments in the miRNA field are 
ongoing and increasing at a steady rate; this is  evident by the increasing number of 
studies implicating miRNAs in disease states such as Alzheimer’s disease, diabetes 
and cancer272–281. Technological advancements in RNA-based therapies aid the 
progression in miRNA research and have shown a movement towards investigating 
the potential of miRNAs as a therapy262. 
1.6.1 microRNA Biosynthesis- The Canonical Story 
 The biogenesis of miRNAs is under strict temporal and spatial control and 
their dysregulation is associated with many human diseases282. miRNAs regulate the 
expression of genes encoded for by mRNAs283. Targeting most protein-coding 
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transcripts, miRNAs are involved in nearly all developmental and pathological 
processes in animals283.  
 It has been predicted that miRNAs make up 1-5% of the human genome and 
regulate approximately 30% of protein coding genes284,285. miRNAs make up a large 
family of small, evolutionary conserved, non-coding RNAs between 21-25 
nucleotides in length286. miRNAs are single stranded RNAs, which are derived from 
double-stranded RNA hairpin precursors287,288. miRNA precursors are commonly 
found in clusters throughout different regions of the genome, with a preference for 
intergenic regions and introns of protein-coding genes289. miRNAs are less 
commonly found in exons of transcripts and in antisense transcripts282. Frequently, 
several miRNA loci are located within close-proximity to each other which results in 
a polycistronic transcription unit290. miRNAs found within the same cluster are 
normally co-transcribed however individual miRNAs can undergo modifications at a 
post-transcriptional level291,292. 
  RNA polymerase III (POL-III) was initially thought to mediate miRNA 
transcription due to its role in tRNA and U6 snRNA transcription293. Research efforts 
have identified a caveat in this theory; primary miRNAS (pri-miRNAs) can 
sometimes be over several kilobases in length and contain stretches of more than 
four U bases; these stretches would result in the termination of POL III activity293. 
This evidence suggests an alternative method of miRNA transcription which is now 
known to be driven by RNA polymerase II (POL-II)294. The precise location of miRNA 
promoters have not yet been elucidated, however, from RNA sequencing data, 
ChIP-seq (chromatin immunoprecipitation followed by sequencing), and CpG island 
analyses it can be inferred that some miRNAs share the promoter of the host genes 
from which miRNAs reside within the introns295. It has also been noted that miRNAs 
can have multiple start sites of transcription and that their promoters may be 
distinct from host gene promoters296.  
 1.6.1.1 Nuclear Events in microRNA Biosynthesis  
Mammalian miRNAs can be classified into two broad categories, canonical 
and non-canonical, based on how the pri-miRNA is processed to form the mature 
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miRNA. Canonical mature miRNAs are generated by a two-step cleavage process of 
primary miRNA (pri-miRNA)293,297 (Figure 1.11 298). pri-miRNA processing is a critical 
event in miRNA biogenesis299. pri-miRNAs are larger than mature miRNA (~1kb) and 
may contain 5’ and 3’ modifications identical to those present in mRNAs or pre-
mRNAs300. pri-miRNAs contain a stem-loop structure from which the mature miRNA 
sequence is derived301.  
Only pri-miRNAs which contain the appropriate stem length, a large flexible 
terminal loop of approximately 10 base pairs (bp) and the capability to produce 5’ 
and 3’ single-stranded RNA overhangs will be efficiently processed and mature to 
functional miRNA302. The nuclear processing step of pri-miRNAs to stem-loop 
precursors of ~70 nucleotides (nt) in length is initiated by a core nuclease, RNase 
III, human Drosha299. Drosha forms part of a protein complex termed the 
microprocessor complex which also contains an essential RNA binding protein 
DiGeorge syndrome critical region 8 (DGCR8)299. DGCR8 identifies pri-miRNA 
sequences and induces cleaving via Drosha to form a pre-miRNA303. The exact 
mechanism through which DCGR8 recognises pri-miRNA sequences is unknown. It is 
clear however from bio-informatic analyses that no sequence is universally 
conserved among human pri-miRNAs304, it is therefore assumed that processing 
proteins, such as DCGR8, have to recognise the structural features of pri-miRNAs305. 
Unique cross-regulation between Drosha and DGCR8, which is essential for the 
control of miRNA biogenesis, has been previously described306. DGCR8 stabilises 
Drosha via protein-protein interactions and assists in controlling Drosha protein 
levels306. Meanwhile, Drosha negatively regulates DGCR8 mRNA post-
transcriptionally by cleavage of a hairpin like structure in the 5’ untranslated region 
(UTR) leading to destabilisation of the transcript307. Germline deficiency of Drosha 
causes lethality in embryogenesis, highlighting the importance of miRNAs in 
development308.  
Precise identification of the pri-miRNA is essential for Drosha-mediated 
cleavage of miRNA termini301. During the pri-miRNA processing event the ‘basal’ 
junction acts as the major reference point in determining the cleavage site, the 
‘apical’ junction itself is essential for efficient processing309.  Alternative factors, 
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independent of Drosha and DGCR8, are involved in the processing of pri-miRNAs310. 
These elements reside within the ‘basal’ region (UG motif and the CNNC motif) and 
terminal ‘apical’ loop (UGUG motif) of human pri-miRNAs311. SRp20, a splicing 
factor, binds the CNNC motif and increases processing of human pri-miRNAs310. 
Intronic miRNA processing by Drosha does not affect the processing of host 
genes pre-mRNA as cleavage of pri-miRNA is thought to occur co-transcriptionally 
prior to splicing catalysis312. miRNAs encoded by exonic regions destabilise  the host 
mRNA313. Drosha antagonises follistatin-like 1 (FSTL1) expression through cleavage 
of miR-198 hairpin structure located within the 3’UTR of the FSTL1 mRNA. KSRP 
(KH-type splicing regulatory protein) binds to the terminal loop of miR-198 and 
facilitates cleavage307,314. Upon injury, TGF-β signalling represses KSRP resulting in 
the upregulation of FSTL1307,314.  
Nuclear Events- Regulation of the Microprocessor Complex 
 Drosha mediated processing is essential in establishing miRNAs315. Many 
mechanisms exist that control expression level, activity and specificity of Drosha 
(1.6.1.1). This cross regulation enables homeostasis of the microprocessor activity 
and is highly conserved in animals309. Post-translational modifications of Drosha can 
also affect the processing activity of the microprocessor316,317. Acetylation of Drosha 
by unknown enzymes can inhibit its degradation and increase stability317. 
Phosphorylation of DGCR8 by ERK can increase stability of the protein318. As well as 
this, deacetylation of DGCR8 by histone deacetylase 1 (HDAC1) can increase DGCR8 
affinity for pri-miRNAs316,317. 
 Specific control of Drosha mediated processing is mediated by RNA-binding 
proteins that can selectively interact with Drosha and/or certain pri-miRNAs300. R-
SMAD proteins, SMAD1-3 and SMAD5 promote microprocessor activity via 
interactions with p68319. For example, when R-SMAD proteins are activated by TGF-
β, they interact with p68 and the stem of pri-miRNAs to stimulate Drosha-mediated 
processing of miR21 and miR-199a320,321. 
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1.6.1.2 Nuclear Export  
 Following Drosha processing, pre-miRNAs are transported to the cytoplasm 
of the cell for further processing to produce mature miRNAs262. Exportin 5 (EXP5) 
exports pre-miRNAs322. EXP5 forms a complex with guanosine triphosphate (GTP)–
binding nuclear protein RAN, GTP/RAN, and the pre-miRNA323. The GTP/RAN, pre-
miRNA complex is translocated through a nuclear pore to the cytoplasm where GTP 
undergoes hydrolysis and is replaced by guanosine diphosphate (GDP)323.  
Hydrolysis of GTP results in the disassembly of the transport complex and the 
release of the pre-miRNA in to the cytosol324. EXP5/GDP/RAN complex provides 
support and protection for the pre-miRNA in the cytosol via interactions between 
the double stranded RNA (ds-RNA) stem-loop overhang at the 3’ of the pre-miRNA 
and a tunnel like structure on the export complex324.  
1.6.1.3 Cytoplasmic Processing of pre-miRNA 
Dicer-mediated Processing  
  The nuclear cleavage process by Drosha (1.6.1.1), defines one end of the 
mature miRNA. The pre-miRNA released into the cytosol is cleaved by a Pol III, 
Dicer, near the terminal loop to liberate a small RNA duplex325. Dicer is an RNase III 
endonuclease of ~200kDa. The C-terminal RNase III domains of Dicer form 
intramolecular dimers to create catalytic centres similar to those found in 
Drosha299. Dicer contains a PAZ domain which binds to pre-miRNA termini326. Dicer 
binds to pre-miRNA with a preference for the 3’ overhang generated by Drosha 
processing326.  
 Dicer Regulation 
 Dicer proteins interact with double stranded RNA binding domain proteins 
(ds-RBD). Dicer interacts with TAR-RNA binding protein (TRBP);  TRBP modulates 
efficiency of Dicer-mediated processing of certain pre-miRNAs and fine tunes the 
length of mature miRNA327. Conversely, human Dicer interactions with ds-RBDs do 
not seem to be essential for Dicer-mediated pre-miRNA processing but instead can 
act as positive or negative regulators of the process327.  Following the generation of 
the RNA duplex by Dicer, the duplex is subsequently loaded on to an Ago family 
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protein to form an effector complex termed RNA-induced Silencing Complex 
(RISC)328. RISC assembly involves two steps; the loading of the miRNA duplex and its 
subsequent unwinding309. Ago proteins are ubiquitously expressed and are 
associated with miRNAs and siRNAs329.  
 miRNA duplexes are made up of a passenger strand and a guide strand, and 
incorporation of a miRNA duplex to an AGO protein forms a pre-RISC complex309. 
The passenger strand of the duplex (termed miRNA* (miRNA star)) is discarded and 
the guide strand is incorporated to form a mature RISC330. The strand retained in 
the Ago:RNA complex is determined by the relative thermodynamic stability of the 
two ends of the duplex intermediate331. Mismatches in the guide strand promote 
unwinding of the miRNA duplexes332. The miRNA guides the RISC to its target mRNA 
resulting in silencing via degradation or repression333. 
Intrinsic Regulation of miRNA 
 Alterations in sequence and/or structure of miRNAs can alter their 
maturation and turn-over rates309. Single nucleotide polymorphisms (SNPs) have 
been identified in miRNAs and can have direct effects on their biosynthesis or alter 
their target specificity309. A ‘C’ to ‘T’ SNP in the first C of CNNC motif in pri-miR-
15a~16-1 reduces Drosha-mediated processing resulting in lower miRNA 
production310. Mature miRNA and pre-miRNA are also susceptible to intrinsic 
regulation309. RNA tailing, a process whereby untemplated nucleotidyl addition to 
the 3’ end of RNA occurs, can alter the synthesis and function of both pre-miRNA 
and mature miRNA334. Uridylation and adenylation are forms of tailing seen most 
commonly identified on miRNAs309. miRNAs can be regulated at the RNA stability 
level335. The turnover of mature miRNA has been studied extensively and several 
nucleases have been proposed to be involved in the cleavage and decay of 
miRNAs309. It is unknown how these nucleases achieve target specificity and 
whether this is conserved machinery for miRNA decay309. 
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Figure 1.11: miRNA Biosynthesis- Canonical Pathway. Modified from Heman-
Ackah et al 2013298. The canonical miRNA biogenesis pathway is Drosha/Dicer 
mediated. RNA POL II mediates transcription of genomic loci containing 
miRNA genes. Primary transcript is referred to as pri-miRNA. pri-miRNA is 
processed in the nucleus by Drosha and DGCR8 to produce pre-miRNA. 
Exportin 5 transports pre-miRNA to the cytoplasm where it is further 
processed by RNA POLIII Dicer. The mature miRNA strand complexes with AGO 
proteins to form a functional RISC complex. 
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1.6.2 Non-Canonical Biosynthesis  
 Biosynthesis of miRNAs can be achieved using various alternative methods 
which do not follow canonical biosynthesis336; these alternative mechanisms make 
up the non-canonical pathway of miRNA biosynthesis298 (Figure 1.12). Typically, 
non-canonical miRNAs are distinguished from canonical miRNAs by changes in their 
expression when a certain miRNA processing factor, such as Drosha, Dicer, or 
DGCR8, is removed337,338. Almost all miRNA species in mammals follow the 
canonical pathway for biosynthesis300. Non-canonical miRNAs account for only 1% 
of conserved miRNAs and are typically in low abundance300. The non-canonical 
pathway was first described during mirtron production339, in which, the Drosha-
mediated processing step was bypassed and instead the production of a small RNA 
was facilitated by an mRNA splicing event339. Biogenesis of miR-451 does not 
require Dicer340. Pre-miR-451 is cleaved by AGO2, bypassing Dicer341. Drosha-
mediated processing cleaves a short hairpin structure that is too small to be 
processed by Dicer hence direct loading by AGO2 to form mature miRNA342,343. 
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Figure 1.12: miRNA Biosynthesis- Non Canonical Pathway. Modified 
from  Heman-Ackah et al 2013298.  The non-canonical miRNA biogenesis 
pathway is Drosha/Dicer independent. Cytoplasmic pri-miRNA 
undergoes processing by AGO2. 
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1.6.3 microRNA Mechanism of Action 
 Individual miRNAs control the expression of one or more target mRNAs and 
each mRNA may be regulated by one or more miRNA344. Experimental evidence has 
suggested that the 5’ end of the miRNA is responsible for the specificity and activity 
in binding a target mRNA345. This 5’ region is termed the “seed” region. In animals 
the “seed” region is approximately 6-8nt in length and is highly conserved across 
species346, even slight alterations in the sequence may alter the miRNAs target 
spectre347.  
 miRNAs incorporated within the RISC complex guide RISC to specifically 
recognise target mRNAs and down regulate gene expression by one of two post-
transcriptional mechanisms: (i) translational repression or (ii) mRNA cleavage262. 
miRNAs interact with their target mRNAs by base pairing to specific sequences, 
found in the 3’ untranslated region (UTR) of mRNAs348 by perfect or near perfect 
complementarities349. Genes with longer 3’UTRs usually have higher density of 
miRNA-binding sites and are mainly involved in developmental processes whereas 
genes with shorter 3’UTRs usually have lower density of miRNA-binding sites and 
are involved in basic cellular mechanisms350.  
 The degree of miRNA-mRNA complementarity is a major determinant of the 
regulatory mechanism process be it repression or degradation351. High degree of 
complementarity enables Ago-catalysed degradation of the mRNA target sequences 
through the mRNA cleavage mechanism process351. In contrast, a central mismatch 
omits degradation of the target mRNA as an option and instead facilitates the 
translational repression mechanism351,352. 
1.6.3.1 microRNA-Mediated mRNA Decay 
 In animals, most miRNAs are only partially complimentary to their targets353. 
In this case, AGO proteins are not sufficient to mediate silencing and therefore they 
must interact with GW182 family proteins354. AGO-GW182 complexes silence mRNA 
targets by repressing translation enhancing degradation354. The mechanism through 
which this is achieved is not very well understood, although new insights in to the 
role of GW182 in these processes have emerged354,355. Initially it was believed that 
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miRNAs only repress translation of target mRNAs with little or no effect on mRNA 
abundance356; however it is now known that miRNAs can also promote 
destabilisation of target mRNAs by recruiting deadenylases onto target mRNAs via 
GW182 proteins357.  
1.6.3.2 microRNA Translational Repression  
 Numerous studies have examined the mechanisms through which miRNAs 
mediate translational repression. miRNAs inhibit the initiation step of translation 
and three major mechanisms have been proposed358: (i) GW182-mediated PABP 
displacement359, (ii) recruitment of translational repressors via GW182360 and (iii) 
dissociation of elF4A from the cap binding complex elF4F361. None of these 
mechanisms are mutually exclusive and, they may overlap, occur concurrently, or 
occur with different kinetics to augment the overall silencing effect358.  
1.6.4 miRNAs and Human Disease 
miRNAs play important roles in several physiological and pathological 
processes362. miRNAs are involved in developmental processes including 
metabolism, cell proliferation, apoptosis, and neuronal cell fate363. miRNAs have 
also been implicated in regulation of inflammatory microenvironments364 and 
fibrosis365. The identification of miRNAs involvement in human disease and 
metabolic disorders has led to research focused on the role of miRNAs as important 
regulatory molecules.  Altered miRNA expression has been linked to numerous 
diseases including; myocardial infarction366, neurological disorders such as 
Parkinson’s disease298 and Alzheimer’s disease278, diabetes277, and numerous forms 
of cancer367. Increased expression of miRNAs can function as both oncogenes (by 
down-regulation of tumour suppressor genes) or as regulators of cellular 
differentiation368. Unique miRNA profiles have been identified for a number of 
reproductive cancers; breast and ovary as well as endometroid adenocarcinoma, 
haematological cancers, and thyroid cancer369.  
 Over the preceding decade, the miRNA transcriptome of the retina and 
other ocular tissues (lens and cornea) have been established370. miRNAs often show 
unique tissue-specific expression patterns suggesting potential unique roles for 
50 
 
miRNAs in ocular tissues370,371. miRNAs have already been implicated in several 
ocular diseases such as cataract372, myopia373, age related macular degeneration374, 
and retinoblastoma375. Differentially expressed miRNAs have been identified in 
cataract and non-cataract lens epithelium capsules376,377. In the lens, miRNAs mainly 
target redox homeostasis transcription factor genes378, dysregulation of which leads 
to cataract and cellular abnormalities.  The miRNA transcriptome of the aqueous 
humour has identified several differential miRNAs in healthy and disease 
states377,379. miRNA expression in the AH has been shown to be altered in cataract 
patients378 and more recently glaucoma patients379. It is therefore no surprise that 
miRNA dysregulation in the AH may have pathological effects on ocular tissues 
involved in glaucoma due to permanent AH interactions. Recently miRNAs have 
been localised to the trabecular meshwork and it is thought that they function to 
maintain homeostasis within the TM380,381. Dysregulation of miRNAs in the TM will 
be discussed in Chapter 5 (5.1.1.1). 
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Chapter 2 
Materials and Methods 
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2.1 Tissue Culture 
2.1.1 Tissue Samples 
Cadaveric eyes were provided by the Liverpool Research Eye Bank and 
approved by the local ethics review board (RETH000833) handled in accordance to 
the tenets of the Declaration of Helsinki. Written consent was obtained from the 
next of kin of the deceased donor. Eyes were obtained from the Royal Liverpool 
University Hospital Mortuary by an in-house team of qualified eye-retrievers. Donor 
eyes were excluded if the maximum post-mortem time exceeded 48 hours. Clinical 
and demographic data (age, sex, and ethnicity) was available and tissue was 
obtained from both non-glaucomatous (normal TM) and glaucomatous patients 
(GTM). GTM730-03 and GTM307-04 were a kind gift from Dr. Abbot Clark, 
University of North Texas.  
Donor ID Age Sex Medical History 
NTM LGP-1 57 Male No Glaucoma 
NTM LGP-2 65 Male No Glaucoma 
NTM 009 57 Male No Glaucoma 
NTM 119 94 Male No Glaucoma, 
Cataract Surgery 
NTM 002 57 Male No Glaucoma 
NTM 720 64 Male No Glaucoma 
NTM 020 88 Female No Glaucoma 
NTM 012 71 Unavailable No Glaucoma 
NTM 013 85 Unavailable No Glaucoma 
NTM 029 65 Unavailable No Glaucoma 
GTM 304-04 74 Female POAG 
GTM 730-03 88 Male POAG 
GTM 034 86 Male POAG 
Table 2.1 Human TM Cell Donor Information 
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2.1.2 Dissection of Anterior Segment From Porcine and Human Eyes 
Dissection of the anterior segment was performed under sterile conditions 
(Figure 2.1). Extra-ocular tissue was removed and only intact eyes were used. The 
eyes were immersed in 10% iodine solution for 5 minutes and washed twice in 
sterile 1X Dulbecco’s Phosphate Buffered Saline (DPBS) (DB8537, Sigma, UK) before 
dissection. Holding the globe firmly, but without undue pressure the scleral tissue 
was circumferentially scored approximately 3-5mm posterior to the limbus using a 
#15 scalpel. The anterior segment was dissected by making a circumferential cut 
along the initial score.  The vitreous, lens, iris, and choroidal layer were carefully 
removed. The remaining anterior segment was rinsed three times with sterile PBS 
to remove remaining pigment and placed in incubating media (see 2.1.4).  
2.1.3 Trabecular Meshwork Dissection and Explant Culture 
 Dissection of the TM from the anterior segment was carried out upon 
receiving anterior segments from the internal Research Eye Bank (REB) and 
following whole globe anterior segment dissection. Growth medium as per 
specifications highlighted below (2.1.4) was incubated at 37oC in preparation for 
the tissue. Anterior segments were washed with sterile PBS and it was ensured that 
the iris, lens, and choroid layer were removed. The ciliary body was then carefully 
dissected using a blunt curved forceps. The TM could be visualised as a light grey 
layer close to where the ciliary body was located under a dissection microscope. TM 
was removed carefully using a blunt forceps in a stripping technique and the tissue 
obtained was placed directly in to incubating growth medium. The strip of TM 
obtained was cut into sections of approximately 2-4mm in length and was 
explanted to generate primary human TM cells. Using a sterile forceps an “X” was 
indented to the base of individual wells of a 6 well dish. The TM tissue was carefully 
placed in this region to aid attachment. To further prevent disruption to the TM 
tissue a sterile coverslip was use to keep the tissue in place. Incubating media was 
carefully pipetted dropwise until the tissue was covered. Tissue was allowed to 
attach for up to 4 hours and incubating media was topped up. Media was changed 
carefully daily ensuring no disruption to the tissue occurred. Primary TM cells were 
prone to fungal infections therefore for the initial growth period 2.5µg/mL 
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amphotericin B (A2942, Sigma, UK) supplemented media was used. Older donor 
eyes had a slower growth rate in comparison to younger donor eyes, this was 
counteracted by the addition of basic fibroblast growth factor (1µg/mL) 
(humanBFGF, F0291, Sigma, UK). Failure to produce primary outgrowths from the 
anterior segments or donor corneal rims was observed in eyes that remained in 
culture medium over 3 days prior to dissection, and was frequently caused by 
fungal infections. The latent period prior to cell growth was between several days 
to 4 weeks, which was donor dependent as conditions remained the same 
throughout.  
 Primary TM cells that grew to form a monolayer were gently dissociated 
from the donor tissue using 0.25% Trypsin/EDTA solution (T4049,Sigma, UK). Cells 
were not centrifuged as cell count was low and risk of cell damage or loss was high. 
Dissociated cells were placed directly into a T25 tissue culture flask (Greiner, Bio-
One, UK) with surplus culture medium containing 10% FCS (BioSera, Labtech, UK) to 
counteract the Trypsin/EDTA solution. Primary TM cells were allowed to attach for 
up to 6 hours, following this media containing Trypsin/EDTA was removed and 
cultures were maintained as follows (2.14).  
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Figure 2.1: Representative Images Depicting Human Anterior Segment Dissection 
Protocol. Photographs depicting the dissection of the anterior segment of a human 
globe. A; Whole human globe in preparation for central scoring with #15 blade. B; 
Circumferential cutting of the whole globe to obtain anterior segment. C; Detached 
anterior segment containing some vitreous, the iris, the lens, and the choroid layer. 
D; Careful removal of the choroid layer via “stripping”. E; Final anterior segment 
section containing only the ciliary body and trabecular meshwork. 
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2.1.4 Cell Culture Maintenance 
Human trabecular meshwork cells were cultured in Dulbecco’s Modified 
Eagle’s Medium- low glucose (Sigma, UK) supplemented with 10% fetal calf serum 
(FCS)(Biosera, LabTech UK), 2mM L-glutamine, 100 units’/mL penicillin/100µg/mL 
streptomycin (Pen/Strep), and 2.5µg/mL amphotericin B (Fungizone) (all from 
Sigma, UK). Media was changed every 2-3 days. Cell growth was arrested 24 hours 
prior to experimentation in serum free DMEM supplemented with 2mM L-
glutamine, Pen/Strep, and Fungizone as concentrations above.  
2.1.5 Mycoplasma Testing and Treatment of Cells 
 Mycoplasma testing was routinely carried out on all primary human 
trabecular meshwork cells prior to experimentation with the Sigma LookOut® 
Mycoplasma PCR detection kit (Sigma, UK) according to manufacturers’ 
specifications. Briefly, 100µL of conditioned media was obtained from confluent cell 
cultures. Conditioned media was boiled for 5 minutes at 95oC and placed directly on 
ice for use in End Point PCR described in 2.4.6.  
2.1.6 Sub-Culturing Cells 
Human trabecular meshwork cells were maintained in a 37oC humidified 
incubator (MCO-18AC Panasonic Biomedical, UK) with 5% CO2. Continuous cultures 
were maintained within standard sterile T75 tissue culture (TC) flasks (Greiner Bio-
One, UK). When cells reached confluency they were sub-cultured. Briefly, cells were 
washed with sterile PBS before addition of 0.25% Trypsin/EDTA solution (Sigma, UK) 
for up to 10 minutes or until all cells had detached from the flask. The trypsin was 
neutralised with twice the volume of culture medium. The cell suspension was then 
removed and centrifuged at 1000 revolutions per minute (RPM) for 15 minutes, and 
split as appropriate into new TC flasks, or culture plates. Cell culture media was 
replenished every 2-3 days. Primary cells have increased susceptibility to infection, 
both bacterial and fungal, therefore cultures were observed daily to ensure no 
infection was present. Frequently cultures were lost to this. To counteract this, a 
new incubator specifically for primary cultures was made available which greatly 
decreased infection rates.  
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2.1.7 Long Term Storage of Cells 
 For long term storage trabecular meshwork cells were stock frozen at 
varying passages for use at a later date. Trypsinised cell suspensions were re-
suspended in freezing medium consisting of 80% culture medium, 10% FCS and 10% 
dimethylsulphoxide (DMSO) (Sigma, UK. The suspension was transferred 
cryoprotective vials were placed in a ‘Mr Frosty’ freezing container containing 
isopropanol (Fischer Scientific) at room temperature. The container was then 
placed in a freezer at -80oC for up to 24 hours after which the vials were removed 
and placed in liquid nitrogen. Frozen cells were thawed at 37oC and placed in tissue 
culture flasks containing pre-heated culture media. Liquid nitrogen maintenance is 
essential for long term cell storage. A number of primary cells were lost when liquid 
nitrogen levels were not efficiently maintained, upon thawing cells were unable to 
recover presenting difficulties proceeding with experimentation.  
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2.2 Cells for Experimentation 
 Human trabecular meshwork cells were used for experimentation between 
passage 3 and passage 6. Cell health and growth were continually observed based 
on morphological changes (2.2.1.1) and growth rate, between passaging382. 
Trabecular meshwork cells were not used after passage 10 in experiments as they 
began to show a decrease in growth rate and gross morphological changes. Cells 
were seeded at a density of 20,000 cells per cm2 for immunocytochemistry (ICC) 
and transfection experiments. Cells were seeded at 100,000 cells per cm2 for 
protein and nucleic acid experiments. 
2.2.1 Characterisation of TM Cells 
2.2.1.1 Morphological Assessment of Trabecular Meshwork Cells 
 Preceding experimentation the trabecular meshwork cells were observed 
throughout their life-span under outlined cell culture conditions. These cells were 
viewed under a Brightfield microscope and images were taken using a Nikon TiE 
microscope (Nikon, Surrey, UK). Images were taken serially throughout cell culture 
to monitor growth of the cells ensuring appropriate morphology was maintained 
(Figure 3.1).  
2.2.1.2 Fluorescent Staining of Trabecular Meshwork Cells In Vitro 
 Trabecular meshwork cells were characterised by immunocytochemistry 
(ICC) to stain for the positive presence of TM associated proteins; caveolin-1, 
caveolin-2, aquaporin-4, myocilin, and vimentin. Primary human tenon fibroblasts 
were used as a positive control (Chapter 3, Figure 3.2).   
Sterile coverslips were placed in 6 well TC plates. Trypsinised cells were 
counted using cell counter slides (Bio-Rad, UK) and 20’000 cells per cm2 were plated 
per well and culture plates were maintained as described above (2.1.4). Wells 
intended for myocilin antibody staining were serum starved for 24 hours at 70% 
confluency. Cells were treated with 100nM dexamethasone (DEX) for 16hours prior 
to myocilin staining. All remaining wells were maintained as usual. 
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 After treatment media was removed and cells were washed with PBS. All 
cells were fixed with 4% paraformaldehyde for 15 minutes. Fixed cells were washed 
with PBS and permeabilised with 0.05% Triton-X 100 in PBS for 10 minutes. 
Coverslips were washed with 3 changes of PBS for 15 minutes. To reduce non-
specific binding, coverslips were blocked in 5% goat serum (Sigma, UK) in PBS for 90 
minutes. Coverslips were washed with 3 changes of PBS for 15 minutes and 
incubated in primary antibodies diluted in 5% goat serum in PBS overnight at 4oC. 
Primary antibody concentrations can be found in Table 2.2 below.  Following 
overnight incubation the coverslips were washed with PBS as above, and incubated 
with appropriate Fluorescein isothiocyanate (FITC) conjugated secondary antibody 
(Abcam, 6785, UK) at assay dependent concentrations for 90 minutes at room 
temperature. Coverslips were washed as above, and were prepared for mounting. 
Coverslips were carefully removed from corresponding wells and excess liquid was 
removed. Coverslips were mounted onto slides using Fluoroshield Mounting 
Medium with DAPI (Abcam, UK), and allowed to set overnight at 4oC. Slides were 
visualized using a confocal microscope (Zeiss LSM800, Zeiss, UK). Slides were kept 
for long term storage at -20oC and protected from light.  
Antibody Supplier Raised In Concentration 
Anti-Caveolin-1 (ab32577) Abcam Rabbit  0.22 µg/mL 
Anti-Caveolin-2 (ab79397) Abcam Rabbit 0.22 µg/mL 
Anti-Myocilin (55477) Abcam Mouse 3.1 µg/mL 
Anti-Vimentin (MA5-11883) Invitrogen Mouse 1 µg/mL 
Anti-Aquaporin-4 (46182) Abcam Rabbit 10 µg/mL 
    
Table 2.2: Details for Primary Antibodies Used for ICC 
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2.2.2 Cell Stimulations with TGF-β2 and Dexamethasone 
 TM cells were grown to 70-80% confluency and prior to stimulation cell 
growth was arrested for 24 hours in starvation media containing only L-glutamine, 
and Pen/Strep. Human TM Cells were stimulated with either recombinant human 
TGF-β2 (302-B2-010, R&D Systems, UK) at a concentration of 5ng/mL for 4hours or 
24hours (Chapter 3 and 5) or 100mM dexamethasone (D4902, Sigma, UK) for 
16hours (Chapter 4). The concentration and time chosen for TGF-β2 treatment was 
based on previously carried out optimization that looked at effects of 1ng/mL, 
5ng/mL and 10ng/mL TGF-β2 on normal TM cells over a time period ranging from 
0hours to 72hours (Figure 8.1, Appendix). Vehicle control cells were treated with 
equal volumes of 4mM Hydrogen Chloride (HCl) and 0.1% bovine serum albumin 
(BSA) solution (Sigma, UK), and negative control cells were maintained in starvation 
media only over the specified time period.  
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2.2.3 Transfection for miRNA Manipulation Experiments  
 TM cells were seeded at a density of 20,000 cells per cm2 48hours prior to 
transfection experiments. At 50% confluence cell growth was arrested using 
starvation medium as above (2.14) for 24hours. TM cells were treated with 5ng/mL 
TGFβ-2 and transfected with synthetic human microRNA mimic for miR-145-5p and 
miR-143-3p, miRNA inhibitor for miR-145-5p and miR-143-3p or a scrambled 
negative control (Qiagen, UK). Details of synthetic mimics and inhibitors are 
outlined in Table 2.3. The transfection mix was prepared according to the 
manufacturers’ protocol using a ratio of 15µL HiPerfect Transfection reagent 
(301704, Qiagen, UK) for every 50nMol of miRNA transfected. Ambion® a 
fluorescently labelled negative control siRNA (AM4620, ThermoFisher Scientific, UK) 
was used to monitor transfection efficiency over 24 hours. Media was removed 
after 24 hours and wells were washed with PBS. siRNA negative control cells were 
imaged using Nikon TiE microscope (Nikon, Surrey, UK ) to assess uptake of miRNA 
mimics and inhibitors. TM cells were then prepped for total RNA isolation.   
Candidate miRNA Sequence Qiagen ID 
hsa-miR-145-5p Mimic 5'GUCCAGUUUUCCCAGGAAUCCCU MSY0000437 
hsa-miR-145-5p Inhibitor 5'GUCCAGUUUUCCCAGGAAUCCCU MIN0000437 
hsa-miR-143-3p Mimic 5'UGAGAUGAAGCACUGUAGCUC MSY0000435 
hsa-miR-143-3p Inhibitor 5'UGAGAUGAAGCACUGUAGCUC MIN0000435 
Scrambled Negative 
Control 
Random ID: 1027271 
Table 2.3: miScript miRNA Mimic and Inhibitors. 
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2.3 Protein Based Methods 
2.3.1 Whole Cell Lysis- Protein Extraction 
Adherent cell lysates were prepared for immunoblotting against proteins of 
interest. Confluent cells, grown on a 10cm tissue culture treated dish, were washed 
with PBS following TGF-β2 treatments. Cells were then lysed using SDS/Urea lysis 
buffer (10mM Tris-HCL [pH=6.8], 6.7M Urea, 35nM SDS, 10% Glycerol and 7.4µM 
bromophenol blue) containing 50µM phenylmethysulfonyl fluoride (PMSF) and 
50µM N-methylmaleimide) to inhibit endogenous proteases. Prior to use 5% β-
Mercaptoethanol (final volume) was added to each lysate to reduce for SDS-PAGE. 
Protein lysates were stored at -20oC. 
2.3.2 SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
 Prepared protein lysates and 6µL protein ladder (Precision Plus Protein ™ 
Dual Color Standards, Bio-Rad, UK) were loaded into a 10% Precast Ready Gel (Bio-
Rad, UK) in running buffer  (10X Running buffer; 25mM Tris base (Sigma, UK), 190 
mM glycine, (Sigma, UK) 0.1% sodium dodecyl sulfate (SDS) (Sigma, UK)), and 
separated at 120V. The gel, filter paper and nitrocellulose membrane were soaked 
in transfer buffer (10X Transfer buffer; 25mM Tris base (LiCor, UK), 190 mM glycine, 
(LiCor, UK) 20% Methanol (SDS) (Sigma, UK)),  for approximately 10 minutes. 
Separated protein samples were then transferred onto a nitrocellulose membrane 
using semi-dry Bio-Rad TurboBlot transfer system at 25V (1.3A) for 7 minutes. 
Membranes were blocked for 1 hour at room temperature (RT) in Odyssey® TBS-
Blocking Buffer (Li-Cor Biosceiences, Nebraska, USA) prior to primary antibody 
incubation. Primary antibody information is outlined in Table 2.4. Primary 
antibodies were diluted in blocking buffer at assay dependent concentrations, and 
membranes were probed overnight at 4oC. Membranes were washed in 3 changes 
of TBS/0.1% Tween (TBS-T) for 15 minutes and probed for 90 minutes at 37oC with 
IRDye® 800CW or IRDye®680RD conjugated secondary antibodies (Li-Cor) diluted in 
blocking buffer at a concentration of 60ng/mL. Membranes washed as above in 
TBS-T and imaged using an Odyssey® CLx 9120 Infrared Imaging System.   
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Antibody Supplier Raised In Concentration 
Anti-SMAD2/3 (8828S) Cell Signalling Rabbit  0.22 µg/mL 
Anti-pSMAD2/3 (8685S) Cell Signalling Rabbit 3.1 µg/mL 
Anti-α-SMA (5694) Abcam Rabbit 0.1 µg/mL 
Anti-GAPDH (8245)(181602) Abcam Mouse/Rabbit 0.01 µg/mL 
Table 2.4 Primary Antibody Details for Protein Analyses.  
2.4 Nucleic Acid Based Methods 
2.4.1 Ribonucleic Acid (RNA) Extraction  
 Total RNA from primary normal TM and GTM cells was extracted using 
AllPrep® DNA/RNA/miRNA Universal Kit (Qiagen, UK) as per manufacturers’ 
specifications. Briefly, cells grown in a monolayer were trypsized and lysed. The 
lysate was passed through a QIAshredder column (Qiagen, UK, catalogue number 
79654). DNAse 1 “on column digestion” was carried out prior to subsequent steps 
as per manual. The RNA was washed several times before elution of total RNA, 
including miRNAs, with 40µL of RNAse free water centrifuged for 1 minute at 
≤8000xg. A second elution with 30µL RNAse free water was carried out in the same 
manner to ensure a higher RNA yield.  RNA quality and concentration was analysed 
prior to long term storage at -80oC until experimental use. 
2.4.2 Nucleic Acid Concentration Measurements on NanoDrop 2000 
Spectrophotometer  
 Total RNA concentration of a sample can be determined 
spectrophotometrically by measuring absorbance at 260nm. Absorbance can also 
be measured at 280nm to determine presence of protein contamination. Thus, a 
260/280 ratio is used to identify pure RNA. A ratio of approximately 2.0 is defined 
as pure RNA. 1µL of “blank” sample (RNAse free water) was used to calibrate the 
instrument. 1µL of RNA samples was pipetted directly on to the instruments 
pedestal then used to measure absorbance at 260nm and 280nm as well as RNA 
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sample concentrations (ng/µL) and purity by the NanoDrop 2000 (Thermofisher 
Scientific, UK).  
2.4.3 RNA Quality Assurance with Agilent Bioanalyser 2100 
 Bioanalyser 2100 (Agilent Technologies, UK) is the first commercially 
available assay that utilises Chip based technologies for nucleic acid separations. 
The LabChip Technology separates nucleic acids using a microfluidic platform. The 
Chip contains micro-channels of glass which are filled with polymer and a 
fluorescent dye. Fluorescent dye molecules are inserted into the RNA to enable 
them to be detected by the systems lasers. Once the RNA is loaded they are 
separated according to size migrating towards the positively charged ions.  Size and 
concentration of the RNA is correlated with fluorescence. Bioanalyser software 
utilises an algorithm to present the data as electropherograms and “slab gel like 
images”. RNA loaded is compared to a ladder consisting of randomised RNA sizes in 
order to determine unknown concentrations. 18S and 28S ribosomal RNA peaks are 
used to determine the integrity of RNA samples loaded. RNA integrity is presented 
as an RNA Integrity Number (RIN) between 1 and 10. RNA samples with a RIN of 10 
are considered high quality RNA samples. 
 The RNA 6000 Nano Kit was used to perform quality assurance on both 
normal TM and GTM RNA samples. Procedure was followed based on Agilent RNA 
6000 Nano Kit ® as per manufacturers’ specifications. Briefly, 550µL of RNA 6000 
Nano gel matrix was passed through a spin filter and centrifuged at 1,500xg for 10 
minutes. Aliquots of 65µl were transferred into RNase-free microfuge tubes and 1µl 
of RNA 6000 Nano dye concentrate was added before the gel/dye mix was 
centrifuged at 13,000xg for 10 minutes. Gel-dye mix (9 µl), Agilent RNA 6000 Nano 
Marker (5µl) and ladder (1µl) or RNA samples (1 µl) were pipetted into marked 
wells on the chip. The fully prepared chip was vortexed at 2400 rpm at 1 minute. 
The chip was run on the Bioanalyser 2100 system. Results can be seen in Figures 8.2 
and 8.3 (Appendix).  
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2.4.5 cDNA Synthesis  
 0.5-1.0µg RNA was reverse transcribed with miScript II RT kit (Qiagen, UK) as 
per manufacturers’ specifications. Briefly, template RNA and H2O mixture was 
added to the reverse transcription master mix containing 5x HiFlex Buffer, 10x 
Nucleics Mix and miScript Reverse Transcriptase (volumes highlighted in Table 2.5). 
The mixture was incubated for 60 minutes at 37oC then for 5 minutes at 90oC to 
inactivate the miScript reverse transcriptase, using a Veriti 96 well Thermal Cycler 
(Applied Biosystems™, ThermoFischer Scientific, UK). cDNA quality was assessed via 
End Point Polymerase Chain Reaction (PCR).  
Component Volume 
5x miScript HiFlex Buffer 4µL 
10x Nucleics Mix 2µL 
miScript Reverse Transcriptase 2µL 
H2O Variable (Up to 12µL) 
RNA Template (0.5-1.0µg) Variable (Up to 12µL) 
Total volume 20µL 
Table 2.5: Reverse Transcription Reagent Volumes for cDNA Synthesis.  
2.4.6 End-Point PCR  
 End-point PCR thermocycling reagent volumes are outlined in Table 2.6. 
Diluted cDNA template was added to the end-point master mix and products were 
amplified using the Veriti Thermal Cycler.  
Component Volume 
cDNA template 1µL 
Red Taq Enzyme (Sigma) 12.5µL 
Primer Pair 2.5µL 
H2O 9 µL 
Total Volume 25 µL 
Table 2.6: End-Point PCR Reagent Volumes for Primer Efficiency and cDNA 
Integrity Analysis. 
66 
 
2.4.6 Agarose Gel Electrophoresis  
 End-Point PCR products were separated on 1.5%-2% agarose gels. Agarose 
gels were prepared by boiling 1.5-2g agarose (Sigma, UK) in 1X Tris-acetate-EDTA 
(TAE) buffer (Sigma, UK). Once cooled 3.5µL/100mL ethidium bromide (EtBr) was 
added to allow DNA visualisation under UV light. Gel was poured in to gel cast and 
allowed to set in a fume hood at RT. The gel was placed in an electrophoresis tank 
filled with 1X TAE. Up to 4µL 1kB DNA ladder (NEB, UK) was added to the first well 
and 10µL of PCR product was added to each well thereafter. Product separation 
was carried out at 120V for up to 45 minutes and bands were visualised using 
ChemiDoc Gel Imaging System (Bio-Rad, USA).   
2.4.7 Primer Design and Optimization 
 All primers used in this thesis were designed by Primerdesign Ltd 
(Primerdesign Ltd, UK) or sequences were obtained from Primer Bank website 
(http://pga.mgh.harvard.edu/primerbank/).  Hybridization of the primers to the 
desired section of DNA was verified using NCBI nucleotide BLAST 
(https://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE_TYPE=BlastSearch).  
For each primer set, pairs were diluted to 10µM final concentration (10µL 
sense primer, 10µL  antisense primer and 80µL H2O).End Point PCR was used as 
described above (2.4.6) to assess a range of different annealing temperatures for 
each primer pair to identify optimal working conditions. For each primer pair, a 
standard curve was prepared using 3-fold serial dilutions of a mixture of cDNA from 
RNA extracted from human TM cells. Dilutions were made for at least 5 
concentrations ranging from 300ng-4ng to ensure complete coverage of the range 
of expected gene expression. Each concentration was performed in duplicate. Slope 
of the standard curve and q-PCR efficiency for each primer pair was determined. 
Primer pairs with an efficiency of 1.8-2 were accepted. Melt curve analyses were 
also used to determine efficiency and specificity of primer pairs. Glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) is a commonly used housekeeping gene for 
mRNA expression analyses383 and is stably expressed in TM cells. GAPDH expression 
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is not affected by TGF-β2 or corticosteroid treatments and was therefore chosen as 
a reference gene for mRNA expression analyses and protein analysis experiments.  
 miRNA primer assays were obtained from Qiagen (miScript Primer Assays, 
Qiagen, UK) for the detection or miRNA targets: hsa-miR-143-
3p(MS00003514,miScript Primer Assay, Qiagen, UK), hsa-miR-145-5p (MS00003514, 
miScript Primer Assay, Qiagen, UK) and hsa-miR-4328 (MS00021665, miScript 
Primer Assay, Qiagen, UK). Small nucleolar RNA 61  (MS00033705, miScript Primer 
Assay, Qiagen, UK) (SNORD61) was used as a reference gene for miRNA q-PCR 
experiments as other small RNAs have relevant expression levels to miRNAs and are 
likely to have similar behaviour during extraction and reverse transcription 
compared to longer transcripts384.  
2.4.8 Relative quantification real-time PCR (q-PCR) 
 Relative quantification (ΔΔCt method) real-time PCR was performed to 
investigate the expression of specific mRNA targets in normal TM and GTM 
samples. q-PCR was performed on LightCyler480 or LightCycler96 instruments 
(Roche, UK) according to manufacturers’ specifications. Unlabelled gene-specific 
primers listed in Table 2.9 and PrecisionPLUS SYBR q-PCR Master Mix (Primerdesign 
Ltd, UK) or microRNA probes listed in Table 2.10 (Qiagen, UK) and miScript SYBR® 
Green PCR mix with miScript universal primer (miScript primer assays, Qiagen, UK) 
were used in q-PCR reactions as below (Table 2.7 and Table 2.8). 
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PrecisionPLUS SYBR q-PCR 
Components Volume 
PrecisionPLUS SYBR Master Mix 5µL 
H2O 3µL 
cDNA Template (1µg) 1µL 
Primer Pair (1:10)(1µM final concentration) 1µL 
Total Volume 10µL 
Table 2.7: mRNA q-PCR Reagent Volumes.    
miScript SYBR®Green PCR Mix 
Components Volume 
2x Quantitect SYBR®Green Master Mix 12.5µL 
10x miScript Universal Primer 2.5µL 
10x miScript Primer Assay 2.5µL 
H2O (RNase free) Up to 7.5µL 
cDNA Template (0.5-1.0ug) Up to 7.5µL 
Total Volume 25µL 
Table 2.8: miRNA q-PCR Reagent Volumes. 
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Primer I.D Primer Sequence 
EDN1 F;5’CCAGGAGCTCCAGAAACAG3’ 
R;5’GAGCAGGAGCAGCGCTT3’ 
NOX4 F;5’CACAGACTTGGCTTTGGATTTC3’ 
R;5’GGATGACTTATGACCGAAATGATG3’ 
FSTL3 F;5’GACTTCATCAGGAACAAGTGGTC3’ 
R;5’AGGTCCGTAGCCATGAGGAT3’ 
FNDC1 F;5’GACTTCATCAGGAACAAGTGGTC3’ 
R;5’AGGTCCGTAGCCATGAGGAT3’ 
KANK4 F;5’CATCTTCAGCCTTGAATTCCTCAT3’ 
R;5’TTCTAATGTGCTAATGTGCTCCTG3’ 
LDLRAD4 F;5’AAGAGTTGGAGCACAGGCTT3’ 
R;5’TTACAGACCAGCGAACCAAGA3’ 
RASL11B F;5’CCTCACCAAACGATTCATCGG3’ 
R;5’ACCTGGAGTGTCTTGAACCTG3’ 
WNT2B F;5’TTGGAGTGGTAGCCATAAGCAT3’ 
R;5’TTGAACGCTGACTGTGTAGGT3’ 
ATP10A F;5’TCGGCATTGTCATCTACGCA3’ 
R;5’AGGAGCAGGACACACCAGA3’ 
PMEPA1 F;5’TTAGACTCCGCTCTTGTTCTCC3’ 
R;5’ATGCTCTCCTCTGGTCACCT3’ 
CDKN2B F;5’GCAAGCCTGTCTGAGACTCA3’ 
R;5’ACACACTCCTAAATATCCCTGGAA3’ 
CDKN2B-AS1 F;5’CCACATCAATGATGAAGCCAGAA3’ 
R;5’TTGATCTCTGCTGTTGAATCAGAAT3’ 
OSR2 F;5’TCTCCACACAAATGTCCCACA3’ 
R;5’TTTCGCCTGAACACTTTGCC3’ 
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DACT1 F:5’CTTCATGCTGTGGCTGTGC3’ 
R:5’GGACGGTAAGGAACTGTCTGT3’ 
LEFTY2 F;5’GGTGGTCTTAATGTAGGTCTTAACTT3’ 
R:5’AGACAGGAAATGGAAGGACACA3’ 
FST F:5’AGGCAAGATGTAAAGAGCAGC’3 
R:5’CAGTAGGCATTATTGGTCTGGTC’3 
PDPN F:5’AACCAGCGAAGACCGCTATAA’3 
R:5’CGAATGCCTGTTACACTGTTGA’3 
SERPINB2 F:5’TCCTGGGTCAAGACTCAAACC’3 
R:5’CATCCTGGTATCCCCATCTACAG’3 
FKBP5 F:5’CTCCCTAAAATTCCCTCGAATGC’3 
R:5’CCCTCTCCTTTCCGTTTGGTT’3 
MMP-1 F:5’ACGGATACCCCAAGGACATCT’3 
R;5’TCAGAAAGAGCATCGATATG’3 
PTK2B F:5’CCCCTGAGTCGAGTAAAGTTGG’3 
R:5’GATACGCACGTCCTCCTTTTC’3 
RGCC F:5’CGCCACTTCCACTACGAGG’3 
R:’CAGCAATGAAGGCTTCTAGCTC’3 
ZBTB16 F:5’CCTCAGACGACAATGACACGG’3 
R:5’CTCGCTGGAATGCTTCGAGAT’3 
VEGFC F:5’GAGGAGCAGTTACGGTCTGTG’3 
R:5’TCCTTTCCTTAGCTGACACTTGT’3 
GRα F:5’GAAGGAAACTCCAGCCAGAA’3 
R:5’TAAGGGGCTCTACAATCGAC’3 
GRβ F:5’TGACTCTACCCTGCATGTACGACCA’3 
R:5’CTATTTTTTGAGCGCCAAGATTGTT’3 
α-SMA F:5’CCGACCGAATGCAGAAGGA’3 
R:5’ACAGAGTATTTGCGCTCCGAA’3 
GAPDH F:5’CGAGCCACATCGCTCAGACACC’3 
R:5’GGTCAATGAAGGGGTCATTGATGGCAAC’3 
Table 2.9: Unlabelled Gene Specific Human Primers. 
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Table 2.10: miScript Universal Primer Sequences. 
 
 
 
 
 
 
 
 
 
 
 
 
 
miRNA Probe Sequence 
hsa-miR-143-3p (MIMAT0000435)  5'UGAGAUGAAGCACUGUAGCUC 
hsa-miR-145-5p (MIMAT0000437) 5’GUCCAGUUUUCCCAGGAAUCCCU 
hsa-miR-4328 (MIMAT0016926) 5'CCAGUUUUCCCAGGAUU 
SNORD 61 Unavailable; Transcript: NR_002735 (73bp) 
72 
 
cDNA template was added separately to corresponding wells of a 96 well 
semi-skirted PCR plate (Starlab, UK) followed by a master-mix as above. The run 
methods for mRNA and miRNA detection are outlined in Table 2.11 and Table 2.12, 
respectively. 
Programme 
Name 
Cycles Temperature  
(oC) 
Time 
(hh:mm:ss) 
Ramp Rate (oC/s) 
Denaturation 1 95 00:05:00 4.4 
Amplification 40 
 95 00:00:10 4.4 
60 00:00:10 2.2 
72 00:00:12 4.4 
Melt Curve 1 
 95 00:00:05 4.4 
60 00:01:00 2.2 
97 Continuous 0.11 
Cooling 1 40 00:00:30 2.2 
 Table 2.11: mRNA RT-q-PCR PrecisionPLUS SYBR Conditions. 
Programme 
Name 
Cycles Temperature  
(oC) 
Time 
(hh:mm:ss) 
Ramp Rate (oC/s) 
Denaturation 1 95 00:15:00 1 
Amplification 45 
 94 00:00:15 1 
55 00:00:30 1 
70 00:00:30 1 
Melt Curve 
 
 
 
1 
 95 00:00:05 4.4 
65 00:01:00 2.2 
97 Continuous 0.11 
Cooling 1 40 00:00:30 2.2 
Table 2.12: miRNA q-PCR Quantitect SYBR Conditions. 
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2.5 RNA-Seq and MicroArray Analyses  
2.5.1 Bioinformatics Methodology 
Exiqon RNA-Seq Analysis 
 RNA-Seq experiments were performed by Exiqon (Exiqon, Denmark) and Dr. 
David Simpson (Queens, University Belfast, QUB) details of which are outlined in 
Chapter 3, Chapter 4 and Chapter 5.  Following RNA-Seq intensity correction and 
base calling (into BCL files), FASTQ files were generates using appropriate bcl2fastq 
software (Illumina Inc, UK), which includes quality scoring of each individual base in 
a read. Subsequently, data was separated for paired-end reads to determine 
whether the second read significantly differs from the first in terms of overall 
quality.  
 Data analysis was initially performed by Exiqon (Exiqon, Denmark) for 
Chapters 3 and 4. The components of Exiqon next generation sequencing (NGS) 
RNA-Seq analysis pipeline include Bowtie2 (v2.2.2), Tophat (v.2.0.11) and Cufflinks 
(v2.2.1). Tophat is a fast splice junction mapper for RNA-Seq reads. Tophat was 
used to align the sequencing reads to the reference genome (h.sapiens, 
hg19/GRC37, UCSC Genome Browser) using the sequence aligner Bowtie2. Tophat 
was also utilised to identify splice junctions for both known and novel transcripts 
from the sequence alignments.  
 Cufflinks receives alignment results from Tophat and it uses them to 
assemble the aligned sequences into transcripts, thus constructing a map of the 
transcriptome. To guide the assembly process, an existing transcript annotation was 
used. In addition, Exiqon performed fragment bias correction which seeks to 
correct for sequence bias during library preparation. Cufflinks then assembled 
aligned reads into different transcript isoforms based on exon usage and also 
determined the transcriptional start sites (TSSs).  
 It is necessary to build linear model groups with samples paired by donor 
eye. The limma functionality of edgeR is ideal for this but requires counts of 
mapped reads as an input. Counts were generated using featureCounts and 
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inference of differential expression was by generalised linear model likelihood ratio 
test (glmLRT) implemented by edgeR.  
IPA RNA-Seq Analyses 
Following analysis by Exiqon, further functional analysis was performed by 
Dr. Brian Lane (University of Liverpool), through Ingenuity Pathway Analysis (IPA). 
IPA v01-08 (Qiagen, UK) Core and Comparison analyses were performed with lists of 
differentially expressed genes (DEGs) generated from expression analyses that 
included gene name, false discovery rate (FDR) p-value and log2 fold change. Unless 
indicated, FDR p-value threshold of 0.01 was used throughout experiments (chapter 
3, 4, and 5) to select lists of DEGs for analysis. Core analysis output included ranked 
lists of Canonical Pathways (processes with biological or molecular biology 
significance defined by the Ingenuity Knowledge Base) and single molecule 
UpStream Regulators of a single DEG supplied. The canonical pathways and 
upstream regulators identified in two or more Core analyses were compared in 
Comparison analyses. Comparisons were performed by hierarchical clustering 
based on process enrichment score or activation z-score.  
 Fishers exact tests reported as a likelihood value (-log(p-value)) were 
performed to assess canonical pathway enrichment. Canonical pathways and 
UpStream Regulators were ranked by activation z-score which is a weighted statistic 
that correlates measured gene expression with the expected direction of 
expression of the DEG list supplied. The activation score is equivalent to a zero-
centred normal distribution z-score therefore only scores of +/- 1.96 were regarded 
as significant and the sign of the z-score indicates the direction of regulation of the 
process.  
R/Bioconductor RNA-Seq Analyses 
Analyses using named Bioconductor packages 
(v3.6;http://www.bioconductor.org) were conducted in R v 3.4.3 (http://cran.t-
project.org), statistical programming environment. Heat maps were generated using 
the Bioconductor package pheatmap, using a Pearson Correlation distance and a 
complete agglomeration method, with a gene-wise scaled and centred log2 
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transformed data. Principal component analysis (PCA) was used to identify the main 
components of variation in a data set. By identifying three principal components, 
large data sets can be visualised to demonstrate the naturally arising sample classes 
based on their expression profiles. The R package, prcomp, was used to perform 
PCA on data grouped by samples in columns and genes in rows. The first principal 
components were visualised using the R package 3dplot.  
2.5.2 Statistical Analyses 
Large numbers of statistical tests may result in false positives regardless of 
the null hypothesis being true. Procedures for controlling the false positive rate are 
commonplace in transcriptomics, the most notable being the Bonferroni correction. 
Bonferroni correction is used to control for study-wide error rate. Bonferroni critical 
P (alpha) is calculated by dividing the study-wide error rate by the number of tests 
performed. Typically critical P level for significance is set to 0.05, however these 
false positives can be controlled for by setting critical P levels at a lower value. 
Bonferroni correction is appropriate only when a single false positive in a set of 
tests would arise. Bonferroni correction is limited by the problem that error rate 
control cannot be localised to individual tests, and this correction does not 
distinguish between exploratory and data-driven testing. In this thesis, the 
Benjamini-Hochberg method derived from limiting false discovery rates to control 
error rates in multiple comparisons was used.   
Benjamini-Hochberg controls the false discovery rate, i.e. the portion of 
significant results that are actually false positives. Following next generation 
sequencing and microarrays the false discovery rate was set at 0.01. Benjamini-
Hochberg method ranks discoveries’ individual p-values from smallest to largest 
and ranked on a scale of 1-∞ respectively. Individual p-values  are compared to its 
Benjamini Hochberg critical value, (i/m)Q, where i is the rank, m is the total number 
of tests, and Q is the chosen FDR (0.01). The largest p-value that has p<(i/m)Q is 
significant, and all smaller p-values are also significant.  
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Chapter 3 
Transforming Growth Factor-β2 Modulates Gene Expression 
in the Human Trabecular Meshwork  
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3.1 Introduction 
 All TGF-β isoforms are expressed within the eye and localisation studies 
have identified the presence of TGF-β2 in the anterior segment of both healthy and 
diseased eyes385,386. TGF-β2 and related family members have been implicated in 
ocular disease and TGF-β2 signalling plays a central role in fibrotic ocular diseases 
and wound healing387,388. Physiologically, TGF-β is produced by the ciliary 
epithelium and lens epithelium in its latent form389. Aqueous humour (AH) bathes 
many tissues in the anterior segment of the eye; the corneal endothelium, 
trabecular meshwork, and iris390. The normal physiological AH contains various 
cytokines and growth factors of which TGF-β is predominant391,392. 
Multiple studies have identified elevated concentrations of TGF-β2 in the AH 
of primary open angle glaucoma (POAG) patients393–396. TGF-β2 is a major driver of 
extracellular matrix (ECM) secretion and deposition220, and in POAG it has been 
unequivocally shown that the increased concentration of TGF-β2 in the AH drives 
ECM expression and deposition in the trabecular meshwork (TM) cells397. 
Alterations within the ECM can restrict the outflow across the TM, providing a 
physical resistance affecting the contractile properties of the TM157, which in turn 
results in elevated intraocular pressure (IOP)119.  The specific molecular changes 
which lead to increased outflow resistance in the TM in POAG are unknown, 
however, there are two non-exclusive hypotheses or models: the ECM hypothesis 
and the contractility hypothesis130,397. In glaucoma the actin meshwork forms a 
cross-link pattern increasing the rigidity and contractility of the TM253, which leads 
to increased outflow resistance in the TM398–400. The alternative hypothesis 
proposes that changes in the ECM of the TM are related to elevated IOP397. The 
most characteristic structural change is an increase in ECM, with an accumulation of 
“plaque material”119,156,401, which correlates with the degree of axonal damage in 
the optic nerve130. Perfusion of normal TM in organ culture with TGF-β2 also 
induces changes in the ECM and pathological changes similar to those seen in the 
TM of POAG patients402.  
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TGF-β2 driven alterations in TM physiology are clinically relevant as elevated 
IOP is currently the only modifiable risk factor for POAG and is a key player in the 
disease pathogenesis52. There is overwhelming evidence from several prospective 
randomised multi-centre studies showing that reduction of IOP is neuro-protective, 
in the sense that it delays or even prevents the structural and functional damage of 
optic nerve axons in glaucoma403,404. Understanding the role of TGF-β2 in driving 
structural and functional alterations in the outflow pathway is essential to develop 
new therapies based on the modulation of TGF-β2 signalling in the trabecular 
meshwork164. 
Gene expression studies are essential in further developing our 
understanding of the role TGF-β2 may play in POAG. Three microarray studies have 
analysed alterations in gene expression in the TM induced by TGF-β2 in cultured 
human TM cells405,406; none of these studies made the complete datasets publicly 
available. Oligonucleotide Human Genome U133A arrays (Affymetrix) were used to 
study alterations in gene expression of 22,215 genes in cultured human TM cells 
from 5 donors treated for 72hrs with 1ng/mL of TGF-β2405. Significant differential 
gene expression was based on a twofold fold change: 19 genes were up-regulated, 
and 2 genes down-regulated. Proteomic analysis of the same cells was performed 
with two-dimensional electrophoresis and mass spectrometry. This initial 
microarray and proteomics study identified alterations in ECM components and cell 
cytoskeletal proteins405.   
Using the same U133A Affymetrix array, and RNA extracted from cultured 
TM cells treated with 300pM TGF-β2 for 72hrs, alterations in several genes involved 
in growth factor signalling, ECM homeostasis and cell cytoskeleton were 
identified407. 16 genes were found to be differentially expressed following 
treatment with TGF-β2; these included; vascular endothelial growth factor (VEGF), 
follistatin-like 3 (FSTL3), fibroblast growth factor 5 (FGF5), latent binding protein-1 
and -2 (LTBP1 and 2), and SMAD7407. Subsequently, using a more comprehensive 
array (Affymetrix GeneChip® Human Genome U133 Plus 2.0 Array) containing 54K 
probe sets, on RNA from  cultured TM cells from donors with glaucoma (n=3) 
treated with 5ng/mL of TGF-β2 for 16 hours, a twofold or greater up-regulation in 
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ECM-related genes compared to untreated control cells was detected406. The full 
dataset was not made publicly available, however examples of the altered genes 
included thrombospondin 1, plasminogen activator inhibitor (PAI) – 1, collagen 4A1 
(COL4A1) and ADAM metallopeptidase with thrombospondin type 1 motif 5 
(ADAMTS5)406. 
Across all three microarray studies common genes were limited to v-maf 
musculoaponeurotic fibrosarcoma oncogene homolog (MAF), PAI-1 and 
LTBP1244,405,406. Several key genes previously identified using q-PCR in prioritised 
targets were not detected in these microarray studies, although there is significant 
evidence they are regulated by TGF-β in the human TM. Among these were, 
thrombospondin-1, fibronectin, collagen type VI, tissue transglutaminase, αβ-
crystallin, myocillin, connective tissue growth factor (CTGF) and TGF-β1408–413. 
At their core, microarrays are simple devices to simultaneously measure the 
relative concentration of many different DNA or RNA sequences and they are not 
without their limitations. Firstly, arrays provide indirect measures of relative 
concentration. Due to kinetics of hybridisation, the signal level at a given location 
on the array is not linearly proportional to concentration of the species hybridising 
to the array. Secondly, especially with respect to complex mammalian genomes, it 
is often difficult to design arrays in which multiple DNA/RNA sequences will not 
bind to the same probe on the array. This is particularly problematic for gene 
families and genes with splice variants414. Finally, microarrays can only detect 
sequences that they have been designed to detect; novel and unknown transcripts 
cannot be identified through microarrays. This is highlighted in the data obtained 
for fibronectin expression obtained in the microarray studies244,405,407.  All three 
studies failed to detect more than a two-fold upregulation in fibronectin244,405,407 
despite multiple previous studies reporting a significant increase in fibronectin 
expression and protein levels in response to TGF-β2 treatment of human cultured 
TM cells415. Fibronectin undergoes high levels of alternative splicing generating up 
to 20 protein isoforms and limited probe coverage in the microarray design244.   
RNA-Seq technology offers significant benefits over previous microarray 
technologies. In RNA-Seq millions of RNAs are randomly sampled and sequenced 
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simultaneously. The sequence identifies each ‘read’ and a digital expression value is 
obtained for each gene by counting the number of reads assigned to it. Both known 
and novel transcripts and splicing events can be detected. This technology offers 
increased specificity and sensitivity, for enhanced detection of genes, transcripts, 
and differential expression. With array hybridisation technology, gene expression 
measurement is limited by background at the low end and signal saturation at the 
high end. RNA-Seq technology quantifies discrete, digital sequencing read counts, 
offering a broader dynamic range. RNA-Seq provides unbiased detection of novel 
transcripts and the sequencing coverage depth allows for easier detection of rare 
and low-abundance transcripts416.  
  
 
 
3.2 Aim 
 The aim of this study was to employ RNA-seq to investigate genome-wide 
alterations in the transcriptome of normal trabecular meshwork cells in the 
presence or absence of TGF-β2 and detect pathophysiological mechanisms 
underlying glaucoma. 
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3.3 Materials and Methods 
3.3.1 Sample Collection, Preparation, and Tissue Culture Establishment 
 Cadaveric eyes were provided by the Liverpool Research Eye Bank and 
handled in accordance to the tenets of the Declaration of Helsinki (Ethics Code; 
RETH000833). Globes were excluded if the maximum post-mortem time exceeded 
48hours. Human trabecular meshwork cells were cultured directly from the anterior 
segment using the explant method described previously (2.1.3). Cells were 
maintained in DMEM-low glucose (Sigma, UK) supplemented with 10% fetal calf 
serum (Bio Sera, UK), 2mM L-glutamine (Sigma, UK), Pen/Step (Sigma, UK), and 
2.5ug/mL Fungizone (Amphotericin B, Sigma, UK). Samples were incubated at 37oC 
(5%CO2 and 95% humidity) for 7-14 days with a medium changed every 2 days 
ensuring not to disturb the explant. Glaucomatous TM samples (n=3) were also 
used in this experiment and cultured as above. Specific culture techniques are 
outlined in Chapter 2 (2.3).  
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Donor I.D Age Sex Medical History 
LGP-1 57 Male No Glaucoma 
History 
LGP-2 65 Male No Glaucoma 
History 
NTM002 57 Male No Glaucoma 
History 
NTM009 57 Male No Glaucoma 
History 
NTM720 64 Male No Glaucoma 
History 
NTM020 88 Female No Glaucoma 
History 
GTM 304-04 74 Female POAG 
GTM 730-03 88 Male POAG 
GTM 034 86 Male POAG 
    
Table 3.1: Human TM Cell Donor Information 
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3.3.2 Characterisation of Human Trabecular Meshwork Cells 
 The phenotype of the cultured cells was assessed on the basis of the 
distinctive morphology of human TM cells and positive immunofluorescence (IF) 
staining of caveolin1 (CAV1), caveolin2 (CAV2), aquaporin 1 (AQP1), and myocilin 
(MYOC). Experimental details are highlighted in section 2.2.1. 
3.3.3 TGF-β2 Stimulations 
All confluent cells were mycoplasma tested as described previously (2.1.5) 
prior to experimentation. Human TM cells between passages 5 and 7 were grown to 
80% confluence and growth arrested using serum free medium prior to stimulation. 
Cells were stimulated with recombinant human TGF-β2 (R&D Systems, UK) at a 
concentration of 5ng/mL for 4 hours or 24hours. Vehicle control cells were 
stimulated with equal volumes of 4mM HCl and 0.1%tv BSA solution. Treatment 
time points and concentration were determined based on preliminary experiments 
which evaluated the activation of the TGF-β signalling pathway with 1ng/mL, 
5ng/mL and 10ng/mL TGF-β2 over a time period of 0-72 hours. Following 4 and 24 
hours of stimulation total RNA was extracted (2.4.1). 
3.3.4 Total RNA Extraction and QC 
 Total RNA from human cultured trabecular meshwork cells was isolated 
using the Qiagen Universal All Prep kit (Qiagen, UK) as per manufacturers’ 
specifications, described in (2.4.1). Total RNA was quantified initially on the 
Nanodrop-2000, and quality was determined by the Bioanalyser 2100 as described 
in (2.4.2 and 2.4.3 respectively). 
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3.3.5  RNA-Seq of Cultured Normal Human Trabecular Meshwork Cells 
3.3.5.1 Template Preparation, rRNA Depletion, and cDNA Library Construction, 
Purification and QC 
 All mRNA sequencing experiments were conducted at Exiqon Services, 
Denmark. Two groups of mRNA libraries were prepared: a group of 5 control 
human trabecular meshwork samples (referred to as ‘CK’_group in the remainder of 
Chapter 3) and a group of 5 treated samples (referred to as ‘TK’_group in the 
remainder of Chapter 3). The starting material of total RNA (100ug) was enriched 
for mRNA using the oligodT bead system and the isolated mRNA was enzymatically 
fragmented. First and second strand synthesis were performed and the double 
stranded cDNA was purified (AMPure XP, Beckman Coulter, Denmark). The cDNA 
was end repaired, 3’ adenylated and Illumina sequencing adaptors ligated onto the 
fragments ends. Following this the mRNA stranded libraries were pre-amplified 
with PCR and purified (AMPure XP).  
 Libraries size distribution was validated and quality was inspected on a 
Bioanalyser high sensitivity DNA chip (Agilent Technologies, UK). High quality 
libraries were quantified using q-PCR, the concentration normalised and the 
samples pooled according to the project specification (number of reads).  
 The library pools were re-quantified with q-PCR and optimal concentration 
of the library pool was used to generate the clusters on the surface of a flowcell 
before sequencing on an instrument using Nextseq 500, High Output sequencing kit 
(51 cycles) according to the manufacturer instructions (Illumina Inc., USA).  
3.3.6 RNA-Seq Data Analysis 
 Following sequencing, intensity correction and base calling (into BCL files), 
FASTQ files were generated using appropriate bcl2fastq software (Illumina Inc.) 
which includes quality scoring of each individual base in a read. At this stage the 
data was separated for paired-end reads to determine whether the second read 
significantly differs from the first in terms of overall quality.  
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 Data analysis was performed by Exiqon (Exiqon, Denmark). The components 
of Exiqon NGS RNA-Seq analysis pipeline include Bowtie2 (v.2.2.2), Tophat (v2.0.11) 
and Cufflinks (v2.2.1) as described in Chapter 2 (2.5.1). 
As we were comparing groups, Cuffdiff, normally used for unpaired samples 
to calculate FPKM (number of fragments per kilobase per million mapped 
fragments) was replaced with featureCounts.  
 featureCounts was used to calculate the counts of mapped reads in specific 
genes when groups with paired samples were compared, and generalised linear 
model likelihood ratio test (glmLRT) implemented by edgeR was used to test 
differential expression across submitted samples using featureCounts input. 
 Post processing of Cufflinks and Cuffdiff was performed using CummeRbund 
and Bioconductor software to generate visual representations of sequencing 
results.  
3.3.7 mRNA-Seq Data Validation 
 Validation of RNA samples (CK_group and TK_group) was performed using 
Primer Design Ltd primer assays (Primer Design Ltd, UK). Specific q-PCR conditions 
are outlined in Chapter 2 (2.47). q-PCR was performed for selected significantly 
altered differentially expressed genes. 1ug of total RNA was reverse transcribed 
into cDNA using miScript II RT (Qiagen, UK) kit according to manufacturers’ 
specifications (2.4.5). Real time analysis was performed using Primer Design Ltd. 
custom primers for target genes (see Table 3.2 below). q-PCR was performed on a 
LightCycler®480 real-time PCR system (Roche Diagnostics, Switzerland). All mRNA 
were measured at CT threshold levels and normalised with the average CT values of 
a reference gene; GAPDH. Values were expressed as fold increase over the 
corresponding values for control by the 2-ΔΔCT method. Two independent 
experiments were performed and the average (±SEM) results were calculated using 
GraphPad software (GraphPad Software, San Diego, USA). Data were expressed as 
the mean values ± SEM and analysed using student t-test. Statistical differences in 
the mean were considered statistically significant as p<0.05. 
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Primer 
Name 
Sequence  
EDN1 F 5’-CCAGGAGCTCCAGAAACAG-3’ 
R 5’-GAGCAGGAGCAGCGCTT-3’ 
NOX4 F 5’-CACAGACTTGGCTTTGGATTTC-3’ 
R 5’-GGATGACTTATGACCGAAATGATG-
3’ 
FSTL3 F 5’-GACTTCATCAGGAACAAGTGGTC-3’ 
R 5’-AGGTCCGTAGCCATGAGGAT-3’ 
FNDC1 F 5’-GACTTCATCAGGAACAAGTGGTC-3’ 
R 5’-AGGTCCGTAGCCATGAGGAT-3’ 
KANK4 F 5’-CATCTTCAGCCTTGAATTCCTCAT-3’ 
R 5’-TTCTAATGTGCTAATGTGCTCCTG-3’ 
ATP10A F 5’-TCGGCATTGTCATCTACGCA-3’ 
R 5’-AGGAGCAGGACACACCAGA-3’ 
WNT2B F 5’-TTGGAGTGGTAGCCATAAGCAT-3’ 
R 5’-TTGAACGCTGACTGTGTAGGT-3’ 
LDLRAD4 F 5’-AAGAGTTGGAGCACAGGCTT-3’ 
R 5’-TTACAGACCAGCGAACCAAGA-3’ 
PMEPA1 F 5’-TTAGACTCCGCTCTTGTTCTCC-3’ 
R 5’-ATGCTCTCCTCTGGTCACCT-3’ 
CDKN2B F 5’-GCAAGCCTGTCTGAGACTCA-3’ 
R 5’-ACACACTCCTAAATATCCCTGGAA-3’ 
CDKN2B-
AS1 
F 5’-CCACATCAATGATGAAGCCAGAA-3’ 
R 5’-TTGATCTCTGCTGTTGAATCAGAAT-
3’ 
RASL11B F 5’-CCTCACCAAACGATTCATCGG-3’ 
R 5’-ACCTGGAGTGTCTTGAACCTG-3’ 
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Table 3.2: Primer Design Ltd Primer Assays and Custom GAPDH Primer Pair 
Sequence. Custom primer assays were designed by Primer Design Ltd. for RNA-Seq 
validation. GAPDH reference primer was designed in-house.
OSR2 F 5’-TCTCCACACAAATGTCCCACA-3’ 
R 5’-TTTCGCCTGAACACTTTGCC-3’ 
LEFTY2 F 5’-
GGTGGTCTTAATGTAGGTCTTAACTT-3’ 
R 5’-AGACAGGAAATGGAAGGACACA-3’ 
DACT1 F 5’-CTTCATGCTGTGGCTGTGC-3’ 
R 5’-GGACGGTAAGGAACTGTCTGT-3’ 
GAPDH F 5’-CGAGCCACATCGCTCAGACACC-3’ 
R 5’-
GGTCAATGAAGGGGTCATTGATGGCAAC-
3’ 
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3.4 Results 
3.4.1 Characterisation of Human Trabecular Meshwork Cells 
 Human TM cells were cultured directly from human cadaver eyes collected 
from donor patients (n=6). The phenotype of the cells was assessed based on the 
distinctive morphology of human TM cells (Figure 3.1) and positive IF staining of 
caveolin 1, caveolin 2, aquaporin 1, and myocilin (Figure 3.2 A-F). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: Representative Phase Contrast Microscope Images of Human Cultured 
TM Cells. (A) Before TGF-β2 treatment, (B) Post growth arrest, and (C) Post TGF-β2 
treatment, at 4 and 24 hours as indicated. Donor: LGP-1; Scale Bar: 20µm; passage; 
6. Cultured TM cells are known to grow in a monolayer with no multi-layered 
growth417.  
 
 
4 Hours TGF-β2 Treatment 
A 
C 
C 
B 
B 
A 
24 Hours TGF-β2 Treatment 
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Figure 3.2: Representative Fluorescent Confocal Microscope Images of Human TM 
Cells; (A) Vimentin expression is low in human TM cells in comparison to (B) 
Vimentin expression in human tenon fibroblasts. (C) Caveolin 1 and (D) Caveolin 2 
are expressed in human TM cells with localisation to the cytoplasm and perinuclear 
region. (E-F) Myocilin expression in human TM cells is induced by dexamethasone 
stimulation. (G) Aquaporin-4 is expressed in human TM cells, localised to the 
plasma membrane region. Scale Bar: 20µm. 
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HTM031 
HTM031 Untreated 
HTM031 
HTM031 100nM DEX 
Human Tenon Fibroblasts 
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3.4.2 RNA-Seq Analysis of Human Trabecular Meshwork Cells in the Absence or 
Presence of TGF-β 2 
3.4.2.1 RNA-Seq Summary  
 Two mRNA libraries (CK_group and TK_group) constructed using AMPure XP 
beads were pooled and sequenced on a flow cell using NextSeq500, High Output 
sequencing kit to obtain 30 million reads and 50bp paired-end reads. Paired-end 
reads were separated to determine whether the second read significantly differed 
from the first in overall quality. Majority of the data had a Q score greater than 30 
(one base call in 1000 is predicted to be incorrect). Mapping of sequencing data 
represents a useful QC step in RNA-Seq analysis pipeline as it can help evaluate 
quality of samples. For this purpose reads are classified as follows; 
Unmapped Reads: Reads that do not align to the reference genome (H.sapiens, 
hg19 / GRC37, UCSC Genome Browser), out mapped reads or high abundance reads 
such as polyA and polyC homopolymers. 
rRNA reads: RNA reads of ribosomal origin. 
mtRNA reads: RNA reads of mitochondrial origin. 
Mappable reads: RNA reads that align to the reference genome (as above). 
Table 3.3 shows the total number of reads obtained for each sample and genome 
mapping for each sample was on average 82%. Uniformity of the samples mapping 
results suggests that the samples are comparable.  
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Table 3.3: Summary of the Mapping Results for Each Sample. Reads from each of 
the two libraries (CK_Group and TK_Group) were extracted based on their unique 
I.Ds. In total 40-57 million reads per sample were obtained. Based on alignment to 
the reference genome, H.sapiens, hg19 / GRC37, UCSC Genome Browser, the 
number of identified genes per sample was calculated. Reliability of identified 
genes increased with the number of identified fragments. All genes were included 
in statistical comparison of two groups, irrespective of how few calls have been 
made. Table 3.4 (below), indicates that all samples included in this study have 
comparable call rates. 
  
Sample Name Total Readcount rRNA(%) mtRNA(%) Mapped(%) Unmapped(%) 
CK_Group1 57023686 0.71 5.51 80.13 13.65 
CK_Group2 44504091 0.52 2.21 80.21 17.05 
CK_Group3 40024297 0.4 2.04 83.82 13.74 
CK_Group4 47803322 0.27 4.12 82.29 13.32 
CK_Group5 46181400 0.23 4.67 82.07 13.01 
TK_Group1 47487795 0.57 4.51 80.4 14.52 
TK_Group2 40939102 0.16 1.68 84.8 13.36 
TK_Group3 55439358 0.38 1.62 84.05 13.96 
TK_Group4 48512081 0.18 2.27 83.66 13.89 
TK_Group5 44826263 0.81 3.94 82.06 13.19 
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Sample Name Gene Isoform 
CK_Group1 17328 67943 
CK_Group2 17368 65624 
CK_Group3 16837 65785 
CK_Group4 17111 68083 
CK_Group5 16855 64011 
TK_Group1 17050 65102 
TK_Group2 16544 64816 
TK_Group3 16146 64874 
TK_Group4 16451 63755 
TK_Group5 16751 63966 
 
Table 3.4: Number of Genes and Isoforms Identified in Each Sample. All genes and 
isoforms identified in each sample have a fragment count estimation of at least 10 
counts per gene. 
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3.4.2.2 Principal Component Analysis  
 Principal component analysis (PCA) is a method used to identify the main 
components of variation in a data set. By identifying three principal components, 
large data sets can be visualised to demonstrate the naturally arising sample classes 
based on their expression profiles.  
 The R package, prcomp, was used to perform PCA on FPKM transformed 
counts data from control (CK_Group) and treated (TK_Group) cells. The first 
principal components were visualised using the R package 3dplot. In Figure 3.3 
(below), cells are coloured while donor pairs are represented by spheres of the 
same size. Samples separate in different regions of the PCA plot corresponding to 
the principal sources of variation within the experiment. Sample groups in this 
experiment, CK_Group and TK_Group, segregate on the first and second principal 
component axes, but there is a clear relationship between donor pairs, indicating 
the need to incorporate donor source as a factor in an expression analysis of this 
data.  
 When biological differences between samples are pronounced it can be 
seen in the primary components of the variation of the data. Samples separate in 
different regions of the PCA plot corresponding to their biology. Sample groups in 
this experiment, CK_group and TK_Group, tend to cluster on the primary 
component and sample cluster pairs on the secondary component. 
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Figure 3.3: Principal Component Analysis of RNA-Seq Data for Control Untreated 
TM Cells and TGF-β2 Treated TM Cells. The PCA was perfomed on all samples 
passing QC using the top 500 genes that have the largest coefficient of variation 
based on FPKM counts. Cell treatments are coloured according to the key and 
donor pairs are represented by spheres of the same size. Based on normalised 
FPKM (abundance) for each gene for each sample. 
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3.4.2.3 Heat Map and Unsupervised Clustering 
 Heat maps were generated using the Bioconductor package ‘pheatmap’ 
from FPKM counts of control (CK_Group) and treated (TK_Group) cells, using a 
Pearson Correlation distance and a complete agglomeration method, with gene-
wise scaled and centred log2 transformed FPKM count data. 
 The heat map diagram below (Figure 3.4) shows the results of the two-way 
hierarchical clustering of RNA transcripts and samples. It includes 500 genes based 
on the false discovery rate (FDR) p-value in the control (CK_Group) vs treated 
(TK_Group) expression analysis. Each row represents one gene and each column 
represents one donor. The colour represents relative expression level of transcript 
across all donors. The colour scale is shown below; orange represents an expression 
level above the mean; blue represents an expression level below the mean.  
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Figure 3.4 Heat Map and Unsupervised Clustering of Human TM Cells Treated with TGF-
β2. Hierarchical clustering by sample and transcripts was performed on all samples 
passing the QC using the top 500 genes that have the largest coefficient of variation 
based on FPKM counts.  
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3.4.3 Functional Analysis of Gene Pathways Involved in TGF-β2 Stimulation of 
Human Trabecular Meshwork Cells 
3.4.3.1 Differentially Expressed Genes in Human Trabecular Meshwork Cells in 
the Presence or Absence of TGF-β2 Obtained from RNA-Seq Analysis 
 The top 500 differentially expressed genes were ranked by false discovery 
rate (FDR), the most significantly altered based on their FDR are shown in Appendix 
(8.4). From the top 500 DEGs based on FDR the 50 most up- and down-regulated 
genes were ranked by LogFC and are shown in Table 3.5 and 3.6 respectively.  
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Gene ID Gene Name LogFC 
Up-Regulated Genes 
KANK4 KN Motif and Ankyrin Repeat 11.08 
LINC00312 Long Intergenic Non-Protein Coding RNA 312 9.65 
C4orf26 Chromosome 4 Open Reading Frame 26 9.39 
ISLR2 Immunoglobulin Superfamily Containing Leucine 7.91 
LDLRAD4 Low Density Lipoprotein Receptor Class A Domain Containing 4 7.23 
RASL11B RAS Like Family 11 Member B 7.12 
IL11 Interleukin 11 7.08 
LEFTY2 Left-Right Determination Factor 2 6.94 
EDN1 Endothelin 1 6.58 
LMCD1 LIM And Cysteine Rich Domains 1 6.35 
S1PR5 Sphingosine-1-Phosphate Receptor 5 6.14 
NOX4 NADPH Oxidase 4 5.87 
NPPB Natriuretic Peptide B 5.86 
PMEPA1 Prostate Transmembrane Protein Androgen Induced 1 4.81 
SEMA7A Semaphorin 7A 4.61 
CDKN2B Cyclin Depended Kinase Inhibitor 2B 4.29 
FSTL3 Folistatin-Like 3 4.19 
MYOZ1 Myozenin 1 4.13 
INHBE Inhibin Beta E Subunit 4.12 
DGKI Diacylglycerol Kinase Iota 4.05 
FNDC1 Fibronectin Type III Domain-Containing Protein 1 4.02 
TLL2 Tolloid-like 2 3.92 
XYLT1 Xylosyltransferase 1 3.88 
COMP Cartilage Oligomeric Matrix Protein 3.82 
TSPAN13 Tetraspanin 13 3.75 
NUAK1 NUAK Kinase Family Member 1 3.69 
ATP10A ATPase Phospholipid Transporting 10A 3.62 
DACT1 Dishevelled Binding Agonist of Beta Catenin 1 3.58 
CDH2 Cadherin 2 3.49 
TENM4 Teneurin Transmembrane Protein 4 3.47 
ADAMTS4 ADAM Metallopeptidase with Thrombospondin Type 1 Motif 4 3.27 
SPHK1 Sphingosine Kinase 1 3.10 
LANCL2 LanC-like 2 3.01 
PPAPDC1A Phosphatidic Acid Phosphatase Type 2 Domain-Containing Protein 1A 2.99 
ITGA11 Integrin Subunit Alpha 11 2.96 
ADAM19 ADAM Metallopeptidase Domain 19 2.89 
PXDC1 PX Domain Containing 1 2.62 
ENC1 Ectodermanl-Neural Cortex 1 2.50 
DCBLD1 Discoidin, CUB, And LCCL Domain Containing 1 2.46 
SMAD7 SMAD Family Member 7 2.45 
SKIL SKI-like Proto-Oncogene 2.19 
 
Table 3.5: Top 50 Up-Regulated Genes in Cultured Human TM Cells in the Presence or Absence of TGF-β2. 
Pools of 5 donor samples for each group (control CK_Group and TGF-β2 Treated TK_Group) were used to 
generate the results from mRNA-Seq. LogFC= Log fold change. 
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Gene ID Gene Name LogFC 
Down-Regulated Genes 
MOV10 MOV10 RISC Complex RNA Helicase -1.68 
CPA4 Carboxypeptidase A4 -1.83 
ALDH3B1 Aldehyde Dehydrogenase 3 Family Member B1 -1.92 
TENC1 Tensin Like C1 Domain Containing Phosphatase -1.98 
NABP1 Nucleic Acid Binding Protein 1 -1.98 
ZFP36 Zinc Finger Protein 36 -2.13 
UBE2L6 Ubiquitin Conjugating Enzyme E2 L6 -2.17 
PARP14 Poly(ADP-ribose) polymerase Family Member 14 -2.231 
ADM Adrenomedullin -2.24 
S1PR3 Sphinosine-1-Phosphate Receptor 3 -2.25 
ISYNA1 Inositol-3-Phosphate Synthase 1 -2.31 
PHLDA1 Pleckstrin Homology Like Domain Family A Member 1 -2.42 
SMAD3 Smad Family Member 3 -2.46 
GMPR Guanosine Monophosphate Reductase -2.47 
DUSP6 Dual Specificity Phosphatase 6 -2.49 
PARP10 Poly(ADP-ribose) polymerase Family Member 10 -2.62 
RAB27B RAB27B, Member RAS Oncogene Family -2.69 
CSF1 Colony Stimulating Factor 1 -2.69 
SEMA3D Semaphorin 3D -2.71 
TOP2A DNA Tooisomerase II Alpha -2.74 
DDX60 DExD/H-Box Helicase 60 -2.80 
PTX3 Pentraxin 3 -2.93 
WNT2B Wnt Family Member 2B -2.96 
PLEKHA6 Pleckstrin Homology Domain Containing A6 -2.96 
PLEKHG4 Pleckstrin Homology and RhoGEF Domain Containing G4 -3.01 
AKR1C2 Also-Keto Reductase Family 1 Member C2 -3.30 
LINC00341 Spectrin Repeat Containing Nuclear Envelope Family Member 3 -3.31 
AKR1C3 Aldo-Keto Reductase Family 1 Member C3 -3.35 
IFIT3 Interferon Induced Protein With Tetratricopeptide Repeats 3 -3.54 
SLC40A1 Solute Carrier Family 40 Member 1 -3.59 
COL21A1 Collagen Type XXI Alpha 1 Chain -3.62 
PSMB9 Proteosome Subunit Beta 9 -3.64 
TMEM140 Transmembrane Protein 40 -3.65 
AKR1C1 Aldo-Keto Reductase Family 1 Member C1 -3.67 
IFIT2 Interferon Induced Protein With Tetratricopeptide Repeats 2 -3.84 
SLC2A12 Solute Carrier Family 2A Member 12 -4.16 
AKR1B10 Aldo-Keto Reductase Family 1 Member B10 -4.24 
APOL3 Apolipoprotein L3 -4.35 
OSR2 Odd-Skipped Related Transcription Factor 2 -5.37 
STEAP4 STEAP Family Member 4 -5.53 
ADH1B Alcohol Dehydrogenase 1B -7.66 
Table 3.6: Top 50 Down-Regulated Genes in Cultured Human TM Cells in the Presence or Absence of 
TGF-β2. Pools of 5 donor samples for each group (control CK_Group and TGF-β2 Treated TK_Group) 
were used to generate the results from mRNA-Seq. LogFC= Logfold change. 
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3.4.3.2 Visual Identification of RNA Transcripts Obtained by RNA-Seq Analysis 
 Volcano plots provide a way to visualise RNA transcripts displaying large-
magnitude changes which are also statistically significant. The volcano plot was 
constructed by plotting the expression FC on the y-axis, and the log CPM (counts-
per-million) between the two exprimental groups (CK_Group and TK_Group) on the 
x-axis. Two regions of interest exist on the plot; the extreme right of the plot 
indicates high statistical significance and the top and bottom of the plot indicates 
strongly up- or down-regulated genes respectively.  
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Figure 3.5: Volcano Plot Showing the Relationship Between the LogFC and the 
Average Log Counts-per-Million (CPM). The relationship between statistical 
significance and LogFC in normalised expression between the experimental groups, 
CK_Group and TK_Group, are shown in the plot. FC= Fold Change. Key: Up-Reg= 
Significantly up-regulated genes between the two sample groups are indicated by 
the red dots; Not DE= Genes were not differentially expressed between the two 
sample groups; Down-Reg= Genes that were significantly down-regulated between 
the two sample groups are indicated by blue dots. 
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3.4.3.3 TGF-β2 Activated Processes in Cultured Human Trabecular Meshwork 
Cells  
 Exiqon performed a gene ontology (GO) enrichment analysis with genes 
found to be differentially expressed in control (CK_Group) vs treated (TK_Group) 
comparison. Significance was ranked by FDR. Two different statistical tests, Fisher’s 
test and Elim method, were used and compared to generate Table 3.7.  
In house analysis of biological processes was performed on genes with an 
FDR p-value <0.025 in the control (CK_Group) vs treated (TK_Group) expression 
analysis using Core Analysis in the Ingenuity Pathway Analysis (IPA,  Qiagen, UK)418. 
This functional analysis of genes found to be differentially expressed includes the 
identification of enriched canonical pathways (functional processes defined in the 
Ingenuity Knowledge Base), the identification of potential up-stream regulators and 
potential down-stream effects of the differentially expressed gene set. 
Interestingly, similar processes were enriched through IPA in relation to ECM 
organisation, a process identified by Exiqon analysis (Table 3.7). 254 IPA canonical 
pathways were significantly enriched (Fishers’ Exact Benjamini Hochberg (BH) 
adjusted p<0.05). The top ranked canonical pathways with an enrichment score >4 
(Fisher’s Exact BH adjusted p<0.0001) are tabulated in Table 3.8 below.  
 Table 3.7 and Table 3.8 include several canonical pathways and processes of 
direct relevance to the current study; including, RhoA signalling, ECM and 
cytoskeletal organisation, and inflammatory-related processes. Figure 3.7 depicts a 
canonical pathway map for RhoA signalling, a canonical pathway found to be 
enriched through IPA analysis. Figure 3.6 identifies the top canonical pathways of 
the top 1% differentially expressed genes in TGF-β2 treated human TM cells 
compared with control TM Cells. The activation score threshold was +/- 1.96 and 
canonical pathways enriched in this are regarded as significant. The sign of the Z-
score indicates the direction of regulation of the process, and enriched canonical 
pathways of p<0.0001 were determined as statistically significant. 
 Table 3.9 identifies the significantly DEGs associated with the RhoA 
signalling pathway identified in TGF-β2 treated human TM cells. 
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Class of Encoded Proteins Number Affected 
 
Annotated Significant 
Extracellular matrix organization 278 196 
Axon guidance 309 200 
Response to toxic substance 130 92 
Activation of signalling protein activity involved in unfolded 
protein response 
67 51 
Positive regulation of cell migration 217 148 
Regulation of apoptotic process 1041 617 
Negative regulation of multicellular organismal process 599 367 
Collagen fibril organization 41 29 
Cellular response to oxygen-containing compound 587 358 
Neural crest cell development 42 31 
G-protein coupled receptor signalling pathway 453 272 
Negative regulation of apoptotic process 630 367 
Signal transduction 3603 2119 
Single-organism cellular process 8273 4653 
Phagocytosis 130 91 
Artery morphogenesis 41 29 
Hair follicle development 68 49 
Sprouting angiogenesis 48 39 
Inflammatory response 371 232 
Epithelial tube morphogenesis 258 166 
 
Table 3.7: Significant Biological Processes Between the TGF-β2 Treated TM Cells 
and Control Cells (TK_Group and CK_Group). Significant biological processes for 
differentially expressed genes between CK_Group and TK_Group are outlined 
above. Of 17186 genes annotated, 10106 were significantly associated with 
biological processes. 
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Ingenuity 
Canonical 
Pathways 
 -log(p-value) Ratio z-score Downregulated  Upregulated  
Axonal Guidance 
Signalling 
9.60E+00 4.20E-01 NaN 161/445 (36%) 216/445 (49%) 
Epithelial 
Adherens 
Junction 
Signalling 
9.49E+00 5.31E-01 NaN 35/143 (24%) 85/143 (59%) 
Germ Cell-
Sertoli Cell 
Junction 
Signalling 
8.94E+00 5.03E-01 NaN 52/169 (31%) 97/169 (57%) 
Molecular 
Mechanisms of 
Cancer 
8.24E+00 4.22E-01 NaN 146/370 (39%) 185/370 (50%) 
NRF2-mediated 
Oxidative Stress 
Response 
7.41E+00 4.68E-01 -0.745 89/190 (47%) 83/190 (44%) 
Integrin 
Signalling 
7.38E+00 4.58E-01 3.109 74/212 (35%) 118/212 (56%) 
Aryl 
Hydrocarbon 
Receptor 
Signalling 
7.33E+00 5.04E-01 -1.298 75/135 (56%) 45/135 (33%) 
Remodeling of 
Epithelial 
Adherens 
Junctions 
6.78E+00 5.91E-01 3.153 8/66 (12%) 48/66 (73%) 
RhoA Signalling 6.50E+00 5.00E-01 3.742 32/122 (26%) 66/122 (54%) 
Hepatic Fibrosis 
/ Hepatic 
Stellate Cell 
Activation 
6.13E+00 4.53E-01 NaN 62/181 (34%) 81/181 (45%) 
Regulation of 
the Epithelial-
Mesenchymal 
Transition 
Pathway 
5.75E+00 4.44E-01 NaN 69/187 (37%) 81/187 (43%) 
PI3K/AKT 
Signalling 
5.55E+00 4.80E-01 2.449 52/123 (42%) 65/123 (53%) 
Gap Junction 
Signalling 
5.49E+00 4.49E-01 NaN 57/167 (34%) 84/167 (50%) 
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Glioblastoma 
Multiform 
Signalling 
5.45E+00 4.53E-01 1.588 60/159 (38%) 84/159 (53%) 
IL-8 Signalling 5.37E+00 4.34E-01 0.333 79/196 (40%) 90/196 (46%) 
Xenobiotic 
Metabolism 
Signalling 
5.18E+00 4.07E-01 NaN 129/270 (48%) 83/270 (31%) 
Death Receptor 
Signalling 
5.07E+00 5.00E-01 -0.59 51/92 (55%) 34/92 (37%) 
Chronic Myeloid 
Leukemia 
Signalling 
4.99E+00 4.85E-01 NaN 45/103 (44%) 52/103 (50%) 
Colorectal 
Cancer 
Metastasis 
Signalling 
4.99E+00 4.12E-01 0.103 93/243 (38%) 115/243 (47%) 
IGF-1 Signalling 4.94E+00 4.81E-01 1.265 42/106 (40%) 56/106 (53%) 
ILK Signalling 4.90E+00 4.27E-01 1.835 64/192 (33%) 99/192 (52%) 
Actin 
Cytoskeleton 
Signalling 
4.88E+00 4.16E-01 4.613 64/221 (29%) 109/221 (49%) 
Role of Tissue 
Factor in Cancer 
4.86E+00 4.67E-01 NaN 45/120 (38%) 58/120 (48%) 
NGF Signalling 4.63E+00 4.62E-01 1.236 49/119 (41%) 63/119 (53%) 
Ephrin Receptor 
Signalling 
4.62E+00 4.30E-01 2.429 55/172 (32%) 96/172 (56%) 
B Cell Receptor 
Signalling 
4.55E+00 4.22E-01 0.688 70/187 (37%) 88/187 (47%) 
Osteoarthritis 
Pathway 
4.48E+00 4.15E-01 -0.679 75/205 (37%) 93/205 (45%) 
Interferon 
Signalling 
4.40E+00 6.11E-01 -2.4 23/36 (64%) 8/36 (22%) 
HIPPO Signalling 4.37E+00 4.88E-01 -0.756 39/86 (45%) 43/86 (50%) 
UVA-Induced 
MAPK Signalling 
4.33E+00 4.67E-01 -0.729 54/105 (51%) 42/105 (40%) 
Role of 
Macrophages, 
Fibroblasts and 
Endothelial Cells 
in Rheumatoid 
Arthritis 
4.29E+00 3.87E-01 NaN 119/302 (39%) 128/302 (42%) 
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Table 3.8: IPA Biological Processes Identified in TGF-β2 Treated TM Cells. 
Significant biological processes and canonical pathways for differentially expressed 
genes found between CK_Group and TK_Group are outlined above. Processes 
involve ECM organisation associated processes and activated canonical pathways 
including RhoA signalling. NaN = unrepresented value. 
  
Role of NFAT in 
Cardiac 
Hypertrophy 
4.26E+00 4.16E-01 2.138 74/190 (39%) 94/190 (49%) 
FLT3 Signalling 
in 
Hematopoietic 
Progenitor Cells 
4.18E+00 4.88E-01 0 36/82 (44%) 41/82 (50%) 
FcŒ≥ Receptor-
mediated 
Phagocytosis in 
Macrophages 
and Monocytes 
4.13E+00 4.73E-01 0 37/93 (40%) 39/93 (42%) 
Pancreatic 
Adenocarcinoma 
Signalling 
4.07E+00 4.49E-01 -0.801 55/118 (47%) 55/118 (47%) 
CD27 Signalling 
in Lymphocytes 
4.03E+00 5.38E-01 -0.784 30/52 (58%) 20/52 (38%) 
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Figure 3.6: Top Canonical Pathways of the Top 1% Differentially Expressed Genes 
in TGF-β2 Treated Human TM Cells Vs Control TM Cells. IPA revealed the top 
canonical pathways of the top 1% DEGs in TGF-β2 TM cells vs control TM cells. Z-
score threshold was ≤2, and enriched canonical pathways of p<0.0001 were 
determined as significantly enriched. 
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Figure 3.7: Canonical Pathway Map for RhoA Signalling Pathway. The highest (green) and lowest (orange/red) expressed genes derived from 
the RNA-Seq data set of pooled (n=5) control and treated cultured human TM cells.  
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Symbol Entrez Gene Name LogFC FDR (q-value) 
ABL2 ABL proto-oncogene 2, non-receptor tyrosine kinase 0.87 1.01E-06 
ACTA2 actin, alpha 2, smooth muscle, aorta 3.058 8.65E-15 
ACTB actin beta 1.412 6.15E-08 
ACTC1 actin, alpha, cardiac muscle 1 7.447 6.35E-24 
ACTG1 actin gamma 1 0.963 6.72E-05 
ACTG2 actin, gamma 2, smooth muscle, enteric 2.032 1.40E-10 
ACTR2 ARP2 actin related protein 2 homolog 0.742 5.26E-04 
ACTR3 ARP3 actin related protein 3 homolog 1.12 3.91E-07 
ANLN anillin actin binding protein -1.73 1.64E-22 
ARHGAP5 Rho GTPase activating protein 5 0.694 3.96E-05 
ARHGAP6 Rho GTPase activating protein 6 -3.115 1.19E-15 
ARHGAP9 Rho GTPase activating protein 9 1.613 1.85E-03 
ARHGAP12 Rho GTPase activating protein 12 -0.499 1.02E-02 
ARHGAP35 Rho GTPase activating protein 35 -0.726 1.66E-04 
ARPC2 actin related protein 2/3 complex subunit 2 0.913 4.89E-06 
ARPC3 actin related protein 2/3 complex subunit 3 0.419 1.50E-02 
ARPC4 actin related protein 2/3 complex subunit 4 0.52 2.24E-03 
ARPC5 actin related protein 2/3 complex subunit 5 0.935 1.52E-05 
BAIAP2 BAI1 associated protein 2 1.702 8.86E-21 
CDC42EP1 CDC42 effector protein 1 0.678 2.27E-04 
CDC42EP3 CDC42 effector protein 3 -0.853 8.83E-05 
CDC42EP4 CDC42 effector protein 4 -2.196 5.45E-18 
CFL1 cofilin 1 0.866 9.51E-05 
CFL2 cofilin 2 0.574 8.07E-03 
CIT citron rho-interacting serine/threonine kinase -3.495 6.32E-23 
DLC1 DLC1 Rho GTPase activating protein 2.53 4.94E-36 
EZR ezrin 0.677 6.57E-03 
GNA12 G protein subunit alpha 12 0.623 2.11E-04 
IGF1 insulin like growth factor 1 6.666 1.89E-09 
LIMK1 LIM domain kinase 1 1.394 2.14E-17 
LIMK2 LIM domain kinase 2 2.51 4.32E-30 
LPAR1 lysophosphatidic acid receptor 1 -0.656 9.79E-04 
LPAR3 lysophosphatidic acid receptor 3 -1.279 4.72E-03 
LPAR5 lysophosphatidic acid receptor 5 4.143 2.87E-06 
LPAR6 lysophosphatidic acid receptor 6 -1.918 5.77E-10 
MPRIP myosin phosphatase Rho interacting protein 0.551 2.05E-03 
MSN moesin 0.949 3.72E-06 
MYL6 myosin light chain 6 1.01 1.45E-05 
MYL7 myosin light chain 7 7.411 2.03E-38 
MYL9 myosin light chain 9 1.284 3.24E-05 
MYL12A myosin light chain 12A 1.064 1.50E-06 
MYL12B myosin light chain 12B 0.652 9.82E-04 
NEDD4 
neural precursor cell expressed, developmentally 
down-regulated 4, E3 ubiquitin protein ligase 1.508 8.65E-18 
NGEF neuronal guanine nucleotide exchange factor 2.608 9.47E-13 
NRP2 neuropilin 2 0.663 3.76E-04 
PFN1 profilin 1 0.711 4.46E-04 
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PFN2 profilin 2 -0.954 5.74E-09 
PIP5K1A 
phosphatidylinositol-4-phosphate 5-kinase type 1 
alpha 0.781 1.19E-03 
PLD1 phospholipase D1 -1.613 4.27E-13 
PLEKHG5 
pleckstrin homology & RhoGEF domain containing 
G5 0.518 1.99E-02 
PPP1R12A protein phosphatase 1 regulatory subunit 12A 0.724 8.83E-05 
PPP1R12B protein phosphatase 1 regulatory subunit 12B -2.167 9.65E-19 
PTK2 protein tyrosine kinase 2 0.448 5.62E-03 
PTK2B protein tyrosine kinase 2 beta -1.175 6.23E-09 
RAPGEF2 Rap guanine nucleotide exchange factor 2 0.769 1.89E-06 
RHOA ras homolog family member A 0.465 2.21E-02 
RHPN2 rhophilin Rho GTPase binding protein 2 1.723 1.16E-06 
RND3 Rho family GTPase 3 -1.224 9.94E-08 
ROCK1 
Rho associated coiled-coil containing protein kinase 
1 0.392 1.99E-02 
RTKN rhotekin 0.667 8.61E-04 
SEMA3F semaphorin 3F -0.551 1.54E-02 
 
Table 3.9: Differentially Expressed Genes Associated with RhoA Signalling 
Pathway Identified by RNA-Seq. RhoA Signalling Pathway was enriched in human 
TM cells treated with TGF-β2. Only the significantly differentially expressed genes in 
TGF-β2 treated human TM cells, associated with RhoA Signalling pathway are 
shown.   
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3.4.4 q-PCR Assay Validation of Top Differentially Expressed Genes in Cultured 
Human TM in the Presence or Absence of TGF-β2 
 To further confirm the results obtained from the RNA-Seq analysis, a subset 
of the top differentially expressed genes (DEGs) between the control group, 
(CK_Group) and the TGF-β2 group (TK_Group) of cultured human TM cells, were 
analysed using q-PCR with Primer Design custom primer assays (Table 3.2). In 
addition, q-PCR was performed to compare alterations in gene expression between 
control normal TM cells (CK_Group) with that of glaucomatous TM samples for the 
same subset of genes already analysed.  
 Fifteen candidate genes (Table 3.10) were selected for q-PCR analysis on the 
basis of their statistical significance in the RNA-Seq data set and on the basis of 
published literature providing evidence of their involvement in glaucoma 
pathophysiology. The fifteen candidate genes included; endothelin 1 (EDN1), 
follistatin-like protein 3 (FSTL3), KN motif and ankyrin repeat domain-containing 
protein4 (KANK4), ATPase phospholipid transporting 10A (ATP10A), low density 
lipoprotein receptor class A domain-containing 4 (LDLRAD4), fibronectin type 3 
domain-containing 1 (FNDC1), Wnt family member 2B (WNT2B), RAS-like family 11 
member B (RASL11B), prostate transmembrane protein, androgen induce 1 
(PMEPA1), left right determination factor 2 (LEFTY2), odd-skipped related 
transcription factor 2 (OSR2), dishevelled binding antagonist of beta catenin 1 
(DACT1), and cyclin dependent kinase inhibitor 2B (CDKN2B) and its antisense gene 
(CDKN2B-AS1). CDKN2B-AS1 was not identified as one of the top 500 DEGs but 
CDKN2B-AS1 is located in a mapped POAG locus on chr9p21 and it may be involved 
in the regulation of nearby genes including CDKN2B419. Thirteen of the fifteen 
candidate genes demonstrated consistent trends of differential expression by q-
PCR. To further confirm the differential expression of candidate genes an 
independent sample was added to each group increasing the biological replicates to 
6 (CK_Group (n=6), TK_Group (n=6)) as well as three glaucomatous donor samples. 
Statistical analysis was performed using GraphPad (Prism, version 6), and all data 
sets were subjected to two sample students t-tests. Results were classified as 
significantly significant if p<0.05. 
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Table 3.10: Summary of Expression Levels of Candidate Genes Based on RNA-Seq 
Analysis.  FC-Fold Change. Values for CDKN2B-AS1 were unavailable as it was not 
sequenced as a long non-coding-RNA it does not contain a 3’UTR, therefore could 
not be assessed in RNA-Seq library.  
 
 
 
 
 
 
 
Candidate Gene LogFC P-Value 
EDN1 6.581011 5.9E-150 
NOX4 5.868904 2.1E-105 
FSTL3 4.198732 3E-99 
KANK4 11.08088 2.62E-95 
ATP10A 3.624783 4.03E-66 
LDLRAD4 7.225079 1.9E-59 
FNDC1 4.023905 6.79E-57 
WNT2B -2.95701 2.93E-56 
RASL11B 7.122587 2.91E-60 
PMEPA1 4.810826 2.76E-84 
LEFTY2 6.944008 4.88E-62 
OSR2 -5.36648 4.15E-67 
DACT1 3.58056 2.81E-58 
CDKN2B 4.291877 1.41E-92 
CDKN2B-AS1 - - 
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Figure 3.8: Expression Levels of Candidate Genes in Cultured Normal Human TM 
Cells. CK_Group are denoted as “Control” on graphs and TK_Group as “Treated”. 
Candidate genes were identified as significantly differentially expressed through 
RNA-Seq except for CDKN2B-AS1. Paired donors are colour coded. Circles represent 
individual donor gene without TGF-β2 treatment and squares represent donors 
with TGF-β2 treatment. An asterisk (*) denotes significant differential gene 
expression after treatment (two-sample t-test p <0.05). 
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Figure 3.9: Expression Levels of Candidate Genes in Cultured Normal Human TM 
Cells and Glaucomatous TM Cells. CK_Group are denoted as “Control” on graphs 
and glaucomatous samples as “Glaucoma”. Triangles represent control donor gene 
expression and squares represent glaucomatous donor gene expression. An asterisk 
(*) denotes significant differential gene expression after treatment (two-sample t-
test P <0.05). 
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3.5 Discussion 
 Primary-open angle glaucoma (POAG) has complex trait inheritance420. 
Forward genetics is a common approach to dissecting complex traits, like common 
human diseases, and our ability to identify genes for common diseases has greatly 
accelerated over the past several years. However, despite access to the complete 
genome sequence for a diverse number of species, large-scale haplotype maps for 
genotyping, technologies capable of screening DNA polymorphisms and gene 
activity on an unprecedented scale, and well-characterised human cohorts, even 
the largest genome-wide association studies (GWAS) have limited power to detect 
genes with small effects420. GWAS in glaucoma have identified a number of novel 
disease-predisposing genes, but progress in uncovering the mechanisms by which 
these genes lead to glaucoma, which is required to understand disease 
pathogenesis and develop new therapies, has been far slower420. 
 Genes and their downstream products comprise a complex regulatory 
machinery that sustains the delicate homeostasis of an organism in a changing 
environment. The transcriptome is the complete set of transcripts in a cell, and 
their quantity, for a specific developmental stage or physiological condition. 
Understanding the transcriptome is essential for interpreting the functional 
elements of the genome and revealing the molecular constituents of cells and 
tissues, and also for understanding development and disease421,422. The aim of this 
study was to reverse engineer glaucoma in the laboratory using a known 
glaucomatous stimulus in the TM, TGF-β2, and assess genome-wide alterations in 
gene expression and regulation in a holistic, hypothesis-independent and discovery-
driven manner, to identify the genes and pathways dysregulated by glaucoma 
stimuli. 
3.5.1 Genome-Wide Transcriptome Profiling in TGF-β2 Treated Human TM Cells 
Using high-throughput RNA-Seq methods in cultured human TM cells 
treated with TGF-β2 (5ng/mL) for 24 hours there were several significantly 
differentially expressed genes (DEGs) and canonical pathways that were enriched. 
Dose duration and concentration are important factors which must be considered 
when examining gene expression studies. Individual donor characteristics such as 
age, sex, and previous disease history may also play a role in gene expression.  
Due to a lack of model systems to study glaucoma, the use of cultured 
human TM cells provides a means to evaluate their biological properties in relation 
to conditions such as glaucoma. As discussed previously, (Chapter 2, 2.1) primary 
human TM cells used throughout this thesis were obtained from either whole 
donor eyes or from corneal rims. TM cells are inherently in close contact with other 
cell types, and so, it is therefore essential to ensure the correct cell population has 
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been isolated prior to experimentation. The most characteristic marker for human 
TM cells is the increased expression of myocilin following dexamethasone 
treatment423. In comparison to other ocular cell types this induction appears to be 
TM cell specific. Other proteins have been identified in the human TM however 
currently there is no data that differentiates between the different regions of the 
TM. Due to the smaller size of TM cells there is a possibility that TM cell cultures 
may contain contaminants such as fibroblasts424. Vimentin, a known fibroblast 
marker425, was used in our studies to provide assured evidence that no fibroblasts 
were present in our human TM cell cultures. Human tenon fibroblasts were used as 
a positive control in these experiments indicating the presence of vimentin.  
Despite the lack of a single marker for TM cells, in comparison to surrounding 
ocular cells, TM cells also have pronounced phagocytosis rates that can be used as a 
behavioural characteristic. Glucocorticoid treatment has been linked to enhanced 
ECM deposition in the TM, and this is due, in part, to reduced phagocytic 
capabilities. Data highlights phagocytosis as an important function of TM cells426,427.  
 Three studies have examined global changes in gene expression in cultured 
human TM cells treated with TGF-β using cDNA or oligonucleotide arrays244,405,407. 
To our knowledge, this is the first report to use RNA-Seq analysis to investigate the 
human TM transcriptome profile following TGF-β2 treatments. None of the 
microarray-based studies recapitulated the duration of TGF-β2 treatment for 
24hours, and only one of the studies utilised the same TGF-β2 dose (5ng/mL)244. In 
our study we also used 5ng/mL as this value recapitulates the concentration of TGF-
β2 in the glaucomatous AH428 and duration was decided on the basis of SMAD 
phosphorylation assays(Appendix 8.1). Two studies used a 1ng/mL TGF-β2 dose 
over a time course of up to 72hours405,407. Despite these experimental differences, 
common genes were up-regulated in the array studies and in our RNA-Seq dataset 
including; NADPH oxidase 4 (NOX4), SMAD7, follistatin-like 3 (FSTL3) and cyclin 
dependent kinase inhibitor 2b (CDKN2B); the latter two are also up-regulated in 
response to TGF-β1 treatment in cultured human TM cells405. Limited consistency in 
down-regulated genes in our study and the microarray studies was also 
observed244,405,407. However, full datasets for each of the microarray-based studies 
were not made publicly available, therefore, comparisons are limited. 
Rho/ROCK Signalling Pathway 
The Rho/ROCK pathway has pleiotropic functions including the regulation of 
cellular contraction, motility, morphology, polarity, cell division, and gene 
expression429. In the anterior eye Rho/ROCK signalling pathways modulate the 
cytoskeletal integrity of cells, synthesis of ECM components, and the permeability 
of endothelial cells in Schlemm’s canal430. Alterations in the Rho/ROCK signalling 
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pathway and up-regulation of its downstream targets results in the pathogenesis of 
multiple diseases431.  
 Rho is a member of Rho family of small molecular GTP binding proteins. Rho 
has three isomer types: RhoA, RhoB, and RhoC; and these intracellular GTPases 
cycle between a GTP-bound (active conformation) and a GDP-bound (inactive 
conformation)432. The Rho GTPases act as a molecular switch which respond to 
receptor binding on the plasma membrane including heterotrimeric G protein-
coupled receptors, tyrosine kinase receptors, cytokine receptors, frizzled receptors, 
and adhesion receptors432. In TM cells RhoA GTPase activity is stimulated by TGF-β, 
connective tissue growth factor (CTGF), dexamethasone, endothelin-1, ECM 
proteins and mechanical stretch (for review see Rao et al 2017433). Based on the 
RNA-Seq data using Ingenuity Pathway Analysis (IPA) we identified the RhoA 
signalling pathway as significantly enriched in our TGF-β2 treated samples in 
comparison to our untreated controls.   
 Rho kinase (ROCK) is a serine/threonine kinase and one of the major 
downstream effectors of RhoA GTPase. ROCK has two isomers; ROCK1 and ROCK2. 
Rho-kinase proteins are ubiquitously expressed in most tissue, however, ROCK 
isoforms distribute differentially according to their specific functions. ROCK1 has 
high specificity for non-neuronal tissues whereas ROCK2 is commonly found in the 
brain and muscles429. The Rho/ROCK pathway is critical in the formation of actin 
stress fibres and focal adhesions434, and the regulation of actomyosin cytoskeletal 
organisation, cell adhesion, cell morphology, and smooth muscle contraction435. 
Active GTP-bound Rho GTPase activates ROCK which phosphorylates various 
intracellular targets. Specific substrates for Rho/ROCK signalling are myosin light 
chain (MLC), LIM kinase and the regulatory subunit of myosin phosphatase:  myosin 
phosphatase substrate 1 (MYPT1)429 (Figure 3.10). Phosphorylation of MLC is 
dependent on both myosin light chain kinase (MLCK) and myosin light chain 
phosphatase (MLCP). MLC is phosphorylated by Ca2+/calmodulin-dependent MLCK 
and dephosphorylated by CA2+-independent MLCP, and the balance between these 
two components is a critical determinant of MLC phosphorylation436.  LIM kinase 
phosphorylates and inactivates the actin binding/depolymerising factor, coflin, in 
turn inducing actin cytoskeleton remodelling. LIM kinase is predominantly localised 
to the cytoplasm and functionally associated with the cytoskeleton437. LIM kinase 
contains structural features of cyto-regulatory proteins and kinase specific activity 
for coflin.  
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Figure 3.10: Schematic of Rho/ROCK Signalling Pathway. Modified from Rao et al 
2017433. Rho/ROCK signalling cascades are implicated in cytoskeleton 
reorganisation and multiple cellular processes in smooth muscle and non-smooth 
muscle cells. 
 
Our results do not show significant enrichment of ROCK when RhoA 
signalling is activated via TGF-β2 stimulations (ROCK1: LogFC= 0.392, FDR p= 0.019; 
and ROCK2: LogFC= 0.319, FDR p= 0.081). ROCK is implicated in the RhoA-mediated 
inhibition of MLCP as shown in Figure 3.10438. MYPT1 is the best characterised 
substrate for ROCK. ROCK activation by RhoA in turn activates MYPT1. Activated 
MYPT1 inhibits activity of MLCP resulting in enhanced MLC phosphorylation439. This 
phosphorylation catalyses interactions between myosin and actin which 
subsequently results in acto-myosin contraction440. This contractile activity is 
independent of contractile activity stimulated through phosphorylation of MLC by 
Ca2+/calmodulin dependent MLCK.  Thus Rho/ROCK pathway is a master regulator 
of the actin cytoskeleton and cell contractility. Interestingly, increased contractility 
in TM cells during glaucoma pathogenesis has previously been associated with 
ROCK signalling441. Increased contractility leads to a reduction in outflow facilities of 
the drainage angle442. ROCK has previously been localised to the tissues of the AH 
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outflow pathway and it was found that ROCK may be implicated in increased TM 
contractility and ECM deposition. A number of novel therapeutics for glaucoma 
have emerged in recent years targeting Rho/ROCK signalling under the premise that 
inhibition of ROCK may reduce TM cell contractility and ECM reorganisation443. 
However, our results are currently contradictory to this and it is possible that ROCK 
may not be the best therapeutic target. 
The expression of KANK4 was significantly up-regulated in TGF-β2 treated 
human TM cells by RNA-Seq when compared to control human TM cells (FC= 11.08, 
p-value= 2.62E-95). Over-expression of KANK family members, including KANK4 
resulted in an overall repression of RhoA activity444. KANK proteins are 
predominantly distributed in the cytoplasm and KANK4 is involved in the formation 
of actin stress fibres. Thus, KANK proteins including KANK4 may share a common 
function in regulation polymerisation of actin through RhoA activity445. Cells 
expressing KANK family members have significantly decreased formation of actin 
stress fibres444. Limited data on the function of KANK4 in the TM exists but 
inference by analogy to its paralogues KANK2-3, would suggest a role in the 
maintenance of actin fibres within the TM via Rho signalling445. The polymerisation 
and depolymerisation cycle of stress fibres in TM cells may be implicated in 
glaucoma pathogenesis446. KANK4 has not yet been implicated in glaucoma 
pathogenesis but it may have potential role in Fuchs endothelial corneal dystrophy 
(FECD)447. ROCK inhibitors are used in the treatment of corneal endothelial 
dysfunction448.  
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NADPH Oxidase Inhibitor 4 (NOX4) 
TGF-β can control reactive oxygen species (ROS) directly or indirectly by 
down-regulating antioxidant systems and the interplay between TGF-β and ROS has 
been described in both health and disease449,450.  Both TGF-β and ROS have also 
been implicated in glaucoma and therefore interplay between the two may be 
contributing to POAG pathogenesis. Accumulating evidence suggests that NADPH 
oxidase 4 (NOX4) may be an important downstream effector in mediating TGF-β-
induced fibrosis in the heart, lungs and kidneys via the production of ROS451. RNA-
Seq analysis in this study identified NOX4 expression as significantly up-regulated in 
TGF-β2 treated cells (FC= 5.87, p-value= 2.1E-105) and confirmed up-regulation of 
NOX4 by q-PCR (FC= 73.12, p-value= 0.002 Figure 3.8).  
The NADPH oxidase family are widely known for their biological function of 
catalysing oxygen to produce ROS. To date the family includes seven members, 
NOX1-5 and DIOX1-2. NOX4 contributes to the pathogenesis of other ocular 
diseases relating to tissues of the anterior segment452–454. A recent study 
demonstrated that TGFβ1-mediated production of collagen by rabbit conjunctival 
fibroblasts involves a NOX4-derived H2O2 pathway
452. NOX4 is the only isoform of 
the NOX family to constitutively produce hydrogen peroxide (H2O2)
455 and the pro-
fibrotic response by fibroblasts is implemented via the generation of superoxides 
and H2O2 by NOX4
456. 
To date, NOX4 has not been implicated in the TM pathology of POAG. NOX4 
drives TGF-β mediated ECM production in fibrotic diseases451 (Figure 3.11). 
Alterations in the extracellular matrix of the TM is a hallmark of POAG 
pathogenesis457. Increased ECM production and decreased turnover is thought to 
contribute to resistance in outflow facilities thus elevating IOP119,155. Our findings 
suggest that the interplay between TGF-β and NOX4 may be contributing to POAG 
pathogenesis via ROS driven increased ECM production within the TM. Patients 
with POAG have a total reactive anti-oxidant potential of 60%458. Reduction in 
reactive anti-oxidant potential exposes POAG patients to increased risk of oxidative 
damage. Oxidative stress results in damage to the mitochondrial DNA of TM cells, 
as well as proteins and other membranes459. Increased H2O2 also causes 
remodelling of the TM cytoskeleton leading to TM enlargement and decreased 
outflow abilities460. Despite the need for acute NOX4 expression in wound healing 
chronic NOX4 activation is likely to result in fibrosis and organ dysfunction461. The 
exact mechanisms through which the TM undergoes ECM remodelling and eventual 
cell death are unknown, however, it may be attributed to increased H2O2 levels 
caused by enduring NOX4 expression, driven by TGF-β. 
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Figure 3.11: NOX4 Mediated TGF-β-Induced Pro-Fibrotic Responses. Modified 
From Jiang et al 2014451. NOX4 derived ROS aid TGF-β-induced synthesis of ECM, 
fibroblast differentiation. ROS also promote apoptosis. 
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Endothelin 1 (EDN1) 
Endothelin 1 (EDN1) is a potent vasoactive peptide that exerts its actions 
through two receptors endothelin A and endothelin B462,463. EDN1 has a unique 
profile as an endothelium-derived vasoactive factor with powerful and 
characteristically long-lasting vasopressor activity. Elevated expression of EDN1 in 
response to TGF-β2 has previously been shown in cultured trabecular meshwork 
cells and both EDN1 mRNA content and secretion from TM cells were elevated464. 
Our RNA-Seq identified EDN1 expression was significantly up-regulated in human 
TM cells exposed to TGF-β2 (FC= 6.58, p-value= 5.9E-150), which was confirmed by 
q-PCR (FC= 65.39, p-value= 0.0022, Figure 3.8).  
  EDN1 is expressed in all ocular tissues except the cornea465 and the levels in 
the AH are 2-3 times higher than in plasma466. POAG patients have elevated levels 
of EDN1 in their AH and animal models of glaucoma have supported a role of EDN1 
in glaucoma pathogenesis467,468. Endothelin A receptor is expressed in TM cells469 
and in-vitro studies identified increased TM cell contractility in response to elevated 
EDN1 expression470. Increased contractility of TM cells is a hallmark of glaucoma471. 
Contraction of TM cells decreases intracellular space resulting in increased 
resistance to AH outflow. There is accumulating evidence for the role of EDN1 in 
glaucoma pathogenesis472–475. The main risk factor for developing POAG is elevated 
IOP. Normal tension glaucoma, in which glaucomatous optic neuropathy occurs at 
normal IOP, suggests that other factors may be involved in the disease 
pathogenesis, for example, reduced ocular blood flow476,477. Both IOP and ocular 
blood flow are affected by EDN1467. Differential experimental approaches identified 
elevated EDN1 in AH increased IOP478–480. Animal models show a dose dependent 
rise in IOP after intracameral injection of EDN1478. In the bovine eye, EDN1 induced 
the reduction of AH outflow cause by increased TM contraction401. Contractility 
could be blocked by inhibition of the Rho kinase signalling pathway481.  
In addition to the biochemical and morphological changes in the TM during 
glaucoma pathogenesis, the optic nerve head (ONH) is subjected to structural loss 
of RGCs. Physiologically EDN1 helps to maintain IOP by strict control of TM   
contractility. Pathological levels of EDN1 reduce ocular blood flow and increase TM 
cell contractility482. Intravitreal injections of EDN1 reduced ocular blood flow to the 
ONH in healthy volunteers483. Perfusion of EDN1 in animal models also induced 
similar optic neuropathies472.  Thus, ischaemic insult to the ONH occurs and 
subsequent RGC death. An antagonism of EDN1 in both pressure dependent and 
independent pathways provides a promising approach for treatment of glaucoma 
by several mechanisms: (1) reduction of IOP; (2) enhanced ocular blood flow; and 
(3) increased survival of RGCs.    
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Figure 3.12: Pathological Role of EDN1 in Glaucoma. Disruption of physiological 
EDN1 levels results in decreased ocular blood flow and elevated IOP. Pressure and 
ischaemic insults lead to subsequent RGC death i.e. ONH structural loss. 
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Cyclin Dependent Kinase Inhibitor 2B and Cyclin Dependent Kinase Inhibitor 2B 
Antisense Gene (CDKN2B and CDKN2B-AS1) 
Cyclin-dependent kinase inhibitor-2B (CDKN2B) gene and its antisense gene 
CDKN2B-AS1 are located on chr9p21. CDKN2B encodes a cyclin-dependent kinase 
inhibitor, p15INK4b, which plays an important role in the regulation of the cell cycle 
through the inhibition of cyclin-dependent kinase 4 (CDK4)484. The expression of 
CDKN2B is significantly induced by  TGF-β485 and plays a role in the mediation of 
TGF-β-induced cell cycle arrest485,486. TGF-β inhibits cell proliferation by producing 
G1 phase cell cycle arrest485 and CDKN2B, which forms a complex with either CDK4 
or CDK6 preventing their activation, acts as an effector of TGF-β cell cycle arrest487.  
In human TM cells stimulated with TGF-β2, CDKN2B was up-regulated as 
shown by RNA-Seq (FC= 4.29, p-value= 1.41E-92), and confirmed by q-PCR (FC= 
41.57, p-value= 0.0022 Figure 3.8). POAG associated single nucleotide 
polymorphisms (SNPs) have been identified by GWAS and candidate gene 
investigations within the 9p21 locus488–490. The relationship between CDKN2B-AS1 
genetic variants and specific glaucoma features is unknown491. CDKN2B-AS1 is a 
long non-coding RNA which is likely have a functional effect on a target mRNA 
through complementary binding to induce RNA degradation or translational 
inhibition. It has been proposed that CDKN2B-AS1 may influence the nearby genes:  
CDKN2A and CDKN2B; both of which are essential in cell proliferation and 
senescence492. SNPs within or close to CDKN2B-AS1 are associated with a number 
of diseases including glaucoma, coronary artery disease, diabetes and cancer490,492–
497. There is some evidence that CDKN2B-AS1 can regulate the expression of 
CDKN2B and that this relationship may be reciprocal498,499. Given the induction of 
CDKN2B by TGF-β2 in our study we investigated the expression profile of CDKN2B-
AS1 in the same TGF-β2 treated human TM cells and in the glaucomatous samples. 
Only one of six donors exhibited an increase in expression of CDKN2B-AS1 in the 
presence of TGF-β2 (Figure 3.8). However, there was an overall increase in 
expression of CDKN2B-AS1 in the glaucomatous TM; this was not statistically 
significant given the small sample size (Figure 3.9). Further studies are required to 
dissect the role and interplay of CDKN2B and CDKN2B-AS1 in the TM and in 
POAG490. 
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Figure 3.13: Localisation of CDKN2B and CDKN2B-AS1 on Chr9p21. Figure from 
Wiggs et al 2015500. 
 
 
 
 
 
 
 
 
 
 
Figure 3.14: Effects of CDKN2B and CDKN2B-AS1 on Cell Cycle via CDK4 Inhibition. 
Modified from Wiggs et al 2015500.CDKN2B inhibits CDK4 to regulate cell cycle. 
Disruption of cell cycle in disease leads to cellular loss in the TM. 
 
 
132 
 
WNT Signalling Pathway 
Wnt signalling plays multiple roles in embryogenesis and development, 
including cell proliferation, differentiation, migration, cell polarity, and cell survival 
and apoptosis501. In the eye, Wnt signalling pathways are associated with different 
stages of ocular development and growth, cell differentiation, connectivity and 
proliferation502. Alterations in Wnt signalling, due to mutations or external cues, 
result in multiple ocular diseases including, retinal degeneration, cataract, 
congenital ocular malformations, and exudative vitreoretinopathies503. More 
recently, studies have demonstrated a potential role for Wnt signalling in POAG 
pathogenesis504.  
 Wnt proteins are a highly conserved family of secreted glycoproteins that 
signal two types of receptors; seven-pass transmembrane receptors known as 
frizzled proteins (FZD), and single-pass transmembrane co-receptors lipo-protein 
receptor related proteins (LRPs)505,506. Wnt signalling can occur via the canonical 
and non-canonical pathway. The canonical pathway is β-catenin dependent, 
whereas the non-canonical pathway is β-catenin independent507. Several 
extracellular secreted factors regulate Wnt signalling. Secreted frizzled-related 
proteins (SFRPs) and Wnt-inhibitory factor 1 (WIF-1) prevent Wnt binding with FZD 
receptors resulting in inhibition of both canonical and non-canonical pathways508. 
Dickkopf proteins (DKKs) also inhibit Wnt signalling by binding LRP5/6509.  
 WNT2B expression was significantly repressed in our RNA-Seq data (FC= -
2.96, p-value= 2.93E-56), however further validation of this down-regulation could 
not be achieved by q-PCR (Figure 3.8). The WNT2B gene encodes a member of the 
wingless-type MMTV integration site (WNT) family of secreted signalling factors. A 
possible role of Wnt signalling in the ocular outflow system has been previously 
suggested510 and WNT2B expression has been reported in the human TM511512. 
Inhibition of Wnt signalling in TM cells results in persistent increases in intrinsic cell 
stiffness, a key hallmark of POAG pathogenesis513. The expression of secreted 
frizzled-related protein-1 (sFRP-1) is elevated in the glaucomatous TM511. sFRP-1 is 
an antagonist of Wnt signalling and murine and ex-vivo perfusion models supported 
a role for sFRP-1 in elevated IOP in glaucoma by inhibiting Wnt signalling511.  
Interestingly, sFRPs are induced by TGF-β and may therefore drive decreased Wnt 
gene expression in TGF-β treated TM cells as observed by our study and previous 
studies511,514. There is evidence of a cross-inhibition between TGF-β signalling and 
canonical Wnt pathways515: TGFβ-2 inhibits Wnt3a-induced canonical Wnt pathway 
activation and Wnt3a inhibits TGFβ2-induced Smad4 pathway activation510. 
Our data confirms TGF-β2 inhibits Wnt signalling by repressing WNT2B but 
also induces the expression of Wnt antagonists. The DACT1 (dishevelled binding 
agonist of beta cantenin 1), encoding gene was highly represented in our RNA-Seq 
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data (FC= 3.58, p-value= 2.81E-58) and again in q-PCR (FC= 12.71, p-value= 0.0022 
Figure 3.8).  Interestingly, a trend of increased gene expression for DACT1 was also 
observed in glaucomatous TM cells when compared to controls (Figure 3.7.). DACT1 
expression in intestinal epithelial cells is increased by TGF-β516 and mediates TGF-β 
driven apoptosis in renal mesangial cells517.  DACT1 has not been associated with 
ocular disease previously but may play a role of TGF-β-mediated inhibition of Wnt 
signalling in the TM.   
Prostate Transmembrane Protein Androgen Induced 1 (PMEPA1) 
 Prostate transmembrane protein androgen induced 1 (PMEPA1) encodes a 
protein of 252 amino acids with a type 1b trans-membrane domain. PMEPA1 is a 
negative regulator of TGF-β signalling in prostate cancer cells518. The ubiquitin-
mediated proteosomal degradation pathway is an evolutionary conserved cascade 
that tightly regulates TGF-β signalling519. Membrane bound PMEPA1 isoforms are 
able to interact with regulatory SMADs (SMAD2) and ubiquitin ligases, to block TGF-
β signalling independently of the proteasome-mediated degradation520. In our 
study PMEPA1 expression was significantly up-regulated in human TM cells treated 
with TGF-β2 by RNA-Seq (FC=4.81, p-value= 2.76E-84), and corroborated by q-PCR 
(FC=32.28, p-value= 0.0022 Figure 3.7). A microarray analysis of gene expression in 
human optic nerve head astrocytes identified differential expression of SMURF2 in 
response to hydrostatic pressure521. SMURF2 is a SMAD-ubiquitin ligase that 
induces the ubiquitination and degradation of the TGF-β-SMAD2/3 pathway to 
regulate TGF-β signalling. Interaction between SMURF2 and PMEPA1 have 
previously been described in prostate cancer522.  
 Low density lipoprotein receptor class A domain containing 4 (LDLRAD4) an 
important paralog of PMEPA1523,was significantly up-regulated in our RNA-Seq data 
(FC= 7.23, p-value= 1.9E-59). LDLRAD4, also known as C18ORF1, encodes the 
LDLRAD4 protein whose primary function is to negatively regulate TGF-β 
signalling524. It is hypothesised that LDLRAD4 competes with inhibitory SMAD4 and 
prevents propagation of intracellular signals524. In our study LDLRAD4 expression 
was also significantly up-regulated in human TM cells exposed to TGF-β2 for 24 
hours by q-PCR (FC= 10.46, p-value= 0.0043, Figure 3.8).  
Both PMEPA1 and LDLRAD4 have not previously been implicated in 
glaucoma pathogenesis. It is possible that an up-regulation of PMEPA1 and 
LDLRAD4 in TGF-β2 treated human TM cells is a response to internally control the 
acute TGF-β2 insult; however further investigation would be required to implicate 
both genes in the pathogenesis of the disease. 
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Follistatin-like 3 (FSTL3) 
 Follistatin-like 3 (FSTL3) is a member of the follistatin family which differs 
from follistatin (FST) as it lacks the third follistatin domain and a consensus heparin-
binding sequence. Both FSTL3 and FST inhibit the actions of activins and bone 
morphogenic proteins (BMPs) which are members of the TGF-β family that are 
involved in processes such as cell proliferation and differentiation, immune 
response, and wound repair525. In our study FSTL3 expression was significantly up-
regulated in human TM cells exposed to TGF-β2 for 24hours using RNA-Seq (FC= 
4.19, p-value= 3E-99), and confirmed by q-PCR (FC=28.07, p-value=0.0022, Figure 
3.8). Previous gene expression profiling of TGF-β2 treated TM cells by microarray 
identified an up-regulation of FSTL3406. 
 The role of TGF-β2 in POAG is multifaceted and the identification of 
downstream effectors of TGF-β signalling is required to understand disease 
pathogenesis and identify new therapeutic targets. BMPs are members of the TGF-
β superfamily which have been identified in the human TM526 and BMPs can block 
TGF-β2 induction of ECM proteins in the TM. The expression of gremlin, a BMP 
antagonist, is elevated in glaucomatous TM cells 408,527. Interestingly, FST, also a 
BMP antagonist, is expressed in TM cells526. The role of FSTL3 in glaucoma or 
following TGF-β2 induction is unknown. It has been proposed that the increase in 
FSTL3 expression following TGF-β2 stimulations may antagonise BMP7 and or BMP4 
which therefore reduces their antagonism of TGF-β signalling408,527.  
 FSTL3 attenuation of BMP antagonism of TGF-β signalling may have pro-
fibrotic effects528. In murine transgenic models FSTL3 knockout accentuated 
interstitial fibrosis in the heart528. Fibrosis of the TM cells due to biochemical and 
morphological changes during glaucoma pathogenesis and after glaucoma surgery 
is a driver in AH outflow resistance and associated elevated pressure529. 
Components of pro-fibrotic processes are ideal candidates for novel therapeutics in 
attempts to regain efficient AH outflow. The role of FSTL3 in the pathogenesis of 
POAG has not been established. However it is likely that induction of TGF-β 
signalling leads to elevated FSTL3 expression as a means of BMP inhibition, thus 
prolonging TGF-β insult within the TM resulting in TM fibrosis and elevated IOP.  
Odd-skipped Related Transcription Factor 2 (OSR2) 
Odd-skipped related transcription factor 2 (OSR2) encodes a zinc-finger 
protein with extensive similarity to the Drosophila Odd-skipped family of putative 
transcription factors530. Gene expression and phenotypic analyses have indicated 
that the odd-skipped gene product functions to prevent inappropriate expression of 
other segmentation genes531,532. In our study OSR2 expression was significantly 
down-regulated in human TM cells treated with TGF-β2 (FC= -5.37, p-value= 4.15E-
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67), however this could not be confirmed by q-PCR in healthy TM cells treated with 
TGF-β2 (Figure 3.8). The OSR2 promoter possesses SMAD3/4 and ATF binding 
elements. TGF-β2 down-regulates OSR2 resulting in altered cell migration and cell 
cycle regulation in fibroblastic mesenchymal cell lines533. To date no studies have 
identified OSR2 as being implicated in glaucoma.  
Left-right Determination Factor 2 (LEFTY2) 
Left-right determination factor 2 (LEFTY2) encodes secreted ligands of the 
TGF-β family which bind various TGF-β receptors resulting in the recruitment of 
SMAD family transcription factors that are necessary for gene expression 
regulation534. Mutations in LEFTY2 have been implicated in left-right axis 
malformation particularly in the heart and lungs535. In our study LEFTY2 expression 
was significantly up-regulated by RNA-Seq (FC= 6.94, p-value= 4.88E-62) and 
confirmed by q-PCR (FC= 98.30, p-value= 0.0022, Figure 3.7). LEFTY is a known 
inhibitor of TGF-β and is therefore an important component in the homeostasis of 
extracellular matrix (ECM)536. LEFTY2 has not previously been implicated in POAG 
however it is widely accepted that alterations in ECM secretion and deposition 
within the TM is implicated in glaucoma pathogenesis, and TGF-β2 is known to be a 
key driver in these changes537. As an inhibitor of TGF-β2, it is possible that LEFTY2 is 
involved in TGF-β inhibition in human TM cells exposed to elevated TGF-β2. 
 
Ras-like Protein Family Member 11B (RASL11B) 
 Ras-like protein family member 11B (RASL11B) encodes RASL11B protein, a 
member of the small GTPase protein family with a high degree of similarity to 
RAS538. Interestingly, the RASL11B promoter contains an SRF binding site which is 
activated by TGF-β539. In arterial smooth muscle cells TGF-β1 induces the expression 
of RASL11B in artery smooth muscle cells and macrophages540. Macrophages are a 
major source of TGF-β1 in atherosclerotic vessels and stimulate the smooth muscle 
cells in the vessel walls to produce ECM; this is not dissimilar to TGF-β driven ECM 
deposition in the TM in glaucoma540. In our study RASL11B expression was 
identified as significantly up-regulated in human TM cells exposed to TGF-β2 by 
RNA-Seq (FC= 7.12, p-value= 2.91E-60) and confirmed by q-PCR (FC= 164.38, p-
value= 0.0022, Figure 3.8). In a previous, RASL11B was significantly up-regulated 
(FC= 2.9) in glaucomatous human TM cells versus the normal  TM; RNA was directly 
extracted from tissue post-surgery (glaucoma) or post-mortem and analysed on 
Illumina BeadChip arrays541. No further investigation of the potential role of 
RASL11B in glaucoma was pursued in this study 541.   
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Fibronectin Type II Domain Containing 1 (FNDC1) 
Fibronectin type  II domain containing 1 (FNDC1) encodes FNDC1 protein 
and contains a major component of the structural domain of fibronectin (FN)542. 
The biological role for FNDC1 is poorly understood. FNDC1 is reported to be 
involved in G protein signalling543. FNDC1 also known as MEL4B3, has previously 
been reported in skin tumours and is thought to be regulated by TGF-β544. In our 
study, FNDC1 expression was significantly up-regulated in human TM cells treated 
with TGF-β2 by RNA-Seq, (FC= 4.02, p-value= 6.79E-57), and confirmed by q-PCR 
(FC= 15.17, p-value= 0.0087, Figure 3.8). Fibronectin (FN) is a major component of 
the TM extracellular matrix and increased secretion and deposition of FN has been 
shown in glaucomatous TM415. This increased deposition has been attributed to 
enhanced TGF-β signalling and is thought to contribute to increased AH outflow 
resistance observed in POAG patients which results in elevated IOP240. In prostate 
cancer silencing of FNDC1 also represses the expression of FN545. Given the major 
role FN plays in the pathogenesis of POAG the relationship between FNDC1 and FN 
warrant further investigation to understand TGF-β mediated processes in glaucoma 
pathogenesis. 
  
ATPase Phospholipid Transporting 10a (ATP10A) 
ATPase Phospholipid Transporting 10a (ATP10A) encodes ATP10A enzyme 
and is a subfamily of aminophospholipid-transporting ATPases, required for the 
transmembrane transport of phosphatidylserine and 
phosphatidylethanolamine546,547. ATP10A is required to maintain an asymmetric 
distribution of phospholipids. Phospholipid translocation has been implicated in 
vesicle formation, in uptake of lipid signalling molecules and maintaining cell 
morphology546.  ATP10A expression was significantly up-regulated by RNA-Seq in 
TGF-β2 treated human TM cells (FC= 3.62, p-value= 4.03E-66), and by q-PCR (FC= 
10.18, p-value= 0.0022, Figure 3.8). Interestingly,  the expression of ATP10A was 
elevated (FC= 2.92) in human cultured TM cells treated with steroid (triamcinolone 
1mg/mL)548 and ATP10A also lies in a POAG mapped locus (GLC1I) on chr15q11-
13549.  The role of ATP10A in the TM is unknown. 
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Analysis of DEG in Glaucoma TM Samples  
q-PCR analysis of DEGs identified by RNA-Seq in glaucomatous TM (GTM) 
samples compared to healthy controls (Figure 3.7) did not yield statistically 
significant fold changes. Availability of disease donor tissue is limited and therefore 
the number of biological samples (n=3) for this experiment was small. An increase 
in sample size may provide increased statistical power. GTM cells were also 
cultured prior to RNA-Seq and q-PCR analysis and RNA were not directly extracted 
from tissue. GTM cells were also not stimulated by TGF-β2. As AH of POAG patients 
has significantly elevated levels of TGF-β2, GTM had previously been exposed to 
chronic TGF-β2 stimulations which most likely impacts on their gene expression 
profiles. Together with sample size and previous chronic TGF-β exposure may 
explain why no significant difference was observed between the two sample 
groups: control and glaucomatous.  
3.6 Summary 
Isolation and characterisation of primary human TM cells prior to 
sequencing proved difficult in the preparation for these experiments. The human 
TM has reduced cellularity with age, and to re-capitulate normal and disease states 
as effectively as possible older donors were used. This presented challenges with 
regards to effective TM culture growth and cell numbers. Low cell count resulted in 
low RNA yields and reduced quality. This aspect was time consuming and required 
attention to detail.  
Our study provides a comprehensive characterisation of differentially 
expressed genes in response to TGF-β2. It demonstrates that among the set of 
differentially expressed genes, the majority are implicated in cytoskeletal and 
extracellular matrix remodelling of the human trabecular meshwork cells. TGF-β2 is 
implicated extensively in these processes however both TGF-β-related and -
unrelated genes were identified in the TM in association to TGF-β2 stimulations.  
We have successfully identified candidate target genes which warrant 
further investigation regarding their potential role in POAG. NOX4 has not 
previously been implicated in POAG, however increasing evidence suggests that 
oxidative stress, of which NOX4 is a key player, plays a significant role in disease 
pathogenesis. miRNAs regulate a number of target genes, of which NOX4 is 
included. miR-25 regulates NOX4 expression in diabetic nephropathy550 and may 
serve as an endogenous silencing factor and contributor to the regulation of NOX4. 
The potential role for this miRNA as a therapy is of interest moving forward.    
The results obtained through next generation sequencing were not always 
corroborated by q-PCR. Both techniques have varying sensitivity and it important to 
note that whilst sequencing is quantitative, i.e the number of reads per gene is 
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established, q-PCR is in comparison qualitative. The effects of TGF-β2 are also 
robust and culturing the human TM cells prior to treatment may have had 
alternative effects on gene expression. These contributing factors must be 
considered moving forward and alternative approaches such as direct RNA isolation 
from tissue may provide a more comprehensive outlook on TM gene expression. 
TGF-β2 however is elevated in the aqueous humour of POAG patients, thus effects 
on gene expression that arise in response to this are of importance in 
understanding disease pathophysiology. Furthermore, manipulation of novel 
targets to reduce negative impacts on the aqueous humour outflow pathway is a 
promising step forward in developing new and therapeutics for POAG and this will 
be discussed in Chapter 6.  
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Chapter 4 
A Comparison of Global Gene Expression Profiles in Human 
Trabecular Meshwork Cells Treated with Dexamethasone 
using RNA-Sequencing 
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4.1 Introduction 
Corticosteroid use is widespread in ophthalmology and continues to be the 
mainstay of treatment for inflammatory eye diseases and post-surgically, when 
prolonged treatment is often required. The duration of steroid treatment ranges 
from several weeks, for controlling post-operative inflammation, to long-term (1 
year+) for preventing corneal transplant (keratoplasty) rejection551. Up to 35% of 
patients without a prior glaucoma diagnosis, and up to 80% of those with pre-
existing glaucoma experience clinically significant post-keratoplasty IOP elevation 
with long-term topical corticosteroid use551. The risk of IOP elevation, and the time-
frame during which this occurs, is dependent on steroid potency, pharmacokinetics, 
duration of treatment, route of administration, as well as individual differences in 
responsiveness.  
Steroid-induced elevated IOP results from increased AH outflow resistance, 
caused by several morphological and biochemical changes in the TM. The TM 
expresses glucocorticoid receptors which respond to steroid administration by 
regulating gene expression in the TM driving changes to the extracellular matrix, 
cell cytoskeleton and cross-linked actin networks552. The link between primary 
open-angle glaucoma (POAG) and steroid responsiveness was highlighted when the 
Trabecular Meshwork Inducible Glucocorticoid Response gene (TIGR; renamed 
myocilin), expressed in cultured trabecular meshwork553, was found within the 
GLC1A region of genomic DNA from families affected with chromosome 1q–linked 
open angle glaucoma554. Although TIGR/myocilin is expressed in TM, induced by 
corticosteroids, and linked with the glaucoma phenotype in a subset of 
patients553,554, there is no clear evidence for the pathogenic role of this gene in 
steroid-induced ocular hypertension or glaucoma.  
Armaly555 and Becker556 reported that the general population could be 
divided into three groups based on their response to topical steroid administration: 
(1) high responders, 4–6% of the population, developed an IOP ≥ 31 mmHg or ≥15 
mmHg above baseline; (2) moderate responders, approximately one third of the 
population, had IOPs between 20-31 mmHg, or a pressure rise of 6–15 mmHg; and 
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(3) non-responders, the remaining two thirds, had pressure increases ≤ 6 mmHg 
and IOPs ≤ 20 mmHg. In addition, clinical risk factors for high IOP steroid response 
after glucocorticoid treatment have been described in: patients with primary open 
angle glaucoma (POAG) or glaucoma “suspects”, first-degree relatives with POAG, 
old age or aged less than 6 years, connective tissue disease, especially rheumatoid 
arthritis in men, high myopia and type I diabetes mellitus163,557. Interestingly, almost 
all POAG patients are steroid responders163,202, and steroid-responders who do not 
have POAG are at much higher risk of developing POAG compared to non-
responders163,202. Moreover, relatives of POAG patients have higher rates of steroid 
responsiveness558–560. A better understanding of genetic and molecular mechanisms 
underlying the response to steroids could shed light on our understanding of 
steroid-induced glaucoma and the pathogenic mechanisms in primary open-angle 
glaucoma. 
A number of structural and functional changes occur in the TM with 
glucocorticoid treatment that lead to elevated IOP due to increased outflow 
resistance552. These changes are associated with increased ECM material 
production and deposition561–563, TM actin cytoskeletal re-organisation257, 
decreased TM phagocytic activity195, decreased protease activity564, and changes in 
the synthesis of specific proteins565. Most of the effects of glucocorticoids on the 
TM result from altered gene expression mediated by activated glucocorticoid 
receptor inducing or repressing glucocorticoid response elements (GREs) in 
numerous genes and also through non-GRE pathways566.  
Six studies have examined global changes in gene expression in the cultured 
TM cells treated with dexamethasone using cDNA or oligonucleotide arrays548,567–
571. Some common differentially expressed genes were reported in these studies: 
myocilin (MYOC), growth arrest specific 1 (GAS1), insulin-like growth factor binding 
protein 2 (IGFBP2), serpin peptidase inhibitor clade A member 3 (SERPINA3) and 
serum amyloid A1 and A2 (SAA1; SAA2)548,567–571. However, overall the findings 
were not consistent across studies as, while the dose of dexamethasone (DEX) was 
consistent (100nM), the duration of treatment varied from 24 hours to 21 days and 
different microarray platforms were used (Table 4.1). 
142 
 
 
 
Study Age of 
Donors 
Cell 
Passage 
DEX 
Duration 
Genes 
assessed 
Array Type 
Ishibashi et al. 
2002567 
7, 16, 21 
and 28 yrs 
4-5 7 days 2.400 cDNA  
Lo et al. 
2003568 
unknown 4-6 10 days 9,330 Oligonucleotide  
Leung et al. 
2003569 
unknown 8 10 days 2,400 cDNA  
Rozsa et al. 
2006570 
12,16,17 
yrs 
5 21 days 13,507 Oligonucleotide  
Fan et al. 
2008548 
52 yrs old 8 7 days 22,904 cDNA 
Nehme et al. 
2009571 
3 months 
old and 35 
yrs 
3-6 24 hours 33,000 Oligonucleotide 
(Agilent) 
 
Table 4.1: Summary Table of Previous Microarray Studies of DEX treatment of TM 
Cells. Six individual microarrays examined global gene expression in TM cells with 
specific conditions utilised in each outlined above548,567–571. 
 The variability between study findings may relate to differences in the 
individual responsiveness to DEX treatment of each TM cell donor. Although there 
is a genetic basis to the steroid response, the basis for individual susceptibility to 
develop steroid induced ocular hypertension or glaucoma is unknown163. There is 
some evidence that alternative splicing in the human glucocorticoid receptor might 
impact on individual susceptibility to steroid-induced glaucoma or raised IOP 
(ocular hypertension)552,572. 
Alternative splicing and differential initiation start sites for the human 
glucocorticoid receptor (GR) results in at least six isoforms552. The two major splice 
variants are GRα and GRβ; both of which are expressed in TM cells572. GRα is the 
main ligand-binding physiological and pharmacological receptor for glucocorticoids, 
whereas GRβ acts as a natural dominant-negative inhibitor of GRα activation, and 
so glucocorticoid activity573. Increased expression of GRβ has been implicated in 
glucocorticoid resistance in systemic diseases574 and there is evidence that GRβ 
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expression in the TM might confer individual resistance to glucocorticoid induced 
ocular hypertension. There is decreased GRβ expression in glaucomatous TM cells 
compared to normal TM cells and a reciprocal increase reactivity of the 
glaucomatous TM to dexamethasone induction of myocilin expression, fibronectin 
production and induction of GRE-responsive luciferase constructs575. Conversely, 
increased expression of GRβ in normal TM cells confers a resistance to 
dexamethasone induced protein expression and inhibition of phagocytosis195.  
The response of the TM to glucocorticoids results in large changes in gene 
expression but it is currently unclear which genes or pathways contribute to 
glucocorticoid induced IOP (ocular hypertension and glaucoma)163,552,571.   RNA-Seq 
confers significant advantages over array-based gene expression studies and has 
not previously been performed to assess global alternations in gene expression in 
TM cells stimulated with glucocorticoids.   
  
4.2 Aim  
 The aim of this study was to employ RNA-Seq to investigate alterations in 
the transcriptome of normal trabecular meshwork cells in the presence or absence 
of dexamethasone to detect pathophysiological mechanisms underlying glaucoma 
and potential therapeutic targets. 
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4.3 Materials and Methods 
4.3.1 Sample Collection, Preparation, and Tissue Culture Establishment 
  Cadaveric eyes were provided by the Liverpool Research Eye Bank 
and handled in accordance to the tenets of the Declaration of Helsinki (Ethics Code; 
RETH000833). Cells were maintained in DMEM-low glucose (Sigma, UK) 
supplemented with 10% fetal calf serum (Bio Sera, UK), 2mM L-glutamine (Sigma, 
UK), Pen/Step (Sigma, UK), and 2.5ug/mL Fungizone (Amphotericin B, Sigma, UK). 
Samples were incubated at 37oC (5%CO2 and 95% humidity) for 7-14 days with a 
medium changed every 2 days ensuring not to disturb the explant. When cells had 
reached 80-90% confluence there were transferred into individual T25 tissue 
culture flasks and maintained as above with the subtraction of Fungizone for a 
further week. Cells were characterised as TM cells as previously described (3.2.3). 
Donor I.D Age Sex Medical History 
LGP-1 57 Male No Glaucoma 
LGP-2 65 Male No Glaucoma 
NTM002 57 Male No Glaucoma 
NTM009 57 Male No Glaucoma 
NTM720 64 Male No Glaucoma 
NTM119 94 Male No Glaucoma, 
cataract Surgery 
Table 4.2: Human TM Cell Donor Information. 
 
4.3.2 Dexamethasone Stimulations 
All confluent cells were mycoplasma tested as described previously (2.1.5) 
prior to experimentation. Human TM cells between passages 5 and 7 were grown to 
80% confluence and growth arrested using serum free medium prior to stimulation. 
Cells were stimulated with dexamethasone at a concentration of 100nMol for 16 
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hours. Vehicle control cells were stimulated with equal volumes of 0.1% ethanol. 
Treatment time points and concentration were determined based on previously 
published work outlining human TM cell stimulations195,565. Following 16 hours of 
stimulation total RNA was extracted (2.4.1). 
4.3.3 Total RNA Extraction and QC 
 Total RNA from human culture trabecular meshwork cells was isolated using 
the Qiagen Universal All Prep (Qiagen, UK) kit as per manufacturers specifications, 
described in (2.4.1). Total RNA was quantified initially on the Nanodrop-1000 
(Thermofisher, UK), and quality was determined by the Bioanalyser 2100 (Agilent, 
UK) as described in (2.4.2 and 2.4.3 respectively). 
4.3.4 RNA-Seq of Cultured Normal Human Trabecular Meshwork Cells 
 All RNA-Seq experiments were conducted at Exiqon Services, Denmark as 
previously described (3.2.5). Two groups of mRNA libraries were prepared as 
before: a control group, consisting of untreated cultured human TM cells, 
henceforth referred to as CD_Group, and a dexamethasone (DEX) treated group, 
henceforth referred to as TD_Group. RNA-Seq data analysis was as previously 
described (Chapter 3, 3.35). 
4.3.5 RNA-Seq Data Validation 
 Validation of mRNA-seq results was performed as previously described 
(3.2.7). q-PCR analysis was performed using primers whose sequences were 
obtained from PrimerBank for target genes576, see Table 4.3 below. Data is 
expressed as the mean values ± SEM and analysed using student t-test. Statistical 
differences in the mean were considered statistically significant as p<0.05.  
 Gene expression analysis of glucocorticoid receptor isoforms, GR-α and GRβ 
was also performed to assess differential receptor ratios to identify potential 
steroid-responsive and non-responsive donors. q-PCR was performed using primers 
obtained from PrimerBank (GRα F:5’GAAGGAAACTCCAGCCAGAA’3, 
R:5’TAAGGGGCTCTACAATCGAC’3 and GRβ F:5’TGACTCTACCCTGCATGTACGACCA’3, 
R:5’CTATTTTTTGAGCGCCAAGATTGTT’3). 
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Table 4.3: Primer Pairs for RNA-Seq Validation. Validated primer pairs for target 
genes were obtained from Primer Bank to use for RNA-Seq validation. All q-PCR 
conditions are outline in Chapter 2 (2.4). 
 
 
Gene Target Primer Pair Sequence 
PTK2B F:5’CCCCTGAGTCGAGTAAAGTTGG’3 
R:5’GATACGCACGTCCTCCTTTTC’3 
RGCC F:5’CGCCACTTCCACTACGAGG’3 
R:5’CAGCAATGAAGGCTTCTAGCTC’3 
ZBTB16 F:5’CCTCAGACGACAATGACACGG’3 
R:5’CTCGCTGGAATGCTTCGAGAT’3 
FKBP5 F:5’CTCCCTAAAATTCCCTCGAATGC’3 
R:5’CCCTCTCCTTTCCGTTTGGTT’3 
PDPN F:5’AACCAGCGAAGACCGCTATAA’3 
R:5’CGAATGCCTGTTACACTGTTGA’3 
MMP1 F:5’ACGGATACCCCAAGGACATCT’3 
R:5’TCAGAAAGAGCATCGATATG’3 
VEGFC F:5’GAGGAGCAGTTACGGTCTGTG’3 
R:5’TCCTTTCCTTAGCTGACACTTGT’3 
SERPINB2 F:5’TCCTGGGTCAAGACTCAAACC’3 
R:5’CATCCTGGTATCCCCATCTACAG’3 
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4.4 Results 
4.4.1 RNA-Seq Analysis of Human Trabecular Meshwork Cells in the Absence or 
Presence of Dexamethasone  
4.4.1.1 RNA-Seq Summary 
 CD_group and TD_group libraries constructed using AMPure XP beads were 
pooled and sequenced on a flow cell using NextSeq500, High Output sequencing kit 
to obtain 30 million reads and 50bp paired-end reads. Paired-end reads were 
separated to determine whether the second read significantly differed from the 
first in overall quality. The majority of the data had a Q score greater than 30 (one 
base call in 1000 is predicted to be incorrect). Mapping of sequencing data 
represents a useful QC step in NGS analysis pipeline as it can help evaluate quality 
of samples. Reads were classified, as before (Chapter 3, 3.4.2.1) into; unmapped 
reads, rRNA reads, reads of mitochondrial origin (mtRNA reads), and mappable 
reads. 
Table 4.4 shows the total number of reads obtained for each sample and 
genome mapping for each sample was on average 82%. Uniformity of the samples 
mapping results suggests that the samples are comparable.  
4793 genes were identified as differentially expressed in our DEX treated 
human TM cells when compared to control untreated TM cells. Of these, nine genes 
were assessed by q-PCR based on the literature, and their false discovery rate (FDR) 
and logFC. 
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Table 4.4: Mapping Results for Each Sample from Control Untreated TM Cells and 
DEX Treated TM Cells. Reads from each of the two libraries (CD_Group and 
TD_Group) were extracted based on their unique I.Ds. In total 40-57 million reads 
per sample were obtained. 
  
Sample Name Total 
Readcount 
rRNA(%) mtRNA(%) Mapped(%) Unmapped(%) 
CD_Group1 49309220 0.38 2.61 78.78 18.23 
CD_Group2 25088102 0.45 2.84 82.41 14.3 
CD_Group3 49283932 0.26 4.9 79.7 15.13 
CD_Group4 41486991 0.27 4.92 82.9 11.91 
CD_Group5 42617457 0.57 4.18 81.95 13.29 
TD_Group1 45590998 0.26 2.8 83.98 12.96 
TD_Group2 49413658 0.35 2.74 82.09 14.8 
TD_Group3 53913357 0.27 4.8 81.58 13.34 
TD_Group4 53576647 0.25 4.53 81.75 13.46 
TD_Group5 42474195 0.38 3.84 80.89 14.88 
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Based on alignment to the reference genome, H.sapiens, hg19 / GRC37, 
UCSC Genome Browser, the number of identified genes per sample was calculated. 
Reliability of identified genes increased with the number of identified fragments. All 
genes were included in statistical comparison of two groups, irrespective of how 
few calls have been made. Table 4.5 (below), indicates that all samples included in 
this study have comparable call rates.  
 
Sample Name Gene Isoform 
CD_Group1 16396 63558 
CD_Group2 16154 61603 
CD_Group3 16859 66163 
CD_Group4 17087 67603 
CD_Group5 16558 64825 
TD_Group1 16196 64856 
TD_Group2 16213 64271 
TD_Group3 16539 66574 
TD_Group4 17002 66298 
TD_Group5 16592 65245 
 
Table 4.5: Number of Genes and Isoforms Identified in Each Sample from Control 
Untreated TM cells (CD_Group) and DEX Treated TM Cells (TD_Group). All genes 
and isoforms identified in each sample have a fragment count estimation of at least 
10 counts per gene. 
  
150 
 
4.4.1.2 Principal Component Analysis (PCA) 
 As described in Chapter 3 (3.3.3.2) the R package prcomp was used to 
perform PCA on FPKM transformed counts data from control (CD_Group) and 
treated (TD_Group) TM cells. The first three principal components were visualised 
using the R package 3dplot. In Figure 4.1 (below), cells are coloured according to 
their treatment (red denotes the control (CD_Group), blue denotes the treated 
group(TD_Group), and spheres of the same size represent donor pairs. Samples 
separate in different regions of the PCA plot corresponding to the principal sources 
of variation within the experiment. The sample groups in this experiment 
(CD_group and TD_Group) segregate on the first and second principal component 
axes, but there is a clear relationship between donor pairs, indicating the need to 
incorporate donor source as a factor in an expression analysis of this data.  
 When biological differences between samples are pronounced it can be 
seen in the primary components of the variation of the data. Samples separate in 
different regions of the PCA plot corresponding to their biology. Sample groups in 
this experiment (CD_group and TD_Group) tend to cluster on the primary 
component and sample cluster pairs on the secondary component.  
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Figure 4.1: Principal Component Analysis of RNA-Seq Data for Control Untreated 
TM Cells and DEX Treated TM Cells. The PCA was performed on all samples passing 
QC using the top 500 genes that have the largest coefficient of variation based on 
FPKM counts. Cell treatments are coloured according to the key and donor pairs are 
represented by spheres of the same size. Based on normalised FPKM (abundance) 
for each gene for each sample. 
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4.4.1.3 Heat Map and Unsupervised Clustering 
 Heat maps were generated using the Bioconductor package ‘pheatmap’ 
from FPKM counts of control and treated cells, using a Pearson Correlation distance 
and a complete agglomeration method, with gene-wise scaled and centred log2 
transformed FPKM count data.  
The heat map diagram below (Figure 4.2) shows the results of the two-way 
hierarchical clustering of RNA transcripts and samples. It includes the 500 genes 
based on FDR p-value in the Control (CD_Group) vs Treated (TD_Group) expression 
analysis. Each row represents one gene and each column represents one sample. 
The colour represents relative expression level of transcript across all samples. The 
colour scale is shown below: orange represents an expression level above the 
mean; blue represents an expression level below the mean. 
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Figure 4.2: Heat Map and Unsupervised Clustering of RNA-Seq Data from 
Control Untreated TM Cells and DEX Treated TM Cells. Hierarchical 
clustering by sample and transcripts was performed on all samples passing 
the QC using the top 500 genes that have the largest coefficient of variation 
based on FPKM counts. 
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4.4.2 Functional Analysis of Gene Pathways Involved in Dexamethasone 
Stimulation of Human Trabecular Meshwork Cells 
4.4.2.1 Differentially Expressed Genes in Human Trabecular Meshwork Cells in 
the Presence or Absence of Dexamethasone Obtained from RNA-Seq Analysis 
 The DEGs were identified based on Benjamini-Hochberg false discovery rate 
(FDR) corrected q-values and ranked; the most significantly altered based on their 
FDR are shown in Appendix (8.3). From the top 500 DEGs based on FDR the 50 most 
up- and down-regulated were ranked by LogFC and are shown in Table 4.6. 
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Gene ID Gene Name LogFC 
Up-Regulated Genes 
GeneName   
ZBTB16 Zinc Finger and BTB Domain Containing 16 8.32 
OCA2 Oculocutaneous Albinism Type 2 7.09 
ALOX5AP Arachidonate 5-Lipoxygenase Activating Protein 6.87 
ALOX15B Arachidonate 15-Lipoxygenase Type B 6.31 
SAA1 Serum Amyloid A1 5.58 
OLAH Oleol-ACP Hydrolase 5.56 
FAM105A Family With Sequence Similarity 105 Member A 5.53 
LGI3 Leucine Rich Repeat LGI Family Member 3 5.26 
RGCC Regulator of Cell Cycle 4.80 
GPR64 Cell Surface Receptor  4.63 
PDK4 Pyruvate Dehydrogenase Kinase 4 3.87 
ADH1B Alcohol Dehydrogenase 1B 3.63 
IP6K3 Inositol Hexakisphosphate Kinse 3 3.62 
SORBS2 Sorbin and SH3 Domain Containing 2 3.38 
C10 Complement Component 10 3.05 
FKBP5 FK506 Binding Protein 5 2.68 
LMO3 LIM Domain Only Protein 3 2.64 
NRCAM Neuronal Cell Adhesion Molecule 2.52 
IMPA2 Inositol Monophosphatase 2 2.47 
AOX1 Aldehyde Oxidase 1 2.35 
PTK2B Protein Tyrosine Kinase 2Beta 2.26 
METTL7A Methyltransferase-like 7A 2.24 
PER1 Period Circadian Clock 1 2.15 
POM121L9P POM121 Transmembrane Nucleoporin Like 9 2.08 
SIK1 Serine/threonin-protein kinase 1 1.97 
KIAA0040 Alcohol Dependence Related Gene 1.95 
CRISPLD2 Cysteine Rish Secretory Protein LCCL Domain Containing 2 1.93 
DUSP5 Dual Specificity Phosphatase 5 1.93 
PISD Phosphatidylserine Decarboxylase 1.76 
ACSL1 Acyl-CoA Synthetase Long Chain Family Member 1 1.75 
DTX4 Deltex E3 Ubiquitin Ligase 4 1.66 
GLUL Glutamate-Ammonia Ligase 1.61 
FBN2 Fibrillin 2 1.58 
AKR1C2 Aldo-keto reducatse Family 1 Member C2 1.54 
GGT5 Gamma-Glutamyltransferase 5 1.54 
SSB Sjogren Syndrome Antigen B 1.41 
RPS6KA2 Ribsomal Protein S6 Kinase A2 1.40 
TRNP1 TMF1-Regulated Nuclear Protein 1 1.39 
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SLC44A1 Solute Carrier Family 44 Member 1 1.36 
PDPN Podoplanin 1.36 
AR Androgen Receptor Gene 1.27 
KLF9 Kruppel-like Factor 9 1.24 
UGP2 UDP-Glucose Pyrophsphorylase 2 1.18 
ERRFI1 ERBB Receptor Feedback Inhibitor 1 1.14 
FAT4 FAT Atypical Cadherin 4 1.11 
GLRX Glutaredoxin 1.06 
TMEM164 Transmembrane Protein 164 1.04 
SQRDL Sulfide:Quinon Oxireductase 1.01 
ID1 Inhibitor of DNA Binding 1 0.97 
KCNE4 Potassium Voltage-Gated Channel Subfamily E Regulatory 
Subunit 4 
0.92 
Table 4.6: Top 50 Up-Regulated Genes in Cultured Human TM Cells +/- 
Dexamethasone. FC= Fold Change. 
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Gene ID Gene Name LogFC 
Down-Regulated Genes 
SERPINB2 Plasminogen Activator Inhibitor Type 2 (aka PAI) -3.59 
NR1D1 Nuclear Receptor Subfamily 1 Group D Member 1 -3.17 
ESM1 Endothelial Cell Specific Molecule 1 -2.89 
GRPR Gastrin Releasing Peptide Receptor -2.69 
PTHLH Parathyroid Hormone-like hormone -2.54 
FST Follistatin -2.53 
CDCP1 CUB Domain Containing Protein 1 -2.49 
ALDH1A3 Aldehyde Dehydrogenase 1 Family Member A3 -2.45 
NR1D2 Nuclear Receptor Subfamily 1 Group D Member 2 -2.41 
NRG1 Neuregulin 1 -2.41 
PER3 Period Circadian Clock 3 -2.32 
C4 Complement Component 4 -2.28 
IL33 Interleukin 33 -2.16 
FAM180A Family With Sequence Similarity 180 Member A -2.12 
LRRN3 Leucine Rich Repeat Neuronal 3 -2.11 
ARL4C ADP-ribosylation Factor-like 4C -2.11 
CXCL12 C-X-C Motif Chemokine Ligand 12 -2.05 
FGF5 Fibroblast Growth Factor 5 -1.91 
HAS2 Hyaluronan Synthase 2 -1.88 
TMEM200A Transmembrane Protein 200A -1.87 
DPF3 Double PHD fingers 3 -1.84 
RGMB Repulsive Guidance Molecule Family Member -1.84 
MMP1 Matrix Metallopeptidase 1 -1.81 
VEGFC Vascular Endothelila Growth Factor C -1.32 
CD274 Receptor PD1 ligand -1.78 
MIR2682 microRNA 2682 -1.77 
IL6 Interleukin 6 -1.74 
POU2F2 POU Class 2 Homeobox 2 -1.68 
HBEGF Heparin Binding EGF-like Growth Factor -1.6 
PLAT Plasminogen Activator Tissue Type -1.56 
IL11 Interleukin 11 -1.53 
TNFRSF11B TNF Receptor Subfamily Member 11b -1.48 
ATP8B1 ATPase Phospholipid Transporting 8B1 -1.40 
CLDN11 Claudin 11 -1.38 
SMURF2 SMAD Specific E3 Ubiquitin Protein Ligase 2 -1.32 
CORO2B Coronin 2B -1.29 
GREM2 Gremlin 2 DAN Family BMP Antagonist -1.25 
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KRT18 Keratin 18 -1.24 
CHRM3 cholinergic Receptor Muscarinic 3 -1.20 
UACA Uveal Autoantigen With Coiled-Coil Domains and Ankyrin 
Repeats 
-1.19 
AMIGO2 Adhesion Molecule with Ig-like Domain 2 -1.19 
KCNQ5 Potassium Voltage-Gated Channel Subfamily Q Member 5 -1.18 
SYNJ2 Synaptojanin 2 -1.16 
LACC1 Laccase Domain Containing 1 -1.10 
MYBL1 MYB Proto-Oncogene Like 1 -1.14 
DOPEY2 Dopey Family Member 2 -1.17 
ARHGAP22 Rho GTPase Activating Protein 22 -1.05 
FAM107B Family With Sequence Similarity 107 Member B -1.02 
RAB3B RAS Oncogene Family Member 3B -1.01 
SLC4A7 Solute Carrier Family 4 Member 7 -0.97 
CDC25B CDC25 Family Member B -0.96 
Table 4.7: Top 50 Down-Regulated Genes in Cultured Human TM Cells +/- 
Dexamethasone. FC= Fold Change. 
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4.4.2.2 Visual Identification of RNA Transcripts Obtained by RNA-Seq Analysis 
 Volcano plots provide a way to visualise RNA transcripts displaying large-
magnitude changes which are also statitistically significant. The volcano plot (Figure 
4.3) was constructed by plotting the expression FC on the y-axis, and the log CPM 
(counts-per-million) between control (CD_Group) and DEX treated (TD_Group) TM 
cells on the x-axis. Two regions of interest exist on the plot; extreme right along the 
x-axis indicated high statistical significance, and extreme above or below indicated 
strongly up- and down-regulated genes respectively.  
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Figure 4.3: Volcano Plot of the Relationship Between the LogFC and the Average 
Log Counts-per-Million (CPM) in Control Untreated TM Cells Compared to DEX 
Treated TM Cells. The relationship between statistical significance and logFC in 
normalised expression between the experimental groups, CD_Group (control, 
untreated TM cells) and TD_Group (DEX) treated TM cells), are shown in the plot. 
FC= Fold Change. Key: Up-Reg = significantly up-regulated genes between the two 
sample groups are indicated by the red dots; Not DE = genes that were not 
differentially expressed between the two sample groups are indicated in grey; 
Down-Reg = genes that were significantly down-regulated between the two sample 
groups are indicated by blue markers. 
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4.4.2.3 Dexamethasone Activated Processes in Cultured Human Trabecular 
Meshwork Cells  
 Biological processes significantly associated with differentially expressed 
protein coding genes identified through RNA-Seq are outlined in Table 4.8 below. 
As before (3.3.3.3) two different statistical tests were utilised to achieve these 
results. The analyses identified several functional groups among the candidate 
genes obtained from RNA-Seq data, of which angiogenesis, axonal guidance 
signalling and p38 MAPK signalling were represented. 
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 Table 4.8: Significantly Altered Biological Processes Found to be Differentially 
Expressed Between DEX Treated and Untreated Control TM Cells. Significant 
biological processes for differentially expressed genes found between the 
untreated control TM cells (CD_Group) and TM cells treated with DEX (TD_Group) 
are outlined above. Of 9383 genes annotated, 3926 were significantly associated 
with biological processes identified. 
Class of Encoded Proteins Number            Affected 
 Annotated Significant 
Angiogenesis 318 159 
Positive regulation of osteoblast 
differentiation 
52 32 
Circadian rhythm 69 41 
Negative regulation of cell proliferation 452 199 
Response to mechanical stimulus 140 64 
Wound healing 496 214 
Positive regulation of transcription from RNA 
polymerase II promoter 
613 244 
Signal transduction 3522 1318 
Negative regulation of epithelial cell 
proliferation 
79 43 
Response to glucocorticoid 88 44 
Positive regulation of DNA replication 50 28 
Response to hypoxia 205 95 
Negative regulation of transcription from 
RNA polymerase II promoter 
467 187 
Chemotaxis 483 213 
Inflammatory response 366 159 
Cell proliferation 1303 567 
Cell division 545 240 
Negative regulation of cytokine-mediated 
signalling pathway 
26 18 
Cellular response to ionizing radiation 46 28 
Positive regulation of protein kinase B 
signalling 
63 33 
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 IPA v 01-08 (Qiagen) Core and Comparison analyses were performed with 
lists of DEGs generated from expression analyses that included gene name, FDR p-
value and log2 fold change. An FDR p-value cut off of 0.01 was used to select lists of 
DEGs for analysis. Core analysis output included ranked lists of Canonical Pathways 
(processes with biological or molecular biology significance defined by the Ingenuity 
Knowledge Base). The canonical pathways identified in two or more Core analyses 
were compared in Comparison analyses. Comparisons were performed by 
hierarchical clustering based on process enrichment score or activation z-score. 
Fishers exact tests reported as a likelihood value (–log(p-value)) were 
performed to test  canonical pathway enrichment. Canonical pathways were ranked 
by activation z-score. The activation score threshold was +/- 1.96 and canonical 
pathways enriched in this are regarded as significant. The sign of the Z-score 
indicates the direction of regulation of the process (Figure4.4). A comparison 
analysis was then performed on IPA to determine the most significantly altered 
canonical pathways in TM cells treated with known glaucoma stimuli, TGF-β2 
(Chapter 3) and dexamethasone. The top 76 processes that over-lap between the 
two treatment groups are outlined below (Figure 4.5) in which Rho signalling, 
inflammatory processes, and actin cytoskeleton signalling are all represented.  
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Figure 4.4: Top Canonical Pathways of the Top 1% Differentially Expressed Genes in 
Human TM Cells +/- Dexamethasone. I.P.A was used to generate the top 24 
canonical pathways associated with differentially expressed genes identified by RNA-
Seq in cultured human TM cells +/- DEX. 
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Figure 4.5: Heat Map of Highest Ranked Over-Lapping Canonical Pathways 
between TGF-β2 Treated Human TM Cells and DEX Treated Human TM Cells.  TGF-
β2 and DEX are known glaucoma stimuli and several processes are enriched when 
human TM cells are exposed to both stimuli independently.  
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4.4.3 q-PCR Assay Assessment of Glucocorticoid Receptor Isoforms Expressed 
in Cultured Human TM +/- Dexamethasone 
 Both glucocorticoid receptor isoforms, GRα and GRβ are present in the 
normal and glaucomatous human TM572. TM cells isolated from glaucomatous 
patients express lower levels of GRβ compared to normal TM cells. Lower GRβ 
expression has been attributed to increased steroid responsiveness, therefore, it 
was in our interest to identify potential steroid responders within our samples 
based on their GRα to GRβ expression levels. In control, untreated samples, 50% of 
our TM samples had lower GRβ expression levels compared to GRα. Post DEX 
stimulation, five out of six samples had higher GR-β expression levels in comparison 
to GR-α. 
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Figure 4.6: Expression Levels of Glucocorticoid Receptor (GRα and β) in Paired 
Human TM Cells +/- DEX Treatments. (A) Untreated TM cells from 6 donors exhibit 
differential GRα and GRβ expression. 50% of the donors (Donors 3, 4, and 6) show 
lower GRβ expression favouring GRα expression in normal cell states. (B) DEX 
treated TM cells continue to exhibit differential GRα to GRβ expression. A switch in 
ratio was observed in only one donor (Donor 3) in response to DEX stimulations. 
Horizontal line represents 50% receptor expression. Ratios above and below this 
are represented by specific receptor keys. GRα is represented by blue bar, GRβ is 
represented by the purple bar. 
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4.4.3.1 q-PCR Assay Validation of Top Differentially Expressed Genes in 
Cultured Human TM in the Presence or Absence of Dexamethasone 
 To validate results obtained from the RNA-Seq analysis, a subset of the top 
differentially expressed genes (DEGs) between the control group (CD_Group), and 
the DEX treated group (TD_Group), of cultured human TM, were analysed using q-
PCR.  
 Nine candidate genes (Table 4.9) were selected for q-PCR analysis based on 
their statistical significance in the RNA-Seq data set and on the basis of published 
literature providing evidence of their involvement in glaucoma pathophysiology. 
Nine candidate genes; protein tyrosine kinase 2 beta (PTK2B), regulator of cell cycle 
(RGCC), zinc finger and BTB domain containing 16 (ZBTB16), FK 506 binding protein 
(FKB5), podoplanin (PDPN), matrix metalloproteinase 1 (MMP-1), vascular 
endothelial growth factor C (VEGFC), serpin family B member 2 (SERPINB2), 
follistatin (FST). Eight of the nine candidate genes demonstrated consistent trends 
of differential expression by q-PCR. MMP-1 expression though decreased in the 
RNA-Seq data was increased when quantified by q-PCR (but not statistically 
significant). To further confirm the differential expression of candidate genes an 
independent sample was added to each group increasing the number of biological 
replicates to 6 in each experimental group; CD_Group (n=6) and TD_Group (n=6). 
Statistical analysis was carried out using Graphpad (Prism, version 6), and all data 
sets were subjected to two sample students t-tests. Results were classified as 
significantly significant if p<0.05.  
  
169 
 
 
 
 
 
 
 
 
  
 
 
 
Table 4.9: Summary of Expression Levels of Candidate Genes based on RNA-Seq 
Analysis.  
  
Candidate Gene LogFC p-value 
PTK2B 2.261071 5.73E-103 
RGCC 4.804257 2.43E-88 
ZBTB16 8.322036 1.85E-77 
FKBP5 2.684064 5.35E-55 
PDPN 1.359751 9.12E-36 
MMP1 -1.80683 8.05E-44 
VEGFC -1.31898 2.3E-47 
SERPINB2 -3.58675 6.65E-50 
FST -2.5333 2.97E-57 
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Donor 1 Control=    ; and Treated=  
Donor 2 Control=    ; and Treated=  
Donor 3 Control=    ; and Treated=  
Donor 4 Control=    ; and Treated= 
Donor 5 Control=    ; and Treated=  
Donor 6 Control=    ; and Treated= 
Figure 4.7: Expression Levels of Candidate Genes in Cultured Human TM Cells. CD_Group 
are denoted as “Control” on graphs and TD_Group as “Treated”. Candidate genes were 
identified as significantly differentially expressed through RNA-Seq. Paired donors are 
colour coded as per legend above. Circles represent individual donor gene expression 
without treatment and squares represent donors with DEX treatment. An asterisk (*) 
denotes significant differential gene expression after treatment (two-sample t-test p 
<0.05). 
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4.5 Discussion 
 Glucocorticoids are a group consisting of natural and synthetic 
(dexamethasone) ligands that have been exploited for anti-immune, anti-allergic, 
and immunosuppressive properties577. The physiological and pharmacological 
actions of glucocorticoids are mediated through the cytoplasmic glucocorticoid 
receptor (GR), which belongs to a nuclear receptor subfamily578. The glucocorticoid 
receptor is a ligand activated transcription factor, involved in mediating numerous 
physiological functions including maintaining homeostasis, normal metabolism and 
immune regulation185.  
 Prolonged exposure to GCs can lead to a number of serious systemic, and 
local adverse side effects193. Ocular side effects of GCs include cataract and ocular 
hypertension which can lead to glaucoma579,580. The mechanism of raised IOP in 
glucocorticoid-induced ocular hypertension resembles POAG in that there is 
impaired aqueous humour outflow in the TM and both ex vivo and in vivo studies 
have established direct roles of glucocorticoids in the TM207,581. Specifically, 
glucocorticoids increase ECM proteins, decrease MMP activity, and increase TIMP 
metallopeptidase 1 (TIMP1) resulting in increased deposition of ECM in the 
TM562,563. Glucocorticoids also reduce the phagocytic activity of the TM cells which 
may lead to further AH outflow resistance and raised IOP427. In addition, 
glucocorticoids are involved in the re-organisation of the TM cytoskeleton, affecting 
TM migration, proliferation and function257,582.  
Glucocorticoid Receptor Isoforms in Steroid Responsiveness in Glaucoma 
 Glucocorticoids are widely used in ophthalmology to supress inflammation, 
reduce symptoms and minimise post-surgical scarring187. Individual responses to 
glucocorticoid therapy in systemic diseases (asthma, cancer, and arthritis) can 
demonstrate variability, and, glucocorticoid resistance or enhanced responsiveness 
between individuals has been reported583–585. Similarly, there are individual 
differences to the susceptibility to develop glucocorticoid-induced ocular 
hypertension208,556. Almost all POAG patients are steroid responders556 and non-
glaucomatous steroid responders are at a higher risk for developing POAG than 
non-glaucomatous non-responders202. Approximately 40% of the normal population 
are considered steroid responders, whereas, in contrast, nearly all POAG patients 
are steroid responders556. A better understanding of genetic and molecular 
mechanisms underlying individual variation in the response to steroids could shed 
light on our understanding of steroid-induced ocular hypertension and ocular 
hypertension leading to POAG.  
Differential GC responsiveness at the molecular level has been attributed to 
the relative expression levels of the two alternatively spliced glucocorticoid 
174 
 
receptor isoforms, GRα and GRβ575,586,587(Figure 4.8). However, a number of 
mechanisms regulate glucocorticoid activity; GC ligand potency, nuclear import of 
GC receptors, as well as alternative splicing and regulation of GRα and GRβ 
levels572. GRα is the biological receptor for GCs and binding of its ligands induces a 
conformational change and release of accessory proteins, followed by translocation 
to the nucleus. Glucocorticoid response elements (GREs) found on GC regulated 
genes facilitate homodimerization of the GR-GC complex. Interaction between GR-
GC complex with GREs drives transcription of genes, whereas binding to negative 
GREs suppresses transcription572. 
 In addition to GREs, GR activity is also regulated by the different ratios of the 
alternatively spliced GRα and GRβ receptor isoforms. The GR encoding gene, 
NR3C1, consists of 9 exons and alternative splicing of the terminal exon generates 
the GRα and GRβ isoforms. Incorporation of exon 9α gives rise to GRα and 
conversely incorporation of 9β gives rise to GRβ588. Exon 9 encodes the ligand 
binding domain; therefore, the resultant isoforms differ greatly in their ligand 
binding properties. GRβ can form heterodimers with GRα however this complex has 
significantly diminished transcriptional activity when compared to GRα 
homodimers588. In this way GRβ acts as a dominant negative inhibitor of GRα 
transcriptional activity and provides enhanced resistance to glucocorticoids.  
Both GRα and GRβ are expressed in the TM575,589, and the GRα/GRβ ratio in 
the TM may play a role in an individual person’s susceptibility to steroid-induced 
ocular hypertension and glaucoma572. The expression of GRβ is lower in TM cells 
isolated from glaucoma patients compared with normal individuals575,590, which 
may explain the high levels of steroid-responsiveness in terms of IOP elevation in 
glaucoma patients. Lower GRβ expression in glaucomatous TM cells results in great 
susceptibility to GCs, leading to ECM and cytoskeletal changes in the TM, increased 
outflow resistance and ultimately raised IOP and glaucoma575,590. In our study we 
investigated the steroid responsiveness of our human TM samples using q-PCR to 
quantify expression levels of GRα and GRβ in control and steroid stimulated TM 
cells. Our results identified slight differential GR expression among patients: 50% of 
our samples were identified as expressing a higher ratio of GRα to GRβ without DEX 
stimulations (Figure 4.6). This may indicate that these samples are part of the 40% 
of the normal population that are steroid responders. Interestingly, after DEX 
stimulations, two of the steroid responders exhibited an increase in GRβ 
expression, whereas only one remained to show GRα expression preferences. 
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Figure 4.8: Alternate Splicing of Glucocorticoid Receptor Generates Two 
Functionally Distinct Splice Isoforms: GRα and GRβ. The ratio between GRα and 
GRβ regulates steroid responsiveness, with lower levels of GRβ related to increased 
steroid responsiveness due to reduced dominant negative inhibition of GRα by GRβ 
and increased ECM expression and elevated IOP.  Modified from Revello and 
Cidlowski 2009591.  
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Genome-Wide Transcriptome Profiling in Dexamethasone Treated Human TM 
Cells 
 Using high-throughput RNA-Seq in cultured human TM cells treated with 
dexamethasone (DEX; 100nM) for 16hrs there were several significantly DEGs and 
networks/canonical pathways that were enriched. Responses to DEX treatment are 
dose and duration sensitive. 16hrs was chosen to monitor acute changes in GC-
induced gene expression rather than alteration induced by chronic GC exposure. 
Ultimately time-dependent responses require assessment but given the resource 
implications a short exposure was chosen as (i) we wanted to assess acute and 
initiating alterations in gene expression, (ii) early events maybe more relevant for 
the identification of potential therapeutic targets, (iii) miRNA expression was 
assessed in parallel and (iv) microarray studies in epidermal keratinocytes show 
consistent responses to 24hr, 48hr and 72hr. Donor characteristics can also play a 
role in gene expression responses. Experiments were limited to male donors to 
reduce variability related to gender and potential oestrogen-GC interactions. As 
glaucoma more commonly affects the ageing population, young donors were also 
excluded from this study. All donors were aged between 57-65 years.  
  
Six studies have examined global changes in gene expression in cultured TM 
cells treated with dexamethasone using cDNA or oligonucleotide arrays548,567–571. 
This is the first study to use RNA-Seq to interrogate alterations in gene expression in 
the TM in response to glucocorticoid treatment. Only one of the microarray-based 
studies recapitulated the dose and duration of DEX treatment for 24 hrs and utilised 
two human eye donors aged 3 months and 35-years old571. A common number of 
genes were up-regulated in the array study571and in our dataset including response 
gene to complement 32 (RGC32), oculocutaneous albinism II (OCA2), serum 
amyloid A1 (SAA1), angiopoietin-like 4 (ANGPTL4), integrin, alpha 10 (ITGA10), 
FK506 binding protein 5 (FKBP51), Kruppel-like factor 15 (KLF15), myocilin (MYOC) 
and zinc finger and BTB domain containing 16 (ZBTB16)571. There was less 
consistency in down-regulated genes in this study and the array study571: Kallmann 
syndrome 1 sequence (KAL1), gamma-aminobutyric acid (GABA) A receptor, beta 1 
(GABRB1) and matrix-remodelling associated 5 (MXRA5). Matrix remodelling-
associated protein 5 (MXRA5, adlican) is a TGF-β1 regulated anti-inflammatory and 
anti-fibrotic protein592. 
 
Protein Tyrosine Kinase 2 Beta (PTK2B) 
Elevated expression of protein tyrosine kinase 2 beta (PTK2B) in response to 
DEX has previously been seen in cultured epidermal keratinocytes treated with 
100nM DEX593. RNA-seq data identified PTK2B was significantly up-regulated in 
human TM cells stimulated with DEX (FC= 2.26, p-value= 5.7E-103) and this was 
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confirmed by q-PCR (FC= 3.933, p-value= 0.0022; Figure 4.7). Protein tyrosine 
kinase 2 beta (PTK2B), also known as focal adhesion kinase 2, is a member of a 
family of non-receptor protein tyrosine kinases, which includes focal adhesion 
kinase 1 (FAK) or protein tyrosine kinase 2. PTK2B is highly conserved with FAK with 
nearly 50% sequence identity and have a similar domain structure594. FAK is 
ubiquitously expressed whereas PTK2B is expressed mainly in the CNS and 
haematopoietic tissue595 with retinal expression reported in  Drosophila596. 
Both PTK2B and FAK are phosphorylated in response to integrin-mediated 
cell adhesion to the ECM. PTK2B is also activated in response to a broad range of 
external stimuli which elevate intracellular Ca2+ concentration or via Src dependent 
pathways597. PTK2B acts in concert with Src to link Gi- or Gq-coupled receptors with 
the mitogen-activated protein (MAP) kinase signalling pathway and/or PI3K 
pathway597,598. Auto-phosphorylation of PTK2B in response to integrin-mediated 
cell adhesion triggers cell migration. 
Both PTK2B and FAK are known to bind to proteins that interact with the 
cytoskeleton (e.g. paxillin599, the Rho-GAP protein Graf, and a LIM domain-
containing protein) suggesting a role in cytoskeletal organisation and alteration in 
cellular morphology in response to extracellular stimuli600–602 (Figure 4.9). There is 
evidence from PTK2B knockout mice that PTK2B is essential to RhoA activation in 
macrophages which show impaired migration when stimulated with chemokines 
due to reduced cell contractility and polarity603.   
 
Figure 4.9: Putative Integrin Signalling Pathways Through PYK2 or FAK (Modified 
from Koch et al 2007597). In response to integrin αvβ3 activation, PYK2 and/or FAK 
are recruited to a signalling complex that consists of Src, paxillin and PLCγ. PYK2 
may be phosphorylated through Src or other Ca2+ dependent pathways whereas 
FAK is phosphorylated through Src. Both PYK2 and FAK can result in activation of 
PI3K and/or MAPK that may lead to cell adhesion and migration. 
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Rho and Rho-associated protein kinases, have been implicated in glaucoma 
pathogenesis (Ch3.4), therefore PTK2B regulation of components of this signalling 
pathway in the TM may also be involved in steroid-induced glaucoma. The 
organization of the actin cytoskeleton is critical for TM cell contractility, motility 
and phagocytosis. Myocilin is highly-inducible in the TM by corticosteroids and 
there is evidence that myocilin increases cell migration via the integrin-FAK-AKT 
signalling pathway604.  
FAK plays a role in TM cell phagocytosis, a central function of the TM, which 
is reduced with dexamethasone treatment and this decline in TM phagocytosis is 
proposed to explain steroid-induced ocular hypertension and glaucoma195. There is 
evidence that phagocytosis in TM cells is regulated by opposing αvβ3 and αvβ5 
integrin–mediated FAK signalling pathways605. Phagocytosis is mediated via the 
actin-cytoskeleton, and, FAK (and its family member PTK2B) are important 
signalling molecules which regulate actin cytoskeleton remodelling600–602. In parallel 
with the role of αvβ5 integrin–FAK in RPE cell phagocytosis a similar system has 
been proposed to be active in TM cells606. Elevated PTK2B expression within the TM 
has not been described before and further work is required to investigate the role 
of PTK2B in actin remodelling and phagocytosis606 in the TM and in relation to 
glaucoma pathogenesis605,607.  
Regulator of Cell Cycle (RGCC) 
Regulator of cell cycle (RGCC) encodes response gene to complement 3 
(RGC-32) in humans. RGCC regulates cell cycle progression and it is induced by p53 
in response to DNA damage608 or by sublytic levels of complement system proteins 
(sublytic C5b-9 specifically), that result in activation of the cell cycle609. RGCC 
expression is also induced in response to complement activation, growth factors, 
and steroid hormones610–612. In our study RGCC expression was significantly up-
regulated in human TM cells stimulated with DEX over 16 hours using RNA-Seq (FC= 
4.80, p-value = 2.43E-88) in comparison to control cells. Statistical significance could 
not be achieved in q-PCR validation. Significant glucocorticoid inducible expression 
of RGCC in the TM was also reported after 24 hours571 and 21 days570 of DEX 
treatment. Based on the responses of rat kidney cells to methylprednisolone, RGCC 
was proposed to be a “corticosteroid-enhanced gene”613. The expression of RGCC is 
also induced in lens epithelial cells in response to corticosteroids614 and may play a 
role in steroid-induced cataract.  
The exact role of RGCC in response to corticosteroids has not been 
identified, nor has a role for RGCC in glaucoma been determined. In human aortic 
endothelial cells there was evidence RGCC mediates cell migration by regulating 
RhoA and ROCK1 expression and actin cytoskeletal organisation615. Overexpression 
of RGCC in lung cancer cell lines promotes cell migration and invasion and induces 
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EMT via the NF-κB signalling pathway616; responses which are inhibited by RGCC 
silencing617. A role for RGCC up-regulation in fibrotic diseases has been reported in 
hepatic fibrosis618 and scarring following glaucoma surgery in rodent models619. 
These studies suggest RGCC may have a role in fibrotic responses which could 
contribute to a reduce outflow facility in the TM and elevated IOP. Overexpression 
of RGCC results in downregulation of E-cadherin, and upregulation of vimentin, 
fibronectin, snail and slug in the human lung cancer A549616. RGCC also plays a 
central role in TGF-β1-induced EMT of human renal proximal tubular cells inducing 
the expression of smooth muscle α-actin (α-SMA) and extracellular matrix proteins 
(collagen I and fibronectin)620. 
Promyelocytic Leukemia Zince Finger (ZBTB16) 
ZBTB16, also known as promyelocytic leukemia zinc finger (PLZF), is a 
member of the Krueppel C2H2-type zinc-finger protein family and encodes a zinc 
finger transcription factor. ZBTB16 is located in the nucleus and is involved in cell 
cycle progression. In our study ZBTB16 expression was significantly up-regulated in 
human TM cells stimulated with DEX via RNA-Seq (FC= 8.32, p-value = 1.85E-77). q-
PCR validation of ZBTB16 expression in TM samples further corroborated the RNA-
Seq findings (FC= 52.6, p-value = 0.01520). Similarly after 21 days of DEX stimulation 
demethylated cytosine-phosphate-guanine (CpG) sites within the ZBTB16 gene 
promoter regions were detected and there were corresponding increases in ZBTB16 
gene expression621. ZBTB16 has been previously reported as a corticosteroid 
responsive transcription factor in other tissues622–624. ZBTB16 is a transcriptional 
repressor involved in cell cycle control and is known to suppress the expression of 
several genes that regulate cell proliferation625. Studies in the corneal endothelium 
support a role for ZBTB16 in the suppression of corneal endothelial cell 
proliferation626. The corneal endothelium and TM cells are derived from the neural 
crest and share similar characteristics627. Further work on the role of ZBTB16 in TM 
cell physiology is required.   
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FK506 Binding Protein (FKBP51) 
 FK506 binding protein 5 (FKBP5 or FKBP51) encodes FKBP51 a member of 
the immunophillin protein family which is a novel steroid receptor-associated 
protein628, and a strong inhibitor of glucocorticoid receptor (GR) function629–631. In 
addition to its GR modulatory properties, FKBP51 interacts with several other co-
chaperones to regulate steroid receptor splicing protein function and modulates a 
number of pathways related to immune function, cell growth and metabolism, 
cytoskeletal organisation, autophagy and DNA methylation632. 
 
 
 
Figure 4.10: FKBP51/FKBP5 Structure. FKBP51 consists of three domains- an FK1 
domain which has PPIase activity and bind immunosuppressants, an FK2 domain 
which is FK1-like but does not bind immunosuppressants, and a C terminal domain 
which has a 3 TPR domain which can bind to Hsp90. FKBP51 is up-regulated in 
response to steroids. Modified from Online Resource (FKBP5 Pharma Ltd)633. 
 
 Glucocorticoid action requires binding of GC ligand to GRα inducing nuclear 
translocation, to regulate gene expression. In the absence of a ligand, GRα remains 
in the cytoplasm as a multiprotein heterocomplex that contains heat shock protein 
(Hsp)90, Hsp70, and an immunophillin, such as FKBP51634. FKBP51 contains a 
peptidyl-prolyl cis/trans isomerase (PPIase) domain and a C terminal 
tetratricopeptide repeat (TPR) domains (Figure 4.10). TPR domains bind Hsp90 and 
aids chaperoning of GR in nuclear translocation630. FKBP51 is bound to mature GRα 
and it has been shown that GC ligand binding induces the release of FKBP51 bound 
to GRα. This allows the incorporation of FKBP family member, FKBP52, to GRα635. 
FKBP52 binds dynein which shuttles the complex from the cytoplasm, via 
microtubules, to the nucleus where it can then exert effects on gene expression 
(Figure 4.11).  
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Figure 4.11: The FKBP51 and FKBP52 Genes Regulate Glucocorticoid Receptor 
Nuclear Translocation. Modified from Trebble 2013636 . FKBP51 is released from 
GRα upon binding of GC ligand. FKBP family member FKBP52 is incorporated and 
induces the binding of Dyenin, a protein required for nuclear translocation via 
microtubules. 
Lower GRβ expression compared to GRα expression is thought to contribute 
to enhanced GC sensitivity in glaucomatous patients as well as non-glaucomatous 
steroid responders590. Interestingly, FKBP51 expression patterns in glaucomatous 
TM is not uniform which may be disruptive of GRβ nuclear import thus contributing 
to the low nuclear GRβ expression and increased glucocorticoid sensitivity observed 
in POAG patients637.  
Our study identified FKBP51 expression was significantly up-regulated in 
human TM cells in the presence of DEX (FC= 2.68, p-value= 3.3E-52).  Up-regulation 
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of FKBP51 was further validated in TM cells by q-PCR (FC= 9.09, p-value= 0.0313, 
Figure 4.7). Significant glucocorticoid inducible expression of FKBP51 in the TM was 
previously reported after 24hours571 and 21 days570 of DEX treatment. In C57BL/6J 
mice, treated with topical 0.1% dexamethasone sodium phosphate ophthalmic 
solution 3 times daily for up to 5 weeks, all mice showed increased FKBP51 
expression at weeks 3 and 5638. DNA methylation of the FKBP51 promoter is lost 
with GC treatment with a concomitant increase in FKBP51 expression in murine 
studies639; similar methylation changes have been reported in the human TM 
treated with 100nM DEX for 21 days640. This data suggests FKBP51 plays a 
significant role in steroid-induced glaucoma, but the mechanism is currently 
unknown. A candidate gene association study typed SNPs in FKBP51 in POAG 
patients but no significant risk alleles were identified641.  
  Similar to GRα, GRβ can also complex with Hsp90, and it has previously 
been reported that Hsp90 is essential for GRβ nuclear transportation642. FKBP51, 
but not FKBP52, is involved in GRα and –β nuclear translocation independent of 
ligand-binding637. Further work identified overexpression of FKBP51 enhanced the 
nuclear transport of GR-β in trabecular meshwork cells637. FKBP51 involvement in 
chaperoning GRβ nuclear translocation may represent a novel therapeutic target 
through which FKBP5 induces glucocorticoid resistance.  
 It is of note that previous reports have stated that FKBP51 have caused 
glucocorticoid resistance in a number primates629. In addition, FKBP51 is known to 
be increased by glucocorticoids570,571, suggesting that regulation of FKBP51 levels 
represents a potential feedback mechanism for inhibiting glucocorticoid responses. 
Recently several miRNAs (miR-124, miR-15a, miR-142, and miR-511) have been 
identified with target sites on the FKBP51 mRNA643–645. Although all miRNAs have 
been shown to regulate FKBP51 mRNA, only miR-511 was found to robustly 
regulate FKBP51 at the protein level108. miR-511 supresses the GC-induced up-
regulation of FKBP51 in cells and primary neurons also, suggesting its role in 
FKBP51s modulatory action on GRs645,646. Our study further confirms FKBP51 
expression is enhanced by glucocorticoids (DEX specifically), further strengthening 
the premise that FKBP51 is a potential therapeutic target and may be a candidate 
for miRNA therapeutics.  
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Podoplanin (PDPN) and Vascular Endothelin Growth Factor C (VEGFC) 
Podoplanin (PDPN) has been localised to the TM of the human anterior 
segment647. PDPN is a mucin-type transmembrane glycoprotein which is reported 
to be a specific lymphatic endothelial cell marker648.  A microarray study based on 
perfused non-glaucomatous human donor anterior segments to identify pressure-
related gene expression was the first to identify PDPN in the human TM649. The 
expression of PDPN was consistently up-regulated in response to elevated 
IOP/perfusion pressure in all donors and immunohistochemical staining localised 
expression to the trabecular meshwork and inner wall of Schlemm’s canal. The 
authors proposed that PDPN represents a novel candidate for pressure regulation 
in the human trabecular meshwork649. In our study PDPN expression was 
significantly up-regulated by RNA-Seq (FC= 1.36, p-value = 3.39E-33) but not in the 
q-PCR validation (FC= 2.38, p-value = 0.384 Figure 4.7). 
Pronounced expression of PDPN in the conventional outflow pathway and 
TM in the normal human eye was confirmed in an immunohistochemical study647 
and expression is altered in POAG650. The trabecular meshwork cells have some 
properties consistent with lymphatic endothelial cells and the aqueous humour 
parallels lymphatic fluid in interstitial spaces650. The aqueous humour ultimately 
drains into Schlemm’s canal (SC) which has some of the structural, molecular and 
functional properties of lymphatic vasculature651. The SC expresses some lymphatic 
markers:  prospero-related homeobox 1 transcription factor (PROX1), vascular 
endothelial growth factor receptor 3 (VEGFR3) and integrin α9; but not lymphatic 
vessel endothelial hyaluronan receptor 1 (LYVE1) and podoplanin651.  
VEGFC/VEGFR3 signalling is an important regulator of the SC652. VEGFC drives the 
proliferation of SC endothelial cells and in adult mice a single injection of 
recombinant VEGFC into the adult eye resulted in sprouting, proliferation, and 
growth of SC endothelial cells, whereas VEGFA obliterated the aqueous outflow 
system653. Furthermore, in an adult mouse a single intracameral injection of 
recombinant VEGFC induced SC growth and resulted in a sustained reduction in 
IOP652. VEGFC expression was downregulated in human TM cells in response to DEX 
treatment using RNA-Seq (FC= -1.32, p-value= 1.44E-44) and with q-PCR validation 
(FC= 0.412, p-value = 0.0022). The role of VEGFC in SC physiology in humans and 
primates is unknown but murine studies652,653 suggest increasing VEGFC reduces 
IOP and the reduction in VEGFC in the TM in response to DEX in this study warrants 
further study. VEGFC may be a therapeutic option in POAG652 and steroid-induced 
glaucoma.  
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Plasminogen Activator Inhibitor 2 (SERPINB2) 
Plasminogen activator inhibitor 2 (PAI-2)  or serpinB2 (SERPINB2) is a serine 
protease inhibitor of the serpin superfamily which acts as a coagulation factor  
(Figure 4.12) inactivating  tissue plasminogen activator (tPA) and urokinase 
plasminogen activator654. SERPINB2 is induced during inflammatory processes and 
infections in many cell types: macrophages, fibroblasts, endothelial cells, and 
differentiating keratinocytes655–657. SERPINB2 non-expressing cells exhibit 
differences in cellular protrusion dynamics in comparison to SERPINB2 expressing 
cells, suggesting that SERPINB2 has an effect on matrix remodelling primarily 
through a novel role in regulation of motility and interactions with the surrounding 
ECM658.  
 
Figure 4.12: PAI-2 Inhibits tPA Activity. Modified from Kohler et al 2000659. 
 
SERPINB2 expression was significantly down-regulated in human TM cells 
stimulated by DEX in our study (FC= -3.59, p-value= 4.66E-47). Validation of 
SERPINB2 decreased expression could not be achieved by q-PCR (FC= 0.34, p-value 
= 0.3052). Significant glucocorticoid down-regulation SERPINB2 expression in the 
TM was also reported after 6-8 days of DEX treatment568. The role of SERPINB2 in 
the TM is not known. The extracellular function of SERPINB2 is to regulate 
fibrinolysis but as SERPINB2 is mainly intracellular its role within the cell is not well 
understood654. SERPINB2 is a direct downstream target of p53 and intracellular 
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SERPINB2 has a direct role in cellular senescence through the stabilisation of p21660. 
SERPINB2 also plays a role in matrix remodelling and carcinogenesis by regulating 
fibroblast motility and interactions with the ECM658. Interestingly, plasminogen 
activator inhibitor 1 (PAI-1), a phylogenetically distinct but regulated coagulation 
factor, is induced in the TM when treated with TGF-β2 which is proposed to inhibit 
ECM degradation via MMP regulation244. This alternative relationship between PAI-
1 and PAI-2 has previously been described661. The ratio of PAI-1/PAI-2 may be a 
useful biomarker in differentiating normal and glaucomatous patients.  
Matrix Metallopeptidase 1 (MMP-1) 
Matrix metallopeptidase 1 (MMP-1) is an interstitial collagenase and 
fibroblast collagenase in humans, part of the MMP enzyme family which exhibit 
different substrate specificities, which together are capable of degrading all 
components of the ECM662,663. A number of studies and experimental finding have 
implicated a role for MMP-1 in glaucoma664–667. Previous studies have shown that 
DEX treatment of cultured human TM cells (100nM for 3-6 days) decreases the 
expression of MMP-1 using q-PCR and collagen degradation assays666. In our RNA-
Seq data MMP-1 expression was decreased in human TM cells treated with DEX 
(FC= -1.81, p-value= 4.4E-41); q-PCR did not confirm this, (FC= 1.26, p-value= 0.0649 
Figure 4.7). Protein, functional studies and time course studies including collagen 
degradation assays and ELISA are required to fully validate this finding but previous 
studies support the down-regulation of MMP-1 with DEX treatment in the human 
TM666. This reduction in MMP-1 may relate to the decreased ECM turnover seen in 
the outflow pathway with corticosteroid treatment552. The DEX induced decrease in 
the expression and activity of MMPs in the TM is likely to contribute to the 
increased outflow resistance observed in steroid responders666.  
MMP-1 reduction in response to DEX has garnered great interest in recent 
years and researchers have begun to investigate the potential of MMP-1 
glucocorticoid-inducible gene virus therapy as a novel treatment of glaucoma666. 
Research so far has investigated the effects of a glucocorticoid-inducible virus 
vector overexpressing recombinant MMP-1 on both human TM cells and perfused 
human anterior segments666. Transfected cells and anterior segments showed 
increased MMP-1 expression in a cyclic manner with the addition and removal of 
DEX666.  
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Follistatin (FST) 
Follistatin (FST) is an autocrine glycoprotein that is expressed in most 
tissues668,669. The essential biological function of FST is binding and neutralising 
transforming growth factor beta (TGF-β) superfamily, including activin, myostatin, 
and bone morphogenic protein (BMP)670–672. FST is a stress responsive protein 
exerting protective effects by neutralising TGF-β2 signalling by antagonising BMP 
and activin669. FST is expressed in the normal and glaucomatous TM526,673 and this 
expression is increased in a dose-dependent manner with TGF-β2 treatment673.  
Our RNA-Seq data indicated that FST expression was significantly down-
regulated in TM cells stimulated with DEX in comparison to normal cells (FC= -2.53, 
p-value= 2.36E-54); down-regulation was further corroborated by q-PCR (FC= -
0.168, p-value = 0.0022). Significant glucocorticoid inducible expression of FST in 
the TM was also reported after 21 days570 of DEX treatment. The biological activities 
and underlying mechanisms for FST involvement in the TM have yet to be explored 
fully673.  
As well as its role in neutralising members of the TGF-β superfamily, FST has 
been shown to be a stress responsive protein. TM cells undergo oxidative stress as 
a result of an imbalance between reactive oxygen species (ROS) and anti-oxidants. 
Studies have shown than FST reduces ROS production and is thought to interact 
with members of the NADPH oxidase inhibitor (NOX) family674. Interestingly, FST 
can be regulated at both transcriptional and post-transcriptional levels675,676, which 
allows an opportunity to manipulate FST expression therapeutically.   
Comparison of Key Enriched Canonical Pathways Following Dexamethasone 
Treatment and TGF-β2 in TM Cells 
 Using IPA Comparison Analysis the enriched canonical pathways were 
compared (Figure 4.5) between TGF-β2 treatment (5ng/mL for 24 hours) and DEX 
treatment (100nM for 16 hours). TGF-β2 results in a greater alteration in gene 
expression but common canonical pathway are either up- or down-regulated when 
compared to DEX treatment. The degree and timing of the TGF-β2 stimulation 
reflects human ex-vivo perfusion models in which TGF-β2 induces raised IOP within 
24 hours244 whereas DEX treatment in the same model system takes at least 7-14 
days207. However, common canonical pathways were activated including actin 
cytoskeleton, RhoA signalling and signalling by Rho family GTPases (Figure 4.5). 
Both DEX and TGF-β2 induce the formation of cross-linked actin networks (CLANs) 
which are believed to stiffen the TM leading to increased aqueous humour outflow 
resistance and increased IOP253. Understanding the molecular mechanisms 
triggered by TGF-β2 and steroid treatments not only improves our understanding of 
the pathogenesis of POAG but also steroid-induced OHT and glaucoma. Given that 
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common pathways like RhoA signalling are activated by TGF-β2 and steroids, this  
supports the use and development of common therapeutic agents. A dual inhibitor 
of LIM and Rho kinase (LX7101) lowered IOP in mice with steroid-induced OHT 
(dexamethasone), this will be discussed further in Chapter 6. Our data supports the 
concept that inhibition of RhoA signalling is a therapeutic option for both POAG and 
steroid-induced OHT/glaucoma.  
4.6 Summary 
 Our study characterises differentially expressed genes in human TM cells in 
response to dexamethasone through RNA-Seq for the first time. This involved the 
isolation of RNA from glucocorticoid treated primary human TM cells in addition to 
healthy normal TM cells. 40% of the normal population are steroid responders and 
this presents an obstacle when investigating a general gene expression profile of 
normal cells in response to a known glaucoma stimulus, dexamethasone. 
Differential expression between different donors is expected, however this is 
further enhanced by individual donor steroid responsiveness. This steroid response 
was considered and an attempt was made to identify the potential steroid 
responsive individuals in the data-set. Alternative methods in the future may 
require a better screening process for steroid responsive samples which will provide 
a more disease appropriate cohort for examining global gene expression and aid in 
potential novel target identification.  
Among a robust data-set the majority of differentially expressed genes are 
implicated in extracellular matrix remodelling and glucocorticoid receptor 
activation and translocation. A number of differentially expressed genes have the 
potential to be manipulated for therapeutic gain in steroid-induced glaucoma. Of 
particular interest is FKBP51, a member of the immunophilin family. FKBP51 is 
involved in the translocation of GRβ to the nucleus and has already been shown to 
directly regulated by miRNAs, a promising future therapeutic technique. Going 
forward, investigation of the roles of miRNAs in the human TM particularly in 
relation to FKBP51 would be of interest. Elucidating the outcome of enhanced 
FKBP51 expression in the TM in order to enhance GRβ expression thus enhancing 
steroid sensitivity may play a pivotal role in reducing steroid-inducible pathological 
effects observed frequently in glaucoma. The potential role of miRNA therapies and 
FKBP51 as a novel therapeutic target for POAG and this will be discussed in Chapter 
6.  
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Chapter 5 
Identification of TGF-β2 Inducible miRNAs in Human 
Trabecular Meshwork Cells 
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5.1 Introduction 
5.1.1 miRNAs and Glaucoma 
Much of the current research on miRNAs is focused on the role of miRNAs in 
cellular pathology and physiology, typically using the gene expression profiling 
approach. miRNAs have already been shown to participate in the regulation of most 
cellular functions, and there is also substantial evidence implicating miRNA 
expression changes in multiple diseases (for review see Li et al 2012362). The clinical 
relevance of genetic mutations affecting miRNA genes or miRNA binding sites has 
not been thoroughly investigated. However, some functional polymorphisms in 
miRNA genes have been discovered that might be relevant in the progression of 
diseases such as acute lymphoblastic leukaemia677 and diabetic retinopathy678. Due 
to the ability of miRNAs to modify cellular functions and their involvement in 
multiple pathologies, there has been emerging interest in developing new 
technologies for their therapeutic use including ocular diseases such as macular 
degeneration679.  
Elevated IOP due to decreased outflow facility in the trabecular meshwork is 
a major risk factor for POAG680. Increased outflow resistance results from 
alterations in the TM cells and key components of the ECM681. A number of miRNAs 
have been detected in the TM in both health and disease381. miRNAs play important 
roles in several physiological and pathological processes including the regulation of 
inflammatory microenvironments, cell cycle and apoptosis, contractility, cell 
senescence and fibrosis368. Several of these pathways are dysregulated in the TM in 
glaucoma. Most studies have investigated the role of miRNAs in the biology of the 
TM and in relation to glaucoma pathogenesis381. There are an increasing number of 
studies examining extracellular miRNAs in the aqueous humour which drains 
through the TM. Analysis of the patients undergoing cataract surgery identified up 
to 264 miRNA species in AH using PCR arrays, of which miR-202, miR-193b, miR-
135a, miR-365, and miR-376a were the most abundant682. Three studies have 
reported differentially expressed miRNAs in glaucomatous AH using microarray 
systems and PCR arrays379,683,684. However, these studies failed to detect any 
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common differentially expressed miRNAs; among the significantly differentially 
expressed miRNAs were; miR-92a, miR-1587, miR-143, miR-518, miR-122, and miR-
451379,683,684.   
 Regulation of ECM synthesis and degradation is important for outflow 
physiology and in the pathogenesis of the outflow pathway in glaucoma685. ECM 
dynamics are central to TM function in health and disease and the miR-29 family 
are amongst the best characterised miRNAs regulating the ECM686. The miR-29 
family consists of three members: miR-29a, miR-29b, and miR-29c; they share a 
common seed region and are predicted to target overlapping sets of genes involved 
in ECM regulation and homeostasis686. The miR-29 family have potent anti-fibrotic 
effects in multiple organs365 and in the TM381. Both TGF-β2 and chronic oxidative 
stress alter the expression of the miR-29 family in TM cells687. Transfection of 
normal human TM cells with a miR-29b mimic results in a down-regulation of ECM 
components including collagens, fibronectin, and laminin (LAMC1) and 
SPARC/osteonectin687. Treatment of human TM cells with TGF-β2 results in down-
regulation of miR-29b expression and the activation of pro-fibrotic pathways and 
ECM deposition688. Similarly, oxidative stress in human TM cells down-regulates 
miR-483-3p expression which has an inhibitory effect in ECM production by 
repressing SMAD4 expression. Oxidative stress and TGF-β2 drive ECM deposition in 
the TM by down-regulating anti-fibrotic miRNAs which may contribute to outflow 
resistance and raised IOP in POAG380,687,689,690.  
 The cytoskeleton and actomyosin system in the TM plays a central role in 
cell contractility and the pathogenesis of glaucoma433. Rho-associated protein 
kinase (ROCK) inhibitors are entering the clinical realm in glaucoma treatment691. A 
number of miRNAs regulate RhoA signalling pathway in multiple disease states692. 
The miR-200 family is one of the best studied families which can regulate epithelial 
to mesenchymal transitions (EMT) by repressing the ZEB1/2 transcription factors 
and cell contractility693. miR-200c is highly expressed in the TM where it is involved 
in the regulation of TM cell contraction and IOP469. Luciferase reporter assays 
provide evidence that miR-200c directly represses key components of the RhoA 
pathway including RhoA kinase, and, human TM cells transfected with miR-200c 
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mimic inhibits collagen gel contraction assays469. Intracameral injection of the miR-
200c mimic in the rat eye decreased IOP while an adenoviral driven miR-200c 
sponge elevated IOP694. In the kidney the miR-200 family and miR-205 were 
markedly down-regulated in response to TGF-β. There is an interplay between TGF-
β, ZEB1/2 and the miR-200 family which regulates EMT, cell contractility and 
motility and the ECM (Figure 5.1)695. Further work is required to dissect this 
pathway in the TM and the development of raised IOP.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1: Interplay Between miR-200 Family, TGF-β, and ZEB1/2 in EMT 
Regulation. Modified from Sabbah et al 2008. miRNAs regulate the expression of 
critical EMT signalling elements.  
 
 
 
 
 
TGFβ 
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The TM is subject to mechanical and cyclical stress due to fluctuations in IOP 
and blood pressure. Laboratory studies modelling mechanical stress and alterations 
in miRNA expression have identified an up-regulation in several miRNAs implicated 
in fibrosis including miR-27b, miR-16, miR-26 and let-7381. TGF-β1 release in human 
alveolar cells is inhibited by miR-16696. Similarly, miR-24 in human TM cells targets 
components involved in TGF-β1 processing697. 
 TGF-β is a multifunctional cytokine that plays a central role in wound healing 
and tissue repair. Following tissue wounding or inflammation, the tissue is a source 
of TGF-β and in many diseases excessive TGF-β contributes to the pathological 
excess of tissue fibrosis and inflammation that compromises normal organ 
function698. Most components of the TGF-β signalling pathway are known to be 
targeted by one or more miRNA, and the regulation of TGF-β signalling molecules 
by miRNAs influences the pathogenesis of fibrotic diseases699. In addition to 
regulating the fibrotic response in cells TGF-β can also regulate expression of 
miRNAs through enhancing maturation of miRNAs700. Following TGF-β treatment 
direct changes in the expression of several miRNAs have been detected in different 
cells701. TGF-β treatment also induces the up-regulation of pre-miRNAs and mature 
miRNAs but not pri-miRNAs702. These miRNAs are regulated post-transcriptionally 
by a genome-independent mechanism; these miRNAs are termed TGF-β/BMP-
regulated miRNAs320,702. TGF-β-regulated miRNAs contain R-SMAD binding elements 
(R-SBE) in their primary transcript. SMAD proteins directly associate with R-SBE and 
drive TGF-β-mediated miRNA processing. Mutations to the R-SBE abolished TGF-β- 
mediated processing703.  Similar to SMAD proteins, RNA helicases p68 interact with 
other transcription factors including p53 and the association of p68 and p53 
facilitates Drosha processing of a subset of miRNAs704.  
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Figure 5.2: Cross-talk Between TGF-β and miRNAS. TGF-β can regulate the 
expression of miRNAs via their target SMAD proteins. SMAD3 binds to gene 
promoters inducing transcription of fibrotic genes in addition to pro-fibrotic 
miRNAs. Additionally, numerous miRNAs modulate components of the TGF-β 
signalling pathway and drive the TGF-β-induced fibrotic response. Modified from 
Kang et al 2016699. 
5.2 Aim 
 The aim of this study was to employ both microarray-based techniques and 
RNA-sequencing to investigate alterations in the non-coding genome of human 
trabecular meshwork cells stimulated with TGF-β2. The overall outcome was to 
identify and functionally characterise TGF-β-inducible miRNAs. 
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5.3 Materials and Methods 
5.3.1 Tissue Culture and TGF-β2 Stimulations 
 TGF-β2 stimulated cultured human TM cells were prepared as previously 
described (Chapter 3, Table 3.1). Human TM cells were treated for an additional 
time-point (4hours) during this experiment due to miRNA turnover rates. Two time-
points allowed for a wider range of coverage during the microarray experiments. 
For the most part miRNAs are stable, however, subsets of miRNAs, more commonly 
miRNA*s have much faster turnover rates705 and therefore earlier time points allow 
a broader range to be detected in an array setting. All human TM cells were used 
between passages 5-7. In this study two donor glaucomatous TM cells were also 
cultured as before but not stimulated with TGF-β2. In total normal human TM cells 
from 5 donors (+/- TGF-β2) and untreated glaucomatous TM cells (n=2 cadaveric 
donors) were studied. Table 5.1 contains all human TM donor information for 
samples used the miRNA array experiments in this chapter. In addition, normal 
human TM cells from 3 further donors were used in the miRNA manipulation 
experiments and Table 5.2 contains their information.  
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Donor I.D Age Sex Medical History 
LGP-1 57 Male No Glaucoma History 
LGP-2 65 Male No Glaucoma History 
NTM002 57 Male No Glaucoma History 
NTM009 57 Male No Glaucoma History 
NTM720 64 Male No Glaucoma History 
NTM020 88 Female No Glaucoma History 
GTM 304-04 74 Female POAG 
GTM 730-03 88 Male POAG 
Table 5.1: Human TM Donor Information for miRNA Array Experiments. 
 
 
Donor I.D Seq I.D Age Sex Medical history 
NTM012 Group 1 71 Unavailable No Glaucoma History 
NTM013 Group 2 85 Unavailable No Glaucoma History 
NTM029 Group 3 65 Unavailable No Glaucoma History 
Table 5.2: Human TM Donor Information for miRNA Manipulation Experiments. 
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5.3.2 miRNA Isolation and QC 
 The Qiagen Universal All Prep kit (as per manufacturers’ specifications) was 
used to isolate miRNA from human trabecular meshwork cells (normal and 
glaucomatous) as described in (Chapter 2, 2.4.1). Total RNA including miRNA was 
quantified using the NanoDrop-2000, and quality determined by the Bioanalyser 
2100 as described in Chapter 2 (2.4.2 and 2.4.3 respectively). Samples with R.I.N 
below 8 were discounted.   
5.3.3 Microarray Analysis of Human TM Cells 
 All microRNA array aspects of this study were carried out by Exiqon services, 
Denmark. The quality of total RNA was verified by an Agilent 2100 Bioanalyser 
profile upon arrival at Exiqon. 750ng total RNA from both treatment group 
(TK_group as it will be henceforth referred to) and reference group (CK_group as it 
will be henceforth referred to) was labelled with Hy3 ™ and Hy5™ fluorescent label, 
respectively, using miRCURY LNA™ microRNA Hi-Power Labelling kit, Hy3™/Hy5™ 
(Exiqon, Denmark), following manufacturers’ specifications. The Hy3™-labelled 
samples and a Hy5™ labelled reference RNA sample were mixed pair-wise and 
hybridised to the miRCURY LNA™ microRNA Array 7th Gen (Exiqon, Denmark), which 
contains capture probes targeting all microRNAs for human, mouse or rat 
registered in the miRBase V18.0. Hybridisation was performed according to the 
miRCURY LNA™ microRNA Array instruction manual using a Tecan HS4800™ 
hybridisation station (Tecan, Austria). After hybridisation the microarray slides were 
scanned and stored in an ozone free environment (ozone level below 2.0ppb) in 
order to prevent potential bleaching of fluorescent dyes. The miRCURY LNA™ 
microRNA Array slides were scanned using the Agilent G2565BA Microarray Scanner 
System (Agilent Technologies, INC., USA) and the image analysis was carried out 
using the IMAGene® 9 (miRCURY LNA™ microRNA Array Analysis software, Exiqon, 
Denmark). The quantified signals were background corrected (Normexp with offset 
value 10, see Ritchie et al. 2007) and normalised using the global LOWESS (Locally 
Weighted Scatterplot Smoothing) regression algorithm. Due to the high number of 
miRNAs that were tested in parallel, microarrays are prone to give false positive 
results, i.e. miRNAs are found to be statistically different between two conditions, 
197 
 
but in reality, are not. The false positive rate was controlled for in this experiment 
by multiple testing correction that adjusted p-values derived from multiple 
statistical tests. For this expression analysis, the calculated p-values were based on 
moderated t-statistics. Furthermore, the Benjamini and Hochberg multiple testing 
adjustment method has been applied to the p-values. Samples have been paired 
according to donor pair.  An expression analysis for glaucoma diseased group (GTM) 
compared to the control CK_Group was also performed using simple comparison 
methods. 
 
5.3.4 microRNA Array Data Validation 
 To validate the most significantly altered miRNAs identified by microRNA 
array analysis in the sample and control groups (TK_group and CK_group), miScript 
SYBR® Quantitect (Qiagen, UK) q-PCR assays were performed (see Table 5.3 below). 
Briefly, 1ug of total RNA (including miRNA) was reverse transcribed to cDNA using 
miScript II RT kit (Qiagen, UK) according to manufacturers’ specifications outlined in 
Chapter 2 (2.4.5).  q-PCR was performed on a Lightcyler® 480 real-time PCR system 
(Roche Diagnostics, Switzerland). All miRNA levels were measured at CT threshold 
levels and normalised with the average CT values of reference targets; SNORD61 
and SNORD68. Values were expressed as fold increase over the corresponding 
values for control by the 2-ΔΔCT method. Two independent experiments were 
performed and the average (±SEM) results were calculated using GraphPad 
software (GraphPad Software, San Diego, USA). Data were expressed as the mean 
values ± SEM and analysed using student t-test. Statistical differences in the mean 
were considered statistically significant as p<0.05. 
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5.3.5 Human Trabecular Meshwork Transfection Optimization  
Two miRNAs (hsa-miR-145-5p and hsa-miR-143-3p) were significantly up-
regulated in the miRNA array experiment and validated by q-PCR. Primary human 
trabecular meshwork cells were transfected with mimic and inhibitors for two 
candidate miRNAs as detailed in Table 5.3 below to investigate their involvement in 
target gene regulation. 
  The amount of miRNA mimic or inhibitor needed to efficiently down-
regulate or up-regulate a target gene can vary widely, depending on the miRNA, cell 
type, and chosen analysis method. To determine the concentration that provides 
optimal results, optimisation experiments using varying mimic and inhibitor 
concentrations as well as varying amounts of transfection reagent, HiPerfect 
Transfection Reagent (Qiagen, UK), were performed.   
Primary human TM cells between passages 5-7, were seeded at a density of 
20,000 cells per cm2 for transfection experiments.  At 50% confluence cell growth 
was arrested by the addition of serum free DMEM-low glucose for 24 hours as 
before (Chapter 2, 2.1.4). There were four experimental conditions optimised for 
each human donor TM cells (n=2): TGF-β2 treatment-only control cells, scrambled 
oligonucleotide control and TGF-β2 cells, TGF-β2 TM cells and miR-143 mimic and 
inhibitor, and TGF-β2 TM cells and miR-145 mimic and inhibitor (Table 5.3) for 24 
hours. Scrambled control, mimics and inhibitors were used at three different doses, 
(50nM, 75nM, and 100nM) and the HiPerfect volumes ranged from 9µL/mL to 
18µL/mL final volume.  Both a scrambled negative control and an Ambion A 
fluorescently (FAM) labelled siRNA (AM 4611, Thermo Fisher Scientific, UK) negative 
controls were used to aid in correct interpretation of results, and to determine 
transfection efficiency respectively.  
 Transfection efficiency was determined by the FAM labelled siRNA control 
24hours after transfection using fluorescent microscopy. The effect of mimic and 
inhibitor transfections (hsa-miR-145-5p and hsa-miR-143-3p) on target mRNAs was 
measured by q-PCR (Table 5.4). Briefly, total RNA was isolated as above and 1µg 
total was revere transcribed using miScript RT II kit (Qiagen, UK) as before (5.2.2 
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and 5.2.3 respectively). q-PCR was performed using Primer Design Ltd. SYBR green 
(UK) on a LightCycler480® real-time PCR system (Roche Diagnostics, Switzerland).  
All mRNA levels were measured at CT threshold levels and normalised with the 
average CT values of a reference gene; GAPDH. Independent experiments were 
performed and statistically analysed as before (Chapter 3, 3.2.7). 
 
Candidate miRNA Sequence 
hsa-miR-145-5p Mimic (miR-145m) 5'GUCCAGUUUUCCCAGGAAUCCCU3’ 
hsa-miR-145-5p Inhibitor (miR-145i) 5'GUCCAGUUUUCCCAGGAAUCCCU3’ 
hsa-miR-143-3p Mimic (miR-143m) 5'UGAGAUGAAGCACUGUAGCUC3’ 
hsa-miR-143-3p Inhibitor (miR-145i) 5'UGAGAUGAAGCACUGUAGCUC3’ 
Scrambled Negative Control (SNC) ID: 1027271 
 
Table 5.3: miScript miRNA Mimic and Inhibitors. Synthesised miScript miRNA 
mimics and inhibitors for both hsa-miR-143-3p and hsa-miR-145-5p were supplied 
by Qiagen, UK. A scrambled negative control (Qiagen, UK) was used throughout 
experiments. 
 
5.3.5.1 q-PCR Assessment of miRNA Mimics and Inhibitors of miR-145-5p on 
Target Genes and EMT-related Genes  
 A literature and bioinformatics search was used to identify validated targets 
of miR-145-5p; validated targets have been confirmed experimentally and not 
solely based on in silico predictions706. Many bioinformatics tools have been 
developed to predict miRNA:miRNA and miRNA:mRNA interactions. Bioinformatic 
tools are useful for accurate and rapid identification of miRNA targets with 
potential cellular roles to enable functional characterisation and validation in a 
biological model. Web based tools provide multiple search options, two of which 
we utilised; the target gene symbol, and the species-specific miRNA name. 
Displayed results for gene symbol searches provide multiple miRNA targets 
associated with a given mRNA. Conversely miRNA specie-specific searched provide 
200 
 
miRNA targeted mRNAs whose 3’ UTR contain a seed region associated with the 
miRNA of interest. Two validated miRNA target interaction web-interfaces were 
employed: miRTarBase(v8) (http://mirtarbase.mbc.nctu.edu.tw/php/index.php) 
and Validated Target Module of miRWalk 2.0 (http://zmf.umm.uni-
heidelberg.de/apps/zmf/mirwalk2/)707,708.  Using the specie-specific search option 
three experimentally validated mRNA targets were identified as regulated by miR-
145-5p and miR-143-3p: TGF-βR2 (miR145)709, CTGF710 (miR-145 and miR-143) and 
SMAD2711 (miR-145). CTGF is involved in glaucoma pathogenesis via remodelling of 
the actin cytoskeleton of the TM, which results in increased resistance to AH 
outflow and in turn elevated IOP712. In addition, there was significant evidence miR-
145-5p is a major repressor of EMT713 and TM cells can undergo an EMT-like 
phenomena resulting in an increased fibrotic phenotype599. Therefore, the impact 
of miRNA inhibitors on TGF-β2 induced alterations in E-cadherin, N-cadherin, and 
vimentin were assessed; and the EMT transcriptional regulators: zinc finger protein 
SNAI1 (SNAIL) and zinc finger protein SNAI2 (SLUG). Primer sequences for miRNA 
validated gene targets (TGF-βR2, SMAD2, CTGF) and EMT-related genes are given in 
Table 5.4 below.  
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Gene  Primer Sequence 
TGF-βR2 F:5’ –TCCTGTGGACGCGTATCG-3’ 
R: 5’ –TGTCAGTGACTATCATGTCGTTATTAACC-3’ 
SMAD2 F: 5'-AGATCCATAATGAATCCAGAACTTC-3' 
R: 5'-GAAGAAAAATCTAAAAGCCCTCTATG-3' 
CTGF F: 5’-GCTTACCGACTGGAAGACACG-3’ 
R; 5’-CGGATGCACTTTTTGCCCTT-3’ 
E-Cadherin F: 5’-TCATGAGTGTCCCCCGGTAT-3’ 
R: 5’-GTCAGTATCAGCCGCTTCAGAT-3’ 
N-Cadherin F; 5’-CCACAG CTCCACCATATGACT-3’ 
R: 5’-CCCCAGTCGTTCAGGTAATC-3’ 
SLUG F: 5’-CGCCTCCAAAAAGCCAAAC-3’ 
R: 5’-CGGTAGTCCACACAGTGATG-3’ 
SNAIL F: 5’-ACCCCAATCGGAAGCCTAACT-3’ 
R:5’-GGTCGTAGGGCTGCTGGAA-3’ 
Vimentin F: 5’-AGAACCTGCAGGAGGCAGAAGAAT-3’ 
R: 5’-TTCCATTTCACGCATCTGGCGTT-3’ 
Table 5.4: Primer Sequences used for q-PCR of Validated mRNA Targets of miR-
145 and miR-143 and EMT-related Genes. Primer sequences were obtained from 
Primer Bank and primers were synthesised by Eurogentec (TGF-βR2, SMAD2 and 
CTGF) and Eurofins (E-cadherin, N-cadherin, SLUG, SNAIL and vimentin). 
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5.3.6 RNA-Seq Analysis of Genome-wide Transcriptional Effects of miRNA 
Inhibitors of miR-145-5p and miR-143-3p to Identify Target Genes 
 The experimental identification and validation of miRNA:mRNA interactions 
can be performed using a number of approaches. Gene:miRNA interactions can be 
cell and disease context specific; and given the conflicting results of q-PCR based 
validation, an RNA-Seq approach was applied to provide indirect evidence of 
miRNA:mRNA targets. As miR-145-5p and miR-143-3p were up-regulated in the 
TGF-β2 treated human TM cells specific miR-143 and miR-145 inhibitors (143i and 
145i respectively) were transfected and genome-wide alterations in mRNA 
expression was measured by RNA-Seq. 
 Human TM cells (n=3) were grown to 50% confluence as before (5.2.5) and 
growth arrested for 24hours. TM cells were co-transfected with 5ng/mL TGF-β2 and 
100nM miRNA inhibitor for either 143i, 145i or both (143i and 145i). Control cells 
were TGF-β2 treated only and TGF-β2 treated plus scrambled negative control. TM 
cells were transfected for 24hours. 100nM was chosen as inhibitor dose to ensure 
complete inhibition of the target miRNA as per manufacturers’ instructions.  
 Total RNA was extracted as before and subjected to QC analysis using the 
Agilent Bioanalyser 2100. 1µg total RNA was used for RNA-Seq at the Core Facility 
at Queens University Belfast (QUB; Dr. David Simpson). 
5.3.7 RNA-Seq of TGF-β2 Positive Cells Co-Transfected with miRNA Inhibitors 
(miR-143i and miR-145i) 
 There were five experimental conditions for each of the donor TM 
cells/biological replicates (n=3): TGF-β2 treatment only control TM cells 
(TC_Group), scrambled oligonucleotide control and TGF-β2 TM cells (SNC_Group), 
TGF-β2 TM cells and miR-143 inhibitor (143i_Group), TGF-β2 TM cells and miR-145 
inhibitor (145i_Group), and TGF-β2 TM cells transfected with miR-143 inhibitor and 
miR-145 inhibitor (143i/145i_Group). 
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5.3.7.1 cDNA Library Construction, Purification and QC 
 RNA sequencing experiments were conducted at Queens University, Belfast. 
The starting material, 500ng RNA, was enriched for mRNA using the oligodT bead 
system and the isolated mRNA was enzymatically fragmented. Library preparation 
was achieved using TruSeq RNA Library kit (Illumina, USA). Library quantification 
was assessed using NanoDrop 2000 (Thermo Fisher Scientific, UK) and diluted based 
on NanoDrop values to produce average fragment sizes up to 20nM. Libraries were 
then quantified by q-PCR and diluted to 4nM.  Optimal concentration of the library 
pool was used to generate clusters on the surface of a flowcell before sequencing 
using Nextseq 500, High Output sequencing kit (Illumina, USA) for 75 cycles single 
end reads. 
5.3.7.2 RNA-Seq Data Analysis of TGF-β2 Positive Cells Co-Transfected with 
miRNA Inhibitors (143i and 145i) 
 Expression analysis was performed on the following treatment groups, 
SNC_Group, 143i_Group, and 145i_Group, compared to the TGF-β2 treatment only 
group, TC_Group. NGS analysis was performed using Partek Flow (6.017) running on 
64-bit linux machine with a Safari 11 browser. FASTQ files were filtered to remove 
sequences with a Phred score<30 and adaptors were removed. Sequence alignment 
was achieved using TopHat (4.1) running Bowtie (1.0). Alignment quality statistics 
were calculated.  Raw gene counts data were generated by quantification to the 
Partek E/M annotation model (based on Xing et al 2006) using hg19-Ensembl 
Transcripts Release 75.  
 Counts were imported into edgeR. A linear model of gene expression was 
constructed comparing gene expression in pairs of cells treated with inhibitors or 
scrambled control, with TGF-β2 treatment used as a common reference. Inference 
of differential expression was by log ratio test using gImLRT.  
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5.3.8 RNA-Seq Validation  
5.3.8.1 ACTA2 Differential Gene Expression Validation by q-PCR 
 Validation of RNA samples (TC_Group, SNC_Group, 143i_Group, and 
145i_Group) was performed using q-PCR for selected significantly differentially 
expressed genes. 1ug of total RNA was reverse transcribed using miScript II RT kit 
according to manufacturer’s specification, outlined in Chapter 2 (2.4.5). Real time 
analysis was performed using primer pairs for ACTA2 (Actin, Alpha 2, Smooth 
Mucle, Aorta; smooth muscle actin) obtained from Primer Bank (ACTA2; 
F:5’GTGTTGCCCCTGAAGAGCAT-3’,R:5’-GCTGGGACATTGAAAGTCTCA-3’ and GAPDH; 
F:5’-CGAGCCACATCGCTCAGACACC-3’, R:5’GGTCAATGAAGGGGTCATTGATGGCAAC-
3’). q-PCR was performed on a LightCylcer® 480 real-time PCR system (Roche 
Diagnostics, Switzerland) according to conditions outlined in Chapter 2 (2.5.4). All 
mRNA levels were measured at CT threshold levels and normalised with the average 
CT values of a reference gene; GAPDH. Values were expressed as fold increase over 
the corresponding values for control by the 2-ΔΔCT method. Two independent 
experiments were performed and the average (±SEM) results were calculated using 
GraphPad software (Graphpad Software, San Diego, USA). Data is expressed as the 
mean values ±SEM and analysed using student t-test. Statistical significance was 
p<0.05. 
5.3.8.2 ACTA2 Differential Protein Expression Validation by Western Blot 
Analysis 
 Protein lysates were isolated from groups (TC_Group, SNC_Group, 
143i_Group, and 145i_Group) as described in Chapter 2 (2.3.1). Protein lysates 
were separated by SDS-PAGE and transferred to nitrocellulose membranes by semi-
dry Bio-Rad TurboBlot transfer system (Bio-Rad, UK). Membranes were blocked for 
1 hour at room temperature in Odyssey® TBS-Blocking Buffer (Li-Cor Biosciences, 
USA). Primary ACTA2 antibody was used at a concentration of 1µg/mL and primary 
GAPDH antibody at a concentration of 0.1µg/mL, and membranes were probed 
overnight at 4oC. Membranes were probed for 90 minutes, following membrane 
washes (3X5minute washes), with IRDye® 800CW and IRDye®680RD conjugated 
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fluorescent secondary antibodies (Li-Cor) diluted in blocking buffer at a 
concentration of 60ng/mL. Membranes were washed and imaged using Odyssey® 
CLx9120 Infrared Imaging System (Li-Cor Biosciences, USA).   
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5.4 Results 
5.4.1 miRNA Array Data Analyses 
5.4.1.1 Calls and Threshold Filtering  
 The threshold of detection was calculated for each individual microarray 
slide as 1.2 times the 25th percentile of the overall signal intensity across the array 
slide. miRNAs with intensities above the threshold in less than 20% (or 2) of the 
samples were removed from the final dataset used for expression analysis. For this 
experimental data set a total of 1609 probes were discarded by the filtering 
procedure. Figure 5.3 (below), indicates a summary of present calls for each 
sample, i.e. the number of miRNAs above the background threshold. Biologically 
identical samples should have present call numbers within the same range. All 
obtained numbers of present calls were within the expected range, and comparable 
for all samples.  
 
 
 
 
  
  
 
   
 
Figure 5.3: Present Calls and Threshold Filtering Plot. Plot above shows number of 
miRNAs detectable above background threshold for each sample out of a possible 
2102 possible miRNAs. CK=control group, TK=treatment group. GTM= 
glaucomatous sample; 4 and 24 respectively refer to TGF-β2 stimulation time 
period (hrs). 
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5.4.1.2 miRNA Expression Analysis of TGF-β2 Treated TM Cells  
 A miRNA expression analysis for TK_24 vs. CK_24 was performed. The 
miRNA profiling identified 3 miRNAs from a total number of miRNAs analysed (447) 
by the miRCURY LNA™ microRNA Array that were significantly expressed between 
the control (CK_Group) and TGF-β2 treated (TK_Group) groups (p<0.05). 11 miRNAs 
from a pool of 425 were significantly expressed between the control (CK_Group) 
and glaucomatous samples (GTM). Both sets of results were obtained from the 
24hour time-point. No statistically significant differential expression was reported 
from the CK_Group and TK_Group exposed to TGF-β2 for 4 hours. Significantly 
differentially expressed miRNAs for each analysis are shown in Table 5.6 and Table 
5.7 respectively.  
 
 
Probe ID Annotation Average Hy3 logFC p-value 
147771 hsa-miR-4328 7253 0.0665 2.99E-02 
42641 hsa-miR-145-5p 7462 0.605 2.99E-02 
13177 hsa-miR-143-3p 8101 0.957 2.99E-02 
 
Table 5.6: Differentially Expressed miRNA Genes in the TGF-β2 Treated TM. Table 
5.6 denotes statistically significant differentially expressed miRNA candidates 
ranked according to p-value. Results were obtained from comparing control 
CK_Group against treated TK_Group at a 24hour time point (n=5). 
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Probe ID Annotation Average Hy3 CK_Group GTM logFC 
42629 hsa-miR-376c-3p 6518 -0.449 -1.866 -1.417 
11091 hsa-miR-377-3p 6929 -0.224 -1.632 -1.408 
10943 hsa-miR-136-5p 7886 -0.368 -1.676 -1.308 
10995 hsa-miR-199a-3p 
/hsa-miR199b-3p 
8366 -0.251 -1.426 -1.175 
29562 hsa-miR-199a-5p 8204 -0.186 -1.352 -1.166 
146086 hsa-miR-30a-5p 6839 -0.166 0.957 1.123 
13177 hsa-miR-143-3p 8101 -0.759 0.346 1.105 
13140 hsa-miR-138-5p 8016 -0.274 0.800 1.074 
11041 hsa-miR-29c-3p 8939 -0.521 0.526 1.047 
147771 hsa-miR-4328 7253 -0.633 0.396 1.028 
28191 hsa-miR-30e-5p 6914 -0.149 0.864 1.013 
 
Table 5.7: Differentially Expressed miRNA in the Normal and Glaucomatous TM. 
Significantly differentially expressed miRNAs ranked according to absolute value of 
log fold change (logFC) when the normal TM miRNA population (CK_Group n=5) 
was compared to the glaucomatous TM (GTM; n=2). 
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5.4.1.2.1 Volcano Plot Analysis of Untreated and TGF-β2 Treated Human TM 
Cells 
 A volcano plot analysis of the data obtained between untreated, control 
(CK_Group) and TGF-β2 treated (TK_Group) provides a visual representation of 
those miRNAs that display large-magnitude changes that are statistically significant. 
The volcano plot was constructed by plotting the negative log of the p-value on the 
y-axis (base 10); this results in data points with low p-values appearing towards the 
bottom of the plot. The log fold-change (logFC) between the two experimental 
groups is plotted on the x-axis; the logFC is used so that up and down-regulated 
miRNAs appear equidistant from the centre of the plot. Plotting points in this 
manner resulted in two regions of interest in the plot; those points that are found 
towards the top of the plot that are either far right or far left. These points 
represent values that display large magnitude fold changes as well as high statistical 
significance. Three differentially expressed miRNAs are shown on the volcano plot 
as significantly up-regulated in TGF-β2 treated human TM cells.   
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Figure 5.4: Volcano Plot Analysis of Untreated and TGF-β2 Treated Human TM 
Cells miRNA Expression. The above volcano plot shows the relationship between 
the logarithm of the p-values and the log fold-change (logFC) between untreated 
control (CK_Group) and TGF-β2 treated TM cells (TK_Group). The top statistically 
significant differentially expressed miRNAs are marked with an annotation: hsa-
miR-4328, has-miR145-5p, and hsa-miR-143-3p (n=5). 
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5.4.2 q-PCR Assay Validation of Top Differentially Expressed miRNAs in 
Cultured Human TM +/- TGF-β2 
 To validate the results obtained from the miRNA array, all three candidate 
miRNAs identified between the control CK_Group and treated TK_Group, were 
analysed using q-PCR with miScript primer assays (Qiagen, UK): hsa-miR-4328, hsa-
miR-145-5p and hsa-miR-143-3p. Differential expression of the top three candidates 
was also validated in glaucomatous samples (GTM). Expression profiles were 
analysed by q-PCR with two reference targets used as controls, small nucleolar 
RNA, C/D box 68 (SNORD68) and Small nucleolar RNA, C/D box 61 (SNORD61). All 
three candidates demonstrated consistent trends of differential expression by q-
PCR. There was no statistical significance observed when results were subjected to 
two sample students t-tests. Results were only classified as statistically significant 
when p<0.05.  
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Figure 5.5: q-PCR Validation of Significantly Up-regulated miRNAs from 
Microarray Data of TGF-β2 Cultured Human TM Cells. CK_Group are denoted as 
“Control” on graphs and TK_Group as “Treated” represent miRNAs from untreated 
control and TGF-β2 treated TM cells. The miRNAs, miR-143, miR-145 and miR-4328 
were identified as significantly differentially expressed in the microarray. Individual 
human TM donor pairs are indicated by same coloured symbols on the graphs 
(n=6). Female donors are indicated by circle markers, whilst male donors are 
indicated by triangles. All donors have no previous glaucoma history. 
Female No Glaucoma History         
Male No Glaucoma History         
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Figure 5.6: Expression Levels of miR-143, miR-145 and miR-14328 in Cultured 
Human Glaucomatous TM Cells. The CK_Group are denoted as “Control” on graphs 
representing untreated TM cells and glaucomatous cells (GTM) as “glaucomatous”. 
The expression of miR-143 and miR-4328 were identified as up-regulated in the 
GTM compared to controls in the microarray data (see Table 5.7).  
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5.4.3 Human Trabecular Meshwork Transfection Optimisation 
5.4.3.1 Human TM Cell Viability with Varying Volumes of HiPerfect Reagent 
 Human TM cells were subjected to increasing volumes of HiPerfect 
Transfection Reagent (Qiagen, UK) to assess cell death and viability prior to 
transfection. Cells were transfected with a FAM labelled siRNA with varying 
volumes of HiPerfect reagent from 0µL to 18µL. Bright-field images of the TM cells 
were obtained to assess cell death rates under varying volumes of transfection 
reagent and fluorescent images were obtained as a means of monitoring 
transfection success rates.  
 Figure 5.7 (below) shows that with the highest volumes of HiPerfect 
Transfection reagent, 15µL and 18µL, no cell death occurred over the proposed 
transfection time-frame; 24hours. This can be seen from the healthy morphology of 
the human TM cells and lack of any apparent cellular debris.  
 FAM labelled siRNA uptake was shown to be successful with both volumes 
of reagent (15µL and 18µL) for 24 hours also through fluorescent imaging. TM cells 
exposed only to HiPerfect Reagent and no siRNA were used as a negative control. 
Transfection efficiency of TM cells is typically very low, with efficiency rates of 
approximately 10%714. Possible explanations for this observation include TM 
decreased capacity to take up exogenous DNA due to their phagocytic 
phenotype714. 
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Figure 5.7: Transfection Optimisation; Cell Viability Assessment. Human TM cells 
were transfected with FAM labelled siRNA and varying volumes of HiPerfect 
Transfection Reagent. Figure 5.7 is representative images of human TM cells after 
24hours transfection with siRNA and 15µL and 18µL HiPerfect Transfection reagent. 
(A) and (D): Brightfield images of human TM cells after transfection with 15µL and 
18µL respectively; (B) and (E): Fluorescent imaging of human TM cells after 24hours 
highlighting uptake of FAM labelled siRNA; (C) and (F): Control fluorescent images 
were taken of cells exposed only to HiPerfect Reagent and no siRNA; and (G) 
Composite of brightfield imaging and fluorescent imaging indicating areas of siRNA 
uptake. Scale bar = 20µM.  
Cell Count= 134 Cells 
Transfected Cell Count=18 
% Transfection Rate=14% 
A B 
G 
C 
F E D 
15µL HiPerfect Reagent 
18µL HiPerfect Reagent 
Merge 
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5.4.3.2 Effects of miRNA Inhibitors (miR-143i and miR-145i) on Target Gene 
and EMT-related Gene Expression  
 To investigate key miRNA:mRNA relationships in TGF-β2 treated TM cells of 
miR-145-5p and miR-143-3p the effects of miRNA inhibitors (143i and 145i) were 
assesses by q-PCR in three experimentally validated mRNA targets: TGF-βR2, 
SMAD2 and CTGF. Predicted target genes for miR-145-5p mimics and inhibitors 
were not statistically altered in this experiment. Limited sample size and 
transfection efficiency may be causative of this. Increasing sample number may be 
beneficial for identification of key target genes and this will require some more 
experimental work. At mRNA level EMT-related genes and validated targets for 
miR-143 and miR-145 were unaffected by q-PCR.    
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Figure 5.8: TGF-βR2 Expression Profiles in TGF-β2 TM Cells Treated with a miR-
145-5p Mimic and Inhibitor. q-PCR shows a trend that miR-145 mimic increases 
TGF-β2 expression and miR-145i decreases expression. Untreated; human TM 
donor cells without TGF-β2 stimulation. Scrambled; TGF-β2 treated human TM 
donor cells transfected with scrambled negative control. I50-I100; Concentrations 
of synthesised inhibitor, 50nM to 100nM. (n=2) (Error Bars S.E.M).    
TGF-βR2 Expression Profiles 
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Figure 5.9: SMAD2 Expression Profiles in the Presence of Synthesised Mimics and 
Inhibitors for miR-145-5p. SMAD2 expression profiles normalised to GAPDH. hsa-
miR-145-5p synthesised mimic does not stably regulate SMAD2expression .. 75nM 
concentration decreases expression whilst 100nM concentration appears to return 
to stable expression levels similar to the controls. The hsa-miR-145-5p synthesised 
inhibitor however has distinct effects on SMAD2 expression levels with expression 
seen to decrease as concentration of inhibitor increases from 50nM to 100nM.  
Untreated; human TM donor cells without TGF-β2 stimulation. Scrambled; TGF-β2 
treated human TM donor cells transfected with scrambled negative control. I50-
I100; Concentrations of synthesised inhibitor, 50nM to 100nM. (n=2).  
SMAD2 Expression Profiles 
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Figure 5.10: CTGF Expression Profiles in the Presence of Synthesised Mimics and 
Inhibitors for miR-145-5p. q-PCR shows no obvious regulation of CTGF gene 
expression in the presence of synthesised mimics or inhibitors for hsa-miR-145-5p. 
Untreated; human TM donor cells without TGF-β2 stimulation. Scrambled; TGF-β2 
treated human TM donor cells transfected with scrambled negative control. I50-
I100; Concentrations of synthesised inhibitor, 50nM to 100nM. (n=2) (Error Bars 
S.E.M). 
CTGF Expression Profiles 
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Figure 5.11: E-Cadherin Expression Profiles in the Presence of Synthesised Mimics 
and Inhibitors for miR-145-5p. q-PCR shows no obvious regulation of E-Cadherin 
gene expression in the presence of synthesised mimics and inhibitors for hsa-miR-
145-5p. Untreated; human TM donor cells without TGF-β2 stimulation. Scrambled; 
TGF-β2 treated human TM donor cells transfected with scrambled negative control. 
I50-I100; Concentrations of synthesised inhibitor, 50nM to 100nM. (n=2). 
E-Cadherin Expression Profiles 
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Figure 5.12: N-cadherin Expression Profiles in the Presence of Synthesised Mimics 
and Inhibitors for miR-145-5p and miR-143-3p. q-PCR shows no obvious regulation 
of N-cadherin gene expression in the presence of synthesised mimics or inhibitors 
for hsa-miR-145-5p. Untreated; human TM donor cells without TGF-β2 stimulation. 
Scrambled; TGF-β2 treated human TM donor cells transfected with scrambled 
negative control. I50-I100; Concentrations of synthesised inhibitor, 50nM to 
100nM. (n=2). 
N-Cadherin Expression Profiles 
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Figure 5.13: SLUG Expression Profiles in the Presence of Synthesised Mimics and 
Inhibitors for miR-145-5p. q-PCR shows no obvious regulation of SLUG gene 
expression in the presence of synthesised mimics or inhibitors for hsa-miR-145-5p. 
Untreated; human TM donor cells without TGF-β2 stimulation. Scrambled; TGF-β2 
treated human TM donor cells transfected with scrambled negative control. I50-
I100; Concentrations of synthesised inhibitor, 50nM to 100nM. (n=2).  
SLUG Expression Profiles 
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Figure 5.14: SNAIL Expression Profiles in the Presence of Synthesised Mimics and 
Inhibitors for miR-145-5p and miR-143-3p. q-PCR shows no obvious regulation of 
SNAIL gene expression in the presence of synthesised inhibitors for either hsa-miR-
145-5p however there is a trend of down-regulation of gene expression in the 
presence of hsa-miR-145-5p mimic. Untreated; human TM donor cells without TGF-
β2 stimulation. Scrambled; TGF-β2 treated human TM donor cells transfected with 
scrambled negative control. I50-I100; Concentrations of synthesised inhibitor, 
50nM to 100nM. (n=2). 
SNAIL Expression Profiles 
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Figure 5.15: Vimentin Expression Profiles in the Presence of Synthesised Mimics 
and Inhibitors for miR-145-5p. q-PCR shows no obvious regulation of vimentin gene 
expression in the presence of synthesised hsa-miR-145-5p mimic, and up-regulation 
of gene expression in the presence of hsa-miR-145-5p inhibitor. Untreated; human 
TM donor cells without TGF-β2 stimulation. Scrambled; TGF-β2 treated human TM 
donor cells transfected with scrambled negative control. I50-I100; Concentrations 
of synthesised inhibitor, 50nM to 100nM. (n=2). 
Vimentin Expression Profiles 
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5.4.4 RNA-Seq Analysis of hsa-miR-145-5p and hsa-miR-143-3p Inhibitor 
Target Expression Profiles 
 mRNA-Seq of human TM cells co-transfected with miR-143 and miR-145 
inhibitors in addition to TGF-β2 treatment was performed to identify putative 
mRNA targets for miR-143-3p and miR-145-5p in human TM cells in the presence of 
TGF-β2.  
 5.4.4.1 mRNA-Seq Summary 
mRNA libraries were produced to include the four sample groups, 
(TC_Group, SNC_Group, 143i_Group, and 145i_Group) using TrueSeq Stranded 
mRNA Library Prep and sequenced on a flow cell using NextSeq500, High Output 
sequencing kit to obtain between 22-32 million reads per sample. Library 
quantification was achieved using the KAPA Library Quantification kit for Illunmina 
Platforms. The majority of runs had a Q score greater than 30 (1 base call in 1000 is 
predicted to be incorrect).  
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Table 5.9: Summary of Mapping Reads For Each Sample. Reads for each sample 
across all five groups (TC_Group, SNC_Group, 143i_Group, 145i_Group, and 
143i/145i_Group), were extracted based on their unique I.Ds. In total 22-32 million 
reads per sample were obtained. Based on alignment to the reference 
genome,H.sapiens, hg19/GRC37, UCSC Genome Browser, the number of identified 
genes per sample was calculated.  
 
 
Sample Name Total Readcount Aligned Unaligned Unique Non-Unique 
TC_Group 1 26257923 27415156 1031217 23861788 1364918 
TC_Group 2 28747199 30041559 1094412 26152220 1500567 
TC_Group 3 27965304 29173068 1090187 25450977 1424140 
SNC_Group 1 26045301 27448597 956619 23601077 1487605 
SNC_Group 2 26783023 28128363 1131127 24092400 1559496 
SNC_Group 3 26914107 28128802 1057954 24419986 1436167 
143i_Group 1 28176784 29633954 1084492 25460369 1631923 
143i_Group 2 26158969 27394637 1142051 23507945 1508973 
143i_Group 3 24479616 25500634 1039169 22143908 1296539 
145i_Group 1 27996179 29481077 1008993 25382838 1604348 
145i_Group 2 27603982 28854358 1057198 25072821 1473963 
145i_Group 3 25474624 26723828 1007477 23029942 1437205 
143i/145i_Group 
1 
26731699 27805408 1136038 24216487 1379174 
143i/145i_Group 
2 
26568459 27864475 1041491 24018138 1508830 
143i/145i_Group 
3 
28751348 30034351 1165728 26019018 1566602 
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5.4.4.2 Principal Component Analysis  
 PCA reduces the dimension of a large data set and allows biological 
differences between samples to be observed in the primary components of the 
variation of the data. Figure 5.16 shows a PCA plot of the raw counts data. While 
the effect of TGF-β2 treatment is segregated, the effect of the miRNA inhibitors are 
not clearly resolved. This could be a result of mixed cell populations and low 
transfection efficiencies. There is some association of samples from the same donor 
eye. Different treatments are represented by different colours on the plot as shown 
by the key. Donors are shown as spheres of the same size.  
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Figure 5.16: Principal Component Analysis Across All Sample Groups. TGF-β2 
treatments tend to segregate however little segregation is observed between 
individual inhibitor and scrambled control treatment groups.  
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5.4.5 Functional Analysis of Genes Associated With miR-143 and miR-145 
Inhibition Following TGF-β2 Treatment 
5.4.5.1 Differentially Expressed Genes in Human Trabecular Meshwork Cells 
Post miR-143/miR145 Inhibition Following TGF-β2 Treatment 
 The top 500 differentially expressed genes were ranked by FDR, available in 
Appendix (8.6). From this list we isolated the top 50 DEGs based on FDR and ranked 
them according to Log fold change (LogFC). LogFC for the top up- and down-
regulated genes was obtained from mRNA-Seq data analysed using Partek Flow 
(6.017) software. For this experiment differentially expressed genes have been 
divided between two sample groups and details are outlined in tables below. 
Differential gene expression was calculated using the control TGF-β2 only group 
(TC_Group) and the miR inhibitor groups (143i_group and 145i_Group).  
   The 50 most significantly up-regulated genes and down-regulated in human 
TM cells treated with TGF-β2 and transfected with miR-143 inhibitor (143i) are 
shown in Table 5.10 and 5.11 respectively. Similarly, the 50 most significantly up-
regulated genes and down-regulated genes in human TM cells treated with TGF-β2 
and transfected with miR-145 inhibitor (145i) are shown in Table 5.12 and 5.13 
respectively. These genes were filtered by their FDR then subsequently by logFC. 
Targets of miRNA inhibitors that are directly affected usually have increased 
expression profiles while the converse is true of indirectly affected genes.  
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Gene Name LogFC p-value 
Up-Regulated Genes 
TPPP3 4.94 1.09E-08 
FAM111B 4.73 4.81E-09 
NFATC2 4.38 4.95E-15 
PKMYT1 4.34 1.78E-09 
PTHLH 4.24 1.38E-13 
FOSB 4.13 1.34E-15 
RRM2 4.06 1.01E-11 
RRAD 4.02 3.31E-19 
DTL 3.97 1.27E-08 
CLSPN 3.87 1.46E-07 
MKI67 3.79 6.91E-12 
TOP2A 3.64 1.12E-10 
WDR76 3.09 1.8E-07 
E2F1 2.73 3.70E-09 
TNFAIP3 2.56 8.14E-13 
ANLN 2.54 3.30E-08 
MCM5 2.51 4.27E-12 
TCF19 2.47 5.69E-11 
HMGA2 2.39 1.32E-14 
HAS2 2.38 4.63E-08 
PRC1 2.38 1.01E-07 
CHAF1A 2.36 2.84E-08 
MCM2 2.17 7.49E-09 
RGMB 1.99 3.38E-20 
TRIB1 1.88 5.55E-09 
FOSL1 1.84 2.86E-08 
NET1 1.81 1.11E-08 
SRGAP1 1.78 4.11E-13 
MCM4 1.60 3.44E-09 
CD44 1.59 7.50E-15 
PNP 1.58 1.29E-10 
AKAP12 1.48 1.44E-08 
ARHGAP22 1.36 7.06E-13 
CDK6 1.34 5.25E-09 
EFHD2 1.31 3.17E-11 
TSPAN5 1.17 3.36E-12 
FLNC 1.14 1.26E-08 
RALA 1.09 3.61E-08 
DCBLD2 1.08 4.61E-08 
UGCG 1.06 7.49E-08 
PIK3CD 1.03 3.92E-09 
WNT5A 1.01 1.74E-09 
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FHOD1 1.00 1.84E-08 
S100A10 0.99 1.18E-13 
POU2F2 0.98 2.93E-09 
FRMD6 0.98 6.61E-13 
LMNA 0.91 2.69E-08 
ZFP36L1 0.72 8.48E-08 
TUBA1C 0.60 3.50E-09 
VIM 0.56 1.14E-08 
Table 5.10: Top 50 Uniquely Up-Regulated Genes in Human TGF-β2 Treated Cells 
Exposed to miR143 Inhibitor (143i). LogFC= Log fold change.  
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Gene Name LogFC p-value 
Down-Regulated Genes 
GAL3ST3 -4.02 6.67E-12 
LEFTY2 -3.64 8.13E-09 
TMEM119 -2.74 2.56E-09 
NXPH3 -2.64 1.72E-20 
PKP2 -2.42 9.86E-19 
SLC7A14 -2.31 2.44E-11 
THBD -2.22 3.54E-09 
CLIC3 -2.12 6.03E-09 
PPFIBP2 -2.08 6.98E-12 
SLC6A6 -2.07 3.60E-28 
FRY -2.06 1.52E-10 
PPM1H -2.06 2.05E-12 
SYNPO2 -2.02 2.67E-12 
ARL4D -1.99 2.70E-10 
PTGIS -1.94 1.54E-13 
GPC4 -1.90 8.73E-14 
SGK223 -1.87 6.91E-17 
DAPK1 -1.76 2.42E-12 
PCDH7 -1.76 1.06E-09 
COL4A4 -1.76 3.06E-10 
OPN3 -1.74 5.29E-14 
COL8A1 -1.62 7.52E-12 
SLC22A23 -1.58 7.48E-09 
C10orf54 -1.53 2.46E-10 
CLDN11 -1.49 1.06E-09 
SORT1 -1.48 4.39E-10 
FILIP1L -1.45 7.39E-10 
AMACR -1.43 8.02E-09 
SVEP1 -1.42 5.10E-15 
PRSS12 -1.42 7.59E-18 
C1orf198 -1.42 7.46E-15 
SERAC1 -1.40 5.88E-09 
IQCJ-SCHIP1 -1.39 9.55E-10 
PPAP2A -1.37 4.46E-16 
KIAA0355 -1.36 7.15E-10 
ACTA2-AS1 -1.36 4.03E-09 
MEGF6 -1.29 1.54E-11 
SNX30 -1.29 1.12E-10 
SESN3 -1.27 2.20E-14 
ATXN1 -1.21 1.76E-10 
RUSC2 -1.14 1.40E-14 
233 
 
C2CD3 -1.05 5.91E-09 
ARMC9 -1.04 8.78E-10 
CTIF -1.01 2.65E-10 
OSBPL9 -0.91 1.91E-09 
NEO1 -0.78 3.45E-09 
KIAA1462 -0.74 1.59E-09 
DAB2 -0.73 7.93E-09 
WNK1 -0.71 5.25E-09 
LTBP1 -0.61 9.62E-09 
 
Table 5.11: Top 50 Uniquely Down-Regulated Genes in Human TGF-β2 Treated 
Cells Exposed to miR143 Inhibitor. LogFC= Log fold change.  
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Gene Name                           LogFC p-value 
Up-Regulated Genes 
TPPP3 5.17 5.56E-10 
MCM10 4.96 6.16E-08 
FAM111B 4.81 2.14E-09 
FOSB 4.41 4.1E-18 
PKMYT1 4.40 8.82E-10 
NFATC2 4.39 4.37E-15 
RRAD 4.39 1.39E-24 
PTHLH 4.37 3.91E-14 
RRM2 4.22 1.31E-12 
DTL 4.06 5.45E-09 
CLSPN 4.02 3.10E-08 
MYBL2 4.01 5.86E-08 
MKI67 3.97 4.45E-13 
WDR76 3.23 3.16E-08 
KIFC1 3.12 8.75E-08 
E2F1 2.73 4.71E-09 
MCM5 2.64 2.31E-13 
ANLN 2.58 2.27E-08 
TNFAIP3 2.55 1.12E-12 
HAS2 2.51 7.46E-09 
CHAF1A 2.46 5.32E-09 
LRRC8C 2.43 3.81E-09 
MCM2 2.33 3.68E-10 
HMGA2 2.31 4.04E-13 
DDX60L 2.19 2.60E-09 
UHRF1 2.18 6.47E-09 
SRGAP1 2.11 1.36E-18 
MCM7 2.07 7.58E-08 
TRIB1 1.97 9.42E-10 
RGMB 1.97 1.11E-19 
SIK1 1.88 9.90E-09 
FOSL1 1.80 6.12E-08 
MCM4 1.72 1.79E-10 
CD44 1.50 2.06E-13 
MCM3 1.48 6.25E-08 
AKAP12 1.48 1.55E-08 
EGR1 1.45 3.84E-08 
CDK6 1.42 5.60E-10 
MYO10 1.28 1.77E-08 
CRIP2 1.23 5.90E-08 
ARHGAP22 1.20 3.47E-10 
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Table 5.12: Top 50 Uniquely Up-Regulated Genes in Human TGF-β2 Treated Cells 
Exposed to miR145 Inhibitor (145i). LogFC= Log fold change.  
  
UGCG 1.19 8.15E-10 
S100A10 1.17 2.26E-18 
FLNC 1.11 3.17E-08 
FRMD6 1.11 3.2E-16 
POLR2B 1.07 2.73E-08 
FHOD1 0.97 6.41E-08 
ZFP36L1 0.76 1.67E-08 
SERPINE1 0.69 2.67E-08 
PLEC 0.67 3.47E-08 
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Gene Name LogFC p-value 
Down-Regulated Genes 
GAL3ST3 -4.42 2.23E-12 
NXPH3 -2.94 1.73E-22 
PALMD -2.93 6.23E-10 
MYH11 -2.67 4.09E-16 
COL11A1 -2.65 8.49E-14 
THBD -2.54 1.68E-10 
PKP2 -2.53 2.15E-19 
PTGIS -2.42 1.85E-17 
PPFIBP2 -2.36 1.73E-13 
CLIC3 -2.35 6.47E-10 
GPC4 -2.27 8.59E-17 
PPM1H -2.26 1.26E-13 
COL4A4 -2.18 5.25E-13 
SLC7A14 -2.12 3.66E-10 
SLC6A6 -2.06 1.03E-27 
SYNPO2 -2.03 2.82E-12 
CDKN2B -2.03 5.59E-09 
SLC22A23 -2.00 1.39E-12 
C10orf54 -2.01 2.04E-14 
DAPK1 -1.95 9.41E-14 
SGK223 -1.89 5.98E-17 
FRY -1.83 3.93E-09 
CLDN11 -1.81 1.84E-12 
COL8A1 -1.81 3.35E-14 
PIK3IP1 -1.81 2.89E-09 
ARL4D -1.79 4.78E-09 
FILIP1L -1.73 2.84E-12 
OPN3 -1.73 1.21E-13 
PPAP2A -1.58 1.73E-19 
SORT1 -1.55 6.57E-11 
ACTA2 -1.54 3.42E-10 
SESN3 -1.54 1.3E-18 
AMACR -1.53 1.63E-09 
SVEP1 -1.52 1.13E-16 
PRSS12 -1.48 3.11E-19 
ACTA2-AS1 -1.48 4.07E-10 
C1orf198 -1.42 8.3E-15 
SLC25A4 -1.39 2.67E-09 
ANKH -1.37 5.27E-10 
PDE5A -1.33 2.88E-09 
SNX30 -1.23 6.56E-10 
MEGF6 -1.22 1.56E-10 
RUSC2 -1.18 2.1E-15 
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ARMC9 -1.01 2.95E-09 
SNX25 -0.97 7.70E-10 
CTIF -0.96 1.60E-09 
TINAGL1 -0.93 3.53E-09 
NEO1 -0.82 6.39E-10 
WNK1 -0.77 4.06E-10 
KIAA1462 -0.75 1.17E-09 
 
Table 5.13: Top 50 Uniquely Down-Regulated Genes in Human TGF-β2 Treated 
Cells Exposed to miR145 Inhibitor. LogFC= Log fold change.  
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The scrambled negative control group (SNC_Group) was used to identify 
genes that were differentially expressed independently of transfection effects. 
Figure 5.17, Venn diagram below illustrates the overlap in DEGs between miRNA 
inhibitor groups 143i_Group, 145i_Group, and the scrambled control group 
SNC_Group. While many genes were differentially expressed by the scrambled 
control and the two individual inhibitors, there are uniquely expressed genes by 
inhibitor treatments. 
 
Figure 5.17: Venn Diagram of Overlap of Differentially Expressed Genes Between 
Scrambled Negative Control, 143i, or 145i Transfected TM Cells Treated with TGF-
β2. There is an overlap of differentially expressed cells between the SNC_Group and 
143i- or 145i_Group. However, there are unique DEGs for both the 143i_Group and 
145i_Group that are independent to the scrambled control. The unique genes for 
143i and 145i and both 143i/145i are given in Table 8.4 (Appendix).  
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Uniquely expressed genes in 143i_Group and 145i_Group outlined in Table 
5.14 and Table 5.15, were filtered on FDR and subsequently on LogFC investigated 
for validated targets that have been confirmed experimentally using two validated 
miRNA target interaction web-interfaces: miRTarBase (v8) and the Validated Target 
Module of miRWalk 2.0.  Sixteen experimentally validated targets were identified as 
regulated by miR-145-5p and miR-143-3p (Table 5.16). 
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Gene LogFC 
Up-Regulated Genes 
PBK 3.665 
CCNE2 3.62 
RRM2P3 3.58 
ESCO2 3.50 
PLK4 3.49 
DEPDC1 3.44 
KIF15 3.41 
KIAA0101 3.37 
BLM 3.28 
KIF14 3.18 
KIF2C 3.15 
RAD54L 3.14 
DLGAP5 3.02 
RAD51AP1 2.92 
HMMR 2.89 
TTK 2.82 
C11orf82 2.70 
HELLS 2.56 
RAD51 2.42 
WDR62 2.42 
LMNB1  2.39 
FANCD2 2.38 
GINS1 2.35 
PSMC3IP 2.32 
PPP1R14C 2.29 
CCNA2 2.25 
CDCA2 2.17 
MAD2L1 2.13 
CHAF1B 2.09 
WNT7B 2.08 
FANCA 2.06 
CDC6 2.05 
CDC25A 2.05 
GINS4 2.01 
RFC3 2.00 
CENPE 1.99 
FBXO5 1.97 
PLK1 1.97 
EZH2 1.93 
RP11-424C20.2 1.91 
RECQL4 1.88 
GINS3 1.88 
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ZWINT 1.83 
MELK 1.82 
KIF20B 1.78 
TIMELESS 1.69 
RNASEH2A 1.66 
FANCG 1.59 
APCDD1L 1.57 
NCAPG2 1.52 
HMGB2 1.51 
 
Table 5.14: Top 50 Unique Up-Regulated Genes Identified in TGF-β2  Treated TM 
Cells Transfected with 143i and 145i by RNA-Seq. Top 50 Unique up-regulated 
genes for 143i and 145i independent of the SNC_Group were identified.  
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Gene LogFC 
Down-Regulated Genes 
EXTL1 -2.16 
LYPD6 -2.01 
LMOD1 -1.86 
KCNE4 -1.84 
MYOZ1 -1.79 
ANK1 -1.72 
VSTM2L -1.65 
WFDC1 -1.58 
GLIS1 -1.48 
PALM -1.47 
IL12A -1.46 
PIEZO2 -1.44 
HSD17B6 -1.41 
RP11-379K17.5 -1.31 
SHOX -1.30 
PRELP -1.25 
PRUNE2 -1.24 
DDR1 -1.24 
ARSI -1.21 
ANGPT1 -1.20 
FAM115B -1.19 
KLHL24 -1.19 
DIO2 -1.18 
FOXF2 -1.18 
SLIT2 -1.17 
SH3RF2 -1.09 
ARNT2 -1.07 
YPEL2 -1.06 
CNN1 -1.01 
KIF26B -0.98 
STON1 -0.98 
LDLRAP1 -0.95 
GTF2IP1 -0.95 
YPEL3 -0.94 
FAM198B -0.94 
LIMK1 -0.94 
PDK2 -0.94 
PPP1R3C -0.93 
AHR -0.92 
BDNF -0.92 
HDAC5 -0.92 
TP53INP1 -0.91 
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TAPT1 -0.90 
MSRB1 -0.90 
COL4A5 -0.89 
ACSS2 -0.87 
CDKN2A -0.87 
CXCR5 -0.87 
PRICKLE1 -0.87 
PGPEP1 -0.85 
CCDC107 -0.85 
 
Table 5.15: Top 50 Unique Down-Regulated Genes Identified in TGF-β2  Treated 
TM Cells Transfected with 143i and 145i by RNA-Seq. Top 50 Unique down-
regulated genes for 143i and 145i independent of the SNC_Group were identified.  
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Table 5.16: Unique Differentially Expressed Genes Identified in TGF-β2-Treated 
TM Cells Transfected with 143i and 145i by RNA-Seq which are Validated miR-145 
and miR-143 Targets. Unique DEGs for 143i and 145i independent of the 
SNC_Group were identified. Validated targets of both miR-145 and miR-143 were 
identified using miRTarbase (V8) and miRWalk 2.0 and cross-referenced against 
DEGs identified by RNA-Seq.  
  
Gene Gene Name logFC miRNA Target 
LMNB1 Lamin B1 2.397 miR-145 
PODXL Podocalyxin-like 2.101 miR-145 
ARHGAP11A Rho GTPase Activating Protein 11A 1.092 miR-145 
ZWILCH Zwilch kinetochore protein 0.915 miR-143 
SH2B3 SH2B adaptor protein 3 0.908 miR-145 
ZEB1 Zinc finger e-box binding homeobox 1 0.779 miR-143/ miR-145 
U2SURP U2 SnRNP associated SURP domain 
containing  
0.764 miR-145 
CSE1L Chromosome segregation 1-like 0.758 miR-145 
ABCE1 ATP binding cassette subfamily E 
member 1 
0.757 miR-145 
EPT1 Selanoprotein 1 0.704 miR-145 
HSPH1 Heat shock protein family H Member1 0.67 miR-143 
JMJD1C Jumonji domain containing protein 0.663 miR-145 
BCCIP BRCA1 and CDKN1A interacting protein 0.643 miR-143 
TUBA1B Tubulin alpha 1B 0.442 miR-143 
SRSF1 Serine and arginine rich splicing factor 1 0.416 miR-145 
MSN Moesin  0.359 miR-143 
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5.4.5.2 Comparison Analysis of 143i and 145i in Human TM Cells +/- TGF-β2 
 A comparison analysis was performed on IPA between 143i, 145i and SNC to 
determine the most significantly altered genes in the TGF-β signalling pathway, in 
addition to significantly differentially expressed genes upstream of miR-145-5p and 
ZEB1. Only genes identified as independent of SNC were considered truly 
differentially expressed and not a product of transfection background. Figure 5.18 
identifies evidence of TGF-β signalling pathway alterations in response to 145i but 
not in response to 143i or as an effect of transfection protocol. Figure 5.19 is 
indicative of the complexity of miRNA:mRNA modulation. miR-145 expression is 
affected by 143i and scrambled negative control (SNC). Figure 5.20 shows the up-
regulation of ZEB1 by 143i and 145i independently of SNC.  
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Figure 5.18: Comparison Analysis of Canonical TGF-β Signalling Pathway Between 
143i, 145i and SNC Transfected TGF-β2 Treated Human TM Cells. TGF-βR2 is 
significantly up-regulated in response to 145i but not 143i and SCN. Up-regulation 
following miRNA inhibitor transfections is indicative of a more direct effect of 
miRNA inhibitors. To identify true effects of 143i or 145i SNC column should have 
no colour change (white= unaffected), and 143i or 145i would be coloured 
according to up-regulation (red) or down-regulation (green).  
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Figure 5.19: Comparison Upstream Analysis of miR145 Between 143i, 145i and 
SNC Transfected TGF-β2 Treated Human TM Cells. miRNA:mRNA modulations are 
complex networks which can have many off target effects. FSCN1 is down-regulated 
by 145i but not 143i or SNC. This is likely to be due to off target effects. CCNA2 
(cyclin A2) is up-regulated by 143i and 145i. miR-145 is affected my 145i and SNC. 
This may indicate SCN is having undesirable off target effects which can directly and 
indirectly regulate genes. To identify true effects of 143i or 145i SNC column should 
have no colour change (white= unaffected), and 143i or 145i would be coloured 
according to up-regulation (red) or down-regulation (green). 
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Figure 5.20: Comparison Upstream Analysis of ZEB1 Between 143i, 145i and SNC 
Transfected TGF-β2 Treated Treated Human TM Cells. EMT-like phenomena have 
been described in TM cells and miR143/145 are thought to regulate EMT. ZEB1 
expression is increased by 143i and 145i but not SCN1 indicating undesirable effects 
of miR-145 and miR-143 transfection. To identify true effects of 143i or 145i SNC 
column should have no colour change (white= unaffected), and 143i or 145i would 
be coloured according to up-regulation (red) or down-regulation (green).   
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5.4.5.3 Validation of hsa-miR-145-5p and hsa-miR-143-3p Inhibitor Effects of 
ACTA2 at mRNA Level 
 Human TM cells were transiently transfected with human miRNA inhibitors 
against hsa-miR-145-5p (145i) and hsa-miR-143-3p (143i) or a scrambled negative 
control (SNC). 143i did not diminish ACTA2 gene expression when compared to 
TGF-β2 treated control TM cells. Both 145i and the SNC appeared to diminish 
ACTA2 expression at the mRNA level when compared to the treated control. A 
Oneway ANOVA and Dunn’s multiple comparisons test was performed on GraphPad 
Prism and no significant difference was found between individual treatment groups 
and TGF-β2 control cells.
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Figure 5.21: q-PCR Analysis of ACTA2 Gene Expression in Transfected TGF-β2 
Human TM Cells. Human TM cells were treated with TGF-β2 and transfected with 
143i, 145i or scrambled negative control (SNC). 145i diminish ACTA2 expression at 
the mRNA level compared to TGF-β2 treated cells. SNC also diminished ACTA2 
mRNA expression however, ACTA expression was enhanced by 143i.   
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5.4.5.4 Validation of hsa-miR-145-5p and hsa-miR-143-3p Inhibitor Effects 
ACTA2 at Protein level 
 Human TM cells were transiently transfected with human miRNA inhibitors 
against hsa-miR-145-5p (145i) and hsa-miR-143-4p (143i) or a scrambled negative 
control (SNC). Total protein extracts from human TM cells were probed against an 
anti-α-SMA antibody. Both hsa-miR145-5p inhibitor and hsa-miR143-3p inhibitor 
alone diminished α-SMA expression. Expression levels were compared to a TGF-β2 
positive protein extract.   
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Figure 5.22: ACTA2 Protein Expression Reduced in Presence of miRNA Inhibitors. 
(A) Human TM cells were stably transfected with synthetic miRNA inhibitors to hsa-
miR-145-5p (145i) and hsa-miR143-3p (143i) or a scrambled negative control (SNC). 
Whole cell lysates for TGF-β positive only cells (+), non-coding cells (+,Scram), and 
miR-145 inhibitor (+,145), miR-143 inhibitor (+,143). (B) Densitometric units of 
ACTA2 were determined using Fiji analysis software, relative to GAPDH and referred 
as a fold change of control, TGF-β2 cells.   
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5.5 Discussion 
Target miRNA Identification 
 TGF-β2 plays a central role in the pathophysiology of glaucoma in the TM 
affecting ECM dynamics, oxidative stress, cellular contractility, and 
senescence164,715. Patients with POAG have elevated levels of TGF-β2 in their AH 
and multiple in vitro and in vivo experiments have demonstrated that TGF-β2 plays 
a central role in the pathogenesis of glaucoma in the TM394,397. TGF-β2 dysregulates 
the expression of multiple genes involved in complex processes as was shown in 
Chapter3. TGF-β2 can also influence and drive the expression of multiple miRNAs 
via SMAD proteins. TGF-β2 induced alterations in miRNA expression can provide an 
insight into the regulation of cellular function and dysregulated pathways in the TM 
in glaucoma, as well as, identifying miRNAs as potential therapeutic targets381.  
 In this study, global alterations in miRNA expression were investigated using 
a commercial microarray platform (Exiqon, Denmark) in human cultured TM cells 
treated with 5ng/mL TGF-β2 for 24 hours. Three miRNAs were significantly up-
regulated following TGF-β2 treatment: miR-143-3p (FC= 0.957, p-value= 2.99E-2), 
miR-145-5p (FC= 0.605, p-value= 2.99E-2) and miR-4328 (FC=0.0665, p-value= 
2.99E-2). In addition, using the same microarray platform glaucomatous TM cells 
had significantly elevated expression of miR-143-3p (FC= 1.074, p-value= 2.99E-2) 
and miR-4328 (FC= 1.028, p-value= 2.99E-2). Detection of miRNAs by q-PCR is 
technically demanding due to their small size and inherently low expression716: 
statistical significance could not be achieved by q-PCR analysis (Figure 5.5).  
 Previous literature on the physiology and targets of miR-4328 is limited. 
miR-4328 expression was identified in keloid scar formation717, bone formation718, 
mucinous cystadenocarcinoma719 and steroid-induced hepatic steastosis720. 
Interestingly, in keloid scar formation miR-4328, miR-143-3p and miR-145-5p were 
significantly down-regulated721. Given the limited data regarding miR-4328 and 
significant literature base for miR-143-4p and miR-145-5p the subsequent 
experimental work focused on the latter miRNAs.  
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 Both miR-143-3p and miR-145-5p form a bicistronic miRNA cluster 143/145 
located on chr5q33 in humans (Figure 5.23)722; miR-143 is approximately 1.7kB 
from miR-145. It is proposed that the cluster is transcribed together but given these 
miRNA can have different independent cellular functions723, and cellular 
distributions722 their regulation, targets and expression may not be inter-linked. 
Both miRNAs have a common promoter, but miR-145 also has a specific upstream 
regulatory element of approximately 1.5kB which might favour independent 
regulation724. The mechanism of this differential expression is not known724.  TGF-β 
strongly induces the expression of miR-143 and miR-145725. The majority of authors 
have focused on the role of the miRNA 143/145 cluster in cardiovascular disease726 
and cancer727.   
   
   
Figure 5.23: The miR143/145 Cluster. Modified from Kent et al 2014722. (A) Mature 
miRNA sequences of miR-143 and miR-145. (B) The secondary structures of pre-
miR-143 and pre-miR145 stem loops. Mature miRNA sequences are blue (miR143) 
and green (miR-145). miRNA* sequences are grey. (C) Genome organisation and 
major primary transcript structure of the miR-143/145 cluster.  
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 Expression of miR-143 is highest in fibroblasts and smooth muscle cells but 
is also expressed in epithelial and endothelial cells. The expression of miR-145 is 
more restricted to mesenchymal cells (fibroblasts and smooth muscle cells). miR-
143 and miR-145 are essential in the differentiation of vascular smooth muscle cells 
(VSMCs) during development725 and their expression can induce the differentiation 
of neural crest stem cells into VSMCs; this effect is dependent on TGF-β and is 
proposed to reflect an EMT-type process725. miR-145 alone is sufficient to 
differentiate stem cells into VSMCs725. 
 miR-143 and miR-145 are also molecular triggers of VSMC phenotypic 
switching728,729. VSMC retain phenotypic plasticity and can switch between a 
differentiated or contractile state and a de-differentiated or synthetic state (Figure 
5.24)730. TGF-β family members (TGF-β and BMP4) promote the ‘contractile 
phenotype’ whereas PDGF stimulates the synthetic state (Figure 5.24)731. PDGF 
represses the expression of miR-143 and miR-145 (transcriptionally and post-
transcriptionally) when VSMC de-differentiate into the synthetic state728 whereas 
TGF-β induces miRNA-143 and miR-145 expression and a contractile state730. Over-
expression of miR-145 up-regulates the expression of VSMC differentiation markers 
which are the hallmark of a contractile phenotype: smooth muscle alpha actin (α-
SMA, ACTA2), calponin, and smooth muscle-myosin heavy chain728 (SM-MHC). 
 
 
 
 
256 
 
 
Figure 5.24: Regulation of Vascular Smooth Muscle Cell Phenotype. Modified from 
David-Dusenbery et al 2011730.  Phenotypic plasticity and regulation of vascular 
smooth muscle cell (VSMC). Several stimuli can induce a switch between a de-
differentiated synthetic VSMC and a differentiated contractile VSMC. The process is 
regulated by miRNA expression as shown and alters VSMC phenotypic behaviour. 
Target miRNAs Affect TM Cell Contractility 
TGF-β2 increases the expression of α-SMA in human TM cells altering the 
actin cytoskeleton and enhancing contraction of the cells252. In Chapter 3 the RhoA 
signalling pathway was significantly activated in human TM cells treated with TGF-
β2 (Chapter 3, 3.4.3). RhoA signalling is involved in the regulation of α-SMA 
expression and cell migration732.  α-SMA expression was significantly decreased in 
human TM cells co-treated with TGF-β2 and miRNA inhibitor miR-145-5p (FC= -
1.5476, p-value= 3.42E-10). This decrease was observed by q-PCR in human TM cells 
for miR-145-5p inhibitor but was not statistically significant (FC= 1.96) (Figure 5.22). 
Protein analysis identified the diminished expression of α-SMA protein in response 
to both miR-143-3p and miR-145-5p inhibitors when compared to a TGF-β2 positive 
control (Figure 5.23). This supports the concept that TGF-β acting via miR-145 up-
regulates α-SMA expression in the TM. Actin cytoskeleton reorganisation in TM 
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cells results in the formation of cross-linked actin networks582,733,734 (CLANs) and 
these are induced in human TM cells in the presence of TGF-β2254 and 
corticosteroids257. α-SMA is a key component of CLANs. Glaucomatous TM cells 
contain greater numbers of CLANs (mean= 1.03) in comparison to aged-matched 
normal TM cells(0.67)735,736, supporting the association between actin remodelling 
and POAG. CLANs are believed to increase stiffness of TM cells thus increasing AH 
outflow resistance, as well as disturbing TM homeostasis256.  
 This concept is further supported by data from the targeted deletion of miR-
143/145 in mice (miR-143/145 dKO mice)694. The deletion of miR-143 and miR-145 
resulted in a 19% decrease in IOP which is equivalent to a 2 fold increase in outflow 
facility; the eye of the mice were microscopy and structurally normal694. 
AntagaomiR transfections against miR-143 and miR-145 in human TM cells resulted 
in abnormalities in F-actin stress fibre including fibre length and variable effects on 
cell contraction (inter-donor variability)694. A number of genes were selected as 
potential predicted/validated miR-143/145 targets from the literature and others 
involved in actin dynamics and contractility694. Several miR-143/145 validated 
targets from studies in VSMCs did not show consistent results in luciferase reporter 
assays suggesting cell-type specific miRNA effects on mRNA regualation694. The 
authors proposed that an unbiased genome wide approach should be employed to 
investigate miR-143/145 regulated genes in human TM cells694.  
Target miRNA Manipulations 
 With this in mind, a combined approach was used in this study combining 
validated targets for miR-143/145 from the literature and a hypothesis independent 
genome-wide approach using RNA-Seq following miRNA inhibition. Validated 
targets were selected from those involved in TGF-β signalling (TGF-βR2: miR-145709; 
SMAD2:miR-145711) and glaucoma pathogenesis712 (CTGF: miR-143/145)710,737,738. 
The transfection of miR-143/145 mimics and inhibitors did not detect a significant 
alteration of these targets in TM cells. This might reflect the low transfection 
efficiency in TM cells or cell-specific miRNA effects714. Given miR-145 is a repressor 
of EMT, and central role of EMT in TGF-β driven fibrosis in the TM599, markers of 
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EMT were assessed following miR-145 manipulation; no significant alterations were 
detected by q-PCR.  
 The ability of a miRNA to target an mRNA is often cell specific and miRNA 
expression profiles can be altered when cells are taken from a tissue environment 
and placed in a cell culture environment739. Target prediction tools, though useful 
for rapid identification of validated targets for specific miRNAs, do not provide cell 
specific information and therefore may provide difficult to replicate when used in 
different model systems. In addition, human TM cells have enhanced phagocytic 
capabilities which results in difficult transfection conditions. Despite identifying a 
low transfection rate amongst cells using a FAM labelled siRNA, untransfected cells 
were not removed from the environment prior to protein and mRNA analyses. The 
presence of untransfected cells within the population may be indicated by the 
inability to detect significant alterations in TM cells treated with TGF-β2 and relative 
miRNA mimics and inhibitors when compared to TGF-β2 only controls.  
Core and Comparison Analyses 
 Given these findings and those of other authors investigating the role of 
miR-143/145 in the TM694 a genome-wide RNA-Seq experiment was performed to 
assess differential gene expression and pathway analysis in human TM cells treated 
with TGF-β2 transfected with a scrambled negative control (SNC, inhibitors of miR-
143 (143i) and miR-145 (145i). Strikingly, transfection of the SNC resulted in 
significant DEGs and altered pathways; many of these over-lapped with miR-143 
and miR-145 inhibition. Manipulating the miR-143 and miR-145 regulatory network 
resulted in complex transcriptome alterations, both direct and indirect. To dissect 
specific alterations two approaches were taken: (1) a direct comparison of DEGs 
between SNC, 143i, and 145i; and (2) a ‘Comparison Analysis’ in Ingenuity Pathway 
Analysis concentrating on alterations in canonical pathways and upstream 
regulation between enriched processes  identified in two or more Core analyses.  
 From the set of genes identified by the direct comparison of SNC, 143i and 
145i (Table 5.14), known validated miR-143 and miR-145 targets were identified 
from miRTarBase v8 and miRWalk2.0 (see Table 5.16). From the direct comparison 
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of SNC, 143i, and 145i further evidence was found to support the relationship 
between miR-143/145 Rho signalling and cytoskeletal remodelling. Both moesin 
(MSN) and Rho GTPase activating protein 11A (ARHGAP11A) have increased 
expression in response to both miR-143 and miR-145 inhibitors. MSN closely 
regulates α-SMA and inhibition of MSN reduces the expression of α-SMA in the 
mouse cornea740. ARHGAP11A induces cell cycle arrest and apoptosis through p53 
binding741. p53 has been associated with POAG whereby it induces apoptosis in 
response to cell death742. In addition, p53 post-transcriptionally modifies 
miRNAs704, therefore may be involved in a regulatory feedback loop. Up-regulation 
demonstrates the complexity of miRNA regulation by 143i and 145i and is indicative 
of a complex signalling network.  
From the ‘Comparison Analysis’ of the TGF-β signalling pathway in IPA 
(Figure 5.18), miR-145 is specifically reducing the expression of the TGF-βR2 
compared with the SNC and 143i. This has previously been shown and was 
evaluated by q-PCR which was not significant although there was a trend suggesting 
miR-145 regulated TGF-βR2 (Figure 5.8). The finding of the RNA-Seq experiments 
highlight the advantages and sensitivity of RNA-Seq in terms of dynamic range and 
quantification compared with q-PCR743. The upstream analysis (Figure 5.20) 
demonstrated that ZEB1 expression was up-regulated by both 143i and 145i versus 
SNC. This was also seen in the direct comparison of DEGs. ZEB1 is a transcriptional 
repressor and an inducer of EMT744. Enhanced expression by 145i may explain the 
failure of miR-145 inhibitor transfection to alter the expression of EMT markers 
(Figures 5.11- 5.14). The up-regulation of ZEB1 by 143i and 145i demonstrates the 
complexity of miRNA regulation and a potentially deleterious off-target effect. 
Similarly, the variability seen in the data is complicated by evidence from up-stream 
analysis (Figure 5.20) that miR-145 expression is up-regulated by the SNC and miR-
143 inhibitor; suggesting a complex regulatory system.  
 The phenotypic switch from a contractile and synthetic VSMC is regulated 
by a complex and synergistic network and similar mechanisms are likely in TM cells. 
Contractile smooth muscle genes (α-SMa, SM-MHC, calponin and desmin) contain a 
converse cis-regulatory element: the CArG box (CC(A/T)6GG)
725. Serum response 
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factor (SRF) and either myocardin or myocardin-related transcription factor (MRTF)-
A/B bind to CArG box elements located within the promoter of contractile smooth 
muscle genes to regulate the transcription and differentiation of a contractile 
VSMC725. The miRNA cluster miR-143/145 promoter also contains a CArG box725 and 
SMAD binding elements (SBE)320,702. SRF and SRF co-factors (myocardin and MRTF-
A/B) activate miR-143/145 promoter725,745. TGF-β up-regulated the expression of 
both myocardin and the miR-143/145 cluster via SBEs746 and via the activation of 
RhoA signalling and ROCK1 which induces MRTF-A expression; MRTF-A also binds 
the CArG box in the miR-143/145 cluster (Figure 5.25)730.  
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Figure 5.25: Summary of miR143/145 Regulation. Modified from David-Dusenbery 
et al 2011730. Multiple extracellular signals promote VSMC differentiation through 
the regulation of miR-143/145. 
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PDGF negatively regulated miR-143/145 expression indirectly via p53 to 
maintain a de-differentiated synthetic VSMC728. PDGF activates Src which inhibits 
p53 promotion of miR-143/145 expression via transcriptional and post-
transcriptional mechanisms704,747. The miR-143/145 cluster is a central target of 
multiple signalling pathways which regulate the VSMC phenotype and are also most 
likely to regulate the contractile and synthetic behaviour of TM cells. Further work 
is required to determine the regulation of the miR-143/145 cluster and 
pathophysiology in the TM cell and in glaucoma. Interestingly, a recent study 
assessing the miRNA content of AH from normal and glaucomatous patients 
identified 181 differentially expressed miRNAs between both cohorts: miR-143 was 
significantly up-regulated in AH of glaucomatous patients684. 
5.6 Summary 
 This is the first description of miRNAs expressed in human TM cells in 
response to TGF-β2 treatment. We successfully identified three miRNAs that are 
significantly differentially expressed in response to TGF-β2, miR-143, miR-145 and 
miR-4328. miR-4328 is relatively unexplored therefore due to time constraints we 
focused our remaining experiments on the potential role of miR-143 and miR-145 in 
the human TM, two well described miRNAs. The miR-143/145 cluster plays a 
fundamental role in governing VSMC and SMC-like differentiation during 
physiological and pathological events, and expression is enhanced in response to 
TGF-β2. Our work further demonstrates the possible effects of the miR-143/145 
cluster and miR-145 independent effects on TM cytoskeleton stabilisation and 
remodelling in response to TGF-β2. This research highlights the need for further 
understanding of the intricate regulatory network of miR-143/145 before suitable 
effective therapies may be developed.  
 Functional relevance of miRNAs in human TM cells required stable 
transfection of target miRNA mimics and inhibitors. TM cells are inherently difficult 
to transfect and a constant low transfection yield was obtained. This proved 
frustrating when identification of putative targets for these miRNAs could not be 
effectively identified. We have hypothesised that the lack of correlation between 
our dataset and previously publish work, in relation to miR-143 and miR-145 
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validated targets, may have been cause by a mixed cell population, i.e. transfected 
and untransfected cells. The number of untransfected cells greatly outnumbered 
transfected cells therefore a true evaluation of the functions of the miRNA mimics 
and inhibitors could not be reported. Future work would benefit from a cell sorting 
technique to isolate only stably transfected cells to evaluate the potential 
phenotypic and genotypic effects miR-143 and miR-145 are exerting on human TM 
cells. We have shown that α-SMA is down-regulated at mRNA and protein levels 
and this corroborates previously published data. It is hypothesised that miR-
143/miR-145 enhance TM cell contractility and to investigate this collagen 
contraction assays may potentially be a logical step forward. There are a number of 
obstacles to overcome with miRNA delivery to the TM and effective delivery must 
be considered prior to future work. miRNA delivery to ocular tissues is discussed 
further in Chapter 6.  
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Chapter 6 
Emerging and Novel Glaucoma Therapeutics 
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Current Therapies for Glaucoma 
 All treatments of glaucoma currently used in clinic target lowering IOP as a 
method to slow disease progression. Current therapies broadly make up five drug 
classes: cholinergic agonists, sympathomimetics, β blockers, carbonic anhydrase 
inhibitors, and prostaglandin analogues748. In addition to pharmaceutical therapy 
there are several surgical options for the treatment of POAG: glaucoma filtration 
surgery, shunt implants and laser trabeculoplasty749. IOP is modulated by 
decreasing aqueous humour production or by increased outflow facility. Current 
drug treatments are not selective to eye tissues and were originally developed for 
other diseases748. Prostaglandin analogues, and cholinergic agonists (pilocarpine), 
lower IOP mainly by increasing AH outflow through the conventional and 
uveoscleral pathways. Pilocarpine increases contractility of the ciliary body thus 
increasing outflow750. Prostaglandin analogues, first identified in monkeys for their 
IOP lowering effect751, increased the uveoscleral outflow and conventional AH 
outflow752,753. Sympathomimetics754, β blockers (timolol)755,756, and carbonic 
anhydrase inhibitors85,757, all decreased aqueous humour production by exerting 
their effects on the ciliary epithelium. When drug pharmacological intervention fails 
to lower IOP, invasive measures including laser treatment, surgery, or shunt 
implants may be used. Laser treatment mechanically increases outflow by 
damaging the TM tissue758. Glaucoma filtration surgery increases outflow facility 
through creation of a fistula for AH to bypass the non-functional TM759. Filtration 
surgery has a high 5-year failure rate and associated cataract complications760. 
Shunt implants are designed to maintain the opening made by surgery with a 
physical tube-like stent761. 
 Glaucoma-associated morphological changes include increased extracellular 
matrix secretion and deposition in the TM762, changes to the ECM composition of 
the ONH763, and increased TM cell contractility250. New therapies in development 
modulate the signalling pathways involved in both ECM and cytoskeletal re-
structuring. Adenosine receptor ligands are currently being developed. Adenosine 
receptors (ARs) are expressed in the ciliary body764, TM765 and Schlemm’s canal766 
and regulate the production of cAMP; AR classes, A1-A3, have differential effects on 
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ECM turnover767,768. A1 and A3 activate phospholipase C (PLC) which is part of the 
extracellular signal related kinase (ERK1/2) pathway. Activation of ERK1/2 leads to 
secretion of MMPs and accelerated ECM turnover. A2 also modulates ERK1/2 
pathway however, this activates connective tissue growth factor (CTGF), thus 
increasing ECM deposition712. Therefore, depending on the AR class, agonists or 
antagonists should theoretically lower IOP by enhanced ECM turnover. A1 agonists 
enhance ERK1/2 signalling leading to specific MMP-2 and MMP-9 increase767,769,770. 
Consistent with this, outflow increase can be reversed by MMP inhibition769. Both 
A1 and A3 reduce TM cell volume which in turn independently increase outflow 
facility765. However, their molecular structures are still not well established and 
there is both species specificity and selectivity issues with AR agonists; this is an 
important area for further investigation to reverse TGF-β driven ECM abnormalities 
in the TM. More recently a gene therapy for steroid-induction of MMP-1 has been 
described771 which may circumvent issues arising with the use of AR agonists.  The 
GRE.MMP1 gene vector successfully induced MMP one expression in the TM in 
response to corticosteroids771.  
 In addition to AR ligands, Rho-associated protein kinase (ROCK) inhibitors 
are also in late stage development and early clinical use772. As discussed in Chapter 
3 (3.5), ROCKs are serine/threonine kinases that are downstream effectors of Rho 
GTPases. ROCKs phosphorylate substrates involved in the regulation of F-actin 
stress fibre formation, focal adhesion, and cell-cell adhesion and migration 
properties429,773. Downstream effects on actin cytoskeleton organisation and 
smooth muscle cell contractility is relevant to many cellular processes and 
dysregulation, and the Rho/ROCK signalling system is evident in diseases 
throughout the body774,775.  Known substrates of ROCK are myosin light chain (MLC) 
kinase, LIM homeobox gene Lin11, ISL LIM Homeobox 1 (Is11) and LIM kinase776. 
The Rho signalling pathway is relevant for AH outflow and glaucoma777. Both ROCK1 
and ROCK2 are expressed in the TM, ciliary body, and corneal epithelium. Selective 
roles of ROCK1 and ROCK2 in glaucoma is still unknown, however ROCK1 and 
ROCK2 knockout mice have lower IOP than wild type mice778.  
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 ROCK therapies are being actively investigated to treat an array of diseases 
from cancer to glaucoma775,779,780. ROCK inhibitors (R1-R13) were derived from 
calmodulin antagonists, namely isoquinolone781. Similar to other kinase inhibitor 
targets, ROCK inhibitors competitively bind in the ROCK ATP binding pocket782. It is 
therefore difficult to ensure ROCK inhibitors selectivity over alternative kinase 
binding pockets, for example R-1 has been shown to inhibit protein kinase C-related 
protein kinase 2 (PRK2), cyclic GMP-dependent protein kinase G (PKG) and protein 
kinase C (PKC)783. R-1 in complex with ROCK1 and ROCK2 demonstrates differences 
in pocket shape and physiochemical properties compared to other kinases784, giving 
rise to a new generation of ROCK inhibitors, with more potent inhibition and 
specificity; these are currently either being evaluated in glaucoma models or in 
clinical trials (Table 6.1)783,785,786. Animal perfusion studies and in vivo studies in 
normal tension and ocular hypertensive rabbits have been used to test ROCK 
inhibitors787. Repeatedly, ROCK inhibitors decrease IOP by increased AH drainage 
through the TM via cytoskeletal re-structuring787–789.  Bovine eyes perfused with R-3 
results in cellular morphology changes of TM and Schlemm’s canal cells, decreases 
the number of focal adhesions and widens extracellular spaces in the TM400,790. It is 
thought that these morphological changes are caused by the decrease in MLC 
kinase phosphorylation following ROCK inhibition. In addition to lowering IOP, 
ROCK inhibitors increase ONH blood flow, and, prevent post-operative scarring in a 
glaucoma surgery model by inhibiting collagen deposition and fibro-proliferation in 
rabbits791–793. 
Compound Clinical Trials for IOP Reduction 
R-2- Ripasudil Phase II, Approved for glaucoma and ocular 
hypertension treatments in Japan 
R-4- RKI-983 Discontinued following Phase II 
R-11- Scaffold for AMA-0076 Phase II-Completed 
R-12- AR-12286 Phase II-Ongoing 
R-13- AR-13324 Phase II-Ongoing 
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Table 6.1: ROCK Inhibitors Approved for Clinical Trials for the Treatment of 
Elevated IOP794. 
  
269 
 
Novel Molecular Target Identification by mRNA-Seq 
 Glaucoma is a multi-faceted disease and with current therapies sole aim to 
lower IOP there is potential for advancements in this area by identification of key 
molecular targets involved in disease pathogenesis. We investigated the molecular 
changes associated with known glaucoma stimuli, TGF-β2 and dexamethasone and 
identified a range of differentially expressed genes that are likely implicated in 
POAG and steroid-induced glaucoma.  
LIM Kinase Inhibitors 
 In our study the Rho/ROCK signalling pathway was significantly enriched in 
response to TGF-β2, dexamethasone, and following the transfection of human TM 
cells with miR-143 and miR-145 inhibitors. Interestingly, neither ROCK1 (LogFC= 
0.392, FDR p= 0.019) nor ROCK2 (LogFC= -0.319, FDR p= 0.081) were significantly 
differentially expressed across all three data sets. However, LIM kinase was 
significantly altered (LIMK1: LogFC= 1.394, FDR p= 2.14E-17 and LIMK2: LogFC= 
2.51, FDR p= 4.32E-30) (Chapter 3, Table 3.9), and may be an alternative more 
effective target of the Rho signalling pathway in glaucoma. LIM kinases 1 and 2 
(LIMK1 and LIMK2) regulate cytoskeletal dynamics by phosphorylating and 
deactivating cofilin, a protein required for depolymerisation of actin filaments. LIM 
kinases have been investigated in several diseases for their role in various cellular 
processes such as cell barrier integrity, axonal elongation, cell migration and cell 
growth arrest795. In conjunction with the growing interest in LIM kinases, LIM kinase 
inhibitors have also been reported (Table 6.2).  A LIM kinase inhibitor, dabrafenib, 
has been approved for use in melanoma cancers, and is thought to inhibit tumour 
cell invasion through mediation of upstream signalling factors796,797. 
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Compound Name Clinical Trials 
Dabrafenib (Tafinlar) Melanoma Cancer- Phase 2 and Phase 3 
Dabrafenib/Panitumumab  - 
Dabrafenib/Panitumumab/Trametinib - 
Dabrafenib/Trametinib BRAF V600E Positive Cancer- Approved 
Dabrafenib/Trametinib/vermuafenib Advanced Solid Cell & Breast Cancer-Phase 1 and Phase 2 
Table 6.2: LIM Kinase Inhibitors in Clinical Trials and Approved for Use.  
IOP Lowering Effects of LIM Kinase Inhibitors 
 LIMK inhibitors are thought to lower IOP through inducing depolymerisation 
of actin filaments in the trabecular meshwork, resulting in relaxation of the 
tissue794. POAG patients exhibit numerous structural changes in the TM including 
increased contractility which can result in decreased outflow facility and in turn 
elevated IOP798. Relaxation of the TM with LIMK inhibitors may counteract this 
effect, thus reversing a cause of elevated IOP. LIMK inhibitors offer more benefits 
than ROCK inhibitors as they are downstream from ROCK in the signalling cascade, 
their effects therefore are more specific to actin polymerisation and may offer 
fewer side effects than ROCK inhibitors. In a steroid induced glaucoma mouse 
model, LIMK2 inhibitors reduce IOP to baseline levels799. Furthermore, porcine eye 
perfusion with LIMK2 inhibitors increases outflow facility in the eye799. More 
recently an optimised LIMK2 inhibitor, LX7101, was described and has since proven 
to have high efficacy in a mouse model of ocular hypertension, and lowered IOP in 
glaucoma patients in phase I clinical trials789.  
Alternative Effects of LIM Kinase Inhibitors for Glaucoma 
 Reportedly, ROCK inhibitors have IOP-independent effects which are 
beneficial in glaucoma treatment. As a downstream molecule of the ROCK signalling 
pathway, LIMK inhibitors, may also have alternative uses. Reduced ocular blood 
flow in glaucomatous eyes causes RGC apoptosis800. ROCK inhibitors increase ocular 
blood flow in rabbit glaucoma models, presumably through the relaxation of 
vascular smooth muscle792. LIMK  is a recognised regulator of vascular smooth 
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muscle migration801 and therefore it is likely that LIMK inhibitors may increase 
ocular blood flow by similar mechanisms of ROCK inhibitors. Further investigation is 
required as a therapy to lower IOP while increasing ONH perfusion would be a 
major therapeutic advancement in glaucoma treatment. 
Insulin-Like Growth Factor Inhibitors 
 Insulin-like growth factor (IGF)-1 signalling results in the activation of the 
Rho/ROCK signalling pathway802. Interestingly, IGF-1 was significantly altered in our 
data set (LogFC= 6.666, FDR p= 1.89E-09), and therefore may also be an alternative 
target of the Rho signalling pathway in glaucoma. In the IPA Comparison analysis 
(Chapter 4; Table 4.5) both TGF-β2 and DEX treatment activated IGF-1 signalling. 
IGF-1 receptors are widely distributed in the eye and IGF-1 receptor antagonists 
prevent retinal neovascularisation in murine models indicating a key role of IGF-1 in 
the eye803. Increased signalling for IGF-1 in the eye leads to an accumulation of 
vascular endothelial growth factor (VEGF)804. There is evidence that glaucoma 
patients have elevated levels of VEGF in the aqueous humour and additionally, 
there is evidence for a role of VEGF in wound healing after glaucoma filtration 
surgery805. The increase of IGF-1 in the eye of transgenic IGF-1 over-expressing mice 
causes an increase in globular cells in the iridiocorneal angle which are not present 
in control eye806. Furthermore, mice had separation of ganglion cell nuclei 
indicative of ganglion cell loss which is suggestive that the mice developed 
glaucoma when IGF-1 is highly expressed806. IGF receptor inhibitors have been 
investigated for their roles in treatment of advanced cancers807. IGF has been 
implicated in cancer cell proliferation, survival and metastases due to its activation 
of downstream oncogenic proteins, phosphoinositide 3-kinase (PI3K), protein 
kinase B (Akt) and MAPKs.  
IGF-1 Inhibitor Potential in Glaucoma  
 CTGF is a primary response gene in human trabecular meshwork cells and is 
associated with the stabilisation of the actin cytoskeleton712. Physiological 
concentrations of IGF-1 induce the expression of CTGF in trabecular meshwork 
cells808. We investigated the response of CTGF expression to miRNA-145 inhibition 
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(Chapter 5, Figure 5.10) in TGF-β2 treated human TM cells, however no obvious 
regulation by miRNAs was observed.  Little is known about the function of IGF-1 in 
the TM. Rho/ROCK signalling is a common pathway linking IGF-1 and CTGF, which is 
implicated in TM cell contractility809. IGF-1 inhibitors may potentially reduce the 
expression of CTGF in the TM of glaucoma patients resulting in increased relaxation 
of the outflow pathway, increasing outflow facility and lowering IOP. IGF-1 
inhibitors may also be beneficial as post-surgical treatments to prevent elevated 
VEGF activity following glaucoma filtration surgery. Given the evidence the role of 
IGF-1 signalling in glaucoma warrants further investigation.  
NADPH Oxidase (NOX) 4  Inhibitors 
TGF-β2 is elevated in the aqueous humour of the eye and we have identified 
elevated expression of NADPH oxidase (NOX) 4 in TGF-β2 treated human TM cells 
by RNA-Seq experiments (Chapter 3). TGF-β2 can control the production of reactive 
oxygen species (ROS), and NOX4 is an important downstream effector of TGF-β2 
that is significantly expressed in human TM cells in the presence of TGF-β2. NOX4 
produces ROS  as their sole function and are recognised a key modulators of signal 
transduction pathways and have a pathological role after excessive activation under 
chronic stress810. NOX4 inhibitors have been previously described in a range of 
models of chronic inflammatory and fibrotic diseases811. GKT137831 (NOX4/1 
inhibitor) was developed following a high-throughput screen for NOX4 inhibitors812. 
The exact mechanism of action of NOX4 inhibitors remains unknown, however, they 
have been shown to have no scavenging abilities813. Clinical trials in patients with 
GKT137831 demonstrated excellent tolerability and reduction of various markers of 
chronic inflammation810.  
Role for NOX4 Inhibitors in Glaucoma 
 NOX4/1 inhibitors have previously been described for their used in 
ischaemic retinopathies, in particular GKT137831814. GKT137831 suppresses retinal 
neovascularisation and neuroglial cell inflammation814, indicating a therapeutic role 
for NOX4 inhibitors in ocular disease. Increased H2O2 by NOX4 causes remodelling 
of the TM cytoskeleton resulting in TM enlargement and decreased outflow 
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facility460. NOX4 inhibitors offer a novel therapeutic treatment for glaucoma as a 
reduction in NOX4 derived H2O2 may result in the inhibition of pathological TM 
remodelling thereby maintaining outflow facilities. Interestingly GKT137831 also 
reduced the expression of CTGF and α-SMA, two key genes associated with 
glaucoma pathogenesis, in dermal fibroblast wounds815. Previous studies of the 
actions of NOX4, in addition to our RNA-Seq data, are consistent with the 
hypothesis that NOX4 inhibition may be useful in blocking pro-fibrotic and TM 
contractile effects of TGF-β2 on TM cells and warrant consideration for further 
development as potential glaucoma therapeutic agents.  
Endothelin 1 Inhibitors  
 Glaucoma pathogenesis is a combination of reduced ocular blood flow and 
elevated IOP which ultimately leads to retinal ganglion cell death and visual loss816. 
Endothelin 1 (EDN1), a potent vasoconstrictor, was elevated in the TM in the 
presence of TGF-β2, as identified by our RNA-Seq experiment (Chapter 3); as well as 
in response to dexamethasone treatment. EDN1 is implicated in the pathogenesis 
of both POAG and steroid-induced glaucoma. 
 The heterogeneous nature of corticosteroid-induced IOP elevation indicates 
that other factors may also have a possible role. EDN1 is encoded for by the 
endothelin-1 gene and is expressed in several tissues including the non-pigmented 
ciliary epithelium590. EDN1 expression levels rise after 24hours exposure to DEX 
(100nM)195. In the TM of steroid responders, stimulation with dexamethasone 
results in the increased contractility of the TM as well as the decreased release of 
nitric oxide817. Several reports state that nitric oxide donors can relax the TM and 
lower IOP818,819. Endothelin receptor A activation is promoted by DEX treatment 
potentiating the contraction of the TM817. Glaucoma patients have elevated levels 
of EDN1 in both plasma and aqueous humour474. Both IOP and ocular blood flow 
are affected by EDN1467. Differential experimental approaches identified that 
elevated EDN1 levels in AH increase IOP478–480. Animal models have demonstrated a 
dose dependent rise in IOP after intracameral injection of EDN1478. In the bovine 
eye, EDN1 induced a reduction of AH outflow cause by increased TM contraction401. 
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Antagonism of EDN1 in both pressure dependent and independent pathways 
provides a promising approach for glaucoma treatment. 
EDN1 Antagonism in Glaucoma 
 Current endothelin (ET) receptor antagonists are classified as ETA or ETB 
selective depending on their relative affinity for a receptor subtype820. It has been 
proposed that EDN1 maintains IOP homeostasis by exerting its effects through 
endothelin receptor B817. Bosetan was the first mixed ETA/ETB antagonist clinically 
approved for the treatment of pulmonary arterial hypertension821. ETA antagonists 
demonstrate a dose dependent reduction in blood pressure and systemic vascular 
resistance822. In contrast ETB receptor antagonism produces mild vasoconstriction 
and pressor effect823. Therefore, it is likely ETA receptor antagonists would be 
beneficial for their use in glaucoma. EDN1 antagonism offers unprecedented 
benefits over conventional IOP lowering drugs as EDN1 can also positively regulate 
ocular blood flow. EDN1 antagonism offers IOP dependent and independent 
pathway manipulation with the overall therapeutic benefit of increased retinal 
ganglion cell survival. Pressure-independent pathways provide novel therapies for 
normal-tension glaucoma which are currently unavailable.  
SERPINB2 Agonists 
 SERPINB2 (PAI-2) is significantly down-regulated in TM cells in response to 
dexamethasone as described in Chapter 4 and elsewhere568. The exact role of PAI-2 
in TM cells is unknown. It is proposed that PAI-2 is involved in ECM remodelling 
characteristic of steroid-induced glaucoma, and regulation of cellular senescence 
through p21 stabilisation660. Decreased expression of PAI-2 in glaucoma may lead to 
decreased outflow facility in the TM as a result of matrix remodelling and cellular 
senescence. TGF-β2 increases PAI-1 expression in TM cells661 while dexamethasone 
down-regulates PAI-2 in the TM.  
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PAI-1 and -2 Therapies in Glaucoma  
 The fibrinolytic system plays an important role in vascular and tissue 
remodelling and impaired function of both PAI1 and PAI2 has profound effects on 
vascular house-keeping and remodelling capacity. Two PAI-2 agonists have been 
developed, but only tenecteplase has been approved for clinical use in stroke 
pateints824. Tenecteplase has a higher fibrin specificity and greater resistance to 
inactivation by PAI-1 (its endogenous inhibitor). PAI-2 agonists for glaucoma offer 
unique opportunities to regulate tPA activation and in turn ECM re-modelling in the 
TM.  In pulmonary fibrosis PAI-1 antagonists demonstrate efficacy in preventing 
bleomycin-induced pulmonary fibrosis in mice825. Furthermore, a non-inhibitory 
PAI-1 reduces pathological accumulation of ECM through competitive antagonism 
of native PAI-1, thus restoring plasmin generation and increasing plasmin-
dependent degradation of matrix components826. Competitive antagonism of native 
PAI-1 by non-inhibitory PAI-1 antagonists would be beneficial for POAG treatments 
where elevated TGF-β2 concentration in the AH is disrupting ECM turnover. 
Reduction of pathological ECM accumulation in the TM would alleviate elevated IOP 
and increase outflow facility.  
Follistatin  
 Follistatin (FST) is a stress responsive protein required for neutralising TGF-
β2 by antagonising BMP and activin670. FST expression was identified in human TM 
cells in response to TGF-β2 in this study and in the literature673. Our RNA-Seq data 
identified FST as significantly down-regulated in response to DEX and this was also 
observed in alternative studies570,673. FST is required to reduce ROS and is thought 
to interact with NOX family members674. FST reduction in response to corticosteroid 
could be detrimental to RGC and TM cell health during glaucoma pathogenesis as 
susceptibility to ROS would increase. 
 FST is regulated at transcriptional and post-transcriptional levels675,676 
which allows for opportunity to manipulate FST expression therapeutically. FST 
gene therapy clinical trials have investigated the potent antagonistic effects of FST 
on myostatin as a treatment for Becker muscular dystrophy (BMD)827.  Follistatin 
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gene therapy for sporadic inclusion body myositis successfully decreased fibrosis in 
4 out of 6 treated subjects828. Gene therapy offers a unique targeted mechanism829 
to effectively induce the expression of FST in a controlled manner and may have 
beneficial effects on steroid-induced glaucoma pathogenesis. The inverse is true for 
POAG whereby FST expression is increased in response to TGF-β2 in a dose 
dependent manner. The role of elevated FST expression in response to TGF-β2 is 
unknown however it may be involved in protection of TM and retinal ganglion cells 
from ROS; however further studies are required. Post-transcriptional modification 
of FST may offer a unique gene silencing approach for FST in glaucoma therapies.  
MMP 
 MMP activity in the trabecular meshwork is disrupted in glaucoma patients 
as well as in vitro studies in the anterior segment and cultured TM cells. Outflow 
resistance is generated in the TM through continuously remodelling of the ECM 
governed by MMPs830. In our study MMP-1 was significantly down-regulated in 
human TM cells in response to dexamethasone (Chapter 4) (FC= -1.81, p-value= 
4.4E-41). This reduction in MMP-1 may relate to the decreased ECM turnover seen 
in the outflow pathway with corticosteroid treatment552. An adenoviral vector 
containing inducible MMP-1 has been generated and extensively characterised in 
primary cell and organ culture systems666. Infection of the systems with the vector 
induced high levels of both MMP-1 mRNA and protein666. Importantly, expression 
of MMP-1 could be synchronised with corticosteroid treatment circumventing 
adverse side-effects observed during steroid-induced glaucoma666.  More recently, 
adeno-associated viral vectors for MMP-3 secretion have been described831. Adeno-
associated viral vectors overcome short-lived effects of adenovirus vectors and 
allow the sustained expression of MMP-3 in the AH of mice infected with the 
vector831. These results are promising with regards to the advent of novel gene 
therapies in for the treatment of POAG and steroid induced glaucoma.  
miRNA Therapeutics in Glaucoma 
 The expression of miRNAs is altered in various diseases and it is feasible to 
manipulate miRNAs in vivo832. There are two distinct possibilities to exploit miRNAs 
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for therapeutic interventions: (1) exogenous miRNAs can be applied to substitute 
for endogenously expressed miRNAs or (2) small molecule antagonists can be used 
to lower the gene regulatory effect of native miRNAs833. The latter approach allows 
the use of synthetic oligonucleotides for enhancing instead of silencing gene-
expression in comparison to down-regulation by siRNAs833. Synthetic miRNAs can 
assume the regulatory role of natural miRNAs. Discovery and development of 
miRNA therapeutics requires the identification of signature miRNA, validation of 
signature miRNA by loss/gain of function studies in vitro, pharmacological analysis 
(in vivo miRNA delivery studies), and clinical trials834.  
MRX34, a miR-34a mimic, was the first miRNA mimic to enter cancer clinical 
trials for its use in tumour growth and progression inhibition835. Antagonistic 
oligonucleotides on the other hand, which target pathology-related miRNAs are a 
promising therapeutic strategy for the treatment of cancer, hepatitis C and other 
diseases836. Antagonistic miRNAs were the first miRNA inhibitors shown to work in 
mammals837. The first reported use of miRNA antagonistic oligonucleotides in vivo 
was against miR-122838. miRNA-122 required structural optimisation through the 
use of locked nucleic acids (LNAs)839 leading to the production of miravirsen for the 
treatment of chronic hepatitis C virus infections. Miravirsen is a phosphorothioated 
oligonucleotide with multiple LNA nucleosides, which binds to miR-122 and silences 
pathological expression effectively840. In addition to antagonistic oligonucleotides 
“decoy” transcripts or miRNA sponges are currently under investigation for their 
therapeutic abilities841. miRNA sponges bind RNA transcripts to sequester and 
inhibit specific miRNAs841. The first decoy described consisted of an adenoviral 
vector with two sites for the muscle-specific miRNA-133842. This decoy confirmed 
the loss of miR-133 expression in mouse and disease models to lead to cardiac 
hypertrophy842. 
 Elevated IOP is attributed in part to increased ECM deposition in the outflow 
pathway. A number of miRNAs have been implicated in this process and inhibition 
of their reduced protein expression of key genes involved in ECM turnover and 
deposition381. miR-29 family members in particular regulate the expression of ECM 
components in TM cells and this is driven by TGF-β2 signalling688,843. miR-24 
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regulates the expression of TGF-β1 in TM cells in response to mechanical stress697. 
miR-200c inhibits the contraction of TM cells and miR-200c mimic decreases IOP in 
rats following intracameral injections469. Conversely, inhibition of miR-200c with an 
adenoviral vector expressing a molecular sponge to miR-200c leads to a significant 
decrease in IOP469. 
 Three differentially expressed miRNAs were identified in our human TM 
cells stimulated by TGF-β2: miR-143, miR-145, and miR-4328. Two of these: miR-
143 and miR-4328, were also significantly expressed in glaucomatous cells when 
compared to healthy controls. Recently, the miR-143/miR-145 miRNA cluster has 
been implicated in elevated IOP and deletion of the cluster resulted in up to 20% 
decrease in IOP in mice694. miR-143 and miR-145 mechanistically regulate actin 
dynamics within the TM, and so TM cell contractility. We have further shown this 
by the reduction of α-SMA at the protein level following miR-143 and miR-145 
inhibition. The RhoA/ROCK signalling pathway has been implicated in glaucoma and 
it is likely that miR-143 and miR-145 are involved in the regulation of key members 
of the signalling pathway. Evidence for both miR-143 and miR-145 regulation of 
components of the actin remodelling system makes them attractive future novel 
therapies for a more targeted glaucoma therapy. miRNAs have a wide potential 
therapeutic range in POAG from IOP regulation to ECM homeostasis.  
In addition, we identified a novel target for miRNA regulation in human TM 
cells stimulated by DEX in Chapter 4. FKBP51 is a member of the immunophilin 
family responsible for the nuclear translocation of glucocorticoid receptor β 
(GRβ)637. Enhanced GRβ expression in glaucoma patients is attributed to decreased 
sensitivity to glucocorticoids and poorer prognostic outcome590. FKBP51 represents 
a novel target for steroid-induced glaucoma in which FKBP51 induced 
glucocorticoid resistance. Interestingly, a number of miRNAs643–645., in particular 
miR-511 robustly regulate the expression of FKBP51. miR-511 suppresses the 
expression of FKBP51 in primary neurons in response to glucocorticoids645,646 which 
is indicative that FKBP51 may be a candidate for miRNA therapies in steroid 
glaucoma.  
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Drug Delivery for Glaucoma 
 Controlled drug delivery to the eye is a fundamental problem in the 
treatment of glaucoma, due to low drug contact time and poor ocular 
bioavailability due to the drainage pathway and tear turnover844. Novel delivery 
systems have the potential to mitigate the challenges of drug delivery efficiency 
whilst reducing systemic side effects.  
 Strategies for enhanced drug delivery include drug reformulation into 
nanoparticles, such as nanospheres or liposomes685. Nanoparticles have large 
surface areas and can be composed of several materials with multifunctional 
surface groups, which enable the drugs to reach targeted sites and to improve 
bioavailability. In vivo examination of topically administered nanoparticles in rabbits 
identified no inflammatory reaction, tissue alteration or damage to the epithelial 
layer of the cornea in response to nanoparticles845, indicating their potential for 
targeted drug delivery to the eye.  
 Efficient gene delivery into the anterior segment of the eye is feasible 
through the use of adenoviral and adeno-associated viral (AAV) vectors, and 
lentiviruses. Viral vectors contain the transgene, a promoter and potentially a gene 
regulatory sequence. Adenoviral drug delivery induce high inflammatory responses 
at high concentrations and gene expression is relatively short (1-3 weeks)846. 
Adenoviruses are not recommended as a final vector for gene therapy but are 
useful in pre-clinical studies847. Adenoviruses for Rho signalling molecules and 
MMP-1  decrease TM outflow resistance in organ culture848 and reduce IOP in 
animal models849.  
 AAV vectors can express the transgene for up to five years after a single 
dose. AAVs are not functional in the trabecular meshwork due to their inability to 
form double stranded DNA within the cell847. AAVs vectors carrying neuroprotective 
genes and injected intravitreally successfully protect RGCs in rat hypertensive 
models850. Additionally, AAV expressing MMP-3 in mice resulted in the secretion of 
MMP-3 in the AH and subsequent MMP-3 delivery to the outflow tissues facilitated 
targeted ECM degradation831. Lentiviruses are integrated into the host genome and 
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successfully transduce for long periods of time. There are however associated risks 
and integration can lead to undesirable side effects851. Non-viral vectors transduce 
in the TM and vectors carrying pigment-derived epithelium factor (PEDF) protected 
RGC in rats852. Non-viral vector gene delivery systems have been used to target 
specific tissues involved in the pathogenesis of glaucoma and effective long-term 
gene expression in the TM following intracameral delivery showed limited side 
effects on surrounding ocular tissues829. 
 Gene silencing with siRNAs has also been investigated for its use in 
glaucoma therapy. Perfusion of labelled naked siRNA to human anterior segments 
identified incorporation of the siRNA by the TM853. Subsequently perfusion of siRNA 
for glucocorticoid receptor degraded receptor RNA, and in the presence of DEX 
reduced the expression of glucocorticoid-induced genes (myocilin and angiopoietin-
like7)853. Naked delivery of miRNAs has been described in cancer research854 and 
therefore their use in glaucoma therapies is also feasible. However, the naked 
delivery of both miRNAs and siRNAs still lack efficiency; but studies coupling siRNAs 
to different polymers to form nanoparticles increase the efficiency of siRNA and 
miRNA delivery855.  
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Chapter 7 
Summary and Future Work  
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To the best of our knowledge, this is the first identification of differentially 
expressed genes in the TM in response to TGF-β2 and dexamethasone 
characterised by RNA-Seq. In Chapter 3, we describe a comprehensive 
characterisation of differentially expressed genes in response to TGF-β2 in normal 
human TM cells, and associated gene expression in glaucomatous TM cells. TGF-β2 
is a known glaucoma stimulus and is elevated in the aqueous humour of POAG 
patients856, thus effects on gene expression that arise in response to this are of 
importance in understanding disease pathophysiology. Through Core analysis we 
demonstrate that among the large data set of differentially expressed genes, the 
majority are implicated in cytoskeletal and extracellular matrix remodelling of the 
human trabecular meshwork cells. TGF-β2 is implicated extensively in these 
processes243,537, interestingly however, both TGF-β-related and -unrelated genes 
were identified in the TM in association to TGF-β2 stimulations. Comparison 
analyses further implicated RhoA signalling pathway in cytoskeletal re-organisation 
processes in the TM following exposure to TGF-β2. Rho/ROCK signalling pathway is 
a master regulator of the actin cytoskeleton and cell contractility434. Increased 
contractility in TM cells during glaucoma pathogenesis has previously been 
associated with ROCK signalling430, and increased contractility leads to a reduction 
in outflow facilities of the drainage angle469. Novel therapies are currently being 
developed and have entered clinical trials targeting ROCK1/2 in the RhoA pathway 
for their involvement in glaucoma pathogenesis787. Interestingly, we did not identify 
ROCK as being significantly enriched in our data set, and we believe this might be 
indicative of alternative pathway molecules downstream of ROCK having a more 
significant role in cytoskeletal remodelling of the TM. Current therapies have the 
sole aim of lowering intraocular pressure and do not address other contributing 
factors of the disease such as reduced ocular blood flow which in turn leads to 
retinal ganglion cell death. We have identified significantly altered genes that have 
been implicated in reduced ocular blood flow (EDN1, FST, NOX4). This provides us 
with a cohort of novel targets that if manipulated may reduce negative impacts on 
the aqueous humour outflow pathway and ocular blood flow in a promising step 
forward in developing new therapeutics for POAG. 
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As well as identification of differentially expressed genes associated with 
POAG, in Chapter 4, we describe the implications corticosteroids, namely 
dexamethasone, have on gene expression in human TM cells. Steroid-induced 
glaucoma is a result of enhanced ECM deposition and decreased matrix 
metallopeptidases in the TM199. Core analysis of differentially expressed genes in 
dexamethasone stimulated TM cells, demonstrated that the majority of the data 
set are involved in extracellular matrix remodelling, and glucocorticoid receptor 
modulation. Glucocorticoid receptor isoforms have been implicated in steroid 
responsiveness in glaucoma857. Preferential GRα expression over GRβ in TM cells of 
glaucoma patients suggests a role of GRα in steroid responsiveness in terms of IOP 
elevation572. We have identified FKBP51 gene as significantly up-regulated in out 
data-set in response to dexamethasone. FKBP51 is responsible for nuclear import of 
GRα and we believe up-regulation of this gene enhances steroid-responsiveness in 
glaucoma patients due to the suppression of GRβ expression. In addition, we 
further confirm the reduction of matrix metallopeptidases in TM cells in response 
to corticosteroids. MMP-1, a matrix metallopeptidase essential for the regular 
turnover of ECM, is significantly down-regulated in our data set. Down-regulation of 
MMPs results in elevated IOP cause by reduced outflow facility.  A number of the 
differentially expressed genes that we have identified in the TM in response to 
dexamethasone have the potential to be manipulated therapeutically (MMP-1, 
FKBP51, PAI-2), lending substantial new information to drug development for 
steroid-induced glaucoma and indeed POAG where ECM turnover is also 
disrupted632,771,825.  
Dysregulation of gene expression in response to stimuli can be regulated by 
miRNAs in the TM. There is increasing evidence for the role of miRNAs in the 
trabecular meshwork in health and glaucoma381. In Chapter 5 we identify the 
differential expression of three miRNAs: miR-145-5p, miR-143-3p, and miR-4328 in 
human TM cells in response to TGF-β2. The miR-143/145 cluster plays a 
fundamental role in vascular smooth muscle cell-like differentiation during both 
physiological and pathological events724,725. miR-143 and miR-145 mRNA targets are 
linked to the Rho signalling pathway, and are known to regulate actin dynamics in 
284 
 
the TM. A miRNA microarray of human TM cells stimulated with TGF-β2 and further 
RNA-Seq of human TM cells transfected with miR-143 and miR-145 inhibitors has 
strengthened the association of miR143/145 with the RhoA signalling pathway in 
glaucoma pathogenesis. Unfortunately, a number of differentially expressed genes 
identified by RNA-Seq following miR-143 and miR-145 inhibition were also 
differentially expressed in the presence of a scrambled negative control indicating 
the complex nature of miRNA manipulation, and the potential for a number of off 
target effects that must be considered before a therapeutic target can be inferred.  
Several novel drugs are currently being developed for the treatment of 
glaucoma which have been discussed in Chapter 6. Across all three of our studies 
we have identified a number of novel therapeutic candidates that if manipulated 
may reduce pathological effects of glaucoma. As suggested previously, alternative 
molecules within the Rho signalling pathway may prove more effective targets over 
ROCK molecules. We have identified that both Lim kinase and IGF-1 are 
differentially expressed in our data set and manipulation of these molecules via 
inhibitors may be effective in reducing TM cytoskeletal re-organisation and 
contraction. Furthermore, EDN1 was significantly up-regulated in our data set in the 
presence of TGF-β2 and is also up-regulated in the AH of glaucoma patients. EDN1 
is a potent vaso-constrictor involved in the contraction of TM cells and ischaemic 
insult in the eye. We propose that antagonism of EDN1 expression via its more 
potent receptor, ETA, has the potential not only reduce TM contractility but also by 
enhancing ocular blood flow and provide significant benefit in glaucoma treatment. 
A range of potential novel therapies have been discussed in Chapter 6 based on 
differentially expressed genes we have identified in TM cells stimulated with known 
glaucoma stimuli; TGF-β2 and dexamethasone. The majority of potential drug 
targets we have identified are involved in ECM remodelling, cytoskeletal 
remodelling, and enhanced ocular blood flow to reduce pathological effects of the 
disease.  
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This comprehensive characterisation of differentially expressed genes, 
associated with both POAG and steroid-induced glaucoma, provide us with an 
extensive data-set future study. Manipulating both RhoA signalling associated 
molecules and other novel targets would address the pathophysiology of glaucoma 
and would be a significant advance on the current pharmacological IOP-lowering 
drugs.  
 All experiments throughout this thesis were performed using cultured 
human trabecular meshwork cells obtained from either whole donor eyes or 
corneal buttons. Preferentially, direct isolation of RNA from tissue would have been 
utilised, as this would provide a more realistic view of global gene expression of 
normal TM cells and circumvent effects of tissue culture. TM cells naturally occur in 
a labile environment, and are only exposed to a stiffer environment in disease 
states, such as glaucoma. Culturing TM cells directly on tissue culture plastic is a 
drastic change from their natural environment and should be considered for future 
work. As the trabecular meshwork ages, TM cellularity decreases. The TM tissue 
which can be successfully extracted from whole donor eyes and corneal buttons is 
relatively small in size. These two factors are contributors to the decision to culture 
the TM cells rather than opt for direct RNA extraction. For sequencing and 
microarray experiments, high quality and quantity of RNA is essential, therefore 
culturing of human TM cells to obtain optimal RNA quantities of high quality was 
essential for this thesis.  
 
Future Work  
(i) Functional Analysis of RNA-Seq Targets 
 While this PhD has added to the characterisation of differentially expressed 
genes associated with known glaucoma stimuli, TGF-β2 and dexamethasone, the 
functional significance of these differentially expressed genes remains unclear. 
Gene function can often be examined by defining when and where a gene is 
expressed within the cell. To evaluate this, the use of a reporter gene for specific 
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gene targets may be useful. Replacing the coding portion of the target gene with a 
reporter gene will allow for monitored tracking of its protein product. Furthermore, 
fluorescent in situ hybridisation (FISH) would be a powerful tool for assessing the 
expression and localisation of RNA as a sub cellular level in donor anterior segment 
whole mounts or trabecular meshwork tissue specimens. Direct RNA extraction 
from TM tissue would yield a better understanding of differential gene expression 
and omitting the input cell culture may have. 
 Targeted mutations can also be useful in revealing specific gene functions. A 
number of genes we have identified are found on known glaucoma loci and 
functional analyses of these may be useful in elucidating a role of these genes in 
glaucoma pathogenesis. Reverse genetics allows for the direct manipulation of a 
gene target in vitro which can then be transferred in to a cell where integration in 
to the chromosome occurs. This approach is useful in highlighting the phenotypic 
aspects associated with a mutant gene. In the same way that cells can be 
engineered to express a dominant negative version of the protein providing a loss-
of-function phenotype, cells can also be engineered to display a gain-of-function 
mutation. To assess the exact effect of the specific genes we have identified in our 
RNA-Seq experiments on the TM gain-of-function analyses would allow us to 
decipher phenotypic changes induced by genes of interest.  
 We would also like to assess the impact of these genes on ECM deposition 
through protein analyses. Western blot is a useful tool in identifying protein 
expression which can then be quantified by flow cytometry. ECM proteins including 
collagens, fibronectin and GAGs, are elevated in the glaucomatous TM. We have 
identified genes that are responsible for the enhanced deposition of ECM. Protein 
analysis following TM cell exposure to specific genes of interest may indicate 
specific roles of genes in ECM deposition, and preferential expression of ECM 
components. Protein analysis will further implicate genes in glaucoma pathogenesis 
as well as provide a better insight in to their specific roles. 
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(ii) miRNA Manipulations and Functional Analyses 
In Chapter 5 we identified significantly differentially expressed miRNAs in the 
human TM stimulated with TGF-β2. Identification of putative targets in the TM for 
miR-143 and miR-145 proved difficult as no significant differential expression of 
validate mRNA targets was observed by q-PCR. Following this RNA-Seq of TM cells 
treated with TGF-β2 and miR-143 and miR-145 inhibitors identified a subset of 
uniquely differentially expressed genes when compared to TGF-β2 TM control cells. 
Interestingly, the scrambled negative control was shown to have significant off 
target effects. For future miRNA manipulation experiments we propose the use of 
stable over-expression of known-down of miRNAs with viral vectors. Viral vectors 
incorporate well in to TM cells and exert their effects for up to 3 weeks allowing for 
functional assays to be performed829.  
 It was known that miR-143 and miR-145 effect the actin cytoskeleton of the 
TM via α-SMA and we further identified the down-regulation of α-SMA in the 
presence of an miR-145 inhibitor. To further validate this relationship functional 
assays need to be performed. TM collagen gel contraction assays will allow for the 
assessment of miR-145 effects on TM cell contraction in vitro. In addition, actin 
structures are easily visualised by actin antibodies and fluorescent phalloidins in 
fixed cells. Pronounced actin staining is present in the TM of glaucomatous human 
eyes736, therefore re-organisation in the presence of TGF-β2 and phenotypic 
rescues following miRNA manipulation may be visualised in TM cells.  
 Stable transfection of miRNAs has proven difficult thus far and future 
investigation may benefit from cell sorting prior to progressing with 
experimentation. miRNA mimics and inhibitors have the potential to be 
fluorescently tagged without exerting undesirable effects or affecting q-PCR 
outcomes. Fluorescently tagged miRNAs within the cell would provide an 
opportunity to sort cells using flow cytometry and by-pass the contamination by the 
untransfected cell population. It is worth considering however, the low number of 
transfected cells that will be obtained may be further reduced through the use of 
flow and a greater yield, or pooling technique may need to be utilised.  
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 Further investigation of miRNA function may be achieved through the use of 
the human anterior segment perfusion system. miRNAs can be delivered naked to 
the anterior segment using the perfusion system. IOP of perfused eye can be 
artificially altered using TGF-β2 and glucocorticoids, and continuous IOP read-outs 
may be obtained. The effects of miRNAs on IOP can be monitored in this way 
following naked delivery of miRNAs to the anterior segment, to assess for 
fluctuations or significant changes in IOP following miRNA treatment. These 
experiments could provide us with a more comprehensive idea of the in situ effects 
of miRNAs in the human trabecular meshwork.  
(iii) Novel Therapies and the Organ Culture System of the Anterior 
Segment 
Recently we have established the human and porcine organ culture system of 
the anterior segment (Figure 7.1). Human and porcine anterior segments can be 
maintained on specialised petri dishes for up to 4 weeks which provides us with the 
means to assess the effects of our glaucoma stimuli of interest, TGF-β2 and 
dexamethasone, on the TM in situ to gain better physiological insights in to the 
effect these stimuli are having in glaucoma pathogenesis858. Furthermore, we could 
benefit here from direct RNA extraction from TM tissue following perfusion as well 
as isolating TM cells for single cell sequencing.  
In Chapter 6 we describe the potential therapeutic gains of manipulation of 
differentially expressed genes identified by RNA-Seq in this PhD. MMP-1 was 
significantly down-regulated in response to dexamethasone in our corticosteroid-
induced glaucoma study. Viral gene vectors have recently been described for 
steroid-inducible MMP-1 expression in the TM771. Over-expression of MMP-1 would 
also be beneficial in POAG where excess ECM deposition decreased outflow facility. 
Perfusion of the organ culture system with TGF-β2 to enhance ECM deposition 
similar to those effects observed in glaucoma, following perfusion with an MMP-1- 
inducible vector, similar to the MMP-1 vector described771, would allow for the 
assessment of gene viral vectors as potential therapeutic strategies based on their 
effect on TM morphology in situ.  
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Perfusion of anterior segments with miR-145 and or miR-143 offers us the 
opportunity to assess drug concentrations, as well as, their ability to regulate TM 
contractility, regulate IOP, and ECM production and in a physiological environment. 
Furthermore, packaging of miRNAs must be considered. This model can also be 
employed to assess miRNA delivery using different strategies. miRNAs can be 
delivered naked to the eye exterior and exert desired effects on tissue locally853. 
Other delivery technologies including nanoparticles844 and peptide-gels859 can be 
assessed in this model, as well as, their effect in situ in the TM to elucidate their 
therapeutic potential. Perfusion systems are useful as they allow for 
characterisation of the same TM in situ both before and following and following the 
experiment, this is crucial in truly identifying phenotypic changes that may be 
occurring in the tissue in response to stimuli and drugs.  
(iv) Target Genes and Pathways 
A number of potential therapeutic targets were identified throughout this thesis 
in relation to both glaucoma stimuli, TGF-β2 and dexamethasone. A common factor 
across all three chapters was the potential involvement of the RhoA signalling 
pathway in glaucoma pathogenesis. Future work should focus on elucidating the 
key RhoA related proteins that are dysregulated in glaucoma pathogenesis and 
investigate the ability of miRNA143 and miR-145 to enhance or subdue their 
expression. ROCK1 and ROCK2 inhibitors have already been developed and are 
currently being investigated in clinical trials and through perfusion systems for the 
roles in decreasing IOP. We have not identified ROCK1 or ROCK2 as significantly 
enriched in our dataset, however we have identified LIMK as significantly enriched, 
another pivotal player in the RhoA signalling pathway. It would be of interest to 
investigate the potential role of LIMK in human TM cells particularly following TGF-
β2 and dexamethasone treatment. 
As well as investigating the RhoA signalling pathway, future work should be 
focused on manipulation of identified mRNA targets. NOX4 is of particular interest 
as it has already been shown to be successfully regulated by miRNAs and is involved 
in aspects of glaucoma that are not currently being treated. Oxidative stress 
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contributes to the loss of RGCs and this is not currently modifiable by any available 
drug therapy. Regulation of chronic NOX4 expression is promising and will have 
largely beneficial antioxidant effects within the TM. It may be of interest to induce 
oxidative stress in TM cells and investigate the time frame under which NOX4 
chronic expression occurs. Following oxidative stress manipulations of NOX4 with 
miRNAs would be key experiments in order to restore normal function and prevent 
cellular loss.  
 The datasets generated throughout this thesis have provided the field with a 
number of potential therapeutic targets some of which have novel outcomes that 
have not yet been addressed in glaucoma. Alternative targets provide 
unprecedented benefits when tackling a multifaceted disease such as glaucoma.  
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 Figure 7.1: Anterior Segment Organ Culture Perfusion Setup. Whole globes are bisected and anterior segments are maintained in 
culture in a modified perfusion chamber. IOP is constantly monitored and in situ evaluation of drug targets can be performed following the 
experiment
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